

EUROPEAN PATENT APPLICATION

(B2)
69 Application number 87109919.8

70 Date of filing 09.07.87

71 Int. Cl.: C 07 D 233/68, C 07 D 403/14,
C 07 D 403/10, C 07 D 405/10,
C 07 D 403/06, C 07 D 233/64,
C 07 D 233/61, C 07 D 233/60,
C 07 D 233/84, C 07 D 233/70,
C 07 D 233/90

69 Priority: 11.07.86 US 884920
22.06.87 US 50341

71 Applicant: E.I. DU PONT DE NEMOURS AND COMPANY,
1007 Market Street, Wilmington Delaware 19808 (US)

63 Date of publication of application 20.01.88
Bulletin 88/3


72 Inventor: Cardin, David John, 1921 Julian Road,
Wilmington Delaware 19803 (US)
Inventor: Duncia, John Jones Vytautas, 35-B Martine
Court, Newark Delaware 19711 (US)

64 Designated Contracting States AT BE CH DE ES FR GB
GR IT LI LU NL SE

74 Representative von Kreisler, Alek, Dipl.-Chem. et al.,
Deichmannhaus am Hauptbahnhof, D-5000 Köln 1 (DE)

54 Angiotensin II receptor blocking imidazoles.

67 Substituted imidazoles such as



are useful as angiotensin II blockers. These compounds
have activity in treating hypertension and congestive heart
failure.

B(7-D9,12-91,12-F5,12-F18)

NEW ⁸³³ ARYL SUBSTIT. IMIDAZOLE CPDS. + USEFUL AS
ANGIOTENSIN-2 BLOCKERS FOR TREATING HYPERTENSION
AND CONGESTIVE HEART FAILURE

18299
CP#4

EP 0 253 310 A2

ANGIOTENSIN II RECEPTOR BLOCKING IMIDAZOLES

Related Application


This application is a continuation-in-part of
5 U.S. Application Serial No. 884,920, filed July 11,
1986.

BACKGROUND OF THE INVENTIONField of the Invention


This invention relates to novel substituted
10 imidazoles, and processes for their preparation,
pharmaceutical compositions containing them and
pharmaceutical methods using them.

The compounds of this invention inhibit the
action of the hormone angiotensin II (All) and are
15 useful therefore in alleviating angiotensin induced
hypertension. The enzyme renin acts on a blood plasma
 α_2 -globulin, angiotensinogen, to produce angiotensin
I, which is then converted by angiotensin converting-
enzyme to All. The latter substance is a powerful
20 vasopressor agent which has been implicated as a
causative agent for producing high blood pressure in
various mammalian species, such as the rat, dog, and
man. The compounds of this invention inhibit the
action of All at its receptors on target cells and
25 thus prevent the increase in blood pressure produced
by this hormone-receptor interaction. By administering
a compound of this invention to a species of mammal
with hypertension due to All, the blood pressure is
reduced. The compounds of this invention are also
30 useful for the treatment of congestive heart failure.

K. Matsumura, et al., in U.S. Patent 4,207,324
issued June 10, 1980 discloses 1,2-disubstituted-4-
haloimidazole-5-acetic acid derivatives of the formula:




5
 10 Wherein R^1 is hydrogen, nitro or amino; R^2 is phenyl, furyl or thienyl optionally substituted by halogen, lower alkyl, lower alkoxy or di-lower alkylamino; R^3 is hydrogen or lower alkyl and X is halogen; and their physiologically acceptable salts. These compounds have diuretic and hypotensive actions.
 15 Furukawa, et al., in U.S. Patent 4,355,040 issued October 19, 1982 discloses hypotensive imidazole-5-acetic acid derivatives having the formula:




20
 25 Wherein R^1 is lower alkyl, cycloalkyl, or phenyl optionally substituted; X^1 , X^2 , and X^3 are each hydrogen, halogen, nitro, amino, lower alkyl, lower alkoxy, benzyloxy, or hydroxy; Y is halogen and R^2 is hydrogen or lower alkyl; and salts thereof.
 30 Furukawa, et al., in U.S. Patent 4,340,598, issued July 20, 1982, discloses hypotensive imidazole derivatives of the formula:

35



5
Wherein R^1 is lower alkyl or, phenyl C_{1-2} alkyl optionally substituted with halogen or nitro; R^2 is lower alkyl, cycloalkyl or phenyl optionally substituted; one of R^3 and R^4 is $-(CH_2)_nCOR^5$ where R^5 is
10 amino, lower alkoxy or hydroxyl and n is 0, 1, 2 and the other of R^3 and R^4 is hydrogen or halogen; provided that R^1 is lower alkyl or phenethyl when R^3 is hydrogen, $n=1$ and R^5 is lower alkoxy or hydroxyl; and salts thereof.

15 Furukawa et al., in European Patent Application 103,647 discloses 4-chloro-2-phenylimidazole-5-acetic acid derivatives useful for treating edema and hypertension of the formula:



Where R represents lower alkyl and salts thereof.

30 The metabolism and disposition of hypotensive agent 4-chloro-1-(4-methoxy-3-methylbenzyl)-2-phenylimidazole-5-acetic acid is disclosed by H. Torii in Takeda Kenkyushoho, 41, No 3/4, 180-191 (1982).

Frazer et al., in European Patent Application 125,033-A discloses 1-phenyl(alkyl)-2-(alkyl)-
35 thioimidazole derivatives which are inhibitors of

dopamine- β -hydroxylase and are useful as antihypertensives, diuretics and cardiotonics.

European Patent Application 146,228 filed October 16, 1984 by S.S.L. Parhi discloses a process for the preparation of 1-substituted-5-hydroxymethyl-2-mercaptoimidazoles.

A number of references disclose 1-benzyl-imidazoles such as U.S. Patent 4,448,781 to Cross and Dickinson (issued May 15, 1984); U.S. Patent 4,226,878 to Ilzuka et al. (issued October 7, 1980); U.S. Patent 3,772,315 to Regel et al. (issued November 13, 1973); U.S. Patent 4,379,927 to Vorbrüggen et al. (issued April 12, 1983); amongst others.


Pals et al., Circulation Research, 29, 673 (1971) describe the introduction of a sarcosine residue in position 1 and alanine in position 8 of the endogenous vasoconstrictor hormone All to yield an (octa)peptide that blocks the effects of All on the blood pressure of pithed rats. This analog, [Sar¹, Ala⁸] All, initially called "P-113" and subsequently "Saralasin", was found to be one of the most potent competitive antagonists of the actions of All, although, like most of the so-called peptide-All-antagonists, it also possesses agonistic actions of its own. Saralasin has been demonstrated to lower arterial pressure in mammals and man when the (elevated) pressure is dependent on circulating All (Pals et al., Circulation Research, 29, 673 (1971); Streeten and Anderson, Handbook of Hypertension, Vol. 5, Clinical Pharmacology of Antihypertensive Drugs, A. E. Doyle (Editor), Elsevier Science Publishers B.V., p. 246 (1984)). However, due to its agonistic character, saralasin generally elicits pressor effects when the pressure is not sustained by All. Being a peptide, the pharmacological effects to

5
saralasin are relatively short-acting and are only
manifest after parenteral administration, oral doses
being ineffective. Although the therapeutic uses of
peptide AII-blockers, like saralasin, are severely
5 limited due to their oral ineffectiveness and short
duration of action, their major utility is as a
pharmaceutical standard.

To date there are no known non-peptide
antagonists of AII which are useful orally or which
10 bind in vitro in the IC_{50} ranges we observe.


Summary Of The Invention

According to the present invention there are
provided novel compounds of formula (I) which have
15 angiotensin II-antagonizing properties and are useful
as antihypertensives.











(1)

30 wherein



858

88015687



859

88015687

R^2 is H; Cl; Br; I; F; NO_2 ; alkyl of 1 to 4 carbon atoms; acyloxy of 1 to 4 carbon atoms; alkoxy of 1 to 4 carbon atoms; CO_2H ; CO_2R^9 ; NHSO_2CH_3 ; NHSO_2CF_3 ;

5

CONHOR^{12} ; SO_2NH_2 ; ; aryl; or furyl;

R^3 is H; Cl; Br; I or F; alkyl of 1 to 4 carbon atoms or alkoxy of 1 to 4 carbon atoms;

10 R^4 is CN, NO_2 or CO_2R^{11} ;

R^5 is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms alkenyl or alkynyl of 2 to 4 carbon atoms;

15 R^6 is alkyl of 2 to 10 carbon atoms, alkenyl or alkynyl of 3 to 10 carbon atoms or the same groups substituted with F or CO_2R^{14} ; cycloalkyl of 3 to 8 carbon atoms, cycloalkylalkyl, of 4 to 10 carbon atoms; cycloalkylalkenyl or cycloalkylalkynyl of 5 to 10 carbon atoms;

20 $(\text{CH}_2)_6\text{Z}(\text{CH}_2)_m\text{R}^5$ optionally substituted with F or CO_2R^{14} ; benzyl or benzyl substituted on the phenyl ring with 1 or 2 halogens, alkoxy of 1 to 4 carbon atoms, alkyl of 1 to 4 carbon atoms or nitro;

25 R^7 is H, F, Cl, Br, I, NO_2 , CF_3 or CN;






R^8 is H, CN, alkyl of 1 to 10 carbon atoms, alkenyl of 3 to 10 carbon atoms, or the same groups substituted with F; phenylalkenyl wherein the aliphatic portion is 2 to 6 carbon atoms;

30 $-(\text{CH}_2)_m$ -imidazol-1-yl; $-(\text{CH}_2)_m$ -1,2,3-triazolyl optionally substituted with one or two groups selected from CO_2CH_3 or alkyl of 1 to 4 carbon atoms; $-(\text{CH}_2)_m$ -tetrazolyl;


35 $-(\text{CH}_2)_n\text{OR}^{11}$; $-(\text{CH}_2)_n\text{OCR}^{14}$; $-(\text{CH}_2)_n\text{SR}^{15}$;

- 860


88015687



15



20





R^{10} is alkyl of 1 to 6 carbon atoms or perfluoro-alkyl of 1 to 6 carbon atoms, 1-adamantyl, 1-naphthyl, 1-(1-naphthyl)ethyl, or $(\text{CH}_2)_p\text{C}_6\text{H}_5$;

25 R^{11} is H, alkyl of 1 to 6 carbon atoms, cyclo-alkyl of 3 to 6 carbon atoms, phenyl or benzyl;

R^{12} is H, methyl or benzyl;

R^{13} is $-\text{CO}_2\text{H}$; $-\text{CO}_2\text{R}^9$; $-\text{CH}_2\text{CO}_2\text{H}$; $-\text{CH}_2\text{CO}_2\text{R}^9$;

30






35

861

88015687

-CONHOR¹²; -SO₂NH₂;




R¹⁴ is H, alkyl or perfluoroalkyl of 1 to 8 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, phenyl or benzyl;

R¹⁵ is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, phenyl, benzyl, acyl of 1 to 4 carbon atoms, phenacyl;

R¹⁶ is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, (CH₂)₆C₆H₅, OR¹⁷, or NR¹⁸R¹⁹;

R¹⁷ is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, phenyl or benzyl;

R¹⁸ and R¹⁹ independently are H, alkyl of 1 to 4 carbon atoms, phenyl, benzyl, α-methylbenzyl, or taken together form a ring of the formula



Q is NR²⁰, O or CH₂;

R²⁰ is H, alkyl of 1-4 carbon atoms, or phenyl;

R²¹ is alkyl of 1 to 6 carbon atoms, -NR²²R²³,

or -CHCH₂CO₂CH₃;

NH₂.

88015687


862

R^{22} and R^{23} independently are H, alkyl of 1 to 6 carbon atoms, benzyl, or are taken together as $(CH_2)_u$ where u is 3-6;

R^{24} is H, CH_3 or $-C_6H_5$;

5

R^{25} is $NR^{27}R^{28}$, OR^{28} , $NHCONH_2$, $NHCSNH_2$,



10 R^{26} is hydrogen, alkyl with from 1 to 6 carbon atoms, benzyl, or allyl;

R^{27} and R^{28} are independently hydrogen, alkyl with from 1 to 5 carbon atoms, or phenyl;

R^{29} and R^{30} are independently alkyl of 1-4




15 carbon atoms or taken together are $-(CH_2)_q-$;

R^{31} is H, alkyl of 1 to 4 carbon atoms, $-CH_2CH=CH_2$ or $-CH_2C_6H_4R^{32}$;



R^{32} is H, NO_2 , NH_2 , OH or OCH_3 ;

X is a carbon-carbon single bond, $-CO-$, $-O-$, $-S-$,

20



25



30 Y is O or S;

Z is O, NR^{11} , or S;

m is 1 to 5;

n is 1 to 10;

p is 0 to 3;

35 q is 2 to 3;

88015687

863

14

r is 0 to 2;

s is 0 to 5;

t is 0 or 1;


5

and pharmaceutically acceptable salts of these compounds:


provided that:

(1) the R^1 group is not in the ortho position:

10


(2) when R^1 is . X is a single bond.

15

and R^{13} is CO_2H . or . then R^{13} must

be in the ortho or meta position; or when R^1 and X are as above and R^{13} is NHSO_2CF_3 or NHSO_2CH_3 . R^{13} must be ortho:

20

(3) when R^1 is . and X is other than

25

a single bond. then R^{13} must be ortho except when $X = \text{NR}^{23}\text{CO}$ and R^{13} is NHSO_2CF_3 or NHSO_2CH_3 . then R^{13} must be ortho or meta:

30

(4) when R^1 is 4- CO_2H or a salt thereof. R^6 cannot be S-alkyl:

(5) when R^1 is 4- CO_2H or a salt thereof. the substituent on the 4-position of the imidazole cannot be CH_2OH . $\text{CH}_2\text{OCOCH}_3$. or $\text{CH}_2\text{CO}_2\text{H}$:


35


88015687

864

(6) when R^1 is . X is $-OCH_2-$, and


R^{13} is $2-CO_2H$, and R^7 is H then R^6 is not C_2H_5S :

(7) when R^1 is $-CONH-$ , and R^6 is n-hexyl then R^7 and R^8 are not both hydrogen;

(8) when R^1 is $-NHCO-$ , R^6 is not methoxy-benzyl;



(9) the R^6 group is not $-CHCH_2CH_2CH_3$ or CH_2OH .

Preferred for their antihypertensive activity are novel compounds having the formula:








(II)

88015687



- 10 R^6 is alkyl of 3 to 10 carbon atoms, alkenyl of 3 to 10 carbon atoms, alkynyl of 3 to 10 carbon atoms, cycloalkyl of 3 to 8 carbon atoms, benzyl substituted on the phenyl ring with up to two groups selected from alkoxy of 1 to 4 carbon atoms, 15 halogen, alkyl of 1 to 4 carbon atoms, and nitro;

- R^8 is phenylalkenyl wherein the aliphatic portion is 2 to 4 carbon atoms, $-(\text{CH}_2)_m$ -imidazol-1-yl, $-(\text{CH}_2)_m$ -1,2,3-triazolyl optionally substituted with one or two groups selected from 20 CO_2CH_3 or alkyl of 1 to 4 carbon atoms,



35

88015687

866

12/

R^{10} is H, alkyl of 1 to 5 carbon atoms, CN , or $\text{NR}^{18}\text{R}^{19}$;

X is carbon-carbon single bond, $-\text{CO}-$, $-\text{CON}-$,
 R^{23}

5 $-\text{CH}_2\text{CH}_2-$, $-\text{NCO}-$, $-\text{OCH}_2-$, $-\text{CH}_2\text{O}-$, $-\text{SCH}_2-$,
 R^{23}

$-\text{CH}_2\text{S}-$, $-\text{NHCH}_2-$, $-\text{CH}_2\text{NH}-$ or $-\text{CH}=\text{CH}-$; and

10 pharmaceutically acceptable salts of these
 compounds.

More preferred are compounds of the preferred
 scope where:

15 R^2 is H, alkyl of 1 to 4 carbon atoms, halogen, or
 alkoxy of 1 to 4 carbon atoms;

R^6 is alkyl, alkenyl or alkynyl of 3 to 7 carbon atoms;

R^7 is H, Cl, Br, or CF_3 ;

20

R^8 is $-(\text{CH}_2)_m\text{OR}^{11}$; $-(\text{CH}_2)_m\overset{\text{O}}{\text{O}}\text{CR}^{14}$; $-\text{CH}=\text{CH}-\overset{\text{R}^{14}}{\underset{\text{O}}{\text{C}}}\text{HOR}^{15}$;

$-(\text{CH}_2)_m\overset{\text{O}}{\text{C}}\text{R}^{16}$; $-\text{CH}_2\text{NH}\overset{\text{O}}{\text{C}}\text{OR}^{10}$;

25

$-(\text{CH}_2)_m\text{NHSO}_2\text{R}^{10}$; $-\text{CH}_2-\text{N}=\text{N}-\text{N}=\text{N}-\text{H}$; or $-\text{COR}^{16}$;


R^{10} is CF_3 , alkyl of 1 to 6 carbon atoms or
 phenyl;

30

R^{11} is H, or alkyl of 1 to 4 carbon atoms;

R^{13} is CO_2H ; $\text{CO}_2\text{CH}_2\text{OCOC}(\text{CH}_3)_3$; NHSO_2CF_3

and



35

887

88015687

241

R¹⁵ is H, alkyl of 1 to 4 carbon atoms, or acyl of 1 to 4 carbon atoms;
 R¹⁶ is H, alkyl of 1 to 5 carbon atoms; OR¹⁷; or



n is 1 to 5;

10 X = single bond, -O-; -CO-; -NHCO-; or -OCH₂-; and pharmaceutically acceptable salts.

Specifically preferred for their antihypertensive activity are:

- 15 • 2-Butyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-5-(hydroxymethyl)imidazole.
- 2-Butyl-4-chloro-1-[(2'-carboxybiphenyl-4-yl)methyl]-5-(hydroxymethyl)imidazole.
- 2-Butyl-4-chloro-1-[(2'-carboxybiphenyl-4-yl)methyl]-5-[(methoxycarbonyl)aminomethyl]imidazole.
- 20 • 2-Butyl-4-chloro-1-[(2'-carboxybiphenyl-4-yl)methyl]-5-[(propoxycarbonyl)aminomethyl]imidazole.
- 2-Butyl-4-chloro-1-[(2'-carboxybiphenyl-4-yl)methyl]imidazole-5-carboxaldehyde
- 2-Butyl-1-[(2'-carboxybiphenyl-4-yl)methyl]imidazole-5-carboxaldehyde
- 25 • 2-(1E-Butenyl)-4-chloro-1-[(2'-carboxybiphenyl-4-yl)methyl]-5-(hydroxymethyl)imidazole
- 2-(1E-Butenyl)-4-chloro-1-[(2'-carboxybiphenyl-4-yl)methyl]imidazole-5-carboxaldehyde
- 30 • 2-Propyl-4-chloro-1-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-5-(hydroxymethyl)imidazole
- 2-Propyl-4-chloro-1-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-carboxaldehyde
- 2-Butyl-4-chloro-1-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-carboxaldehyde
- 35

88015687

868

247

- 2-(1E-Butenyl)-4-chloro-1-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-5-hydroxymethylimidazole
 - 2-(1E-Butenyl)-4-chloro-1-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-carboxaldehyde
- 5 and pharmaceutically acceptable salts thereof.

Note that throughout the text when an alkyl substituent is mentioned, the normal alkyl structure is meant (i.e., butyl is n-butyl) unless otherwise
10 specified.

Also within the scope of this invention are pharmaceutical compositions comprising a suitable pharmaceutical carrier and a compound of Formula (I), and methods of using the compounds of Formula (I) to
15 treat hypertension and congestive heart failure. The compounds of this invention can also be used as diagnostic agents to test the renin angiotensin system.

It should be noted in the foregoing structural formula, when a radical can be a substituent in more
20 than one previously defined radical, that first radical can be selected independently in each previously defined radical. For example, R^1 , R^2 and R^3 can each be CONHOR¹². R^{12} need not be the same substituent in each of R^1 , R^2 and R^3 but can be
25 selected independently for each of them.

Synthesis

The novel compounds of Formula (I) may be prepared using the reactions and techniques described
30 in this section. The reactions are performed in a solvent appropriate to the reagents and materials employed and suitable for the transformation being effected. It is understood by those skilled in the art of organic synthesis that the functionality
35 present on the imidazole and other portions of the

88015687

869

12

27
molecule must be consistent with the chemical transformations proposed. This will frequently necessitate judgment as to the order of synthetic steps, protecting groups required, deprotection conditions, and activation of a benzylic position to enable attachment to nitrogen on the imidazole nucleus. Throughout the following section, not all compounds of formula (I) falling into a given class may necessarily be prepared by all methods described for that class. Substituents on the starting materials may be incompatible with some of the reaction conditions required in some of the methods described. Such restrictions to the substituents which are compatible with the reaction conditions will be readily apparent to one skilled in the art and alternative methods described must then be used.

20

25

30

35

— 870

88015687

12




88015687

Generally, compounds of Formula (2) can be prepared by direct alkylation onto imidazole (1) prepared as described in U.S. 4,355,040 and references cited therein, with an appropriately protected benzyl halide, tosylate or mesylate (2) in the presence of base, as shown in path a). Preferably, the metallic imidazolide salt is prepared by reacting imidazole (1) with a proton acceptor such as MH where M is lithium, sodium or potassium in a solvent such as dimethylformamide (DMF) or by reacting it with a metal alkoxide of formula MOR where R is methyl, ethyl, t-butyl or the like in an alcohol solvent such as ethanol or t-butanol, or a dipolar aprotic solvent such as dimethylformamide. The imidazole salt is dissolved in an inert aprotic solvent such as DMF, and treated with an appropriate alkylating agent (2). Alternatively, imidazole (1) can be alkylated with a benzyl halide (2, where X=Br, Cl) in the presence of a base such as sodium carbonate, potassium carbonate, triethylamine or pyridine. The reaction is run in an inert solvent such as DMF or DMSO at 20°C to the reflux temperature of the solvent for 1-10 hours.


For example, the 4-nitrobenzyl intermediate (3a, wherein $R^1 = 4\text{-NO}_2$, $R^2 = R^3 = \text{H}$) may be obtained by direct alkylation onto imidazole (1) with a 4-nitrobenzyl halide, tosylate or mesylate in the presence of base.

If R^7 and R^8 are different, mixtures of two regioisomer alkylation products (3b, and 3c) are obtained in which R^7 and R^8 are interchanged. When R^8 is CHO the alkylation is such that the benzyl group becomes attached to the adjacent nitrogen preferentially. These isomers possess distinct physical and biological properties and can usually be separated and isolated by conventional separation techniques such as chromatography and/or crystallization.

88015687




3d



3e


10 3d: $R^6 = n\text{-Bu}$, $R^7 = \text{Cl}$
 $R^8 = \text{CH}_2\text{CO}_2\text{Me}$.

3e: $R^6 = n\text{-Bu}$,
 $R^7 = \text{Cl}$
 $R^8 = \text{CH}_2\text{OH}$



15

$R^2 = R^3 = \text{H}$



$R^2 = R^3 = \text{H}$

In all series examined, the more rapidly eluted isomer of a given pair has greater biological potency than the less rapidly eluted isomer. The absolute structure of the compounds 3d and 3e has been confirmed by X-ray crystallographic analysis to establish the relationship between structure, physical properties and biological activity. Sulfonamide 3d is the more rapidly eluted isomer in its series, acid 3e is the less rapidly eluted isomer in its series.

Alternatively, any properly functionalized benzylamine derivative (4) may be converted to imine (5) by treatment with an acylamino ketone (5) in the presence of an inert solvent such as benzene, toluene, or the like, and a catalytic amount of p-toluene-sulfonic acid or molecular sieves. N. Engel, and W. Steglich, Liebigs Ann. Chem., 1916, (1978), or in the presence of a. umina, F. Texier-Boulet, Synthesis, 679 (1985). The resulting imine (6) can be cyclized

873

88015687

22

to the N-benzyl imidazole (1) with phosphorus pentachloride (PCl_5), phosphorus oxychloride (POCl_3) or triphenylphosphine (PPh_3) in dichloroethane in the presence of a base such as triethylamine. N. Engel and
 5 W. Steglich, Liebigs Ann. Chem., 1916, (1978).

Acylamino ketone (5) is readily obtainable from amino acids via the Dakin-West reaction. H.D. Dakin, R. West, J. Biol. Chem., 78, 95 and 745 (1928), and various modifications thereof. W. Steglich, G. Höfle,
 10 Angew. Chem. Int. Ed. Engl., 8, 981 (1969); G. Höfle, W. Steglich, H. Vorbrüggen, Angew. Chem. Int. Ed. Engl., 17, 569 (1978); W. Steglich, G. Höfle, Ber., 102, 883 (1969), or by selective reduction of acyl cyanides, A. Pfaltz, S. Anwar, Tet. Lett., 2977 (1984),
 15 or from α -halo, α -tosyl or α -mesyl ketones via the appropriate substitution reactions that one skilled in the art will readily recognize.

The functionalized benzylamines (4) may be made from the corresponding benzyl halide, tosylate or
 20 mesylate (2) via displacement with a nitrogen nucleophile, a procedure familiar to one skilled in the art. This displacement may be achieved using azide ion, ammonia, or phthalimide anion, etc., in a neutral solvent such as dimethylformamide, dimethylsulfoxide
 25 etc., or under phase transfer conditions. The benzyl halide (2) may be made by a variety of benzylic halogenation methods familiar to one skilled in the art, for example benzylic bromination of toluene derivatives with N-bromosuccinimide in an inert solvent such as
 30 carbon tetrachloride in the presence of a radical initiator such as benzoyl peroxide at temperatures up to reflux conditions.

A wide variety of toluene derivatives may be made from simple electrophilic substitution reactions on an
 35 aromatic ring. This includes nitration, sulfonation.

phosphorylation, Friedel-Crafts alkylation, Friedel-Crafts acylation, halogenation, and other similar reactions known to one skilled in the art. G. A. Olah, "Friedel-Crafts and Related Reactions," Vol. 1-5, Interscience, New York, (1965).

Another way to synthesize functionalized benzyl halides is via chloromethylation of the corresponding aromatic precursor. Thus, the appropriately substituted benzene ring may be chloromethylated with formaldehyde and hydrochloric acid (HCl) for example with or without an inert solvent such as chloroform, carbon tetrachloride, light petroleum ether or acetic acid. A Lewis acid such as zinc chloride ($ZnCl_2$) or a mineral acid such as phosphoric acid may also be added as a catalyst or condensing agent. R. C. Fuson, C. H. McKeever, Org. Reactions, 1, 63 (1942).

Alternatively, N-benzylimidazoles (3) can also be prepared as shown in path b) by forming an R^6 substituted amidine (7) from an appropriately substituted benzylamine (4) which is in turn reacted with an α -haloketone, α -hydroxyketone (8), α -haloaldehyde, or α -hydroxyaldehyde, F. Kunckell, Ber., 34, 637 (1901).

As shown in path a), imidazole (1) may be alkylated by a variety of benzyl derivatives. These include compounds with latent acid functionalities such as o, m, and p-cyanobenzylhalides, mesylates or tosylates as shown in path c). Nitriles of formula (9) may be hydrolyzed to carboxylic acids of formula (10) by treatment with strong acid or alkali. Preferably, treatment with a 1:1 (v/v) mixture of concentrated aqueous hydrochloric acid/glacial acetic acid at reflux temperatures for 2-96 hours or by treatment with 1N sodium hydroxide in an alcohol solvent such as ethanol or ethylene glycol for 2-96 hours at tempera-

tures from 20°C to reflux can be used. If another nitrile group is present it will also be hydrolyzed. The nitrile functionality can also be hydrolyzed in two steps by first stirring in sulfuric acid to form the amide followed by hydrolysis with sodium hydroxide or a mineral acid to give the carboxylic acid (10).

The nitriles (2) can be converted into the corresponding tetrazole derivative (11) by a variety of methods using hydrazoic acid. For example, the nitrile can be heated with sodium azide and ammonium chloride in DMF at temperatures between 30°C and reflux for 1-10 days. J. P. Hurwitz and A. J. Tomson, J. Org. Chem., **26**, 3392 (1961). Preferably, the tetrazole is prepared by the 1,3-dipolar cycloaddition of trialkyltin or triaryltin azides to the appropriately substituted nitrile as described in detail by Scheme 15.

The starting imidazole compounds (1) are readily available by any of a number of standard methods. For example, acylaminoketone (5) can be cyclized with ammonia or equivalents thereof. D. Davidson, et al., J. Org. Chem., **2**, 319 (1937) to the corresponding imidazole as shown in Scheme 1. The corresponding oxazole can also be converted to imidazole (1) by action of ammonia or amines in general. H. Brederick, et al., Ber., **88**, 1351 (1955); J. W. Cornforth and R. H. Cornforth, J. Chem Soc., 96. (1947).

Several alternative routes to imidazoles (1) are illustrated in Scheme 2. As shown in Scheme 2 equation a), reaction of the appropriate R⁶ substituted imidate esters (12) with an appropriately substituted α-hydroxy- or α-haloketone or aldehyde (8) in ammonia leads to imidazoles of formula (1). P. Dziurron, and W. Schunack, Archiv. Pharmaz., 307 and 470 (1974).

35

876

88015687

22

The starting imidazole compounds (1) wherein R^7 and R^8 are both hydrogen can be prepared as shown in equation b) by reaction of the appropriate R^6 -substituted imidate ester (12) with

- 5 α -aminoacetaldehyde dimethyl acetal (13), M. R. Grimmett, Adv. Heterocyclic Chem., 12, 103 (1970).

As shown in equation c), imidazole (15; wherein R^7 = hydrogen and R^8 = CH_2OH) can be prepared by treatment of the imidate ester (12) with

- 10 1,3-dihydroxyacetone (14) in ammonia by the procedure described in Archive der Pharmazie, 307, 470 (1974).

Halogenation of imidazole (15) or any imidazole wherein R^7 or R^8 is hydrogen is preferably accomplished by reaction with one to two equivalents of

- 15 N-halosuccinimide in a polar solvent such as dioxane or 2-methoxyethanol at a temperature of 40-100°C for 1-10 hours. Reaction of the halogenated imidazole (16) with a benzylhalide (2) in the manner described in Scheme 1 affords the corresponding N-benzylimidazole (17); wherein R^7 is halogen and R^8 is CH_2OH . This
20 procedure is described in U.S. Patent 4,355,040. Alternatively, imidazole (17) can be prepared by the procedure described in U.S. Patent 4,207,324.

- Compounds of formula (17) can also be prepared
25 by treatment of the starting imidazole compound (1) wherein R^7 and R^8 are both hydrogen, with the appropriate benzyl halide followed by functionalization of R^7 and R^8 by treatment with formaldehyde as described in E. P. Godefroi, et al., Recueil, 91, 1383 (1972)
30 followed by halogenation as was described above.

As shown in equation d) the imidazoles (1) can also be prepared by reaction of R^6 substituted amidines (18) with an α -hydroxy- or α -haloketone or aldehyde (8) as described by F. Kunckel, Ber., 34,

- 35 637, (1901).

As shown in equation e), preparation of the nitroimidazoles (1, R^7 or $R^8 = NO_2$) is preferably accomplished by heating the appropriate starting imidazole in a 3:1 mixture of conc. sulfuric acid/conc. nitric acid at 60-100°C for 1-6 hours. Nitration of the imidazole (15) can be achieved by first converting the hydroxymethylimidazole to the corresponding chloromethylimidazole (22) employing thionyl chloride or oxalyl chloride. Nitration, as described above, followed by hydrolysis provides the nitroimidazoles (24).

Imidazoles (21) where R^7 and $R^8 = CN$ can be prepared as shown in equation f) by reaction of R^6 substituted ortho esters, ortho acids or aldehydes (followed by oxidation of the aldehyde) with diaminomaleonitrile (20) by the procedure described by R. W. Begland et al., J. Org. Chem., 39, 2341 (1974). Likewise, R^6 substituted imidate esters (12) also react with diaminomaleonitrile to give 4,5 dicyanoimidazoles (21). The nitrile groups can be further elaborated into other functional groups by methods familiar to one skilled in the art.

25

30






878

35

88015687

22

26
Scheme 2





35

879






88015687

2



880

88015687



As shown in Scheme 1, path a) for benzylidene-
acetals (17) where $R^7 = Cl$ and $R^8 = CH_2OH$, the hydroxyl
methyl groups may be easily converted to the corresponding
halide, mesylate or tosylate by a variety
of methods familiar to one skilled in the art.
Preferably, the alcohol (17) is converted to the
chloride (25) with thionyl chloride in an inert
solvent at temperatures of 20°C to the reflux
temperature of the solvent.

Chloride (25) may be displaced by a variety of
nucleophiles by nucleophilic displacement reaction
procedures familiar to one skilled in the art. For
example, excess sodium cyanide in DMSO may be used to
form cyanomethyl derivatives (26) at temperatures of
20°C to 100°C.

Nitrile (26) may be hydrolyzed to acetic acid
derivative (27), by a variety of methods. These
methods include methods described previously for the
hydrolysis of nitriles of formula (2). Examples of
desired acids and bases for this hydrolysis include
mineral acids such as sulfuric acid, hydrochloric
acid, and mixtures of either of the above with 30-50%
acetic acid (when solubility is a problem), and alkali
metal hydroxides such as sodium hydroxide or potassium
hydroxide. The hydrolysis reaction proceeds under
heating at temperatures ranging from 50-160°C for 2-48
hours. Carboxylic acid (27) may be esterified by a
variety of methods without affecting other parts of
the molecule. Preferably, (27) is refluxed in a
hydrochloric acid/methanol solution for 2-48 hours
to give ester (28).

Ester (28) may be hydrolyzed to carboxylic acid
(27), for instance, after R^1 , R^2 and R^3 have been
elaborated. Various methods, acidic or basic, may be
used. For example, compound (28) is stirred with 0.5N

potassium hydroxide in methanol, or if base soluble, it is stirred in 1.0N sodium hydroxide for 1-48 h at 20°C to reflux temperatures.

- Hydroxymethyl derivative (17) may be acylated to give (22) by a variety of procedures. As shown in path b) acylation can be achieved with 1-3 equivalents of an acyl halide or an anhydride in a solvent such as diethyl ether, tetrahydrofuran, methylene chloride or the like in the presence of a base such as pyridine or triethylamine. Alternatively (17) may be acylated by reaction with a carboxylic acid and dicyclohexylcarbodiimide (DCC) in the presence of a catalytic amount of 4-(N,N-dimethylamino)pyridine (DMAP) via the procedure described by A. Hassner, *Tet. Lett.*, **46**, 4475 (1978).
- 15 Treatment of (17) with a solution of carboxylic acid anhydride in pyridine optionally with a catalytic amount of DMAP at temperatures of 20-100°C for 2-48 hours is the preferred method.

- The ether (30) can be prepared from the alcohol (17) as shown in path c) by methods such as treatment of (17) in a solvent such as dimethylformamide or dimethylsulfoxide with potassium *t*-butoxide, sodium hydride, or the like followed by treatment with R¹¹L at 25°C for 1-20 hours, where L is a halogen, tosylate or mesylate.
- 25

- Alternatively, treatment of (17) with 1-5 equivalents of thionyl chloride in chloroform for 2-6 hours at 25°C followed by treatment of the intermediate (25) with 1-3 equivalents of MOR¹¹, where M is sodium or potassium, for 2-10 hours at 25°C either in R¹¹OH as solvent or in a polar solvent such as dimethylformamide or the like will also yield ether (30).
- 30

- The ether (30) can also be prepared for example by heating (17) for 3-15 hours at 60-160°C in R¹¹OH containing an inorganic acid such as a hydrochloric acid or sulfuric acid.
- 35

- 883 88015687

Compound (11) preferably by catalytic hydrogenolysis (over an appropriate catalyst such as 10% palladium on carbon) in methanol at 25°C for 1-6 hours or by treatment with zinc metal in acetic acid.

As shown in Scheme 2, the trifluoromethyl imidazoles (22) can be prepared from the corresponding iodoimidazoles (22) by treatment with trifluoromethyl copper. J. Am. Chem. Soc., 108, 832 (1986).


10 N-arylimidazoles of formula I (compounds wherein $x=0$) can be prepared by the following methods, it being understood by one skilled in the art that certain manipulations, protecting and deprotecting steps, and other synthetic procedures disclosed above
15 may be necessary to produce compounds with the desired combinations of R^6 , R^7 , R^8 and R^{13} .

As shown in Scheme 4, equation a) the reaction of aniline derivative (34) with imidate ester (12) to form the substituted amidine (35) provides material
20 which can be cyclized with dihydroxyacetone to form structure (36). Subsequent elaboration into (1) provides the N-arylimidazole compounds of the invention.

Alternatively as shown by equation b) the
25 Marckwald procedure, described by Marckwald et al., Ber., 22, 568, 1353 (1889); Ber., 25, 2354 (1892) can be used to form a 2-mercaptoimidazole (38) from aniline derivative (34) via isothiocyanate (37). Desulfurization of (38) with dilute nitric acid
30 followed by anion formation at the 2-position of the imidazole (39) and reaction with R^6X where X is Cl, Br, I, allows the formation of (40) which can be subsequently elaborated to I.

A variation of Marchwald's process as shown in equation c) using an α -aminoketone (41) and isothiocyanate (27) can also be employed, see Norris and McKee, *J. Amer. Chem. Soc.*, 77, 1056 (1955) can also be employed. Intermediate (42) can be converted to (1) by known sequences. The general procedure of Carboni et al., *J. Amer. Chem. Soc.*, 89, 2626 (1967) (illustrated by equation d)) can also be used to prepare N-aryl substituted imidazoles from appropriate haloaromatic compounds (43; X=F, Cl, Br) and imidazoles (1):




Scheme 4



885

88015687

33
Scheme 4 (continued)




886

88015687

In various synthetic routes R^1 , R^2 and R^3 do not necessarily remain the same from the starting compound to the final products, but are often manipulated through known reactions in the intermediate steps as shown in Schemes 5-22. All of the transformations shown in Schemes 5-10 and 12 can also be carried out on the terminal aromatic ring (i.e., biphenyl ring).

Scheme 5



As shown in Scheme 5, compounds where R^1 is a sulfonic acid group may be prepared by oxidation of the corresponding thiol (45). Thus, an N-benzylimidazole derivative bearing a thiol group may be converted into a sulfonic acid (46) by the action of hydrogen peroxide, peroxyacids such as metachloroperoxybenzoic acid, potassium permanganate or by a variety of other oxidizing agents. E. E. Reid, Organic Chemistry of Bivalent Sulfur, 1. Chemical Publishing Co., New York, 120-121 (1958).


from deprotection of the corresponding alkyl ether or thioethers. Thus, for example, a methyl ether or a methyl thioether derivative (44) of an N-benzylimidazole containing one or more aromatic rings may be converted into the free phenol or thiophenol (45) by the action of boron tribromide methyl sulfide, P. G. Willard and C. F. Pryhle, Tet. Lett., 21, 3731 (1980); trimethylsilyl iodide, M. E. Jung and M. A. Lyster, J. Org. Chem., 42, 3761 (1977); KSEt and derivatives thereof, G. J. Feutrill, R. N. Mirrington, Tet. Lett., 1327, (1970), and a variety of other reagents.


Alternatively, N-benzylimidazoles may be sulfonated by stirring with H_2SO_4 at a variety of different concentrations or with other sulfonating agents such as chlorosulfonic acid or sulfur trioxide with or without complexing agents such as dioxane or pyridine at temperatures from 0 to 200°C with or without solvent, K. LeRoi Nelson in Friedel-Crafts and Related Reactions, III part 2, G. A. Olah, ed., Interscience Publ., 1355 (1964).

The synthesis of compounds where R^1 is a sulfate, phosphate or phosphonic acid are depicted in Scheme 6:

888

88015687





hydroxyl group (47) may be readily converted into the corresponding sulfate (48) or phosphate (49). As shown in equation a), reaction of the phenol with a sulfur trioxide-amine complex will give the corresponding sulfate (48). E. E. Gilbert, Sulfonation and Related Reactions, Interscience, New York, chapter 6 (1965). Reaction of the phenol (47) with phosphorus pentachloride followed by hydrolysis will give the corresponding phosphate (49). G. M. Kosolapoff, Organophosphorus Compounds, John Wiley, New York, 235 (1950).

As shown in equation b) N-benzylimidazoles may be converted into the corresponding phosphonic acids by reaction with phosphorus trichloride (PCl_3) and aluminum chloride (AlCl_3) in an inert solvent for 0.5-96 hours from temperatures of 25°C to the reflux temperatures of the solvent. Appropriate workup followed by reaction with chlorine (Cl_2) and subsequent hydrolysis of the tetrachloride (51) gives the phosphonic acid derivative (52). G. M. Kosolapoff in Org. Reactions, 6, R. Adams, editor, John Wiley and Sons, New York, 297 (1951). Another more direct route involves reaction of the N-benzylimidazole with PSCl_3 and AlCl_3 followed by hydrolysis. R. S. Edmunson in Comprehensive Organic Chemistry, Vol. 2, D. Barton and W. D. Ollis editors, Pergamon Press, New York, 1285 (1979).


Alternatively, equation c) illustrates that aryl phosphonic acids (52) may be formed from reaction of the corresponding diazonium salt (53) with PCl_3 in the presence of Cu(I) followed by hydrolysis with water (ibid. p. 1286).

As shown in equation d), the aryl halides (55) may be photolyzed in the presence of phosphite esters to give phosphonate esters (56). R. Kluger, J. L. W.

Chen, *J. Am. Chem. Soc.*, **99**, 2302, (1977). These same aryl halides also react with phosphite esters in the presence of nickel or palladium salts to give phosphonate esters. P. Tavs, *Chem. Ber.*, **103**, 2428 (1970), which can be subsequently converted to phosphonic acids (52) by procedures known to one skilled in the art.


N-Benzylimidazoles containing an aldehyde or ketone (57) may be reacted with a phosphorus trihalide followed by water hydrolysis to give α -hydroxyphosphonic acid derivatives, G.M. Kosolapoff, *op. cit.*, 304, as shown in Scheme 7.

Scheme 7



Compounds where R^1 is $-\text{CONHOR}^{12}$ may be prepared as shown in Scheme 8, by the treatment of a carboxylic acid (10) with 1-4 equivalents of thionyl chloride for 1-10 hours. This reaction can be run without solvent or in a nonreactive solvent such as benzene or chloroform at temperatures of 25-65°C. The intermediate acid chloride is then treated with 2-10 equivalents of the appropriate amine derivative, $\text{H}_2\text{N}\cdot\text{OR}^{12}$, for 2-18 hours at temperatures of 25-80°C in a polar aprotic solvent such as tetrahydrofuran or dimethylsulfoxide to give the hydroxamic acid (59).

Scheme 8



Alternatively, the carboxylic acid (10) can be converted to the hydroxamic acid (59) according to the procedure in *J. Med. Chem.*, 28, 1158 (1985) by employing dicyclohexylcarbodiimide, 1-hydroxybenzotriazole, and $\text{H}_2\text{NOR}^{12}$ or according to the procedure described in *Synthesis*, 929 (1985) employing the Vilsmeier reagent and $\text{H}_2\text{NOR}^{12}$.

893

88015687

5

10


15

20

25

30

35



894

88015687

42


Aniline intermediates (51) are disclosed in U.S. Patent No. 4,355,040 and may be obtained from the corresponding nitro compound precursor by reduction. A variety of reduction procedures may be used such as iron/acetic acid, D. C. Owsley, J. J. Bloomfield, Synthesis, 118, (1977), stannous chloride, P. D. Bellamy, Tet. Lett., 839, (1984) or careful hydrogenation over a metal catalyst such as palladium.

As shown in Scheme 9, aniline intermediates of N-benzylimidazoles may also be prepared from the corresponding carboxylic acid (10) or acid chloride via a Curtius rearrangement of an intermediate acyl azide (60). More modern methods include using diphenylphosphoryl azide as a source of azide, T. Shioiri, K. Ninomiya, S. Yamada, J. Am. Chem. Soc., 94, 6203 (1972), and trapping the intermediate isocyanate (61) produced by the Curtius rearrangement with 2-trimethylsilylethanol and cleaving the resultant carbamate (62) with fluoride to liberate the amine (63), T. L. Capson and C. D. Poulter, Tet. Lett., 25, 3515 (1984). Classical procedures familiar to one skilled in the art may also be employed.

Compounds where R^1 is $-SO_2NH_2$ may be made as shown in Scheme 10:

895

88015687



Sulfonamide compounds (65) may be made by
 15 reacting an arylsulfonyl chloride (64) with ammonia,
 or its equivalent. Unsubstituted arylsulfonamides are
 made by reaction with ammonia in aqueous solution or
 in an inert organic solvent, F. H. Bergheim and
 W. Braker, J. Am. Chem. Soc., 66, 1459 (1944), or with
 20 dry powdered ammonium carbonate, E. H. Huntress and
 J. S. Autenrieth, J. Am. Chem. Soc., 63, 3446 (1941);
 E. H. Huntress and F. H. Carten, J. Am. Chem. Soc.,
62, 511 (1940).

The sulfonyl chloride precursor may be prepared
 25 by chlorosulfonation with chlorosulfonic acid on the
 aromatic ring directly, E. H. Huntress and F. H.
 Carten, ibid.; E. E. Gilbert, op. cit., 84, or by
 reacting the corresponding aromatic diazonium chloride
 salt (53) with sulfur dioxide in the presence of a
 30 copper catalyst, H. Meerwein, et al., J. Prakt. Chem.,
[ii], 152, 251 (1939), or by reacting the aromatic
 sulfonic acid (46) with PCl_5 or POCl_3 , C. M. Suter,
The Organic Chemistry of Sulfur, John Wiley, 459
 (1948).

44

Linked ester compounds of formula (I) where R¹

- O
- is $\text{CO}_2\text{CH}(\text{R}^{24})\text{OCR}^{21}$ can be made by procedures well known in penicillin and cephalosporin chemistry.
- 5 The purpose is to provide materials which are more lipophilic and which will be useful orally by rapid transit from the gut into the bloodstream, and which will then cleave at a sufficiently rapid rate to provide therapeutically useful concentrations of the
- 10 active carboxylic acid form. The following review articles and references cited therein discuss this concept and the chemistry involved in preparing such compounds V. J. Stella, et al., Drugs, 29, 455-473 (1985); H. Ferres, Drugs of Today, 19 (9), 499-538
- 15 (1983); A. A. Sirkula, Ann. Repts. Med. Chem., 10, 306-315 (1975).

Experimental procedures which are applicable to the preparation of chemically stable linked esters are illustrated by equations a-e of Scheme 11.

20

25

30

897


35

88015687

PK

Scheme 111066

5 G. Francheschi et al., J. Antibiotics, 26, (7),
938-941 (1983).




10

67

15


J. Budavin, U.S. Patent 4,440,942



20

68


E. Daehne et al., G.B. Patent 1,290,787



25

69

Perres, Chem. Ind., 435-440 (1980)




898

35

70

88015687


5 In equations a-e: R=



10 Compounds of Formula I where R¹ is -C(CF₃)₂OH
may be prepared as shown in Scheme 12.

15
20
25
30
899

35
88015687



71

72

800

88015687

42

Hexafluoroisopropanol compounds (72) may be prepared by treatment of arylsilane (71) with 1-5 equivalents of hexafluoroacetone in a solvent such as methylene chloride at temperatures ranging from about -50° to 25°C for a period of 2-10 hours. The requisite arylsilane (71) can be prepared using methods known to one skilled in the art such as the procedures described in Chapter 10 of Butterworth's "Silicon in Organic Chemistry".

10

15

20

25



30

901

35

88015687

48



88015687

As shown in Scheme 11, compound (71) in which X = -NHCO and R¹³ = -COOH may be easily prepared, for example, by reacting aniline precursor (61) with a phthalic anhydride derivative in an appropriate solvent such as benzene, chloroform, ethyl acetate, etc. Often the carboxylic acid product will precipitate from solution with the reactants remaining behind. M.L. Sherrill, F.L. Schaeffer, E.P. Shoyer, J. Am. Chem. Soc., 50, 474 (1928).

- 10 When R¹³ = NHSO₂CH₃, NHSO₂CF₃ or tetrazolyl (or a variety of other carboxylic acid equivalents), compound (73) may be obtained by reacting aniline (63) with the requisite acid chloride by either a Schotten-Baumann procedure, or simply stirring in a solvent such as methylene chloride in the presence of a base such as sodium bicarbonate, pyridine, or triethylamine.

Likewise, aniline (63) may be coupled with an appropriate carboxylic acid via a variety of amide or peptide bond forming reactions such as DCC coupling, azide coupling, mixed anhydride synthesis, or any other coupling procedure familiar to one skilled in the art.

Aniline derivatives (63) will undergo reductive animation with aldehydes and ketones to form secondary amines (74). Thus the aniline is first stirred with the carbonyl compound in the presence of a dehydration catalyst such as molecular sieves or p-toluenesulfonic acid. Afterwards the resultant imine is reduced to the amine with a borohydride reducing agent such as sodium cyanoborohydride or sodium borohydride. Standard catalytic hydrogenation reagents such as hydrogen and palladium/carbon can also be employed.

Alternatively, aniline (61) may be monoalkylated by reaction with ethyl formate followed by reduction with, for example, lithium aluminum hydride to produce the N-methyl derivative (74). Anilines (74) may in turn be reacted with carboxylic acid anhydrides and acid chlorides or carboxylic acids by any of the coupling procedures

described previously to yield (73) where $X = -N(CH_3)CO-$.

Aniline (61) or (74) or other intermediate anilines where the amino group may be located on another aromatic ring for example, also react with other anhydrides to make amide-carboxylic acid derivatives of formula (75). Thus, for example, maleic anhydride, 2,3-naphthalenedicarboxylic acid anhydride, and diphenic anhydride are reacted in a similar fashion to phthalic anhydride with aniline (61) or (74) to yield carboxylic acids (76), (77), and (78), respectively.

Phthalimide derivatives of aniline (61) may be made by a variety of methods, preferably by stirring aniline (61) with phthalic anhydride in acetic acid at a temperature between 20°C and reflux. G. Wanag, A. Veinbergs, *Ber.*, 75, 1558 (1942), or by stirring (61) with phthaloyl chloride, a base such as triethylamine, and an inert solvent.

Aniline (61) may be converted into its trifluoromethanesulfonamide derivative or its trifluoroacetamido derivative preferably by reacting it with triflic anhydride or trifluoroacetic anhydride and a base such as triethylamine in an inert solvent such as methylene chloride at -78°C followed by warming to room temperature.

Compounds of structure (I) where X is a carbon-carbon linkage which are depicted as (80) can be made as shown in Scheme 14.

Scheme 14

5

10


15

20

25

30


35



905

88015687

Scheme 14 (Cont'd.)



Equation a) illustrates that the biphenyl compounds (80) can be prepared by alkylation of imidazole (1) with the appropriate halomethylbiphenyl compound (79) by the general procedure described in Scheme 1.


The requisite halomethylbiphenyl intermediates (79) are prepared by Ullman Coupling of (81) and (82) as described in "Organic Reactions", 2, 6 (1944) to provide intermediates (83), which are in turn halogenated. Halogenation can be accomplished by refluxing (83) in an inert solvent such as carbon tetrachloride for 1-6 hours in the presence of a N-halosuccinimide and an initiator such as azobisisobutyronitrile (equation b).

As shown in equation c), derivatives of intermediate (83) in which R¹ is at the 2' position (83a) can also be prepared by the method described in

J. Org. Chem., 41, 1320 (1976), that is Diels Alder addition of a 1,3-butadiene to a styrene (84) followed by aromatization of intermediate (85).

Alternatively, the substituted biphenyl precursors (81; where $R^{13} = \text{COOH}$) and their esters (89) can be prepared as illustrated in equation d), which involves oxazoline compounds as key intermediates, A. I. Meyers and E. D. Mihelich, J. Am. Chem. Soc., 97, 7383 (1975).

10 The substituted biphenyl tetrazoles (83; where

R^{13}  can be prepared from the nitrile precursors ($R^{13}\text{-CN}$) by the methods described in Scheme 1, equation c) and Scheme 15, equation c).


15 However, a preferred method for preparing tetrazoles is described in Scheme 15, equations a) and b). Compounds (90) may be prepared by the 1,3-dipolar cycloaddition of trialkyltin or triphenyltin azides to the appropriately substituted nitrile (83) as in
20 equation a). Alkyl is defined as normal alkyl of 1-6 carbon atoms and cyclohexyl. An example of this technique is described by S. Kozima, et al.,

J. Organometallic Chemistry, 337 (1971). The required trialkyl or triaryl tin azides are made from the
25 requisite commercial trialkyl or triaryl tin chloride and sodium azide. The trialkyl or triaryl tin group is removed via acidic or basic hydrolysis and the tetrazole can be protected with the trityl group by reaction with trityl chloride and triethylamine to
30 give (91). Bromination as previously described herein with N-bromosuccinimide and dibenzoylperoxide affords compound (92). Alkylation of (1) with the appropriately substituted benzyl halide using conditions previously described followed by
35 deprotection of the trityl group via hydrolysis

83015687

affords (80; R¹³ = tetrazole). Other protecting groups such as p-nitrobenzyl and 1-ethoxyethyl can be used instead of the trityl group to protect the tetrazole moiety. These groups as well as the trityl group can be introduced and removed by procedures described in Greene, Protective Groups in Organic Synthesis, Wiley-Interscience, (1980).



Scheme 15



908

88015687

5/2



Compounds of structure 93-95 where X is an
-O-, -S-, or -N- linkage can be prepared as shown

R²⁶

5 in Scheme 16 by alkylation of imidazole (1) with the
appropriate benzyl halide (96).

Scheme 16

10

15


20

25

30

35


a)




93: X=O
94: X=S
95: X=NR²⁶

910

88015687



97: X=O
98: X=S
99: X=NH
100: X=NR²⁶ (R²⁶≠H)



109: X=O
110: X=S
111: X=NH
112: X=NR²⁶ (R²⁶≠H)

911

88015687

The halomethyldiphenyl ether (109) employed as an alkylating agent in the present invention is prepared as shown in equation b). An Ullman ether condensation of the phenol (97) and a halobenzoic acid as described in Russian Chemical Reviews, 43, 679 (1974) provides the intermediate acid (101). The conversion of (101) into (109) is accomplished by esterification with diazomethane to afford (105) followed by halogenation employing the procedure used in the preparation of (79). The diphenylsulfide (110) and the diphenylamine (111) can be prepared from the appropriate thiophenol (98) or aniline (99) by this procedure.

The tertiary diphenylamine (112) can be prepared from the secondary aniline (100) by the above procedure. Alternatively (107) can be alkylated by one of the following procedures: 1) direct alkylation of (~~107~~¹⁰⁷) with $R^{26}L$ where L is a leaving group such as a halogen or tosylate employing phase-transfer conditions and ultrasound as described in Tetrahedron Letters, 24, 5907 (1983). 2) treatment of (107) with 1-1.5 equivalents of an appropriate aldehyde and 0.5-5.0 equivalents of sodium cyanoborohydride in a solvent such as methanol at 25°C at a pH of 3-6 for 1-24 hours, or 3) reductive amination of (~~107~~¹⁰⁷) employing an appropriate carboxylic acid and sodium borohydride as described in J. Am. Chem. Soc., 96, 7812 (1974). The tertiary amine (108) is then halogenated by the procedure previously described to give (112).


912

88015687


5



10




114: $R^{13} = 2-CO_2CH_3$, $X = \text{halide}$
115: $R^{13} = 2-CO_2CH_3$, $X = H$



73a
113, $R^{13} = 2-CO_2CH_3$

15



20

116

25

30

913

35

88015687

Compounds of structure (72) where X is -CO- are prepared as shown in Scheme 17 by alkylation of imidazole (1) with the requisite benzoylbenzyl halides. For example, esters (113) where R^{13} is 2-CO₂CH₃ are prepared by alkylation of imidazole (1) with carbomethoxybenzoyl benzyl halide (114). Ester (113) may be hydrolyzed to the corresponding carboxylic acid (116) by a variety of methods including hydrolysis with a base such as sodium hydroxide or potassium hydroxide in an alcoholic aqueous solvent such as methanol/H₂O at a temperature from 20°C to the reflux temperature of the solvent.

Carboalkoxybenzoylbenzyl halides (114) are prepared by benzylic halogenation of the corresponding toluoylbenzene precursor by a variety of methods previously described herein. For example, methyl 2-(4-methylbenzoyl)benzoate (115) can be refluxed for 2-48 hours with N-bromosuccinimide, benzoyl peroxide and carbon tetrachloride to effect benzylic bromination.

25


30

914

35

88015687

Scheme 18



NMR (200 MHz, CDCl_3) δ 2.86 (t, 2H, J = 7Hz); 1.77 (t of t, 2H, J = 7.7Hz); 1.41 (t of q, 2H, J = 7.7Hz); 0.98 (t, 3H, J = 7Hz). Anal. Calcd. for $\text{C}_9\text{H}_{10}\text{N}_4$: C, 62.05; H, 5.79; N, 32.16. Found: c, 62.28; H, 5.81; N, 32.22. Mass spectrum shows M-H peak. Mass Calcd. for $\text{C}_9\text{H}_{10}\text{N}_4\text{-H}$: 173.0827. Found: 173.0785.

PART B: Preparation of 2-Butyl-4,5-dicyano-1-(4-nitrobenzyl)imidazole

10 2-n-Butyl-4,5-dicyano-1-(4-nitrobenzyl)imidazole was prepared from 2-n-butyl-4,5-dicyanoimidazole by the procedure in Example 1, Part A using 4-nitrobenzyl bromide as the alkylating agent. The product was obtained as an oil. NMR (200 MHz, CDCl_3) δ 8.29 (d, 2H, J = 10Hz); 7.29 (d, 2H, J = 10Hz); 5.36 (s, 2H); 2.67 (t, 2H, J = 7Hz); 1.70 (t of t, 2H, J = 7.7Hz); 1.36 (t of q, 2H, J = 7.7Hz); 0.86 (t, 3H, J = 7Hz). Mass Calcd. for $\text{C}_{16}\text{H}_{15}\text{N}_5\text{O}_2$: 309.1225. Found: 309.1211.

20

PART C: Preparation of 1-(4-Aminobenzyl)-2-butyl-4,5-dicyanoimidazole

A mixture of 2-butyl-4,5-dicyano-1-(4-nitrobenzyl)imidazole (2.00 g, 6.5 mmol, 1 eq), tin dichloride dihydrate (7.30 g, 32.3 mmol, 5 eq) and ethanol (13 mL) was stirred and heated at 70° for 50 minutes. The reaction was terminated by pouring the mixture onto ice and adjusting the pH to 8 with saturated aqueous NaHCO_3 . The aqueous mixture was extracted with ethyl acetate (3 x 100 mL) and the organic layers were dried (MgSO_4) and concentrated to give a thick amber oil. This oil was flash chromatographed over silica gel in 75:25 to 70:30 hexane/ethyl acetate yielding 330 mg of yellow crystals: m.p. 99.0-103.5°. NMR (200 MHz, CDCl_3) δ 6.97 (d, 2H, J = 10Hz); 6.68 (d, 2H, J =


35

990

88015687


IP

As shown in Scheme 18 the toluoyl ketones (73; where X=CO) may be further transformed into a variety of ketone derivatives including compounds where X is



- Reaction of ketone (73a) with a hydroxylamine or an appropriately substituted hydrazine will give the requisite oximes (117) and hydrazones (118). Reaction with alcohols in the presence of an acidic catalyst with removal of water will give ketals (119). Reduction, with lithium aluminum hydride, a metal borohydride, zinc/acetic acid or catalytic hydrogenation will give the corresponding alcohol (120) or fully reduced methylene compound (121). These alcohols may be acylated by a variety of anhydrides or acid halides in the presence of a base with or without solvent to give the corresponding esters (122). The alcohols (120) may be converted into their corresponding ethers (123) by reaction of the metal alkoxide with an alkyl halide, mesylate or tosylate in the appropriate solvent or by treatment with a mineral acid in an alcoholic solvent, or by reaction of the alcohol with diazomethane G. Hilgetag and A. Martini, "Preparative Organic Chemistry", John Wiley, New York, 355-368 (1972).

Compounds of formula (I) where X is $-\text{OCH}_2-$, $-\text{SCH}_2-$, and $-\text{NHCH}_2-$ are prepared as shown in Scheme 19.



917

88015687

35

62


As illustrated in Scheme 19, equation a,
hydrolysis of benzyl ether (124) or methyl ether (125)
affords hydroxy compound (126) which can be alkylated
with the appropriate benzyl halide to give (127). In
5 the case of the methyl ethers (125), the hydrolysis
step can be effected by heating the ether at tempera-
tures of 50°-150°C for 1-10 hours in 20-60% hydrobromic
acid, or heating at 50°-90°C in acetonitrile with 1-5
equivalents of trimethylsilyl iodide for 10-50 hours
10 followed by treatment with water. Hydrolysis can also
be carried out by treatment with 1-2 equivalents of
boron tribromide in methylene chloride at 10°-30°C for
1-10 hours followed by treatment with water, or by
treatment with an acid such as aluminum chloride and
15 3-30 equivalents of a sulfur-containing compound such
as thiophenol, ethanedithiol, or dimethyl disulfide
in methylene chloride at 0-30°C for 1-20 hours fol-
lowed by treatment with water. For compound (124),
hydrolysis can be accomplished by refluxing in
20 trifluoroacetic acid for 0.2-1 hours or by catalytic
hydrogenolysis in the presence of a suitable catalyst
such as 10% palladium on carbon. Deprotonation of
(126) with a base, such as sodium methoxide, sodium
hydride or the like in a solvent such as dimethyl-
25 formamide or dimethylsulfoxide at room temperature
followed by alkylation with an appropriate benzyl
halide at 25°C for 2-20 hours affords ethers of
formula (127), as shown in equation a.

The sulfide (129) can be prepared from the
30 thiophenol (45) by the procedure described above to
prepare the ether (127) from the phenol (126). The
thiophenol (45) can be prepared for example by
treatment of the benzylsulfide (128) with sodium in
liquid ammonia.

The amine (130) can be prepared as shown in equation 5, from the aniline (51), itself available from reduction of the corresponding p nitro compound (3a) which has previously been described. The reductive amination can be carried out by the same procedure as described in Scheme 13 for the preparation of compound (74).

Compounds of Formula (1) where the X linkage is $-\text{CH}=\text{CH}-$, $-\text{CH}_2\text{CH}_2-$, and Δ are prepared as shown in Scheme 20.

Scheme 20



The cis or trans stilbene (112) can be obtained by employing a Wittig reaction between the aldehyde (57) and the phosphorane (131).

5 The stilbene (132) can readily be converted to the saturated derivative (133) for example by catalytic hydrogenation employing a heterogeneous catalyst such as palladium/carbon or platinum/carbon or alternatively with a homogeneous catalyst such as tris(triphenylphosphine)rhodium chloride. The reduction is performed in
10 a solvent such as benzene, tetrahydrofuran or ethanol at 25°C under 1-3 atmospheres of hydrogen for 1-24 hours.

The cyclopropane (134) can be prepared by treating the stilbene (132) with the Simmons-Smith
15 reagent as described in J. Am. Chem. Soc., 81, 4256 (1959), or by treating (132) with methylene diiodide and copper powder as described in J. Am. Chem. Soc., 101, 2139 (1979), or by treatment with the iron-containing methylene-transfer reagent described
20 in J. Am. Chem. Soc., 101, 6473 (1979).

The preparation of compounds of formula (1) where X is $-\text{CF}_2\text{CH}_2-$, $-\text{CF}-\text{CH}-$, $-\text{CH}-\text{CF}-$, $-\text{CF}-\text{CF}-$ and $-\text{CF}_2\text{CF}_2-$ are depicted in Scheme 21.

25





30

920

35

88015687

68
Scheme 21



30
921

35
88015687

87


Vinylene fluorides (137) and (140) can be prepared by reaction of SF_4 or Et_2NSF_3 (DAST) with the appropriate ketone (135) or (138) in which Ar bears a methyl group convertible to a benzylic halide suitable for attachment to an imidazole nitrogen, and Ar' bears a cyano, nitro, ester, or other suitable group which can be subsequently converted to CO_2H , NHSO_2CF_3 , etc. The initially formed difluoroethylene (136) and (139) can be formed in a non-polar solvent such as methylene chloride and subsequently converted to the vinylene fluoride by means of alumina, or converted directly into the unsaturated fluoride by running the reaction in a polar solvent such as tetrahydrofuran, diglyme or N-methylpyrrolidone in the presence of mineral acid. [Equations a and b]. Experimental details of such procedures are found in D.R. Strobach and G.A. Boswell, J. Org. Chem., **36**, 818 (1971); G.A. Boswell, U.S. Patents 3,413,321 (1968) and 4,212,515 (1980).

As shown in equation c an appropriate benzoin (141) may be similarly converted to the corresponding 1,2-difluorostilbene (143). Likewise as shown in equation d an appropriate benzil (144) can be converted to a tetrafluorodiarylethylene (145) using DAST or SF_4 . Experimental details are described in M.E. Christy, et al., J. Med. Chem., **20**, (3), 421-430, (1977).

R²³

Compounds of formula 1 where X = $-\text{CON}-$, $-\text{CH}_2\text{O}-$, $-\text{CH}_2\text{S}-$, $-\text{CH}_2\text{NH}-$, can be made as shown in Scheme 22.

Scheme 22



923

88015687

As previously described, acid (10) can be made by alkylating the appropriate imidazole with methyl 4-chloromethylbenzoate in the presence of a base such as potassium carbonate in a polar solvent such as dimethylformamide followed by hydrolysis of the resulting ester. Compound (10) can be converted to (148) by reaction with the requisite amine (146) (R^{13} may need to be protected and subsequently deprotected) and dicyclohexyl carbodiimide (DCC) in methylene chloride [J. R. Beek, et al., J. Am. Chem. Soc. **90**, 4706 (1968)] or by reaction with tosyl chloride in pyridine [J. H. Brewster and C. J. Ciotti, Jr., J. Am. Chem. Soc., **77**, 6214 (1955)]. Yet another process involves conversion of carboxylic acid (10) to its acid chloride with, for example, thionyl chloride followed by reaction with the amine in aqueous base (Schotten-Baumann conditions) or in an organic solvent in the presence of an acid scavenger such as NaHCO_3 , pyridine or triethylamine, or by other procedures known to form an amide bond between an aromatic acid and an amine.

The compounds where $X = -\text{CH}_2\text{O}-$, $-\text{CH}_2\text{S}-$, and $-\text{CH}_2\text{NH}_2-$ can be made as shown in pathway b. The ester (149) is reduced with a reducing agent such as lithium aluminum hydride in an inert solvent to form the alcohol (150) which can then be reacted with tosyl chloride in pyridine to form tosylate (151), which is in turn reacted in the presence of base with a corresponding phenol (152) thiophenol (153), or aniline (146; where $R^{23} = \text{H}$) to form compounds (154), (155) or (156). Again this may require that R^{13} be protected with a suitable protecting group, however modifications necessary because of specific functional groups are understood to be incorporated by one skilled in the art of organic synthesis.

Alternatively, the alcohol (150) can be converted to the corresponding halide with SOCl_2 , $(\text{COCl})_2$, etc. and the resulting halide can then be reacted with a phenol, thiophenol or aniline in the presence of base to form the desired compound, where X is $-\text{CH}_2\text{O}-$, $-\text{CH}_2\text{S}-$, $-\text{CH}_2\text{NH}-$ respectively.

10

15

20

25

30



925

35

88015687

72

Scheme 22






926

88015687

78

Compounds of Formula (I) where $X = -SO_2NR^{23}$ and $-NR^{23}SO_2$ may be prepared as shown in Scheme 23. As shown in equation 4, sulfonylchloride derivative (157) can be reacted with aniline derivative (158) in a solvent in the presence of an acid scavenger such as sodium bicarbonate, triethylamine or pyridine or under Schotten-Baumann like conditions to give (159). Sulfonylchloride derivative (157) can be obtained by sulfonation of the corresponding benzyl derivative as described earlier, followed by reaction with PCl_5 or $POCl_3$. Likewise, aniline (74) may be reacted in the same manner as described above with sulfonylchloride derivative (160) to give (161).

Scheme 24 shows the preparation of furan analogs of the biphenyl compounds (80). Thus, α -ketoester (162), W. Wierenga and H. I. Skulnick, J. Org. Chem., 44, 310 (1979), or the corresponding nitrile ($Z-CN$) can be easily alkylated via standard procedures already mentioned by an alkyl bromide derivative to give (163). The alkene moiety of (163) can be subsequently cleaved by oxidation, for example, with osmium tetroxide, Fieser and Fieser, V.1, p. 812 (Lemieux-Johnson oxidation) to yield dicarbonyl-containing compound (164). Cyclization in mineral acids, acidic ion-exchange resin, $POCl_3$ /pyridine, or trifluoroacetic anhydride with a catalytic amount of trifluoroacetic acid yields furan (165; $Z-O$). Reaction of (164) with P_4S_{10} , for example, will yield the corresponding thiophene (165; $Z-S$). Reaction of (164) with an amine in refluxing benzene, with azeotropic removal of water or by using molecular sieves to absorb the water will yield the corresponding pyrrole (165; $Z-NR^{11}$). Compounds (166) may be prepared from (165) by standard procedures already described.




88015687

75

Compounds wherein a methylene group is inserted between the terminal aromatic ring and the acidic functionality may be prepared as shown in Scheme 25, equation a). Thus reduction of ester (167) with, for example, lithium aluminum hydride, gives alcohol (168). Conversion of (168) to the chloride (169) via thionyl chloride followed by reaction with cyanide anion as previously described yields nitrile (170). Compound (170) may be hydrolyzed to carboxylic acid (171) by methods already described or reacted with a hydrazoic acid equivalent to produce tetrazole (172).

Compounds wherein R^{13} is a trifluoromethylsulfonyl hydrazide acidic functional group were prepared by the procedure described in equation b). That is, conversion of ester (167) to the hydrazide (173) by standard hydrazinolysis followed by reaction with triflic anhydride affords hydrazides (174).

Scheme 25



The syntheses of compounds wherein R^{11} is substituted and unsubstituted 1,2,3-triazoles are described in Scheme 26. Thus reduction of ester (175) with a reducing agent such as lithium aluminum hydride or diisobutylaluminum hydride gives alcohol (176). Oxidation with MnO_2 or pyridinium chlorochromate converts (176) into aldehyde (177). Nitroethylene derivative (178) is prepared by condensation of aldehyde (177) with nitromethane in the presence of a catalyst, R. M. Letcher and M. P. Sammes, J. Chem. Ed., 62, 262 (1985). Reaction of (178) with sodium azide produces the 1,2,3-triazole (179). (N. S. Zefirov, et al., J. Chem. Soc. Chem. Comm., 1001 (1971)) which may be transformed via procedures already described into product (180).

Aldehyde (177) can also be converted into substituted 1,2,3-triazoles (183) via the sulfone (181). G. Beck, D. Günther, Chem. Ber., 106, 2758 (1973), followed by reaction with sodium azide to give the 1,2,3-triazole (182). Subsequent standard manipulations lead to 1,2,3-triazoles (183) where $E-CN$ and CO_2R^{11} . The nitrotriazole (183; $E-NO_2$) may be synthesized from the unprotected triazole (179; $P-H$) via nitration, R. Hüttel, et al., Chem. Ber., 88, 1586 (1955). C. L. Habraken and P. Cohen-Fernandes J. Chem. Soc., 37 (1972), or from bromonitroethylene derivative (184). G. Kh. Khisamutdinov, et al., Zh. Org. Khim., 11, 2445 (1975), by reaction with sodium azide.

A variety of protecting groups may be used in the manipulation of the above triazoles, amongst which is the trityl group. This group may be easily attached by reaction of the triazole with triphenylmethyl bromide or chloride in an inert solvent such as methylene chloride in the presence of an acid scavenger such as triethyl amine. The trityl

group may be later removed by stirring or refluxing in an acidic medium such as trifluoroacetic acid/water, HCl in methylene chloride, or acetic acid/water. The trityl group may also be hydrogenolyzed using a noble metal catalyst such as palladium and hydrogen.

10

15

20

25


30

932

35

88015687

22



p-protecting group

88015687

The synthesis of trifluoromethyl-1,2,4-triazoles (190) is depicted in Scheme 27. Acid chloride (186) is converted to amide (187) using standard procedures familiar to one skilled in the art. A preferred protecting group is the 2-propionitrile group ($P-CH_2CH_2CN$). Thus (187: $P-CH_2CH_2CN$) can be synthesized from (186) and *N*-aminopropionitrile under Schotten-Baumann like conditions, using aqueous base in an organic solvent to help solubilize (186) and (187). Amide (187) is converted to amidrazone (188) by reaction with PCl_5 or phosgene to make an iminoyl chloride which then in turn is reacted with excess hydrazine. Amidrazone (188) is cyclized to the trifluoromethyl-1,2,4-triazole (189) with trifluoroacetic anhydride and then converted to 190 via bromination, alkylation and deprotection as previously described.

20


25

30

934

35

88015687



935

88015687

Pertinent R⁶ groups may be variously introduced by many procedures including those described in Scheme 28 which describes imidazole construction.

The R⁶ groups so introduced may stand unchanged
5 or may be further elaborated if appropriately functionalized, according to methods familiar to those skilled in the art such as are illustrated in Scheme 28.

10

15

20

25


30

- 936

35

88015687

Scheme 20



937

88015687

5

10

1
B L A N K

P A G E

15

20

25

30

- 938

35

88015687

5

10

B L A N K

P A G E

15

20

25

30

- 939

35

88015687

The 2-alkenylimidazoles (201) can be prepared by bromination of the 2-alkylimidazoles (199) followed by elimination of hydrogen bromide. The bromization is preferably accomplished by UV-irradiation for 1-4 hours of imadoyole (199) and N-bromosuccinimide, in an inert solvent, such as carbon tetrachloride at 25°C. Treatment of the intermediate bromide (200) with a base, such as DBU, triethylamine, or potassium t-butoxide, affords the trans 2-alkenylimidazoles (201). Cis alkenyl derivatives (201) are prepared from the trans alkenyl compounds by treatment with osmium tetroxide and sodium periodate to afford aldehydes (202) followed by Wittig reaction.

15

20

25


30

- 940

35

88015687

Scheme 29



88015687

Alternatively, R^6 groups may be introduced by metallation of a protected imidazole or protected 2-methylimidazole followed by addition of an appropriate electrophile as illustrated in Scheme 30.

5 equations a) and b). The products (alcohols, esters, halides, aldehydes, alkyls) are suitable for further elaboration by methods familiar to those skilled in the art. Metallation of imidazoles is described in K.L. Kirk, J. Org. Chem., 43, 4381 (1978); R.J. Sundberg, J. Het. Chem., 14, 517 (1977); J.V. Hay et al., J. Org. Chem., 38, 4379 (1973); B. Iddon, Heterocycles, 23, 417 (1985).

10 Condensation of 2-methylimidazole and appropriate electrophiles (equation b) with catalytic acid or base as described in A.R. Katritzky (Ed.), "Comprehensive Heterocyclic Chemistry", Vol. 5, p. 431, Pergamon Press, N.Y., 1984 affords products wherein R_6 is alkenyl which are suitable for further elaboration.

20



25

30

942


35

88015687



Various 2-substituted imidazoles can be prepared by reaction of a protected 2-trimethylsilylimidazole with a suitable electrophile by the method described by F.H. Pinkerton and S.F. Thames, J. Med. Chem., **2**, 67 (1972), which can be further elaborated as desired. Alternatively, R⁶ may also be introduced by nickel catalyzed cross-coupling of Grignard reagents with 2-(methylthio)imidazoles (Scheme 31) as described by E. Wenkert and T.W. Ferreira, J. Chem. Soc., Chem. Commun., 840, (1982); E. Wenkert et al., J. Chem. Soc., Chem. Commun., 637, (1979); and H. Sugimura and H. Takei, Bull. Chem. Soc. Japan, **58**, 664 (1985). The 2-(methylthio)imidazoles can be produced by the procedure described in German Patent No. 2,618,370 and the references cited therein.

Scheme 31



944


88015687

92

As shown in Schemes 32-35, elaboration of R^0 can be accomplished by procedures described in Schemes 2, 28 and 30b and by chain extension reactions familiar to those skilled in the art in which R^0 bears a reactive terminal functional group, e.g. -OH, halogen, -CHO, -CO₂R, -CO₂H, -CH=CH₂, -NH₂, -NO₂, -CN, -C-NH, OR

etc., or by degradation reactions such as conversion of an ester to an acid or an alkene to an aldehyde.

Specifically, the hydroxymethyl group can be activated for the displacement reaction by reacting with thionyl chloride, PCl₅ or with carbon tetrachloride/triphenylphosphine to form a corresponding chloro derivative. By a similar reaction bromo and iodo derivatives can be obtained. The hydroxymethyl group can also be activated by forming the corresponding p-toluenesulfonate, methanesulfonate and trifluoromethane sulfonate derivatives. The hydroxyl group can be converted to its corresponding fluoro compound by various fluorinating agents such as DAST as shown in Scheme 32.




Also as shown in Scheme 32, the hydroxyl group can be converted to thiolacetic acid derivative (215). J. Y. Gauthier, Tet. Lett., 15 (1986), and to thiol derivative (216) by subsequent hydrolysis.

5 The hydroxymethyl group on compound (17) can be readily oxidized to an aldehyde group by means of manganese dioxide or ceric ammonium nitrate. The aldehyde group will undergo chain extension reactions such as the Wittig and Wittig-Horner reactions and
10 enter into typical carbon-carbon bond forming reactions with Grignard and lithium reagents as well as with compounds bearing activated methylene groups. Alternatively, the hydroxymethyl group can be oxidized directly to an acid functionality which can in turn be
15 converted to ester and amide derivatives. The esters and amides can be prepared directly from the aldehydes by manganese dioxide oxidation in the presence of sodium cyanide and an alcohol or amine, J. Am. Chem. Soc., 90, 5616 (1968) and J. Chem. Soc. (C), 2355
20 (1971).


 As shown in Scheme 33, the chlorine on compound (25) can be displaced by the anion of dialkyl malonate to give the corresponding malonate derivative (217). The saponification of (217) with NaOH (or KOH) gives
25 the corresponding diacid which can be decarboxylated to give the corresponding propionic acid derivative (218) by heating to 120°C. Alternatively, (218) can be directly obtained by refluxing (217) with a mineral acid such as HCl or sulfuric acid. The free acid (218)
30 can be esterified by heating in a medium of the various alcohols and a catalytic amount of mineral acids such as HCl or sulfuric acid to give the corresponding esters (219). Alternatively the esters can be obtained by reacting the free acid (218) and the
35


corresponding alcohols in the presence of coupling reagents such as DDO or EDO. A similar reaction with various mono-substituted and disubstituted amines produces the corresponding amides (220). A similar reaction with various mercaptans produces the corresponding thioesters.

Scheme 33




As shown in Scheme 34, the chloro group on (25) can be displaced by the sodium salt or potassium salt of the alkyl, aryl or arylalkyl mercaptans to give the corresponding sulfide derivatives (221). The amine derivative (222) can be obtained by treating (25) with ammonia or with the corresponding mono-substituted amines. Alternatively, the chloro group may be displaced by sodium azide to give an azide intermediate which upon reduction with H_2 over a noble metal catalyst or with a reducing agent such as chromous chloride (W. K. Warburton, J. Chem. Soc., 2651 (1961)) yields (222) where R^{10} and R^{11} are hydrogen. This amine can be subsequently alkylated with alkyl halides, or reductively alkylated with aldehydes and ketones to give alkyl derivatives of (222). The amines (222) are converted to the corresponding carbamates (224), sulfonamides (225), amides (226) or ureas (227) by standard procedures illustrated in Scheme 34 and familiar to one skilled in the art. The nitro compound (223) can be obtained by the treatment of (25) with sodium nitrite or potassium nitrite. The nitrate (228) may be synthesized by treatment of (25) with $AgNO_3$. A. F. Ferris, et al., J. Am. Chem. Soc., 75, 4078 (1953).





15 The reaction between the thiopyridyl ester (229) and a suitable Grignard reagent produces the ketones (230).

Scheme 35



30 The compounds of this invention and their preparation can be understood further by the following examples, which do not constitute a limitation of the invention. In these examples, unless otherwise indicated, all temperatures are in degrees centigrade

35 and parts and percentages are by weight.

Example 1**PART A: Preparation of 2-Butyl-4-chloro-1-(4-cyanobenzyl)-5-hydroxymethylimidazole**

To a solution of 2-butyl-4-chloro-5-hydroxymethylimidazole (prepared as described in U.S. 4,355,040; 3.56 g, 40 mmol, 1 eq) in 300 mL methanol was added dropwise a freshly prepared sodium methoxide solution (0.92 g Na, 40 mmol, 1 eq, in 30 mL MeOH). After stirring for 0.5 hours, the methanol was removed in vacuo and the resultant glass was dissolved in 100 mL DMF. To this mixture was added a solution of α -bromo-p-tolunitrile (8.60 g, 44 mmol, 1.1 eq) in DMF and the entire contents stirred overnight under N_2 at room temperature. The solvent was then removed in vacuo and the residue dissolved in 300 mL ethyl acetate and 300 mL H_2O . The layers were separated and the aqueous layer was extracted twice with 300 mL portions of ethyl acetate. The organic layers were dried and evaporated and the crude product flash chromatographed over silica gel in 1:1 hexane/ethyl acetate to give 6.83 g of one regioisomer as a white solid; m.p. 92.5-98.0°. NMR (200 MHz, $CDCl_3$) δ 7.65 (d, 2H, J = 8Hz); 7.13 (d, 2H, J = 8Hz); 5.30 (s, 2H); 4.46 (s, 2H); 2.49 (t, 2H, J = 7Hz); 1.59 (m, 2H); 1.28 (m, 2H); 0.84 (t, 3H, J = 7Hz). Mass Calcd. for $C_{16}H_{18}N_3OCl$: 303.1138. Found: 303.1124.

Continued elution gave 3.56 g of the second regioisomer as a white solid, listed below as the first entry in Table 1.


The intermediates shown below were prepared or could be prepared in accordance with the procedure described in Example 1, Part A using the appropriately substituted imidazole and benzyl halide as starting material.

35

- 952

88015687

100



5

	<u>R¹</u>	<u>R⁶</u>	<u>R⁷</u>	<u>R⁸</u>	<u>MP (°C)</u>
10	4-CN	n-butyl	CH ₂ OH	Cl	98.0-100.0
	4-NO ₂	n-butyl	Cl	CH ₂ OH	56.8- 59.5
	4-NO ₂	n-butyl	CH ₂ OH	Cl	114.5-116.5
	2-CN	n-butyl	Cl	CH ₂ OH	93.0- 95.5

15 **PART B: Preparation of 2-Butyl-4-chloro-1-(4-cyanobenzyl)-5-cyanomethylimidazole**

Thionyl chloride (3.60 mL, 49 mmol, 5 eq) was slowly dripped into a solution of 2-butyl-4-chloro-1-(4-cyanobenzyl)-5-hydroxymethylimidazole (3.0 g, 9.9 mmol, 1 eq) in a minimum of CHCl₃. The mixture was stirred for 2 hours at room temperature after which the solvent was removed in vacuo and the residue suspended in toluene (200 mL). The toluene was removed on the rotary evaporator and this procedure was repeated again to remove all traces of thionyl chloride. The chloride was then dissolved in DMSO (minimum to dissolve) and added to a solution of sodium cyanide (2.90 g, 59 mmol, 6 eq) in DMSO (200 mL). The solution was stirred overnight under N₂ at room temperature after which 500 mL H₂O was added and the aqueous layer was extracted three times with 300 mL of ethyl acetate. The organic layers were dried and concentrated and the residue flash chromatographed in 4:1 hexane/ethyl acetate over silica gel to give 1.62 g of a light yellow solid; m.p. 109.5-113.0° NMR (200 MHz, CDCl₃) δ 7.70 (d, 2H, J = 10Hz); 7.12 (d, 2H, J = 10Hz); 3.51

35


- 953 88015687

289

(s, 2H); 2.60 (t, 2H, J = 7Hz); 1.70 (m, 2H); 1.40 (m, 2H); 0.90 (t, 3H, J = 7Hz). Mass spectrum shows M⁺ 312/314. Mass Calcd. for C₁₇H₁₇ClN₄: 312.1139. Found 312.1126.

5 The intermediates shown below were prepared, or could be prepared, in accordance with the procedure described in Example 1, Part B using the appropriately substituted imidazole and benzyl halide as starting material.

10



15

<u>R¹</u>	<u>R⁶</u>	<u>R⁷</u>	<u>R⁸</u>	<u>MP(°C)</u>
4-CN	n-butyl	CH ₂ CN	Cl	(oil) ^a
4-NO ₂	n-butyl	Cl	CH ₂ CN	117.0-119
4-NO ₂	n-butyl	CH ₂ CN	Cl	(oil) ^b
2-CN	n-butyl	Cl	CH ₂ CN	(oil) ^c
3-CN	n-butyl	Cl	CH ₂ CN	(oil) ^d

25

a NMR (200 MHz, CDCl₃) δ 7.66 (d, 2H, J = 7Hz); 7.12 (d, 2H, J = 7Hz); 5.15 (s, 2H); 3.69 (s, 2H); 2.56 (t, 2H, J = 7Hz); 1.62 (t of t, 2H, J = 7.7Hz); 1.33 (t of q, 2H, J = 7.7Hz); 0.87 (t, 3H, J = 7Hz).

30

b NMR (200 MHz, CDCl₃) δ 8.24 (d, 2H, J = 10Hz); 7.18 (d, 2H, J = 10Hz); 5.20 (s, 2H); 3.67 (s, 2H); 2.55 (t, 2H, J = 7Hz); 1.64 (m, 2H); 1.34 (m, 2H); 0.85 (t, 3H, J = 7Hz).

35

954 88015687

5 NMR (200 MHz, CDCl₃) δ 7.66 (d of d, 1H, J = 10.10 Hz); 7.63 (d of d, 1H, J = 10.10 Hz); 6.74 (d, 1H, J = 10 Hz); 5.37 (s, 2H); 3.64 (s, 2H); 2.55 (t, 2H, J = 7 Hz); 1.67 (m, 2H); 1.34 (m, 2H); 0.85 (t, 3H, J = 7 Hz).
 10 δ NMR (200 MHz, CDCl₃) δ 7.66 (d, 1H, J = 7 Hz); 7.54 (d of d, 1H, J = 7.7 Hz); 7.33 (s, 1H); 7.25 (d, 1H, J = 7 Hz); 5.25 (s, 2H); 3.55 (s, 2H); 2.61 (t, 2H, J = 7 Hz); 1.69 (m, 2H); 1.35 (m, 2H); 0.91 (t, 3H, J = 7 Hz).

PART C: Preparation of 2-Butyl-1-(4-carboxybenzyl)-
4-chloroimidazole-5-acetic acid

15 2-Butyl-4-chloro-1-(4-cyanobenzyl)-5-(cyano-
 methyl)imidazole (0.5 g) and a solution of 1:1 12 N
 HCl/glacial acetic acid (10 mL) were mixed and
 refluxed for 6 hours. The solvents were removed by
 rotary evaporation and the resultant solids were
 20 washed with isopropanol, and filtered. The mother-
 liquor was flash chromatographed on silica gel in 1:1
 hexane/ethyl acetate to give 60 mg of product. Further
 flushing of the column with isopropanol followed by
 preparatory TLC of the evaporated residue gave an
 25 additional 100 mg of product. NMR (200 MHz,
 DMSO-d₆) δ 7.90 (d, 2H, J = 8 Hz); 7.12 (d, 2H, J =
 8 Hz); 5.30 (s, 2H); 3.08 (s, 2H); 2.50 (t, 2H, J =
 7 Hz); 1.49 (m, 2H); 1.24 (m, 2H); 0.79 (t, 3H, J =
 7 Hz). Mass. Calcd. for C₁₃H₁₉ClN₂O₄:
 30 350.1033. Found 350.1066.

Example 2

PART A: Preparation of 2-Butyl-4-chloro-1-(4-nitrobenzyl)imidazole-5-acetic acid

5 2-Butyl-4-chloro-5-(cyanomethyl)-1-(4-nitrobenzyl)imidazole (7.08 g) and a 1:1 mixture of 12 N HCl and glacial acetic acid (175 mL) were mixed and refluxed for 6 hours. The solvents were removed by rotary evaporation and water (300 mL) was then added to the residue. After a few minutes, the product
10 precipitated and was collected and dried to give 7.35 g of a solid; m.p. 207.0-210.0°. NMR (200 MHz, DMSO- d_6 /CDCl $_3$) δ 8.20 (d, 2H, J= 10Hz); 7.22 (d, 2H, J= 10Hz); 5.28 (s, 2H); 3.42 (s, 2H); 2.52 (t, 2H, J= 7Hz); 1.64 (m, 2H); 1.34 (m, 2H); 0.86 (t, 3H, J= 7Hz). Anal. Calcd. for C $_{16}$ H $_{18}$ ClN $_3$ O $_4$: C, 54.63; H, 5.16; N, 11.94. Found: C, 54.52; H, 5.05; N, 12.21.

PART B: Preparation of Methyl 2-butyl-4-chloro-1-(4-nitrobenzyl)imidazole-5-acetate

20 2-Butyl-4-chloro-1-(4-nitrobenzyl)imidazole-5-acetic acid (7.35 g, 20.9 mmol, 1eq); 3.1M HCl in dioxane (34.0 mL, 105.4 mmol, 5 eq) and 100 mL methanol were mixed and refluxed for 7.5 hours. The solvents were removed by rotary evaporation and the
25 residue taken up in methylene chloride and 1 N NaOH (300 mL each). The layers were separated and the organic layer washed two more times with 1N NaOH (300 mL each), dried and concentrated to give 5.43 g of a light pink solid; m.p. 97.5-100.0°. NMR (200
30 MHz, DMSO- d_6) δ 8.23 (d, 2H, J= 9Hz); 7.33 (d, 2H, J= 9Hz); 5.50 (s, 2H); 3.73 (s, 2H); 3.40 (s, 3H); 2.66 (t, 2H, J= 7Hz); 1.53 (m, 2H); 1.22 (m, 2H); 0.76 (t, 3H, J= 7Hz). Mass Calcd. for C $_{17}$ H $_{20}$ N $_3$ O $_4$ Cl: 365.1140. Found: 365.1158.

35

956

88015687

Methyl 2-butyl-5-chloro-1-(4-nitrobenzyl)-
imidazole-5-acetate was also prepared by the procedure
described in Example 2 Part B from 2-butyl-5-chloro-
1-(4-nitrobenzyl)imidazole-5-acetic acid. NMR (200
5 MHz, CDCl_3) δ 8.23 (d, 2H, J= 10Hz); 7.20 (d, 2H,
J= 10Hz); 5.21 (s, 2H); 3.75 (s, 3H); 3.67 (s, 2H);
2.58 (t of t, 2H, J= 7Hz); 1.32 (q of t, 2H, J= 7Hz);
0.86 (t, 3H, J= 7Hz). Mass Calcd. for $\text{C}_{17}\text{H}_{20}\text{ClN}_3\text{O}_4$:
365.1142. Found 365.1132.


10
PART C: Methyl 2-butyl-4-chloro-1-(4-aminobenzyl)-
imidazole-5-acetate

A mixture of methyl 2-butyl-4-chloro-1-(4-nitro-
benzyl)imidazole-5-acetate (5.00 g, 13.7 mmol, 1 eq),
15 iron (2.67 g, 47.8 mmol, 3.5 eq), glacial acetic acid
(5.47 mL, 95.3 mmol, 7 eq), and methanol (250 mL) was
refluxed for 5.5 hours. The solvent was removed by
rotary evaporation. The residue was diluted with
water (300 mL) and extracted five times with 300 mL
20 portions of ethyl acetate. The organic layers were
dried and concentrated. The residue was flash
chromatographed in 75:25 hexane/ethyl acetate over
silica gel to give 4.53 g of a golden yellow oil which
crystallized after standing for several days. NMR
25 (200 MHz, CDCl_3) δ 6.72 (d, 2H, J= 7Hz); 6.60 (d, 2H,
J= 7Hz); 4.99 (s, 2H); 3.61 (s, 3H); 3.47 (s, 2H);
2.60 (t, 2H, J= 7Hz); 1.68 (m, 2H); 1.35 (m, 2H); 0.86
(t, 3H, J= 7Hz). Mass spectrum shows M^+ = 335/337.
Mass Calcd. for $\text{C}_{17}\text{H}_{22}\text{N}_3\text{O}_2\text{Cl}$: 335.1400. Found:
30 335.1407.

The following intermediates were prepared by the
procedure described in Example 2, Part C from the
corresponding nitro intermediates:

35 - 957

88015687



	<u>R¹</u>	<u>R⁶</u>	<u>R⁷</u>	<u>R⁸</u>	<u>MP(°C)</u>
10	4-NH ₂	n-butyl	CH ₂ CO ₂ CH ₃	Cl	(oil) ^a
	4-NH ₂	n-butyl	Cl	OCOCH ₃	(oil) ^b
	4-NH ₂	n-butyl	Cl	CH ₂ OH	(oil) ^c
15	a NMR (200 MHz, CDCl ₃) δ 6.85 (d, 2H, J= 7Hz); 6.63 (d, 2H, J= 7Hz); 4.95 (s, 2H); 3.69 (s, 3H); 2.57 (t, 2H, J= 7Hz); 1.59 (t of t, 2H, J= 7.7Hz); 1.30 (t of q, 2H, J= 7.7Hz); 0.86 (t, 3H, J= 7Hz).				
20	b NMR (200 MHz, CDCl ₃) δ 6.74 (d, 2H, J= 10Hz); 6.60 (d, 2H, J= 10Hz); 4.97 (s, 2H); 4.95 (s, 2H); 3.56 (t, 2H, J= 7Hz); 1.86 (s, 3H); 1.64 (t of t, 2H, J= 7.7Hz); 1.33 (t of q, 2H, J= 7.7Hz); 0.85 (t, 3H, J= 7Hz).				
25	c NMR (200 MHz, CDCl ₃) δ 6.80 (d, 2H, J= 10Hz); 6.69 (d, 2H, J= 10Hz); 5.05 (s, 2H); 4.43 (s, 2H); 2.56 (t, 2H, J= 7Hz); 1.56 (t of t, 2H, J= 7.7Hz); 1.26 (t of q, 2H, J= 7.7Hz); 0.83 (t, 3H, J= 7Hz).				

30

958

35

88015687

105

PART D: Preparation of Methyl 2-butyl-1-[4-(2-carboxybenzamido)benzyl]-4-chloro-imidazole-5-acetate

- A chloroform solution (10 mL) of methyl 2-butyl-4-chloro-1-(4-aminobenzyl)imidazole-5-acetate (500 mg, 1.5 mmol, 1 eq) was mixed with a chloroform solution (10 mL) of phthalic anhydride (221 mg, 1.5 mmol, 1 eq). After five minutes of stirring at room temperature, product began to precipitate. After 24 hours, the product was filtered, washed with a minimum amount of CHCl_3 and dried to give 400 mg of a white solid. After some evaporation, the mother liquor yielded an additional 220 mg of product, both of which had identical melting points: m.p. 109.5 - 112.5°. NMR (200 MHz, $\text{DMSO}-d_6$) δ 10.37 (s, 1H); 7.85 (d, 2H, $J = 8\text{ Hz}$); 7.71-7.50 (m, 5H); 6.96 (d, 2H, $J = 10\text{ Hz}$); 5.12 (s, 2H); 3.60 (s, 2H); 3.49 (s, 3H); 2.55 t, 2, $J = 7\text{ Hz}$); 1.52 (m, 2H); 1.27 (m, 2H); 0.83 (t, 3H, $J = 7\text{ Hz}$). The carboxylic acid could be titrated with 1.000 N NaOH to form the sodium salt. High resolution mass spectrum shows M-18 (loss of H_2O). Calcd. Mass for $\text{C}_{25}\text{H}_{26}\text{ClN}_3\text{O}_5$: 465.1455. Found: 465.1440.

Example 3

- PART A: Preparation of 2-Butyl-5-chloro-1-(4-nitrobenzyl)imidazole-4-acetic acid

- 2-Butyl-5-chloro-4-cyanomethyl-1-(4-nitrobenzyl)imidazole (4.48 g) was converted to the corresponding carboxylic acid by the procedure described in Example 2, Part A. No product precipitated upon the addition of water (300 mL) until the pH was raised to about 3 with conc. ammonium hydroxide to liberate the imidazole from its HCl salt. The precipitated solids were amorphous and ethyl acetate (5 x 300 mL) was used to extract the product. The organic layers were dried

and concentrated to give 3.93 g of a yellow solid. Recrystallization from hexane/ethyl acetate gave 3.06 g of a white solid: m.p. = 138.0-139.5°. NMR (200 MHz, CDCl_3) δ 8.25 (d, 2H, J = 10Hz); 7.21 (d, 2H, J = 10Hz); 5.23 (s, 2H); 3.30 (s, 2H); 2.63 (t, 2H, J = 7Hz); 1.63 (t of t, 2H, J = 7.7Hz); 1.32 (t of q, 2H, J = 7.7Hz); 0.87 (t, 3H, J = 7Hz). Anal. Calcd. for $\text{C}_{16}\text{H}_{18}\text{ClN}_3\text{O}_4$: C, 54.63; H, 5.16; N, 11.94. Found: C, 54.75; H, 5.29; N, 12.14.

10

PART B: Preparation of Methyl 2-butyl-1-[4-(2-carboxybenzamido)benzyl]-5-chloro-imidazole-4-acetate

2-Butyl-5-chloro-1-(4-nitrobenzyl)imidazole-4-acetic acid (Part A) was carried on to methyl 2-butyl-1-[4-(2-carboxybenzamido)benzyl]-5-chloroimidazole-4-acetate: m.p. 150.5-152.5° by the procedure described in Example 2. NMR (200 MHz, $\text{DMSO}-d_6$) δ 13.00 (bs, 1H); 10.40 (s, 1H); 7.87 (d, 1H, J = 8Hz); 7.67 (d, 2H, J = 8Hz); 7.71-7.52 (m, 3H); 7.02 (d, 2H, J = 8Hz); 5.13 (s, 2H); 3.61 (s, 3H); 3.52 (s, 2H); 2.59 (t, 2H, J = 7Hz); 2.53 (t of t, 2H, J = 7.7Hz); 1.28 (t of q, 2H, J = 7.7Hz); 0.82 (t, 3H, J = 7Hz). Mass Calcd. for $\text{C}_{25}\text{H}_{26}\text{ClN}_3\text{O}_5 \cdot \text{H}_2\text{O}$: 465.1455. Found, 465.1460.

25

Example 4

PART A: Preparation of 2-n-Butyl-4-chloro-5-methoxymethyl-1-(4-nitrobenzyl)imidazole

2-n-butyl-4-chloro-5-hydroxymethyl-1-(4-nitrobenzyl)imidazole (10.5 g, 32.4 mmol, 1 eq), conc. sulfuric acid (26 mL) and methanol (300 mL) were mixed and refluxed overnight. The solvent was removed in vacuo and the residue taken up in water (about 300 mL). The pH was adjusted to 5 with 1N NaOH and then this aqueous portion extracted with ethyl acetate

960

88015687

127

(3 x 250 mL). The organic layers were collected, dried (MgSO_4) and the solvent removed in vacuo to yield 11.57 g of an amber oil. NMR (200 MHz, CDCl_3) δ 8.22 (d, 2H, J = 8 Hz); 7.15 (d, 2H, J = 8 Hz); 5.26 (s, 2H); 4.25 (s, 2H); 3.23 (s, 3H); 2.52 (t, 2H, J = 7 Hz); 1.64 (t of t, 2H, J = 7.7 Hz); 1.28 (t of q, 2H, J = 7.7 Hz); 0.81 (t, 3H, J = 7 Hz). Anal. Calcd. for $\text{C}_{16}\text{H}_{20}\text{ClN}_3\text{O}_3 \cdot (\text{H}_2\text{O})_{0.5}$: C, 55.41; H, 6.10; Cl, 10.22. Found: C, 55.21; H, 6.22; Cl, 9.92.

10

PART B: Preparation of 1-(4-Aminobenzyl)-2-n-butyl-4-chloro-5-(methoxymethyl)imidazole

To a solution of 2-n-butyl-4-chloro-5-methoxymethyl-1-(4-nitrobenzyl)imidazole (11.22 g) in methanol (100 mL) under N_2 was carefully added 1.0 g of 10% palladium on charcoal. Hydrogen gas was then bubbled through the solution for 4 hours. The solution was filtered through Celite® and the solvent removed in vacuo to yield 9.23 g of an amber oil. NMR (200 MHz, CDCl_3) δ 7.99 (s, 1H); 6.78 (d of d, 4H, J = 5.5 Hz); 5.05 (s, 2H); 4.24 (s, 2H); 3.27 (s, 3H); 2.59 (t, 2H, J = 7 Hz); 1.62 (t of t, 2H, J = 7.7 Hz); 1.32 (t of q, 2H, J = 7.7 Hz); 0.84 (t, 3H, J = 7 Hz). Mass Calcd. for $\text{C}_{16}\text{H}_{23}\text{ClN}_3\text{O}$: 307.1451. Found: 307.1460.

25

PART C: Preparation of 2-Butyl-1-[4-(2-carboxybenzamido)benzyl]-4-chloro-5-(methoxymethyl)imidazole


The above compound was prepared from 1-(4-aminobenzyl)-2-n-butyl-4-chloro-5-(methoxymethyl)imidazole (3.00 g, 9.7 mmol, 1 eq) and phthalic anhydride (1.44 g, 9.7 mmol, 1 eq) using the procedure of Example 2, Part D. Work-up yielded 1.71 g of an off-white powder, which was washed with acetonitrile.

35

The insoluble material was filtered and dried to yield 1.17 g of a white powder; m.p. 165.5-166.5°C. NMR (200 MHz, DMSO- d_6) δ 13.01 (m, 1H); 10.39 (s, 1H); 7.87 (d, 1H, J = 7Hz); 7.75-7.66 (m, 5H); 7.03 (d, 2H, J = 8Hz); 5.16 (s, 2H); 4.30 (s, 2H); 3.20 (s, 3H); 2.54 (t, 2H, J = 7Hz); 1.54 (t of t, 2H, J = 7.7Hz); 1.30 (t of q, 2H, J = 7.7Hz); 0.83 (t, 3H, J = 7Hz). Anal. Calcd. for $C_{24}H_{26}ClN_3O_4$: C, 63.22; H, 5.75; Cl, 7.78. Found: C, 63.54; H, 5.76; Cl, 7.58.

Examples 5-18 shown in Table 1 were prepared or could be prepared by the procedures described in Examples 2-4 from the appropriately substituted aniline derivative and a suitable anhydride or acid chloride. Other solvents, such as benzene or ethyl acetate may be substituted for chloroform.

Table 1



10

Ex. No.	R	R ⁶	R ⁷	R ⁸	MP (°C)
5		n-butyl	Cl	CH ₂ CO ₂ CH ₃	(oil) ^a
6		n-butyl	Cl	CH ₂ CO ₂ CH ₃	138.0-141.0
7		n-butyl	Cl	CH ₂ CO ₂ CH ₃	184.0-186.0
8		n-butyl	Cl	CH ₂ CO ₂ CH ₃	169.0-170.5
9		n-butyl	Cl	CH ₂ CO ₂ CH ₃	172.0-173.5

963

88015687

END

Table 3 (cont'd.)

Ex. No.	R	R ⁶	R ⁷	R ⁸	MP(°C)	
5	10		n-butyl	Cl	$\text{CH}_2\text{OC}(=\text{O})\text{CH}_3$	140.0-144.5
10	11		n-butyl	Cl	$\text{CH}_2\text{CO}_2\text{CH}_3$	129-131
15	12		n-butyl	Cl	$\text{CH}_2\text{CO}_2\text{CH}_3$	119-121
20	13		n-butyl	Cl	$\text{CH}_2\text{CO}_2\text{CH}_3$	148-151
25	14		n-butyl	Cl	$\text{CH}_2\text{CO}_2\text{CH}_3$	159-160
30	15		n-butyl	Cl	$\text{CH}_2\text{CO}_2\text{CH}_3$	175-176
35						

98015687

88015687


Ex.
No. 8

R⁶


R⁷

R⁸


MP(°C)



n-butyl Cl CH₂CO₂CH₃ 199.0-200.0



n-butyl Cl CH₂OCH₃ 173.5-177.0



n-butyl Cl CH₂CO₂CH₃ 151-153

20

a NMR (200 MHz, CDCl₃) δ 9.48 (bs, 1H); 7.87-7.61 (m, 2H); 7.5-7.04 (m, 5H); 6.9 (d, 2H, J = 9Hz); 4.98 (s, 2H); 3.45 (s, 3H); 3.40 (s, 2H); 2.56 (m, 2H); 1.48 (m, 2H); 1.26 (m, 2H); 0.72 (t, 3H, J = 7Hz).

Example 19

25 Preparation of 2-Butyl-4-chloro-5-hydroxymethyl-1-(4-carboxybenzyl)imidazole

The title compound was prepared from 2-butyl-4-chloro-5-hydroxymethyl-1-(4-cyanobenzyl)imidazole by the method described in Example 2, Part A. NMR (200 MHz, CDCl₃ + DMSO d₆) δ 7.96 (d, 2H, J = 8Hz); 7.13 (d, 2H, J = 8Hz); 5.33 (s, 2H); 4.40 (s, 2H); 2.50 (t, 2H, J = 7Hz); 1.57 (t of t, 2H, J = 7.7Hz); 1.27 (t of q, 2H, J = 7.7Hz); 0.85 (t, 3H, J = 7Hz).

35 - 965

88015687

Example 20

Preparation of 5-Acetoxyethyl-2-butyl-1-(4-carboxybenzyl)-4-chloroimidazole

2-Butyl-1-(4-carboxybenzyl)-4-chloro-5-(hydroxy-
5 methyl)imidazole (2.00 g, 6.2 mmol, 1 eq), acetic
anhydride (1.46 mL, 15.5 mmol, 2.5 eq), triethylamine
(2.59 mL, 18.6 mmol, 3 eq) and THF (50 mL) were mixed
and stirred for 3 days. Water (200 mL) was added to
the solution and the mixture was stirred for 0.5
10 hours. The pH was lowered to 5 with conc. HCl and
the mixture extracted with ethyl acetate (3 x 100 mL).
The organic layers were dried (MgSO_4) and concentrated
to give 2.47 g of a brown oil. This product (2.16 g)
was dissolved in a minimum of ethyl acetate and
15 dicyclohexylamine (DCHA) (1.18 mL, 1 eq) was added and
mixed. The solution was allowed to slowly evaporate
overnight. The DCHA salt so obtained (1.43 g) was
subsequently taken up in ethyl acetate (100 mL) and
washed with 1 N HCl (3 x 100 mL), followed by brine.
20 The organic layer was dried (MgSO_4) and concentrated
to give a yellow oil (670 mg). NMR (200 MHz, CDCl_3)
 δ 8.09 (d, 2H, J = 10Hz); 7.05 (d, 2H, J = 10Hz); 5.20
(s, 2H); 4.98 (s, 2H); 2.58 (t, 2H, J = 7Hz); 1.82 (t of
t, 2H, J = 7.7Hz); 1.33 (t of q, 2H, J = 7.7Hz); 0.86
25 (t, 3, J = 7Hz). Anal. Calcd. for $\text{C}_{18}\text{H}_{21}\text{ClN}_2\text{O}_4$:
C, 59.26; H, 5.80, N, 7.68. Found: C, 58.89; H, 6.17;
N, 7.39. Mass Calcd. for $\text{C}_{18}\text{H}_{21}\text{ClN}_2\text{O}_4$: 364.1200.
Found: 364.1167.

30

966

35

88015687


RE

Example 21Preparation of Methyl 2-butyl-4-chloro-1-[4-(trifluoro-methylsulfonamido)benzyl]imidazole-5-acetate

A solution of triflic anhydride (0.88 mL, 5.2 mmol, 1 eq) in methylene chloride (5 mL) was dripped into a solution of methyl 2-butyl-1-(4-aminobenzyl)-4-chloroimidazole-5-acetate (1.74 g, 5.2 mmol, 1 eq) and triethylamine (1.44 mL, 10.4 mmol, 2 eq) in 20 mL of methylene chloride at -78°C. The solution was kept at -78°C for 1 hour after which it was allowed to warm to room temperature. After 24 hours, the reaction was quenched with water (100 mL) and the pH adjusted to 5 with conc. HCl and the aqueous extracted with methylene chloride (5 x 100 mL). The organic layers were dried (MgSO₄), concentrated, and the residue flash chromatographed in 1:1 hexane/ethyl acetate on silica gel. The crystalline product which formed in the 1:1 hexane/ethyl acetate solution while the crude product was being applied to the column was isolated (1.03 g). Chromatography of the mother liquor yielded an additional 1.03 g of the title compound as a white solid; m.p. 154.0-157.0°. The product could be titrated with 1 equivalent of 1.000 N NaOH. NMR (200 MHz, CDCl₃) δ 7.32 (d, 2H, J= 10Hz; 6.91 (d, 2H, J= 10Hz); 5.15 (s, 2H); 3.62 (s, 3H); 3.46 (s, 2H); 2.55 (t, 2H, J= 7Hz); 1.56 (m, 2H); 1.26 (m, 2H); 0.72 (t, 3H, J=7Hz). Mass Calcd. for C₁₈H₂₁N₃O₄SP₃Cl: 467.0890. Found: 467.0872.

Examples 22-25 in Table 2 were prepared or could be prepared by the procedure described in the above example employing the appropriately substituted 1-(aminobenzyl)-imidazole, which in some instances is followed by ester hydrolysis familiar to one skilled in the art.

Table 2



Ex. No.	R ¹	R ⁶	R ⁷	R ⁸	MP (°C)
22	NHSO ₂ CF ₃	n-butyl	Cl	CH ₂ OH	
23	NHSO ₂ CF ₃	n-butyl	Cl	CH ₂ OCH ₃	
24	NHSO ₂ CF ₃	n-butyl	Cl	CH ₂ OCH ₂ CH(CH ₃) ₂	
25	NHSO ₂ CF ₃	n-butyl	Cl	CH ₂ CO ₂ H	(oil) ^a

^a NMR (200 MHz, CDCl₃) δ 7.29 (d, 2H, J = 10Hz); 6.64 (d, 2H, J = 10Hz); 5.11 (s, 2H); 3.45 (s, 2H); 2.56 (t, 2H, J = 7Hz); 1.60 (m, 2H); 1.30 (m, 2H); 0.85 (t, 3H, J = 7Hz)

Example 26

Preparation of 2-Butyl-4-chloro-5-[(1H-tetrazol-5-yl)methyl]-1-[3-(1H-tetrazol-5-yl)benzyl]imidazole
2-Butyl-4-chloro-1-(3-cyanobenzyl)-5-(cyano-methyl)imidazole (2.00 g, 6.4 mmol, 1 eq): ammonium chloride (0.91 g, 17 mmol, 2.7 eq): sodium azide (1.11 g, 17 mmol, 2.7 eq) and DMF (25 mL) were mixed and stirred at 80°C for 24 hours. The mixture was filtered and the solvent removed by rotary evaporation. The residue was dissolved in water (100 mL) and methylene chloride (100 mL). The layers were separated

and the aqueous layer extracted again with methylene chloride (2 x 100 mL). The aqueous was then acidified with conc. HCl to pH of 3. The solid which precipitated was collected and dried to give 560 mg of the title compound as a tan solid; m.p. 254° (darken), 258° (dec.). The product when titrated with 1.000 N NaOH showed the presence of exactly two acidic functionalities. NMR (200 MHz, DMSO-d₆) δ 8.79 (d, 1H, J = 7Hz); 7.69 (s, 1H); 7.53 (t, 1H, J = 7Hz); 7.10 (d, 1H, J = 7Hz); 5.37 (s, 2H); 4.23 (s, 2H); 2.57 (t, 2H, J = 7Hz); 1.53 (t of t, 2H, J = 7Hz); 1.27 (t of q, 2H, J = 7 Hz); 0.80 (t, 3H, J = 7Hz); Anal. Calcd. for C₁₇H₁₉ClN₁₀: C, 51.19; H, 4.80. Found: C, 51.04; H, 4.69.

15

Example 27

Preparation of 2-Butyl-4-chloro-5-[(1H-tetrazol-5-yl)methyl]-1-[4-(1H-tetrazol-5-yl)benzyl]imidazole

The title compound was prepared from 2-butyl-4-chloro-1-(4-cyanobenzyl)-5-(cyanomethyl)imidazole by the procedure described in Example 26; m.p. 228 (dark), 229.0-230° (dec). Titration with 1.000 N NaOH showed the presence of exactly two acid functionalities. NMR (200 MHz, DMSO-d₆) δ 7.95 (d, 2, J = 7Hz); 7.13 (d, 2, J = 7Hz); 5.34 (s, 2); 4.23 (s, 2); 2.53 (t, 2, J = 7Hz); 1.50 (t of t, 2, J = 7.7Hz); 1.26 (t of q, 2, J = 7Hz); 0.79 (t, 3, J = 7Hz); IR 3420 br, 1930 br, 740 cm⁻¹. Mass Calcd. for C₁₃H₁₉ClN₁₀: 398.1482. Found: 398.1509.

30

7
Example 28

Preparation of 2-Butyl-4-chloro-5-hydroxymethyl-1-(4-N-phthalimidobenzyl)imidazole

1- (4-Aminobenzyl)-2-butyl-4-chloro-5-(hydroxymethyl)imidazole (1.00 g, 3.4 mmol, 1 eq) in 20 mL of methylene chloride was dripped into a stirred solution of phthaloyl chloride (0.49 mL, 3.4 mmol, 1 eq), triethylamine (0.95 mL, 6.82 mmol, 2 eq) and methylene chloride (500 mL). After 11 days, the solvent was removed by rotary evaporation and the residue flash chromatographed in 1:1 hexane/ethyl acetate over silica gel to give 240 mg of the title compound as a light yellow glassy solid: m.p. 65.0-73.5°. NMR (200 MHz, CDCl₃) δ (key peaks only) 7.97 (m, 2H); 7.79 (m, 2H); 7.43 (d, 2, J = 10Hz); 7.11 (d, 2H, J = 10Hz); 4.50 (s, 2H); 2.57 (t, 2H, J = 7Hz); 1.67 (m, 2H); 1.34 (m, 2H); 0.87 (t, 3H, J = 7Hz). Mass Calcd. for C₂₃H₂₂ClN₃O₃: 423.1349. Found: 423.1324.

Example 29

Preparation of Methyl 2-butyl-4-chloro-1-(4-N-phthalimidobenzyl)imidazole-5-acetate

Methyl 2-butyl-1-[4-(2-carboxybenzamido)benzyl]-4-chloroimidazole-5-acetate (1.00 g), methanol (50 mL) and 3.6 mL of 3.1 N HCl in dioxane were refluxed for 6 days. The solvent was removed in vacuo and the residue taken up in ethyl acetate (100 mL). The organic phase was washed with 1 N NaOH (2 x 100 mL) and brine (1 x 100 mL), dried (MgSO₄) and concentrated. The residue was flash chromatographed over silica gel in 75:25 hexane/ethyl acetate to give 400 mg of an oil which eventually crystallized: m.p. 141.5 - 143.0°. NMR (200 MHz, CDCl₃) δ 7.92 (m, 2H); 7.80 (m, 2H); 7.43 (d, 2H, J = 10Hz); 7.08 (d, 2H, J = 10Hz); 5.17 (s, 2H); 3.62 (s, 3H); 3.50 (s, 2H); 2.62 (t, 2H, J = 7Hz); 1.71

(t of t, 2H, J= 7.7Hz): 1.36 (t of q, 2H, J= 7.7Hz);
0.89 (t, 3H, J= 7Hz). Mass Calcd. for $C_{25}H_{26}ClN_3O_4$:
465.1455. Found: 465.1440.

5

Example 30

Preparation of Methyl 2-butyl-4-chloro-1-[4-((N-trifluoromethanesulfonyl)anthranilamido)benzyl]-imidazole-5-acetate

Methyl-1-(4-aminobenzyl)-2-butyl-4-chloro-5-imidazoleacetate (1.00 g, 2.98 mmol, 1 eq), N-(trifluoromethanesulfonyl)anthranoyl chloride which is described in EP 003836, (0.86 g, 2.99 mmol, 1 eq), and sodium bicarbonate (1.25 g, 14.9 mmol, 5 eq) were mixed and stirred in 50 mL methylene chloride (acid chloride was added last). The reaction was worked up after 2.5 hours by filtering, removing the solvent from the filtrate in vacuo and recrystallizing the residue from ethyl acetate/hexane to give 1.07 g of light yellow crystals: m.p. 151.0 - 152.0°. NMR (200 MHz, $CDCl_3$) δ 9.32 (s, 1H); 8.02 (d, 1H, J= 10Hz); 7.79 (d, 1H, J= 10Hz); 7.56 (d of d, 2H, J= 10, 10Hz); 7.50 (d, 2H, J= 10Hz); 7.78 (d of d, 1H, J= 10, 10Hz); 6.86 (d, 2H, J= 10Hz); 5.10 (s, 2H); 3.58 (s, 3H); 3.45 (s, 2H); 2.45 (t, 2H, J= 7Hz); 1.52 (t of t, 2H, J= 7.7Hz); 1.22 (t of q, 2H, J= 7.7Hz); 0.75 (t, 3H, J= 7Hz). Titration of the product with 1.000 N NaOH shows the presence of exactly one acidic functionality. Anal. Calcd. for $C_{25}H_{26}ClF_3N_4O_5S$: C, 51.15; H, 4.46; N, 9.54. Found: C, 50.95; H, 4.26; N, 9.67. Mass Calcd. for $C_{25}H_{26}ClF_3N_4O_5S$: 586.1264. Found: 586.1222.

971

35

88015687

148

EXAMPLE 31

Preparation of 2-Butyl-4-chloro-1-[4-((N-trifluoromethanesulfonyl)anthranilamido)benzyl]imidazole-5-acetic acid

5 Methyl 2-butyl-4-chloro-1-[4-((N-trifluoromethanesulfonyl)anthranilamido)benzyl]imidazole-5-acetate (400 mg, 0.66 mmol, 1 eq) was stirred in 1.0 N NaOH (0.66 mL, 0.66 mmol, 1 eq) for 3 hours under N₂. The pH was adjusted to 5 with 1.0 N HCl and the
10 product precipitate was collected and dried affording 120 mg of the title compound as a white solid. The NMR spectrum shows the methyl ester to be missing. Mass spectrum shows M-CO₂ peak. Mass Calcd. for C₂₃H₂₄ClF₃N₄O₃S: 528.1209. Found: 528.1236.


Example 32

Preparation of 2-Butyl-1-[4-(2-carboxybenzamido)benzyl]-4-chloroimidazole-5-acetic acid

15 The title compound was prepared from methyl 2-butyl-1-[4-(2-carboxybenzamido)benzyl]-4-chloroimidazole-5-acetate by the procedure described in Example 31; m.p. 170.5 - 175.0°.

20 Examples 33-53 in Table 3 were prepared or could be prepared by the procedures described in Examples 30 and 31 using the appropriate aniline and acid chloride starting materials.

170
Table 3











10

Ex. No.	R	R ⁶	R ⁷	R ⁸	MP (°C)
33		n-butyl	Cl	CH ₂ CO ₂ CH ₃	(oil) ^a
34		n-butyl	Cl	CH ₂ CO ₂ CH ₃	
35		n-butyl	Cl	CH ₂ CO ₂ CH ₃	226-228
36		n-butyl	Cl	CH ₂ CO ₂ CH ₃	153-156 (dec.)
37		n-propyl	Cl	CH ₂ OH	
38		n-hexyl	H	CH ₂ CO ₂ CH ₃	

973

88015687










Table 3 (cont'd.)

Ex. No.	R	R ⁶	R ⁷	R ⁸	MP (°C)
5	39 	n-propyl	Cl	CH ₂ OH	
10	40 	n-butyl	Cl	CH ₂ CO ₂ CH ₃	
15	41 	n-propyl	Cl	CH ₂ CO ₂ CH ₃	
20	42 	n-butyl	Cl	CH ₂ OH	
25	43 	CH ₃ CH ₂ CH=CH-	Cl	CH ₂ OH	
30	44 	n-butyl	Cl	CH ₂ OCOCH ₃	
35	45 	n-butyl	Cl	CH ₂ OCOCH ₃	
	46 	n-butyl	CH ₂ CO ₂ H	Cl	

974

88015687

Table 3 (cont'd.)

Ex. No.	R	R ⁶	R ⁷	R ⁸	MP (°C)
5 47		n-butyl	Cl	CH ₂ CO ₂ H	
10 48		n-butyl	Cl	n-butyl	
15 49		n-butyl	CH ₂ CO ₂ H	Cl	
20 50		n-hexyl	Cl	CH ₂ CO ₂ H	
25 51		n-butyl	Cl	CH ₂ CO ₂ CH ₃	74.0-79.5
30 52		n-butyl	Cl		200.5-205.0
35 53		n-propyl	Cl		

a ¹H NMR (200 MHz, CDCl₃) δ 8.69 (s, 1H); 7.82 (s, 1H); 7.75 (d, 1H, J = 7 Hz); 7.59 (d, 2H, J = 10 Hz); 7.55 (d, 1H, J = 7 Hz); 7.45 (t, 1H, J = 7 Hz); 6.87 (d, 2H, J = 10 Hz); 5.06 (s, 2H); 3.60 (s, 3H); 3.46 (s, 2H); 2.54 (t, 2H, J = 7 Hz); 1.55 (t of t, 2H, J = 7, 7 Hz); 1.24 (t of q, 2H, J = 7, 7 Hz); 0.78 (t, 3H, J = 7 Hz).

975

88015687

PART A: Preparation of Ethyl n-heptylimidate hydrochloride

To a solution of caprylonitrile (30 g, 0.24 mol) in 25 mL of absolute ethanol cooled to 0° was bubbled HCl gas (9.6 g, 0.26 mol). After 7 days at 0° the viscous solution was diluted with 250 mL of anhydrous ether and the precipitated product was filtered with suction onto a coarse frit and washed liberally with ether before placing under a vacuum to remove residual solvent. The product was stored under nitrogen at 0° to yield 22 g (44%) of a white solid. NMR (200 MHz, DMSO-d₆) δ 4.40 (q, 2H, J = 7Hz); 3.30 (m, 4H); 2.45 (m, 4H); 1.40-0.75 (m, 12H). Mass. Spec. 172 (M-Cl).

PART B: Preparation of 2-Heptyl-5-(hydroxymethyl)-imidazole

In a high-pressure (bomb) reactor was placed ethyl n-heptylimidate hydrochloride (22 g, 0.11 mol), 1,3-dihydroxyacetone dimer (9.5 g, 0.053 mol) and liquid ammonia (60 g, 3.5 mol). The reactor was sealed and heated to 70° for 12 hours. The crude product (24.7 g) was purified by flash chromatography (silica gel, 300 g; 10:1 EtOAc/EtOH) to give 12.7 g (61%) of a light yellow solid; m.p. 82-84°. NMR (200 MHz, CDCl₃/Acetone-d₆) δ 6.75 (s, 1H); 4.50 (s, 2H); 4.50-4.25 (br s, 2H); 2.60 (t, 2H, 8Hz); 1.75-1.60 (m, 2H); 1.40-1.15 (m, 8H); 0.95-0.75 (m, 3H). Mass Spec. 196, 167 (M-Et), 149 (M-Et-H₂O).

PART C: Preparation of 4-Chloro-2-heptyl-5-hydroxy-
methylimidazole

To a solution of 2-heptyl-5-(hydroxymethyl)-
imidazole (10.0 g, 51 mmol) in EtOH/1,4-dioxane (1:1;
5 600 mL) was added N-chlorosuccinimide (7.9 g, 59
mmol). After being stirred for 1 hour at room
temperature the solvents were removed on a rotary
evaporator and the solid residue was partitioned
between ethyl acetate and water (300 mL each). The
10 organic phase was washed with water (150 mL), dried
(MgSO₄), filtered and concentrated to afford 12.4 g
crude product. Recrystallization (1:1 EtOAc/hexane,
60 mL) gave 5.7 g (45%) of white crystals; m.p.
134-140°. NMR (200 MHz, CDCl₃/CD₃OD) δ 4.50 (s,
15 2H); 4.00-3.80 (br s, 2H); 2.65 (t, 2H, 5Hz);
1.80-1.60 (m, 2H); 1.40-1.20 (m, 8H); 0.90-0.80 (m,
3H). Mass Spec. 230.

PART D: Preparation of 4-Chloro-2-heptyl-5-(hydroxy-
20 methyl)-1-(4-nitrobenzyl)imidazole

To a solution of 4-chloro-2-heptyl-5-(hydroxy-
methyl)imidazole (5.2 g, 20.7 mmol) in dry DMF (100 mL)
was added anhydrous K₂CO₃ (4.3 g, 31.1 mmol) followed
by 4-nitrobenzylbromide (5.4 g, 24.9 mmol). The solu-
25 tion was stirred 3-5 hours at 65-70°. The reaction
mixture was poured into a separatory funnel containing
EtOAc and H₂O (300 mL each). The aqueous phase was
extracted with EtOAc (150 mL) and the combined organic
phases were washed three times with H₂O (150 mL) before
30 being dried (MgSO₄), filtered and concentrated to give
9.0 g brown crude oil. Chromatography (silica gel,
450 g; 1:1 EtOAc/hexanes) gave 1.3 g (17% overall, 35%
of theoretical); m.p. 110-115°. NMR (200 MHz, CDCl₃)
δ 8.20 (d, 2H, 5Hz); 7.20 (d, 2H, 5Hz); 5.35 (s, 2H);
35 4.45 (s, 2H); 3.00-3.00 (m, 1H); 2.50 (t, 2H, 5Hz);

1.75-1.50 (m, 2H); 1.40-1.10 (m, 8H); 0.90-0.75 (m, 3H). Mass Spec. 365.

PART E: Preparation of 1-(4-Aminobenzyl)-4-chloro-
2-heptyl-5-hydroxymethylimidazole

To a solution of 4-chloro-2-heptyl-5-hydroxymethyl-1-(4-nitrobenzyl)imidazole (1.00 g, 2.7 mmol) in EtOH (30 mL) and glacial acetic acid (5 mL) was added iron powder (2.5 g, 44.8 mmol). The mixture was stirred while being refluxed for 20 minutes. The solution was cooled, the iron was removed by filtration, and the solution was partitioned between EtOAc and 20% aq. K_2CO_3 (150 mL each). The organic phase was washed with saturated aqueous NaCl, dried ($MgSO_4$), filtered and concentrated to afford 0.8 g yellow-orange oil. Flash chromatography (silica gel, 25 g; EtOAc/hexanes, 1:1) gave 0.74 g (80%) of yellow-orange oil. NMR (200 MHz, $CDCl_3$) δ 6.80-6.60 (ABq, 4H, 7Hz, 32Hz); 5.10 (s, 2H); 4.45 (s, 2H); 3.75-3.60 (m, 2H); 2.55 (t, 2H, 5Hz); 1.75-1.65 (m, 2H); 1.30-1.15 (m, 8H); 0.90-0.80 (m, 3H). Mass Spec. 335.

PART F: Preparation of 4-Chloro-2-heptyl-5-hydroxymethyl-1-[4-((N-trifluoromethanesulfonyl)-anthranilamido)benzyl]imidazole

To a solution of 1-(4-aminobenzyl)-4-chloro-2-heptyl-5-(hydroxymethyl)imidazole (211 mg, 0.63 mmol) in dry methylene chloride (10 mL) was added anhydrous sodium bicarbonate (263 mg, 3.1 mmol) followed by N-(trifluoromethanesulfonyl)anthranoyl chloride (180 mg, 0.63 mmol). After 2 hours the mixture was filtered, the filtrate was concentrated and the residue was purified by flash chromatography (silica gel, 10 g; EtOAc) to provide 298 mg (81%) of pale yellow solid; m.p. 90-95° (dec.). NMR (200 MHz,

88015687

CDCl₃/CD₃OD) δ 7.75-6.80 (m, 8H); 5.10 (s, 2H);
4.40 (s, 2H); 2.50 (t, 2H, 7Hz); 1.75-1.50 (m, 2H);
1.35-1.15 (m, 8H); 0.95-0.80 (m, 3H). Mass Spec - no
mass ion observed due to apparent decomposition; 424
5 (M-NH₂SO₂CF₃-CH₃).

Example 55

PART A: Preparation of Ethyl 3-methoxypropylimidate hydrochloride

10 This compound was prepared according to the
procedure described in Example 54, Part A. From
3-methoxypropionitrile (30 g, 0.35 mol) and hydrogen
chloride (14.1 g, 0.39 mol) in ethanol (25 mL) there
was obtained 37.7 g (64%) white solid. Mass Spec. 132
15 (M-Cl).

PART B: Preparation of 5-Hydroxymethyl-2-(2- methoxyethyl)imidazole

This compound was prepared according to the
20 procedure described in Example 54, Part B. From ethyl
3-methoxypropylimidate (36.7 g, 0.22 mol), 1,3-dihyd-
roxyacetone dimer (19.7 g, 0.11 mol) and liquid
ammonia (90 g, 5.3 mol) there was obtained 14.0 g
(41%) of an off-white solid following chromatography.
25 m.p. 100-107°. NMR (200 MHz, DMSO-d₆) δ 6.70 (s,
1H); 4.30 (s, 2H); 3.6 (t, 2H, 5Hz); 3.20 (s, 3H);
2.80 (t, 2H, 5Hz). Mass Spec. 156.

PART C: Preparation of 4-Chloro-5-hydroxymethyl- 2-(2-methoxyethyl)imidazole

This compound was prepared according to the
procedure described in Example 54, Part C. From
4-hydroxymethyl-2-(2-methoxyethyl)imidazole (13.5 g,
81.7 mmol) and N-chlorosuccinimide (13.8 g, 103 mmol)
35 was obtained 4.8 g (29%) of light yellow solid fol-

lowing chromatography (silica gel, 500 g; EtOAc): m.p. 102-108°. NMR (200 MHz, CDCl₃/CD₃OD) δ 4.50 (s, 2H); 3.65 (m, 4H); 3.40 (s, 3H); 2.90 (t, 2H, 5Hz). Mass Spec. 190.

5

PART D: Preparation of 4-Chloro-5-hydroxymethyl-2-(2-methoxyethyl)-1-(4-nitrobenzyl)imidazole

This compound was prepared according to the procedure described in Example 54, Part D. From 4-chloro-5-hydroxymethyl-2-(2-methoxyethyl)imidazole (4.3 g, 22.6 g) was obtained 2.2 g (30% overall, 60% of theoretical) of light yellow solid; m.p. 91-95°. NMR (200 MHz, CDCl₃) δ 8.15 (d, 2H, 8Hz); 7.20 (d, 2H, 8Hz); 5.45 (s, 2H); 4.45 (s, 2H); 3.60 (t, 2H, 5Hz); 3.20 (s, 3H); 3.15 (s, 1H); 2.80 (t, 2H, 5Hz). Mass Spec. 325.

PART E: Preparation of 1-(4-Aminobenzyl)-4-chloro-5-hydroxymethyl-2-(2-methoxyethyl)imidazole

This compound was prepared according to the procedure described in Example 54, Part E. From 4-chloro-5-hydroxymethyl-2-(2-methoxyethyl)-1-(4-nitrobenzyl)imidazole (2.2 g, 6.75 mmol) and iron powder (6.7 g, 120 mmol) there was obtained 1.6 g (80%) of light yellow solid; m.p. 164-167°. NMR (200 MHz, CDCl₃/CD₃OD) δ 6.80 (d, 2H, 7Hz); 6.65 (d, 2H, 7Hz); 5.15 (s, 2H); 4.45 (s, 2H); 4.30 (s, 3H); 3.60 (t, 2H, 5Hz); 3.25 (s, 3H); 2.8 (t, 2H, 5Hz). Mass Spec. 295.

30

35

980

88015687

27

PART F: Preparation of 1-[4-(2-Carboxybenzamido)-
benzyl]-4-chloro-5-hydroxymethyl-2-(2-methoxy-
ethyl)imidazole

To an acetonitrile solution (12 mL) of 1-(4-
5 aminobenzyl)-4-chloro-5-hydroxymethyl-2-(2-methoxy-
ethyl)imidazole (150 mg, 0.51 mmol) was added an
acetonitrile solution (2 mL) of phthalic anhydride
(75 mg, 0.51 mmol). After stirring overnight at room
temperature a light yellow precipitate was produced.
10 The mixture was cooled to 0°, filtered with suction
onto a fine fritted funnel and the solid was washed
with cold acetonitrile, chloroform and finally ether
(2 mL each) to afford 180 mg (80%) of light tan solid.
m.p. 185-186° (dec.). NMR (200 MHz, CDCl₃/CD₃OD) δ
15 8.05-6.95 (m, 8H); 5.30 (s, 2H); 4.50 (s, 2H); 3.60
(t, 2H, 5Hz); 3.25 (s, 3H); 2.8 (t, 2H, 5Hz). Mass
Spec. Calcd. for C₂₂H₁₈ClN₃O₃ (M-2H₂O): 407.1037.
Found: 407.1031.

20

Example 56

Preparation of 4-Chloro-5-hydroxymethyl-2-(2-methoxy-
ethyl)-1-[4-((N-trifluoromethanesulfonyl)anthranil-
amido)benzyl]imidazole

This compound was prepared according to the
25 procedure described in Example 54, Part F. From
1-(4-aminobenzyl)-4-chloro-5-hydroxymethyl-2-(2-
methoxyethyl)imidazole (200 mg, 0.68 mmol), N-(tri-
fluoromethanesulfonyl)anthranoyl chloride (190 mg,
0.68 mmol) and sodium bicarbonate (280 mg, 3.3 mmol)
30 in acetonitrile (5 mL) was obtained 300 mg (81%) of
tan solid after chromatography (silica gel, 20 g;
EtOAc/EtOH, 20:1); m.p. 75-95° (slow dec.); one spot
by TLC. NMR (200 MHz, CDCl₃/CD₃OD) δ 8.00-6.80
(m, 8H); 5.15 (s, 2H); 4.4' (s, 2H); 3.60 (t, 2H,
35 5Hz); 3.15 (s, 3H); 2.75 (t, 2H, 5Hz).


981

88015687

178

The following compounds listed in Table 4 were prepared by the procedures described in Examples 54, Parts D, E and 54, Part F or 55, Part F.

Table 4















Ex. No.	R	R ⁶	MP (°C)
57		ethyl	(amorphous solid) ^a
58		i-propyl	(amorphous solid) ^b
59		n-butyl	(amorphous solid) ^c
60		n-pentyl	(amorphous solid) ^d
61			(amorphous solid) ^e
62		ethyl	188-189.5 (free acid)

982

88015687

130
Table 4 (continued)

Ex. No.	R	R ⁶	MP (°C)
5 63		n-propyl	181.5-183 (free acid)
64		n-butyl	188.5-189.5 (Na+ salt)
10 65		n-pentyl	170.5-171.5
—	—	—	—
15 66		n-hexyl	171-171.5
67		n-heptyl	181-182
20 68			
25 69			
70		$\text{CH}_3\text{O}-\text{C}_6\text{H}_4-\text{CH}_2$	150-152
30 71			175-177
—	983		

35

88015687

~~128~~

a NMR δ 8.05 (d, 1H); 7.62 (d, 2H); 7.52 (d, 1H); 7.30 (t, 1H); 7.17 (m, 3H); 6.93 (m, 2H); 5.13 (s, 2H); 2.61 (quart., 2H); 1.15 (t, 3H).

5

b NMR δ 8.04 (d, 1H); 7.63 (d, 2H); 7.51 (d, 1H); 7.28 (t, 1H); 7.13 (m, 3H); 6.89 (m, 2H); 5.14 (s, 2H); 3.11 (sept., 1H); 1.11 (d, 6H).

10

c NMR δ 8.05 (d, 1H); 7.64 (d, 2H); 7.52 (d, 1H); 7.30 (t, 1H); 7.17 (m, 3H); 6.92 (m, 2H); 5.15 (s, 2H); 2.66 (t, 2H); 1.53 (quint., 2H); 1.28 (sext., 2H); 0.83 (t, 3H).

15

d NMR δ 8.07 (d, 1H); 7.68 (d, 2H); 7.52 (m, 2H); 7.30 (m, 4H); 6.93 (t, 1H); 5.29 (s, 2H); 2.83 (t, 2H); 1.56 (m, 2H); 1.24 (m, 4H); 0.82 (t, 3H).

20

e NMR δ 8.03 (d, 1H); 7.61 (d, 2H); 7.51 (d, 1H); 7.28 (t, 1H); 7.10 (m, 3H); 6.91 (t, 1H); 6.78 (s, 1H); 5.09 (s, 2H); 2.46 (d, 2H); 1.62 (m, 6H); 0.99 (m, 5H).

25

30

984

35

88015687

PART A: Preparation of 5-Hydroxymethyl-2-mercapto-
1-(4-nitrobenzyl)imidazole

A mixture of 4-nitrobenzylamine hydrochloride (75
5 g, 0.40 mol), 1,3-dihydroxyacetone dimer (32.1, 0.17
mol) and potassium thiocyanate (51.9 g, 0.53 mol) in
n-butanol (250 mL) and glacial acetic acid (40 mL) was
stirred vigorously at room temperature for 48 hours.
The mixture was suction filtered and the solid was
10 washed thrice with water (300 mL) and thrice with
ether (300 mL) before being dried overnight under
vacuum to give 70.9 g (75%) of a yellow tan powder;
m.p. 214-215° (dec.). NMR (200 MHz, DMSO-d₆) δ
12.25 (s, 1H; absent in D₂O shake); 8.20 (d, 2H,
15 8Hz); 7.40 (d, 2H, 8Hz); 6.90 (s, 1H); 5.40 (s, 2H);
5.25 (t, 1H, 5Hz; absent in D₂O shake); 4.15 (d, 2H,
5Hz; s in D₂O shake). Mass Spec. 265.

PART B: Preparation of 5-Hydroxymethyl-2-methylthio-
20 1-(4-nitrobenzyl)imidazole

An ethanolic solution of sodium ethoxide was
prepared by the gradual addition of sodium hydride
(0.70 g of 60% NaH in mineral oil, 17.6 mmol) to
absolute ethanol (150 mL). To this 5-hydroxymethyl-
25 2-mercapto-1-(4-nitrobenzyl)imidazole (3.9 g, 14.7
mmol) was added and after being stirred 5-10 minutes,
iodomethane (2.5 g, 1.1 mL, 17.6 mmol) was added.
After being stirred 3 hours at room temperature, the
mixture was concentrated on a rotary evaporator and
30 the residue was partitioned between ethyl acetate
(500 mL) and water (250 mL). The aqueous phase was
further extracted with ethyl acetate (250 mL) and the
combined organic phases were washed with water (150
mL), saturated aqueous sodium chloride (150 mL), dried
35 (MgSO₄), filtered and concentrated to leave 4.1 g of

133
yellow-brown solid. Recrystallization from ethyl acetate gave 2.6 g (64%) of light yellow-brown powder: m.p. 160-162°. NMR (200 MHz, DMSO- d_6) δ 8.20 (d, 2H, 7Hz); 7.30 (d, 2H, 7Hz); 6.95 (s, 1H); 5.40 (s, 2H); 5.20 (t, 1H, 5Hz; absent in D_2O shake); 4.40 (d, 3H, 5Hz; s in D_2O shake); 3.40 (s, 2H; monohydrate; δ 3.5 in D_2O); 2.45 (s, 3H). Mass Spec. 279.

10 PART C: Preparation of 1-(4-Aminobenzyl)-5-hydroxy-methyl-2-(methylthio)imidazole

This compound was prepared according to the procedure described in Example 54, Part E, from 5-hydroxymethyl-2-methylthio-1-(4-nitrobenzyl)imidazole (21 g, 75.2 mmol) and iron powder (75 g, 1.3 mol) there was obtained 13.5 g (72%) of a yellow hygroscopic solid. NMR (200 MHz, $CDCl_3$) δ 6.90 (s, 1H); 6.85-6.45 (q, 4H, 5Hz, 51Hz); 5.10 (s, 2H); 4.40 (s, 2H); 2.40 (s, 3H). Mass Spec. 249.

20 PART D: Preparation of 1-[4-(2-Carboxybenzamido)-benzyl]-5-hydroxymethyl-2-(methylthio)-imidazole

This compound was prepared according to the procedure described in Example 55, Part F, though in this case the reaction was run in chloroform and the filtered product was washed with chloroform and ether. From 1-(4-aminobenzyl)-5-hydroxymethyl-2-(methylthio)-imidazole (323 mg, 1.3 mmol) and phthalic anhydride (192 mg, 1.3 mmol) there was obtained 488 mg (95%) of the title compound as a yellow powder; m.p. 115-118° (dec.). NMR (200 MHz, $CDCl_3$ /DMSO- d_6) δ 9.80 (s, 1H); 8.00-6.85 (m, 9H); 5.20 (s, 2H); 4.40 (s, 2H); 2.50 (s, 3H). Mass Spec. 379 ($M-H_2O$).

35

986

88015687

183

Example 73

Preparation of 1-[4-(2-Carboxybenzamido)benzyl]-5-hydroxymethyl-2-methoxyimidazole

By repeating Example 72, Parts C and D, but substituting 5-hydroxymethyl-2-methoxy-1-(4-nitrobenzyl)imidazole as starting material in Part C, the compound 1-[4-(2-carboxybenzamido)benzyl]-5-hydroxymethyl-2-methoxyimidazole can be prepared.

Example 74

PART A: Preparation of *trans*-2-(Trifluoromethanesulfonamido)cyclohexanecarboxylic acid

Ethyl *trans*-2-(trifluoromethanesulfonamido)cyclohexanecarboxylate was synthesized from ethyl *trans*-2-aminocyclohexanecarboxylate [E. J. Moriconi and P. H. Mazzocchi, J. Org. Chem., 31, 1372 (1966)] by the procedure described in Example 21. The crude product (2.59 g, 8.55 mmol, 1 eq) was then hydrolyzed by refluxing in 1.00N NaOH (26.5 mL, 26.5 mmol, 3.1 eq) overnight under N₂. Water (100 mL) was then added and the pH adjusted to 3 using 1N HCl. The aqueous was extracted with ethyl acetate (3 x 100 mL), the organic layers dried (MgSO₄) and concentrated to yield a crystalline white solid which was recrystallized from n-butyl chloride. Obtained 1.71 g of product; m.p. 114.5-118.5°. NMR (200 MHz, DMSO-d₆) δ 12.47 (bs, 1H); 9.52 (bs, 1H); 2.35 (d of d of d, 1H, J = 10, 10, 4 Hz); 2.10-1.13 (m, 9H). Anal. Calcd. for C₈H₁₂F₃NO₄S: C, 34.91; H, 4.39; N, 5.09. Found, C, 34.73; H, 4.22; N, 5.04.

PART B: Preparation of Methyl 2-butyl-4-chloro-1-[4-(trans-2-(trifluoromethanesulfonamido)cyclohexanecarboxamido)benzyl]imidazole-5-acetate and methyl 2-butyl-4-chloro-1-[4-(cis-2-(trifluoromethanesulfonamido)cyclohexanecarboxamido)benzyl]imidazole-5-acetate

trans-2-(Trifluoromethanesulfonamido)cyclohexanecarboxylic acid (500 mg, 1.82 mmol, 1 eq) and thionyl chloride (2.30 mL, 31.5 mmol, 17.3 eq) were mixed and refluxed for 2 hours. The excess thionyl chloride was removed in vacuo and the residue suspended in toluene. The toluene was removed by rotary evaporation and the procedure repeated to remove traces of thionyl chloride. Final rotary evaporation yielded 460 mg of white crystalline acid chloride product which was used without further purification (IR 1789 cm^{-1}).

Methyl 2-butyl-4-chloro-1-(4-aminobenzyl)-imidazole-5-acetate (530 mg, 1.57 mmol, 1 eq), trans-2-(trifluoromethanesulfonamido)cyclohexanoyl chloride (460 mg, 1.57 mmol, 1 eq) and sodium bicarbonate (400 mg, 4.70 mmol, 3 eq) were mixed and stirred in chloroform (20 mL) overnight. Water (100 mL) was then added, and the pH adjusted to 4 with 1N HCl. The aqueous was extracted with methylene chloride (3 x 100 mL) and the organic layers dried and concentrated. Gradient flash chromatography of the residue in 60:40 hexane/ethyl acetate to 100% ethyl acetate over silica gel yielded two isomers: both of which were isolated as glasses. The faster eluting product being the minor cis isomer (170 mg) while the slower being the major trans isomer (520 mg).

- trans-Isomer; NMR (200 MHz, CDCl_3) δ 8.18 (s, 1H); 7.42 (d, 2H, J = 10Hz); 6.84 (d, 2H, J = 10Hz); 6.47 (bd, 1H, J = 8Hz); 5.07 (s, 2H); 3.72 (m, 1H); 3.57 (s, 3H); 3.47 (s, 2H); 2.53 (t, 2H, 7Hz); 2.24-1.32 (m, 13H); 0.82 (t, 3H, J = 7Hz). Anal. Calcd. for $\text{C}_{25}\text{H}_{32}\text{ClF}_3\text{N}_4\text{O}_5\text{S}$: C, 50.63; H, 5.44; N, 9.45. Found: C, 50.64; H, 5.44; N, 9.16. Mass Calcd. for $\text{C}_{25}\text{H}_{32}\text{ClF}_3\text{N}_4\text{O}_5\text{S}$: 592.1734. Found: 592.1731.
- 10 cis-Isomer; NMR (200 MHz, CDCl_3) δ 7.94 (s, 1H); 7.42 (d, 2H, J = 10Hz); 6.88 (d, 2H, J = 10Hz); 6.52 (bd, 2H, J = 8Hz); 5.11 (s, 2H); 3.75 (m, 1H); 3.63 (s, 3H); 3.48 (s, 2H); 2.56 (t, 2H, 7Hz); 2.29-1.25 (m, 13H); 0.86 (t, 3H, J = 7Hz). Anal. Calcd. for $\text{C}_{25}\text{H}_{32}\text{ClF}_3\text{N}_4\text{O}_5\text{S}$: C, 50.63; H, 5.44. Found: C, 49.87; H, 5.65. Mass Calcd. for $\text{C}_{25}\text{H}_{32}\text{ClF}_3\text{N}_4\text{O}_5\text{S}$: 592.1734. Found: 592.1689.

Example 75

20 PART A: Preparation of 2-Butyl-4,5-dicyanoimidazole

Ethyl pentanimidate hydrochloride (42.66 g, 257.8 mmol, 1 eq), diaminomaleonitrile (27.90 g, 258.1 mmol, 1 eq) and pyridine (400 mL) were mixed and refluxed for 48 hours under N_2 . The solvent was removed by rotary evaporation.

The residue was taken up in ethyl acetate and filtered through a pad (3" x 4") of florisil. The solvent was removed in vacuo and the residue flash chromatographed in 60:40 hexane/ethyl acetate over silica gel to give 16.59 g of a yellow solid which was used in the following step without further purification. An analytical sample was prepared by recrystallizing the crude product (3.03 g) from ether/hexane to give 1.55 g of yellow crystals; m.p. 108.0-109.0°.

35

989

88015687

156

10Hz): 5.10 (s, 2H); 2.69 (t, 2H, J= 7Hz); 1.72 (t of
t, 2H, J= 7.7Hz); 1.38 (t of q, 2H, J= 7.7Hz); 0.91
(t, 3H, J= 7Hz). Mass Calcd. for $C_{16}H_{17}N_5$:
279.1483. Found: 279.1489.

5

PART D: Preparation of 2-Butyl-4,5-dicyano-1-[4-((N-
trifluoromethanesulfonyl)anthranilamido)-
benzyl]imidazole

The title compound was prepared by the procedure
described in Example 30 starting with 1-(4-aminobenz-
yl)-2-butyl-4,5-dicyanoimidazole and N-(trifluoro-
methanesulfonyl)anthranilic acid chloride. NMR (200
MHz, $CDCl_3$ + $DMSO-d_6$) δ 7.98 (d, 1H, J= 7Hz); 7.32 (d,
2H, J= 7Hz); 7.62 (d, 1H, J= 7Hz); 7.47 (d of d, 1H,
J= 7.7Hz); 7.24 (d of d, 1H, J= 7.7Hz); 7.15 (d, 2, J=
7.7Hz); 5.32 (s, 2H); 2.75 (t, 2H, J= 7Hz); 1.70 (t of
t, 2H, J= 7.7Hz); 1.37 (t of q, 2H, J= 7.7Hz); 0.92
(t, 3H, J= 7Hz). Mass Calcd. for $C_{24}H_{21}F_3N_6O_3S$:
503.1348. Found: 530.1343.

20

Example 76

PART A: Preparation of Methyl 1-[4-(N-benzylamino)-
benzyl]-2-butyl-4-chloroimidazole-5-acetate

A mixture of methyl 1-(4-aminobenzyl)-2-butyl-
4-chloroimidazole-5-acetate (1.00 g, 3.0 mmol, 1 eq),
benzaldehyde (0.30 mL, 3.0 mmol, 1 eq), 4A⁺ powdered
molecular sieves (enough to make a slurry) and 40 mL
THF was stirred overnight. The next day, more benz-
aldehyde (0.2 mL) and acidic Al_2O_3 (activity 1, 1g)
were added and the slurry stirred another 24 hours.
The solids were filtered and the solvent from the
filtrate removed in vacuo. The residue was dissolved
in methanol (10 : L) and sodium cyanoborohydride was
added (0.19 g, 3.0 mmol, 1 eq). The mixture was

991 88015687

138

stirred for 24 hours, after which the solvent was removed in vacuo to yield a green oil which was flash chromatographed over silica gel in 70:30 hexane/ethyl acetate to give 740 mg of product as an oil. NMR (200 MHz, CDCl_3) δ 7.42 - 7.24 (m, 5H); 6.74 (d, 2H, $J = 7\text{Hz}$); 6.56 (d, 2H, $J = 7\text{Hz}$); 4.98 (s, 2H); 4.31 (s, 2H); 3.61 (s, 3H); 3.48 (s, 2H); 2.60 (t, 2H, $J = 7\text{Hz}$); 1.67 (t of t, 2H, $J = 7.7\text{Hz}$); 1.35 (t of q, 2H, $J = 7.7\text{Hz}$); 0.89 (t, 3H, $J = 7\text{Hz}$). Mass Calcd. for $\text{C}_{24}\text{H}_{28}\text{ClN}_3\text{O}_2$: 425.1868. Found: 425.1853.

PART B: Preparation of Methyl 2-butyl-1-[4-(N-benzyl-N-(2-(trifluoromethanesulfonamido)benzoyl)-amino)benzyl]-4-chloroimidazole-5-acetate

The title compound was prepared from the compound of Part A by the procedure described in Example 30. NMR (200 MHz, CDCl_3) δ 7.59 (d, 1H, $J = 10\text{Hz}$); 7.33-7.16 (m, 6H); 6.89 (d, 2H, $J = 10\text{Hz}$); 6.76 (d, 2H, $J = 10\text{Hz}$); 6.93-6.70 (m, 2H); 5.12 (s, 2H); 5.02 (s, 2H); 3.55 (s, 3H); 3.39 (s, 2H); 2.47 (t, 2H, $J = 7\text{Hz}$); 1.64 (t of t, 2H, $J = 7.7\text{Hz}$); 1.30 (t of q, 2H, $J = 7.7\text{Hz}$); 0.88 (t, 3H, $J = 7\text{Hz}$). Anal. Calcd. for $\text{C}_{32}\text{H}_{32}\text{ClF}_3\text{N}_4\text{O}_5\text{S}$: C, 56.76; H, 4.76; N, 8.27. Found: C, 56.64; H, 4.90; N, 7.98.

Example 77

PART A: Preparation of 2-n-Butyl-4-chloro-5-methoxymethyl-1-[N-methyl-4-aminobenzyl]imidazole

1-(4-Aminobenzyl)-2-n-butyl-4-chloro-5-(methoxymethyl)imidazole (10.94 g) and ethyl formate (150 mL) were mixed and refluxed overnight. The excess ethyl formate was removed in vacuo and another 150 mL added and the mixture was refluxed overnight again. The excess ethyl formate was removed in vacuo and the residue flash chromatographed over silica gel in 1:1

hexane/ethyl acetate to yield 9.52 g of a golden oil which slowly crystallized after several days. This oil (9.40 g, 28 mmol, 1 eq) was dissolved in THF and to it LAH (1M in THF, 84.0 mL, 84 mmol, 3 eq) was slowly added via syringe under N₂. After stirring for 1 h, the mixture was worked up as described in Pieser and Pieser, V.1 pg. 584 (Steinhardt procedure) to yield 8.47 g of an orange oil. NMR (200 MHz, CDCl₃) δ 6.84 (d, 2H, J= 10Hz); 6.55 (d, 2H, J= 10Hz); 5.02 (s, 2H); 4.26 (s, 2H); 3.27 (s, 3H); 2.81 (s, 3H); 2.58 (t, 2H, J= 7Hz); 1.67 (t of t, 2H, J= 7.7Hz); 1.35 (t of q, 2H, J= 7.7Hz); 0.87 (t, 3H, J=7Hz). Anal. Calcd. for C₁₇H₂₄ClN₃O: C, 63.44; H, 7.52; N, 13.06. Found: C, 63.60; H, 7.61; N, 12.86.

PART B: Preparation of 2-n-Butyl-4-chloro-5-methoxymethyl-1-[4-(N-methyl-2-carboxy-3,6-dichlorobenzamid)benzyl]imidazole

20 2-n-Butyl-4-chloro-5-methoxymethyl-1-[N-methyl-4-aminobenzyl]imidazole (2.00 g, 6.2 mmol, 1 eq) and 3,6-dichlorophthalic anhydride (1.35 g, 6.2 mmol, 1 eq) were reacted by the procedure described in Example 2, Part D to give 2.37 g of a white powder; m.p. 120.0-123.5°. The NMR shows a 7:2 mixture of conformers in DMSO-d₆. NMR (200 MHz, DMSO-d₆) δ (major conformer only) 14.25 (m, 1H); 7.76-6.85 (m, 6H); 5.09 (s, 2H); 4.18 (s, 2H); 3.06 (s, 3H); 2.37 (t, 2H, J= 7Hz); 1.38 (t of t, 2H, J= 7.7Hz); 1.21 (t of q, 2H, J= 7.7Hz); 0.77 (t, 3H, J= 7Hz). Anal. Calcd. for C₂₅H₂₆Cl₃N₃O₄: C, 55.72; H, 4.86; Cl, 19.74. Found: C, 55.48; H, 4.88; Cl, 19.77.

Example 7B

PART A: Preparation of 2-n-Butyl-1-(4-carbomethoxybenzyl)-4-chloro-5-(methoxymethyl)imidazole

5 2-Butyl-4-chloro-5-hydroxymethyl-1-(4-carboxybenzyl)imidazole (17.6 g), methanol (500 mL) and conc. sulfuric acid (50 mL) were mixed and refluxed overnight. Potassium carbonate (100 g) was then carefully added to the solution which was cooled over ice. The reaction mixture was then stirred for 2.5
10 hours. The solvent was removed in vacuo and the residue dissolved in water (1 L). This aqueous mixture was extracted with ethyl acetate (3 x 400 mL). The organic layers were combined, dried (MgSO_4) and the solvent removed in vacuo to yield
15 15.2 g of an oil. NMR (200 MHz, $\text{DMSO}-d_6$) δ 8.46 (d, 2H, J = 9Hz); 7.68 (d, 2H, J = 9Hz); 5.82 (s, 2H); 4.80 (s, 2H); 4.37 (s, 3H); 3.66 (s, 3H); 3.02 (t, 2H, J = 7Hz); 2.01 (t of t, 2H, J = 7.7Hz); 1.77 (t of q, 2H, J = 7.7Hz); 1.33 (t, 3H, J = 7Hz). Anal. Calcd. for
20 $\text{C}_{18}\text{H}_{23}\text{ClN}_2\text{O}_3$: C, 61.62; H, 6.61; N, 7.99. Found: C, 61.79; H, 6.78; N, 7.82.

PART B: Preparation of 2-n-Butyl-1-(4-carboxybenzyl)-4-chloro-5-(methoxymethyl)imidazole

25 2-n-Butyl-1-(4-carbomethoxybenzyl)-4-chloro-5-(methoxymethyl)imidazole (15.2 g, 43.3 mmol, 1 eq), 0.5 N KOH in methanol (130 mL, 65.0 mmol, 1.5 eq), water (10 mL) and methanol (50 mL) were mixed and refluxed for 4 hours. The solvent was removed in
30 vacuo and the residue dissolved in water (300 mL). The pH was adjusted to 4 with conc. HCl and this aqueous mixture extracted with ethyl acetate (3 x 300 mL). The organic layers were combined, dried (MgSO_4), the solvent removed in vacuo and the crude
35 residue recrystallized from hexane/butyl chloride to

994 88015687

yield 9.6 g of white solid; m.p. 126.5-127.5°. NMR (200 MHz, DMSO- d_6) δ 12.95 (bs, 1H); 7.93 (d, 2H, $J = 9$ Hz); 7.16 (d, 2H, $J = 9$ Hz); 5.30 (s, 2H); 4.31 (s, 2H); 3.19 (s, 3H); 2.50 (t, 2H, $J = 7$ Hz); 1.49 (t of t, 2H, $J = 7.7$ Hz); 1.24 (t of q, 2H, $J = 7.7$ Hz); 0.80 (t, 3H, $J = 7$ Hz). Anal. Calcd. for $C_{17}H_{21}ClN_2O_3$: C, 60.62; H, 6.29; N, 8.32. Found: C, 60.89; H, 6.10; N, 8.03.

10 PART C: Preparation of 2-n-Butyl-1-[4-(N-(2-carboxy-phenyl)carboxamido)benzyl]-4-chloro-5-methoxymethyl)imidazole

2-n-Butyl-1-(4-carboxybenzyl)-4-chloro-5-(methoxymethyl)imidazole (6.00 g, 17.8 mmol, 1 eq),
 15 thionyl chloride (13.0 mL, 178 mmol, 10 eq) and chloroform (100 mL) were mixed and refluxed for 6 h. The solvent was removed in vacuo, and the residue dissolved in toluene. The solvent was removed on the rotary evaporator and the evaporation from toluene
 20 repeated to remove all of the thionyl chloride. This yielded 6.0 g of acid chloride as an amber gum. IR 1776, 1745 cm^{-1} . Anthranilic acid (0.737 g, 5.36 mmol, 1 eq) was dissolved in 1.000 N NaOH (10.75 mL, 10.7 mmol, 2 eq) and water (100 mL) and cooled over
 25 ice. The aforementioned acid chloride (1.91 g, 5.36 mmol, 1 eq) dissolved in THF (50 mL) was slowly added via a dropping funnel to the stirred and cooled anthranilic acid solution. The following day, more anthranilic acid (74 mg, 0.536 mmol, 0.1 eq) was added
 30 to bring the reaction to completion. After 1.5 h, the solution was acidified to pH=5 with 1N HCl and extracted with ethyl acetate (1 x 100mL). The ethyl acetate layer was then washed with water (3 x 50 mL), and brine (1 x 50 mL), dried ($MgSO_4$) and the solvent
 35 removed in vacuo to yield 2.28 g of a brown glass.

995



88015687

1992

This glass was dissolved in a minimum amount of ethyl acetate and dicyclohexylamine ("DCHA", 1 eq) was added thereto. The salt did not crystallize and therefore was flash chromatographed over silica gel starting in 100% ethyl acetate and finishing in 1:1 ethyl acetate/isopropanol to yield 1.44 g of an oil. This oil was dissolved in ethyl acetate (100 mL) and a minimum of methanol, and washed with 1N HCl (2x50mL). The ethyl acetate layer was dried (MgSO₄) and the solvent removed in vacuo to yield 0.52 g of an amber oil. NMR (200 MHz, CDCl₃) δ 12.53 (s, 1H); 8.91 (d, 1H, J= 8Hz); 8.23 (d, 1H, J= 7Hz); 8.08 (d, 3H, J= 7Hz); 7.62 (t, 1H, J= 6Hz); 7.11 (t, 2H, J= 7Hz); 5.30 (s, 2H); 4.30 (s, 2H); 3.30 (s, 3H); 2.72 (t, 2H, J= 7Hz); 1.72 (t of t, 2H, J= 7.7Hz); 1.31 (t of q, 2H, J= 7.7Hz); 0.83 (t, 3H, J= 7Hz). Anal. Calcd. for C₂₅H₂₅ClN₃O₄·(H₂O)_{1.5}: C, 59.81; H, 5.85; Cl, 7.36. Found: C, 59.78; H, 6.38; Cl, 7.51.

Examples 79-84 in Table 5 were made or could be made by procedures described in Example 78 and by methods familiar to one skilled in the art.






Table 5

25						
30						
	Ex. No.	R ⁶	R ⁷	R ⁸	R	MP (°C)
	79	n-butyl Cl		CH ₂ OCH ₃		(1300) ^a

35 - 996

88015687

Table 5 (continued)

Ex. No.	R ⁶	R ⁷	R ⁸	R	MP (°C)
5	n-butyl	Cl	CH ₂ OCH ₃		(glass) ^b
10	n-butyl	Cl	CH ₂ OCH ₃		(white solid) ^c
15	n-butyl	Cl	CH ₂ OCH ₃	 L-isomer	149-152
	n-butyl	Cl	CH ₂ OCH ₃	 L-isomer	134.5-136.0
20	n-butyl	Cl	CH ₂ OCH ₃		

- a NMR (200 MHz, DMSO-d₆) δ 8.01 (d, 2H, J= 7Hz); 7.17 (d, 2H, J= 7Hz); 5.31 (s, 2H); 4.27 (s, 2H); 3.18 (s, 3H); 2.50 (t, 2H, J= 7Hz); 1.50 (t of t, 2H, J= 7.7Hz); 1.21 (t of q, 2H, J= 7.7Hz); 0.80 (t, 3H, J= 7Hz).
- b NMR (200 MHz, CDCl₃) δ 11.52 (s, 1H) 8.55 (d, 1H, J= 7 Hz); 8.0 (d, 2H, J= 7Hz) 7.41 (t, 1H, J= 7Hz); 7.14 (d, 2H, J= 7Hz); 7.04 (d, 1H, J= 7Hz); 5.30 (s, 2H); 4.25 (s, 2H); 3.30 (s, 3H); 2.73 (t, 2H, J= 7Hz); 2.60 (s, 3H); 1.68 (t of t (br), 2H); 1.29 (t of q, 2H, J= 7.7Hz); 0.81 (t, 3H, J= 7Hz).
- c NMR (200 MHz, CDCl₃) δ 12.05 (s, 1H); 8.88 (d, 1H, J= 7Hz); 8.23 (d, 2H, J= 8Hz); 8.11 (d, 1H, J= 7Hz); 7.51 (t, 1H, J= 7Hz); 7.25-7.11 (m, 3H); 5.29 (s, 2H); 4.31 (s, 2H); 3.29 (s, 3H); 2.62 (t, 2H, J= 7Hz); 1.63 (t of t, 2H, J= 7.7Hz); 1.26 (t of q, 2H, J= 7.7Hz); 0.75 (t, 3H, J= 7Hz) IR: 1671, 753 cm⁻¹.

997



88015687

143

PART A: Preparation of Methyl 4'-methylbiphenyl-3-carboxylate

To a stirred solution of 25.2 g of methyl 3-iodobenzoate and 21.0 g of 4-iodotoluene at 180-190° under nitrogen was added 30.3 g of copper powder portionwise over 1 hour. When approximately one-third of the copper had been added, the reaction initiated and the temperature increased spontaneously to 240°. The mixture was allowed to cool to 210°, then was held at 210° during the addition of the remaining copper and for an additional hour. The mixture was allowed to cool to room temperature and was filtered employing benzene as solvent; the resulting filtrate was concentrated in vacuum to provide the crude product. Column chromatography on silica gel (elution = 50-100% benzene/hexane) followed by distillation furnished 7.60 g of methyl 4'-methylbiphenyl-3-carboxylate [bp: 114-115°C (0.025 torr)] as a colorless oil; NMR (200 MHz, CDCl₃): δ 8.27 (br s, 1H); 7.99 (d, 1H); 7.77 (d, 1H); 7.50 (t, 1H); 7.39 (A₂B₂, 4H); 3.94 (s, 3H); 2.41 (s, 3H).

The following methylbiphenyl starting materials were prepared employing the above procedure.

		NMR (200 MHz, CDCl ₃)
a)		δ 7.78 (d, 1H); 7.46 (d, 1H); 7.35 (t, 2H); 7.19 (s, 4H); 3.64 (s, 3H); 2.37 (s, 3H)
b)		δ 7.80 (d of d, 1H); 7.57 (t of d, 1H); 7.41 (m, 2H); 7.19 (s, 4H); 2.37 (s, 3H)

998

88015687

15

Alternatively methyl 4'-methylbiphenyl-2-carboxylate (compound a) and tert-butyl 4'-methylbiphenyl-2-carboxylate can be prepared by chemistry described by A. Meyers via the following five-step procedure.

5

Step 1: Preparation of 2-Methoxybenzoyl chloride

To 30 g of 2-anisic acid in 500 mL of round-bottom flask was added dropwise 50 mL of thionyl chloride. After all of the thionyl chloride was added, the reaction mixture was stirred at room temperature for 18 hours. Excess thionyl chloride was then distilled off by water aspirator and the remaining liquid was vacuum distilled (82°/0.7 mm Hg). Desired 2-methoxybenzoyl chloride was obtained as a colorless liquid, 32 g.

Step 2: Preparation of 4,4-Dimethyl-2-(2-methoxyphenyl)oxazoline

20 g of 2-Amino-2-methyl-1-propanol was dissolved in 100 mL of methylene chloride and the mixture was cooled with ice. Meanwhile, 17 g of 2-methoxybenzoyl chloride prepared from Step 1 was placed in a dropping funnel, diluted with 50 mL of methylene chloride and added dropwise. After the addition of the acid chloride, the cooling ice bath was removed and the reaction mixture was stirred at room temperature for 2 hours.

The reaction mixture was concentrated to remove the solvent and the solids obtained were triturated with water, collected by filtration and washed with water. Thus obtained solids were dried in vacuo to give a colorless light solid, 20.5 g.

The solid was placed in 200 mL of round-bottom flask and 22 mL of thionyl chloride was added slowly to the solid without any solvent. At the beginning of

the addition the reaction was vigorous but was control
lable. After the addition of thionyl chloride was
complete, the yellow reaction mixture was stirred at
room temperature for 1 hour. The reaction mixture was
5 poured into 200 mL of ether and the resulting solids
were collected and washed with ether. The solids were
dissolved in 100 mL of water and the pH of the
solution was adjusted to 10 by adding 1N NaOH. The
aqueous solution was extracted into ether 3 times.
10 The combined ether extracts were dried (Na_2SO_4)
and concentrated to give the desired product as a
white solid, 18 g. m.p. 70-72°.

15 Step 3: Preparation of 2-(4'-Methylbiphenyl-2-yl)-4,4-
dimethyloxazoline

4-Methylphenyl Grignard reagent was prepared
from 2.5 g of magnesium and 13 mL of 4-bromotoluene
in 200 mL of anhydrous THF. The Grignard reagent was
added to 10 g of the product from Step 2 in 100 mL of
20 anhydrous THF and the reaction mixture was stirred at
room temperature for 2 hours. The reaction mixture
was concentrated and the residue was treated with 200
mL of saturated NH_4Cl solution and the mixture was
stirred at room temperature for 30 minutes. The
25 aqueous solution was then extracted with ethyl
acetate. The crude product obtained upon concentration
of the ethyl acetate extracts were purified by flash
column chromatography (silica gel, hexane:ethyl
acetate=2:1) to give the desired compound as a
30 colorless liquid, 11.8 g.

Step 4: Preparation of 4'-Methylbiphenyl-2-carboxylic
acid

A mixture of 10 g of the product from Step 3 and
35 200 mL of 4.5 N HCl was refluxed for 12 hours. During

1000

88015687

this period of time the desired compound was isolated as a brownish oil floating on the surface of the reaction medium. The reaction mixture was cooled to room temperature. The product which was oily initially began to solidify upon cooling. The product was extracted with ethyl ether. Upon concentration of the ether extract the desired product was obtained as a colorless solid, 7 g. m.p. 140-142°.

10 Step 5: Esterification of 4'-methylbiphenyl-2-
1 carboxylic acid

Preparation of methyl 4'-methylbiphenyl-2-
carboxylate

To 100 mL of methanol was added dropwise 5 mL of acetyl chloride with ice cooling. After stirring the mixture for 15 minutes, 5 g of the acid from Step 4 was added at once and the mixture was refluxed for 4 hours. The reaction mixture was concentrated to remove the solvent and the desired methyl ester was obtained as a thick liquid, 5 g.

Preparation of tert-butyl 4'-methylbiphenyl-2-
carboxylate

To a solution of 42.4 g of 4'-methylbiphenyl-2-
25 carboxylic acid in 200 mL of methylene chloride at 0° was added dropwise 20 mL of oxalyl chloride. The reaction was allowed to warm to 25° and then was stirred at 25° for 3 hours. The solvent was removed in vacuo. The residue was dissolved in benzene, and the benzene then removed in vacuo to provide 46.1 g of crude acid chloride.

The acid chloride prepared above was dissolved in 600 mL of tetrahydrofuran. To this solution at 0° was added 26.0 g of potassium t-butoxide portionwise

35

1001


88015687

such that the reaction temperature did not exceed 15-20°C. The resulting mixture was then allowed to stir at 25°C for 1 hour. The reaction mixture was poured into water, and the resulting emulsion was extracted with diethyl ether. The combined organic phases were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated. Distillation provided 49.5 g of tert-butyl 4'-methoxybiphenyl-2-carboxylate (bp 115-120°/0.05 torr). ¹H NMR (200 MHz, CDCl₃): δ 7.73 (d of d, 1H), 7.46-7.27 (m, 3H); 7.18 (s, 4H); 2.40 (s, 3H); 1.30 (s, 9H).

PART B: Preparation of Methyl 4'-bromomethylbiphenyl-3-carboxylate

A solution of 7.31 g of Methyl 4'-methylbiphenyl-3-carboxylate, 5.75 g of N-bromosuccinimide, 0.125 g of azo(bisisobutyronitrile), and 500 mL of carbon tetrachloride was refluxed for 3 hours. After cooling to room temperature the resulting suspension was filtered and then concentrated in vacuo to provide 9.90 g of crude methyl 4'-bromomethylbiphenyl-3-carboxylate which was used in a subsequent reaction without further purification; NMR (200 MHz, CDCl₃): δ 8.28 (s, 1H); 8.05 (d, 1H); 7.79 (d, 1H); 7.67-7.48 (m, 5H); 4.55 (s, 2H); 3.98 (s, 3H).

The following bromomethylbiphenyl intermediates were prepared employing the above procedure.



NMR (200 MHz, CDCl₃)


δ 7.82 (d, 1H);
7.59-7.23 (m, 7H); 4.52
(s, 2H); 3.62 (s, 3H)

35

1002

88015687


b)



δ 7.86 (d of d, 1H);
 7.62 (t of d, 1H);
 7.53-7.21 (m, 6H); 4.52
 (s, 2H)

5

c)



δ 7.79 (d, 1H);
 7.56-7.24 (m, 7H); 4.51
 (s, 2H); 1.25 (s, 9H).

10

PART C: Preparation of 1-[(3'-Carbomethoxybiphenyl-4-yl)methyl]-2-butyl-4-chloro-5-hydroxymethyl-imidazole

To a suspension of 1.43 g of sodium methoxide in
 20 mL of dimethylformamide at 25° was added a solution
 of 5.00 g of 2-butyl-4(5)-chloro-5(4)-hydroxymethyl
 imidazole in 15 mL of DMF. The resulting mixture was
 stirred at 25° for 0.25 hours, and then to this mix-
 ture was added dropwise a solution of 9.90 g of methyl
 4'-bromomethylbiphenyl-3-carboxylate in 15 mL of DMF.
 Finally, the reaction mixture was stirred at 40° for 4
 hours. After cooling to 25°, the solvent was removed
 in vacuo. The residue was dissolved in ethyl acetate,
 and this solution was washed with water and brine,
 dried over anhydrous sodium sulfate, filtered, and
 concentrated. The crude product contains two
 regioisomers, the faster moving one by TLC being the
 more potent isomer. Column chromatography on silica
 gel (elution: 10-25% ethyl acetate/benzene) afforded
 3.85 g of 1-[(3'-carbomethoxybiphenyl-4-yl)methyl]-
 2-butyl-4-chloro-5-hydroxymethylimidazole (m.p.
 162-163°), the regioisomer of higher R_f : NMR (200
 MHz, $CDCl_3$) 8.24 (s, 1H); 8.03 (d, 1H); 7.76 (d,
 1H); 7.52 (t, 1H); 7.33 (m, 2H); 5.27 (s, 2H);
 4.52 (d, 2H); 3.93 (s, 3H); 2.60 (t, 2H); 1.89 (t,
 1H); 1.67 (quint., 2H); 1.35 (sext., 2H); 0.88 (t, 3H).

- 1003

88015687

151 0-200-010
PART D: Preparation of 1-[(3'-Carbomethoxybiphenyl-4-yl)methyl]-2-butyl-5-hydroxymethylimidazole

A mixture of 1.00 g of 10% palladium/carbon and 1.00 g of 1-[(3'-carbomethoxybiphenyl-4-yl)methyl]-2-butyl-4-chloro-5-hydroxymethyl imidazole in 20 mL of methanol was stirred at 25° for five minutes. Hydrogen gas was bubbled into the solution, and the mixture was stirred under H₂(g) (1 atm.) at 25° for 3.5 hours. The mixture was filtered, and the resulting solution concentrated in vacuo. Column chromatography (elution: 0-5% methanol/chloroform) furnished 0.33 g of 1-[(3'-carbomethoxybiphenyl-4-yl)methyl]-2-butyl-5-hydroxymethyl imidazole. NMR (200 MHz, DMSO-d₆) δ 8.20 (s, 1H); 7.98 (d, 2H); 7.65 (t, 1H); 7.41 (A₂M₂, 4H); 6.80 (s, 1H); 5.30 (s, 2H); 5.12 (t, 1H); 4.37 (d, 2H); 3.90 (s, 3H); 2.52 (t, 2H); 1.51 (quint., 2H); 1.27 (sext., 2H); 0.80 (t, 3H).

The following intermediates shown below were also prepared by the procedures described in Part C or Parts C and D above.

25


30

35


1004

88015687

5




10

R⁶R⁷R⁸MP (°C)

15

n-butyl

Cl


CH₂OH

162-163

20

n-butyl


Cl

CH₂OH(oil)^a

25

n-butyl

H


CH₂OH

139-141

30

n-butyl


I

CH₂OH

125-126

35


n-butyl

CH₂OH Cl

116-118

39

n-butyl

CH₂OH Cl

122-124

1005

88015687

a NMR (200 MHz, CDCl_3) δ 7.82 (d of d, 1H);
7.58 (t of d, 1H); 7.44 (t of d, 1H); 7.35 (d
of d, 1H); 7.11 (A_2B_2 , 4H); 5.21 (s, 2H);
4.46 (s, 2H); 2.59 (t, 2H); 1.60 (quint, 2H);
1.29 (sext., 2H); 0.82 (t, 3H).

PART E: Preparation of 1-[(3'-Carboxybiphenyl-4-yl)-
methyl]-2-butyl-4-chloro-5-hydroxymethyl-
imidazole

10 A solution of 0.30 g of 1-[(3'-carbomethoxy-
biphenyl-4-yl)methyl]-2-butyl-4-chloro-5-hydroxymethyl-
imidazole in 16 mL of ethanol and 8 mL of 10% aqueous
sodium hydroxide was refluxed for 5 hours. After
cooling, the reaction mixture was filtered, and the
15 solvent was removed in vacuo. The residue was dis-
solved in water, and the solution was acidified to pH
3.5 using hydrochloric acid. The precipitated solid
was recovered by filtration and recrystallized from
aqueous ethanol to furnish 0.24 g of 1-[(3'-carboxy-
20 biphenyl-4-yl)methyl]-2-butyl-4-chloro-5-hydroxymethyl
imidazole (m.p. 180-181°); NMR (200 MHz, $\text{DMSO}-d_6$):
 δ 8.26 (s, 1H); 8.04 (d, 1H); 7.77 (d, 1H); 7.52 (t,
1H); 7.36 (A_2M_2 , 4H); 5.30 (s, 2H); 4.48 (s, 2H);
2.57 (t, 2H); 1.64 (quint., 2H); 1.34 (sext., 2H);
25 0.87 (t, 3H).

Example 86

PART A: Preparation of 1-[(3'-Carbomethoxybiphenyl-4-
yl)methyl]-2-butyl-4-chloro-5-methoxymethyl-
30 imidazole

A solution of 5.00 g of 1-[(3'-carbomethoxybi-
phenyl-4-yl)methyl]-2-butyl-4-chloro-5-hydroxymethyl-
imidazole and 1.0 mL of conc. sulfuric acid in 200 mL
of methanol was refluxed for 20 hours. After cooling,

the solvent was removed in vacuo, and the residue was poured into saturated sodium bicarbonate solution. The resulting mixture was extracted with methylene chloride, and the combined organic phases were washed with water and brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. Column chromatography on silica gel (elution: 0-20% ethyl acetate/benzene) furnished 5.35 g of 1-[(3'-carbo-methoxybiphenyl-4-yl)methyl]-2-butyl-4-chloro-5-methoxymethylimidazole; NMR (200 MHz, CDCl_3): δ 8.26 (t, 1H); 8.03 (d of t, 1H); 7.76 (d of t, 1H); 7.51 (t, 1H); 7.33 (A_2M_2 , 4H); 5.20 (s, 2H); 4.31 (s, 2H); 3.94 (s, 3H); 3.27 (s, 3H); 2.59 (t, 2H); 1.68 (quint., 2H); 1.34 (sext., 2H); 0.87 (t, 3H).

The following intermediates were prepared or could be prepared using the above described procedure.

20

25


30






- 1007

35

88015687

154



10	<u>R⁶</u>	<u>R⁷</u>	<u>R⁸</u>		<u>MP (°C)</u>
	n-butyl	Cl	CH ₂ OCH ₃		oil ^a
15	n-butyl	Cl	CH ₂ OCH ₃		oil ^b
20	n-butyl	Cl			oil ^c

- 25 a -NMR (200 MHz, CDCl₃) δ 7.82 (d, 1H, J = 7Hz); 7.50 (t, 1H, J = 7Hz); 7.38 (t, 1H, J = 7Hz); 7.30 (d, 1H, J = 7Hz); 7.26 (d, 2H, J = 10Hz); 7.00 (d, 2H, J = 10Hz); 5.14 (s, 2H); 4.32 (s, 2H); 3.63 (s, 3H); 3.28 (s, 3H); 2.60 (t, 2H, J = 7Hz); 1.70 (t of t, 2H, J = 7.7Hz); 1.36 (t of q, 2H, J = 7.7Hz); 0.89 (t, 3H, J = 7Hz).
- 30 b -NMR (200 MHz, CDCl₃) δ 7.88 (d of d, 1H); 7.63 (t of d, 1H); 7.51 (t of d, 1H); 7.41 (d of d, 1H); 7.17 (A₂B₂, 4H); 5.20 (s, 2H); 4.30 (s, 2H); 3.27 (s, 3H); 2.59 (t, 2H); 1.67 (quint, 2H); 1.35 (sext, 2H); 0.87 (t, 3H).

1008

88015687

155

c -NMR (200 MHz, CDCl_3) δ 7.84 (d, 1H); 7.53 (t, 1H); 7.40 (t, 1H); 7.29 (m, 3H); 7.04 (d, 2H); 5.22 (s, 2H); 4.36 (s, 2H); 3.65 (s, 3H); 3.61 (sept., 1H); 2.59 (t, 2H); 1.68 (quint., 2H); 1.33 (sext., 2H); 1.14 (d, 6H); 0.88 (t, 3H).

PART B: Preparation of 1-[(3'-Carboxybiphenyl-4-yl)-methyl]-2-butyl-4-chloro-5-methoxymethyl-
imidazole

By the procedure described in Example 85, Part E, 3.35 g of the title compound was prepared from 5.35 g of 1-[(3'-carbomethoxy)biphenyl-4-yl)methyl]-2-butyl-4-chloro-5-methoxymethylimidazole; NMR (200 MHz, CDCl_3) δ 8.33 (s, 1H); 8.11 (d, 1H); 7.80 (d, 1H); 7.55 (t, 1H); 7.34 (A_2M_2 , 4H); 5.21 (s, 2H); 4.32 (s, 2H); 3.27 (s, 3H); 2.63 (t, 2H); 1.68 (quint., 2H); 1.34 (sext., 2H); 0.86 (t, 3H).

Example 87

Preparation of 1-[(3'-Carboxybiphenyl-4-yl)methyl]-2-butyl-4-chloro-5-acetoxymethylimidazole

A solution of 0.10 g of 1-[(3'-carboxybiphenyl-4-yl)methyl]-2-butyl-4-chloro-5-hydroxymethylimidazole, 5 mg of N,N-dimethylaminopyridine, 0.10 mL of acetic anhydride, and 0.14 mL of triethylamine in 8 mL of tetrahydrofuran was stirred for 4.5 hours at 25°. The reaction mixture was poured into water, and dilute aqueous sodium hydroxide was added until the pH of the solution remained in the range of pH 8-9. The solution was then acidified to pH 3.5 using 10% aqueous hydrochloric acid and extracted with ethyl acetate. The combined organic phases were washed with brine, dried over anhydrous sodium sulfate and concentrated.

1009

88015687

Column chromatography on silica gel (elution: 0.5% 1-propanol/chloroform) furnished 0.065 g of 1-[(3'-carboxybiphenyl-4-yl)methyl]-2-butyl-4-chloro-5-acetoxymethylimidazole, m.p. 172-173°; NMR (200 MHz, DMSO- d_6): δ 8.17 (s, 1H); 7.93 (t, 2H); 7.61 (t, 1H); 7.43 (A_2B_2 , 4H); 5.32 (s, 2H); 4.99 (s, 2H); 2.60 (t, 2H); 1.76 (s, 3H); 1.53 (quint., 2H); 1.28 (sext., 2H); 0.82 (t, 3H).

Example 88

10 Preparation of 1-[(3'-Trimethylacetoxymethoxycarbonylbiphenyl-4-yl)methyl]-2-butyl-4-chloro-5-hydroxymethylimidazole

To a solution of 1.25 g of 1-[(3'-carboxybiphenyl-4-yl)methyl]-2-butyl-4-chloro-5-hydroxymethylimidazole in 10 mL of dimethylformamide at 25° was added 0.17 g of sodium methoxide followed after 5 minutes by 0.45 g of chloromethyl trimethylacetate. The mixture was stirred at 25° for 4 days. The solvent was removed in vacuo and the residue was dissolved in ethyl acetate. This solution was washed with water and brine, dried over anhydrous sodium sulfate, filtered and concentrated. Column chromatography on silica gel afforded 1.38 g of the product as a glassy solid. NMR (200 MHz, $CDCl_3$) δ 7.87 (d, 1H); 7.54 (t, 1H); 7.43 (t, 1H); 7.29 (d, 1H); 7.11 (A_2B_2 , 4H); 5.72 (s, 2H); 5.24 (s, 2H); 4.51 (s, 2H); 2.61 (t, 2H); 2.06 (br s, 1H); 1.68 (quint., 2H); 1.36 (sext., 2H); 1.17 (s, 9H); 0.88 (t, 3H).

Example 89

30 PART A: Preparation of 4'-methylbiphenyl-2-carboxylic acid

Methyl 4'-methylbiphenyl-2-carboxylate (10.0 g, 44.2 mmol, 1 eq), 0.5 N KOH in methanol (265.5 mL, 133 mmol, 3 eq), and water (50 mL) were mixed and refluxed

1010

88015687

under N_2 . After 5 hours, the solvent was removed in vacuo and water (200 mL) and ethyl acetate (200 mL) added. The aqueous layer was acidified with concentrated hydrochloric acid to a pH of 3 and the layers were separated. The aqueous phase was extracted with ethyl acetate (2 x 200 mL), the organic layers collected, dried ($MgSO_4$) and the solvent removed in vacuo to yield 8.71 g of a white solid; m.p. 140.0-145.0. NMR (200 MHz, $DMSO-d_6$) δ 7.72 (d, 1H, J= 7Hz); 7.56 (t, 1H, J= 7Hz); 7.45 (d, 1H, J= 7Hz); 7.40 (t, 1H, J= 7Hz); 7.25 (s, 4H); 2.36 (s, 3H). Anal. Calcd. for $C_{14}H_{12}O_2$: C, 79.23; H, 5.70. Found: C, 79.22; H, 5.47.

15 PART B: Preparation of 4'-Methyl-2-cyanobiphenyl
4'-Methylbiphenyl-2-carboxylic acid (8.71 g, 41 mmol, 1 eq) and thionyl chloride (30.0 mL, 411 mmol, 10 eq) were mixed and refluxed for 2 hours. The excess thionyl chloride was removed in vacuo and the residue was taken up in toluene. The toluene was removed by rotary evaporation and this toluene evaporation procedure was repeated to ensure that all of the thionyl chloride was removed. The crude acid chloride was then added slowly to cold (0°C) concentrated NH_4OH (50 mL) so that the temperature was kept below 15°. After 15 minutes of stirring, water (100 mL) was added and solids precipitated. These were collected, washed well with water and dried under high vacuum over P_2O_5 in a dessicator overnight to yield 7.45 g of a white solid; m.p. 126.0-128.5°. NMR (200 MHz, $DMSO-d_6$) δ 7.65-7.14 (m, 10H); 2.32 (s, 3H). Anal. Calcd. for $C_{14}H_{13}NO$: C, 79.59; H, 6.20; N, 6.63. Found C, 79.29; H, 6.09; N, 6.52.

35

1011

88015687

M22

The above product amide (7.45 g, 35 mmol, 1 eq) and thionyl chloride (25.7 mL, 353 mmol, 10 eq) were mixed and refluxed for 3 hours. The thionyl chloride was removed using the same procedure as described above. The residue was washed with a little hexane which partly solubilized the product, but removed the impurity as well to yield 6.64 g of white solid; m.p. 44.0-47.0°. NMR (200 MHz, DMSO- d_6) δ 7.95 (d, 1H, J = 8Hz); 7.78 (t, 1H, J = 7Hz); 7.69-7.32 (m, 6H); 2.39 (s, 3H). Anal. Calcd. for $C_{14}H_{11}N$: C, 87.01; H, 5.74. Found: C, 86.44; H, 5.88.

PART C: Preparation of 4'-bromomethyl-2-cyanobiphenyl
4'-methyl-2-cyanobiphenyl (5.59 g) was

brominated in the benzylic position by the procedure in Example 85, Part B using benzoyl peroxide as an initiator. The product was recrystallized from ether to yield 4.7 g of product; m.p. 114.5-120.0°. NMR (200 MHz, $CDCl_3$) δ 7.82-7.37 (m, 8H); 4.50 (s, 2H). Anal. Calcd. for $C_{14}H_{10}BrN$: C, 61.79; H, 3.70; N, 5.15. Found: C, 62.15; H, 3.45; N, 4.98.

PART D: Preparation of 2-n-butyl-4-chloro-1-[2'-cyanobiphenyl-4-yl)methyl]-5-(hydroxymethyl)-imidazole

4'-Bromomethyl-2-cyanobiphenyl (4.6 g) was alkylated onto 2-n-butyl-4-chloro-5-(hydroxymethyl)-imidazole by the procedure described in Example 1, Part A. Work-up and flash chromatography in 1:1 hexane/ethyl acetate over silica gel to separate the regioisomeric products yielded 2.53 g of the faster eluting isomer. Recrystallization from acetonitrile yielded 1.57 g of analytically pure product; m.p. 153.5-155.5°. NMR (200 MHz, $CDCl_3$) δ 7.82-7.43 (m, 6); 7.12 (d, 2, J = 8Hz); 5.32 (s, 2); 4.52 (s, 2);

2.62 (t, 2, J = 7Hz); 1.70 (t of t, 2, J = 7.7Hz); 1.39 (t of q, 2, J = 7.7Hz); 0.90 (t, 3, J = 7Hz). Anal. Calcd. for $C_{22}H_{22}ClN_3O$: C, 69.56; H, 5.84; N, 11.06. Found: C, 69.45; H, 5.89; N, 10.79.

5

PART E: Preparation of 2-n-butyl-4-chloro-5-hydroxy-methyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole

2-n-Butyl-4-chloro-1-[(2'-cyanobiphenyl-4-yl)-methyl]-5-(hydroxymethyl)imidazole (11.93 g) was converted to the above product by the procedure described in Example 90, Part C. The product was purified by flash chromatography in 100% ethyl acetate to 100% ethanol over silica gel to yield 5.60 g of a light yellow solid. Recrystallization from acetonitrile yielded 4.36 g of light yellow crystals which still melted broadly. The crystals were taken up in 100 mL of hot acetonitrile. The solid that did not dissolve was filtered off to yield 1.04 g of product as a light yellow solid; m.p. 183.5-184.5°. Upon cooling, the mother liquor yielded an additional 1.03 g of product as a light yellow solid; m.p. 179.0-180.0°. NMR (200 MHz, DMSO- d_6) δ 7.75-7.48 (m, 4H); 7.07 (d, 2H, J = 9Hz); 7.04 (d, 2H, J = 9Hz); 5.24 (s, 2H); 5.24 (bs, 1H); 4.34 (s, 2H); 2.48 (t, 2H, J = 7Hz); 1.48 (t of t, 2H, J = 7.7Hz); 1.27 (t of q, 2H, J = 7.7Hz); 0.81 (t, 3H, J = 7Hz). Anal. Calcd. for $C_{22}H_{23}ClN_6O$: C, 62.48; H, 5.48; Cl, 8.38. Found for the solids which did not dissolve in 100 mL of acetonitrile: C, 62.73; H, 5.50; Cl, 8.26. Found for the solid obtained from the mother liquor: C, 62.40; H, 5.23; Cl, 8.35.

- 1013

35

88015687

Example 90

PART A: Preparation of 2-n-Butyl-4-chloro-5-chloro-methyl-1-[(2'-cyanobiphenyl-4-yl)methyl]-imidazole•HCl salt

- 5 2-n-Butyl-4-chloro-5-hydroxymethyl-1-[(2'-cyanobiphenyl-4-yl)methyl]imidazole (15.00 g, 39.3 mmol, 1 eq) was converted to the chloride by the procedure in Example 1, Part B. The reaction time was 5 hours. The crude solid product was washed with
10 ether to remove the yellow color. The solid white powdery product was then dried under high vacuum, yield 10.02 g; m.p. 152.0-154.0°. NMR (200 MHz, CDCl₃) δ 7.85-7.46 (m, 6H); 7.20 (d, 2H, J=10Hz); 5.47 (s, 2H); 4.50 (s, 2H); 3.06 (t, 2H, J= 7Hz); 1.82
15 (t of t, 2H, J= 7.7Hz); 1.45 (t of q, 2H, J= 7.7Hz); 0.94 (t, 3H, J= 7Hz). Mass Calcd. for C₂₂H₂₁Cl₂N₃: 397.1113. Found: 397.1105.

PART B: Preparation of 2-n-Butyl-4-chloro-1-[(2'-cyanobiphenyl-4-yl)methyl]-5-(methoxymethyl)-imidazole

- 20 2-n-Butyl-4-chloro-5-chloromethyl-1-[(2'-cyanobiphenyl-4-yl)methyl]imidazole•HCl salt (5.00 g, 11.5 mmol, 1 eq), sodium methoxide (1.37 g, 25.3 mmol, 2.2 eq) and methanol (100 mL) were mixed and stirred
25 for 3 days. The solvent was removed in vacuo and ethyl acetate (200 mL) and water (200 mL) added. The layers were separated and the aqueous layer was extracted with ethyl acetate (2 x 200 mL). The
30 organic layers were dried (MgSO₄), the solvent removed in vacuo and the residue flash chromatographed over silica gel in 1:1 hexane/ethyl acetate to yield 4.06 g of a clear light yellow oil. NMR (200 MHz, CDCl₃) δ 7.82-7.43 (m, 6); 7.10 (d, 2H, J= 7Hz);
35 5.23 (s, 2H); 4.32 (s, 2H); 3.30 (s, 3H); 2.60 (t, 2H,

1014

88015687

J= 7Hz); 1.70 (t of t, 2H, J= 7.7Hz); 1.38 (t of q, 2H, J= 7.7Hz); 0.89 (t, 3H, J= 7Hz). Anal. Calcd. for $C_{23}H_{24}ClN_3O$: C, 68.11; H, 6.54; Cl, 9.58. Found: C, 68.70; H, 6.11; Cl, 9.51. Mass Calcd. for $C_{23}H_{24}ClN_3O$: 393.1607. Found: 393.1616.

PART C: Preparation of 2-n-Butyl-4-chloro-5-methoxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-methyl)imidazole

10 2-n-Butyl-4-chloro-1-[2'-cyanobiphenyl-4-yl)methyl]-5-methoxymethyl)imidazole (3.94 g, 10 mmol, 1 eq), sodium azide (1.95 g, 30 mmol, 3 eq), and ammonium chloride (1.60 g, 30 mmol, 3 eq) were mixed and stirred in DMF (150 mL) in a round bottom flask
15 connected to a reflux condenser under N_2 . An oil bath with a temperature controller was then used to heat the reaction at 100°C for 2 days, after which the temperature was raised to 120°C for 6 days. The reaction was cooled and 3 more equivalents each of
20 ammonium chloride and sodium azide were added. The reaction was again heated for 5 more days at 120°C. The reaction was cooled, the inorganic salts filtered, and the filtrate solvent removed in vacuo. Water (200 mL) and ethyl acetate (200 mL) were added to the
25 residue and the layers were separated. The aqueous layer was extracted with ethyl acetate (2 x 200 mL), the organic layers were collected, dried ($MgSO_4$) and the solvent removed in vacuo, to yield a dark yellow oil. Flash chromatography in 100% ethyl acetate
30 yielded 3.54 g of a white glass. NMR (200 MHz, $CDCl_3$) δ 7.83 (d, 1H, J= 7Hz); 7.59 (t, 1H, J= 7Hz); 7.50 (t, 1H, J= 7Hz); 7.39 (d, 1H, J= 7Hz); 7.03 (d, 2H, J= 8Hz); 6.73 (d, 2H, J= 8Hz); 5.08 (s, 2H); 4.12 (s, 2H); 3.18 (s, 3H); 2.32 (t, 2H, J= 7Hz); 1.52
35 (t of t, 2H, J= 7.7Hz); 1.11 (t of q, 2H, J= 7.7Hz);

O.83 (t. 3H. J= 7Hz). Mass Calcd. for
 $C_{23}H_{25}ClN_6O$: 436.1178. Found: 436.1750.

CAUTION! The above reaction although uneventful in our hands can be potentially explosive! Crystals that sublimed and collected in the reflux condenser during the reaction were not analyzed, but potentially could be ammonium azide. Hydrazoic acid, which is shock sensitive, could also be potentially produced during the reaction and work-up. Extreme care should be taken!

Example 91

15 PART A: Preparation of 2-butyl-4(5)-hydroxymethyl-
5(4)-nitroimidazole

To a solution of 5.75 g of 2-butyl-4(5)-hydroxymethylimidazole (prepared as described in U.S. 4,355,040) in 200 mL of aqueous methanol at 25°C was added concentrated hydrochloric acid until the pH of the solution reached pH 3. The solvent was then removed in vacuo, and the residue was dissolved in 100 mL of chloroform. To this solution at 25° was added dropwise 15.0 mL of thionyl chloride, and the mixture was refluxed for 1 hour. After cooling, the solvent and excess thionyl chloride were removed in vacuo to provide a viscous yellow oil.

To a solution of 20 mL of concentrated sulfuric acid and 10 mL of concentrated nitric acid at -10° was added a solution of the yellow oil, prepared above, in 10 mL of concentrated sulfuric acid. The resulting mixture was heated on a steam bath for 2 hours. After cooling, the reaction mixture was poured onto water-ice, and the resulting emulsion was extracted with chloroform. The combined organic phases were

1016

88015687

washed with water and brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was then dissolved in 100 mL of 1:12-propanol/water. The solution was then refluxed for 16 hours. Finally, after cooling, the solution was concentrated in vacuo. Column chromatography (elution: methanol/chloroform) afforded 2.64 g of 2-butyl-4(5)-hydroxymethyl-5(4)-nitroimidazole. NMR (200 MHz, DMSO- d_6): δ 12.92 (br s, 1H); 5.80 (br t, 1H); 4.82 (d, 2H); 2.60 (t, 2H); 1.61 (quint., 2H); 1.25 (sext., 2H); 0.84 (t, 3H).

PART B: Preparation of 1-[(2'-tert-butoxycarbonylbiphenyl-4-yl)methyl]-2-butyl-5-hydroxymethyl-4-nitroimidazole

This compound was prepared according to the procedure described in Example 85, Part C. From 2.64 g of 2-butyl-4(5)-hydroxymethyl-5(4)-nitroimidazole and 5.55 g of tert-butyl 4'-bromomethylbiphenyl-2-carboxylate there was obtained 2.05 g of 1-[(2'-tert-butoxycarbonylbiphenyl-4-yl)methyl]-2-butyl-5-hydroxymethyl-4-nitroimidazole. NMR (200 MHz, $CDCl_3$): δ 7.79 (d, 1H); 7.45 (m, 2H); 7.33 (d, 1H); 7.28 (d, 1H); 7.03 (d, 2H); 5.34 (s, 2H); 4.87 (s, 2H); 2.81 (br s, 1H); 2.67 (t, 2H); 1.73 (quint., 2H); 1.37 (sext., 2H); 1.27 (s, 9H); 0.90 (t, 3H).

PART C: Preparation of 1-[(2'-carboxybiphenyl-4-yl)methyl]-2-butyl-5-hydroxymethyl-4-nitroimidazole

A solution of 1.98 g of 1-[(2'-tert-butoxycarbonylbiphenyl-4-yl)methyl]-2-butyl-5-hydroxymethyl-4-nitroimidazole, 20 mL of trifluoroacetic acid, and 20 mL of methylene chloride was stirred at 25° for 1 hour. At this point, the solution was poured into

1017 88015687

water. The resulting mixture was adjusted to pH 3 using 10% sodium hydroxide solution and then extracted with chloroform. The combined organic phases were washed with brine, dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuo. Column chromatography (elution: methanol/chloroform) provided 1.49 g of 1-[(2'-carboxybiphenyl-4-yl)-methyl]-2-butyl-5-hydroxymethyl-4-nitroimidazole; m.p. 204-205.5°. NMR (200 MHz, DMSO-d₆): δ 7.71 (d, 1H); 7.56 (t, 1H); 7.43 (t, 1H); 7.32 (m, 3H); 7.15 (d, 2H); 5.63 (br s, 1H); 5.42 (s, 2H); 4.83 (s, 2H); 2.54 (t, 2H); 1.50 (quint., 2H); 1.24 (sext., 2H); 0.76 (t, 3H).

15

Example 92

PART A: Preparation of 1-[(2'-tert-butoxycarbonylbiphenyl-4-yl)methyl]-2-butyl-4-iodo-5-(2-methoxyethoxymethoxymethyl)imidazole

To a solution of 5.56 mL of 1.6 M n-butyl-lithium/hexane in 80 mL of tetrahydrofuran at 0° was added dropwise 1.15 mL of i-butanol. To the solution was added 3.28 g of 1-[(2'-tert-butoxycarbonylbiphenyl-4-yl)methyl]-2-butyl-5-hydroxymethyl-4-iodoimidazole followed by 1.15 mL of 2-methoxyethoxymethyl chloride. The resulting solution was stirred at 25° for 16 hours. The mixture was diluted with diethyl ether, washed with water and brine, dried over anhydrous sodium sulfate, filtered and concentrated. Column chromatography afforded 2.61 g of 1-[(2'-tert-butoxycarbonylbiphenyl-4-yl)methyl]-2-butyl-4-iodo-5-(2-methoxyethoxymethoxymethyl)imidazole. NMR (200 MHz, CDCl₃): δ 7.78 (d, 1H); 7.43 (m, 2H); 7.28 (m, 3H); 6.98 (d, 2H); 5.26 (s, 2H); 4.69 (s, 2H); 4.45 (s, 2H); 3.60 (m, 2H); 3.57 (m, 2H); 3.37 (s, 3H); 2.58 (t, 2H); 1.67 (quint., 2H); 1.34 (sext., 2H); 1.26 (s, 9H); 0.87 (t, 3H).

1018

88015687

H5

PART B: Preparation of 1-[(2'-tert-butoxycarbonyl-biphenyl-4-yl)methyl]-2-butyl-5-(2-methoxyethoxymethoxymethyl)-4-trifluoromethylimidazole

5 To a suspension of 22.4 g of cadmium powder powder in 50 mL of dimethylformamide at 25° was added dropwise 8.60 mL of bromochlorodifluoromethane. The resulting mixture was stirred at 25° for 2 hours and then was filtered through a medium-fritted Schlenk
10 funnel under nitrogen pressure to provide a dark brown solution of the trifluoromethyl cadmium reagent.

To a mixture of 15 mL of the above solution and 20 mL of hexamethylphosphoric triamide at 0° was added 2.10 g of copper(I)bromide followed by 2.61 g of
15 1-[(2'-tert-butoxycarbonylbiphenyl-4-yl)methyl]-2-butyl-4-iodo-5-(2-methoxyethoxymethoxymethyl)imidazole in 5 mL of dimethylformamide. The reaction mixture was stirred at 70-75° for 6 hours. After cooling, the mixture was diluted with water and then extracted with
20 methylene chloride. The combined organic phases were washed with water and brine, dried over anhydrous sodium sulfate, filtered, and concentrated. Column chromatography (elution: ethyl acetate/hexane) afforded 2.30 g of 1-[(2'-tert-butoxycarbonylbiphenyl-
25 4-yl)methyl]-2-butyl-5-(2-methoxyethoxymethoxymethyl)-4-trifluoromethylimidazole. NMR (200 MHz, CDCl₃): δ 7.79 (d, 1H); 7.46 (m, 2H); 7.28 (m, 3H); 7.00 (d, 2H); 5.28 (s, 2H); 4.71 (s, 2H); 4.58 (s, 2H); 3.66 (m, 2H); 3.54 (m, 2H); 3.38 (s, 3H); 2.62 (t, 2H);
30 1.70 (quint., 2H); 1.36 (sext., 2H); 1.27 (s, 9H); 0.88 (t, 3H).

PART C: Preparation of 1-[(2'-carboxybiphenyl-4-yl)methyl]-2-butyl-5-hydroxymethyl-4-trifluoromethylimidazole

35 A solution of 2.30 g of 1-[(2'-tert-butoxycarbonylbiphenyl-4-yl)methyl]-2-butyl-5-(2-methoxy-

1019

LEA

88015687

ethoxymethoxymethyl)-5-trifluoromethylimidazole in 200 mL of 1.5 M aqueous tetrafluoroboric acid/acetonitrile was stirred at 25° for 18 hours, and then the mixture was poured into water. The resulting aqueous solution was adjusted to pH 3 employing saturated sodium bicarbonate solution and then was extracted with chloroform. The combined organic phases were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated. Column chromatography (elution: methanol/chloroform) provided 1.38 g of 1-[(2'-carboxybiphenyl-4-yl)methyl]-2-butyl-5-hydroxymethyl-4-trifluoromethylimidazole (m.p. 198-199.5°). NMR (200 MHz, DMSO-d₆): δ 7.75 (d, 1H); 7.54 (t, 1H); 7.43 (t, 1H); 7.32 (m, 3H); 7.10 (d, 2H); 5.36 (s, 2H); 4.51 (s, 2H); 2.56 (t, 2H); 1.56 (quint., 2H); 1.30 (sext., 2H); 0.83 (t, 3H).

Example 93

PART A: Preparation of 4-azidomethyl-2'-methoxycarbonylbiphenyl

To a stirred solution of 4-bromomethyl-2'-methoxycarbonylbiphenyl (150 g, 0.49 mol) in dry DMF (500 ml) was added NaN₃ (80 g, 1.23 mol, 2.5 eq). The mixture was stirred at room temperature overnight (ca. 18 hours), filtered, and the filtrate was partitioned between ethyl acetate and H₂O (500 ml each). The organic phase was washed twice more with H₂O, once with saturated aqueous NaCl solution and dried over anhydrous magnesium sulfate before being filtered and concentrated to leave 111.3 g (85%) of a yellow oil, used in the following step without further purification. NMR (CDCl₃, TMS, δ) 7.9-7.1 (m, 8H); 4.35 (s, 2H); 3.55 (s, 3H) IR V_{max} 2487 cm⁻¹.

88015687

1020

150

PART B: Preparation of 4-aminomethyl-2'-methoxy-
carbonylbiphenyl hydrochloride


The azido compound prepared above was dissolved in liter of methanol. The solution was divided into
 5 three equal volumes and placed in 500 ml Parr bottles. To each flask was added 6.7 g of 5% Pd on carbon (Caution: Pyrophoric! add under a N_2 atmosphere). The flasks were shaken on a Parr hydrogenator under
 10 40-50 psi H_2 for 4-5 hours (overnight is also acceptable). The mixture was suction filtered through a bed of Celite® and the filtrate was concentrated to leave a viscous yellow residue (88 g). This was dissolved in EtOAc (500 ml) to which was added with
 15 stirring a solution of EtOAc saturated with anhydrous HCl (100-150 ml) until precipitation was complete. The amine hydrochloride as produced was suction filtered, washed with EtOAc and hexanes and dried under vacuum to afford 48.5 g (40% overall from the
 20 bromide) white solid; m.p. 204-208°. NMR ($CDCl_3$, CD_3OD ; TMS) δ 7.9-7.25 (m, 8H); 4.2 (s, 2H); 4.1-3.8 (br, 3H; shifts in D_2O); 3.6 (s, 3H). HRMS calcd. for $C_{15}H_{15}NO_2$ (free base); M/Z 241.1103; Found: M/Z: 241.1045.

25 PART C: Preparation of 1-[(2'-carboxybiphenyl-4-yl)-
methyl]-2-propylthio-5-hydroxymethylimidazole








The title compound was prepared from methyl 4'-aminomethylbiphenyl-2-carboxylate by the procedures described in Examples 72, A and B, and 85E; m.p.
 30 194-195°.

The 4-biphenylmethyl compounds in Table 6 were prepared or could be prepared by the procedures illustrated in Examples 85-92 or by procedures
 35 previously described.

5



10

Ex. No.	R ⁶	R ⁷	R ⁸		MP (°C)
15	94	n butyl Cl	CH ₂ OH		168-169.5
19	95	n-butyl CH ₂ OH	Cl		197-198
20	96	n butyl H	CH ₂ OH		154-155
25	97	n butyl H	CH ₂ OH		(amorphous solid) ^a
30	98	n butyl Cl	CH ₂ OCH ₃		166.5-169.0
35	99	n butyl Cl	CH ₂ OCH(CH ₃) ₂		156-158












35

1022

88015687

169








Table 4 (continued)

Ex. No.	R^6	R^7	R^8		MP (°C)
5	100	n-butyl	Br	CH ₂ OH	 175-178
10	101	n-butyl	F	CH ₂ OH	
15	102	n-butyl	I	CH ₂ OH	 165 (dec)
20	103		Cl	CH ₂ OH	
	104		Cl	CH ₂ OH	
25	105	n-butyl	CH ₂ OH	I	 205 (dec)
30	106	n-butyl	Cl	CH ₂ OH	 185-186
	107	ethyl	Cl	CH ₂ OH	 153-156
35	-	1023			

88015687









230

171
Table 6 (continued)

Ex. No.	R ⁶	R ⁷	R ⁸		MP (°C)
108	n-propyl	Cl	CH ₂ OH		198-200
109	n-pentyl	Cl	CH ₂ OH		(amorphous ^b solid)
110	n-hexyl	Cl	CH ₂ OH		84-88
111	n-butyl	Cl	CH ₂ SH		
112	n-butyl	Cl	CH ₂ O 		

1024










88015687

Ex. No.	R ⁶	R ⁷	R ⁸		MP (°C)
10	113	n-propyl Cl	CH ₂ OH		(amorphous ^c solid)
15	114	n-propyl Cl	CHO		(amorphous ^d solid)
20	115	n-butyl Cl	CH ₂ CO ₂ H		221-222
25	116	n-butyl Cl	CH(CH ₃)CO ₂ H		118-120
30	117	n-butyl CH ₂ OH	NO ₂		154-157
35	118	n-butyl CH ₂ OH	Cl		(white ^e powder)
					

1025

88015687

Table 6 (continued)

Ex. No.	R ⁶	R ⁷	R ⁸		MP (°C)
120	n-butyl	Cl			
121	n-butyl	Cl	CH ₂ OCOCH ₃		157-159
122	n-butyl	Cl	CH ₂ OCOCH ₂ CH ₂ - 		
123	n-C ₄ H ₉ S	H	CH ₂ OH		190-191
124	 CH ₂ S	H	CH ₂ OH		194.5-195.5

a -NMR (200 MHz, DMSO-d₆) δ 7.69 (dd, 1H);
 7.54 (d of t, 1H); 7.43 (d of t, 1H); 7.33
 (d, 1H); 7.16 (A₂B₂, 4H); 6.76 (s, 1H);
 5.24 (s, 2H); 4.34 (s, 2H); 2.50 (t, 2H);
 1.49 (quint, 2H); 1.25 (sext, 2H); 0.80 (t,
 3H).

1026

88015687

b -NMR (200 MHz, DMSO- d_6) δ 7.70 (d, 1H),
7.55 (t, 1H), 7.42 (t, 1H), 7.28 (m, 3H),
7.10 (d, 2H), 5.28 (s, 2H), 4.34 (s, 2H),
2.49 (t, 2H), 1.49 (m, 2H), 1.18 (m, 4H),
0.79 (t, 3H).

c -NMR (200 MHz, $CDCl_3/CD_3OD$): δ
7.82-6.93 (m, 8H); 5.21 (s, 2H); 4.47 (s,
2H); 2.55 (t, J= 7.5 Hz, 2H); 1.70-1.59 (m,
2H); 0.92 (t, J= 7.5 Hz, 3H).

d -NMR (200 MHz, $CDCl_3$) 9.65 (s, 1H);
7.95-6.96 (m, 8H); 5.51 (s, 2H); 2.59 (t, J=
7.5 Hz, 2H); 1.70-1.63 (m, 2H); 0.92 (t, J=
7.5 Hz, 3H).

e -NMR (200 MHz, $CDCl_3$) δ 7.76 (d, 1H, J=
7 Hz); 7.57 (t, 1H, J= 7 Hz); 7.49 (t, 1H, J=
7 Hz); 7.40 (d, 1H, J= 7 Hz); 7.02 (d, 2H, J=
8 Hz); 6.81 (d, 2H, J= 8 Hz); 5.03 (s, 2H);
4.28 (s, 2H); 2.46 (t, 2H, J= 7 Hz); 1.47 (t
of t, 2H, J= 7.7 Hz); 1.17 (t of q, 2H, J=
7.7 Hz); 0.73 (t, 3H, J= 7 Hz).

Example 125

Preparation of 1-[(2'-Carboxybiphenyl-4-yl)methyl]-2-
butyl-4-chloroimidazole-5-carboxaldehyde

A mixture of 1.46 g of 1-[2'-carboxybiphenyl-4-
yl)methyl]-2-butyl-4-chloro-5-hydroxymethylimidazole
and 7.30 g of activated manganese dioxide in 40 ml of
tetrahydrofuran was stirred at 25°C for 5 days. The
mixture was filtered through Celite®, and the
filtrate was concentrated in vacuo. Column
chromatography on silica gel (elution: 2-10% methanol/
chloroform) followed by recrystallization from ethyl

1027

88015687

FR

acetate afforded 0.71 g of 1-[(2'-carboxybiphenyl-4-yl)methyl]-2-butyl-4-chloroimidazole-5-carboxaldehyde (m.p. 154-158°C (dec.)). NMR (200 MHz, DMSO- d_6) δ 12.85 (br s, 1H), 9.77 (s, 1H), 7.77 (d, 1H), 7.62 (t, 1H), 7.50 (t, 1H), 7.40 (d, 1H), 7.26 (A_2B_2 , 4H), 5.67 (s, 2H), 2.70 (t, 2H), 1.56 (quint., 2H), 1.28 (sext., 2H), 0.83 (t, 3H).

Example 126

Preparation of Methyl 1-[(2'-carboxybiphenyl-4-yl)methyl]-2-butyl-4-chloroimidazole-5-carboxylate

To a mixture of 1.45 g of 1-[(2'-carboxybiphenyl-4-yl)methyl]-2-butyl-4-chloroimidazole-5-carboxaldehyde and 0.91 g of sodium cyanide in 20 mL of methanol at 25°C was added 0.32 mL of acetic acid followed by 7.25 g of manganese dioxide. The resulting mixture was stirred at 25°C for 40 hours. The reaction mixture was filtered through Celite®, and the filtrate diluted with water. The aqueous solution was adjusted to pH 3 using hydrochloric acid and extracted with methylene chloride. The combined organic phases were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was recrystallized from diethyl ether to afford 0.90 g of methyl 1-[(2'-carboxybiphenyl-4-yl)methyl]-2-butyl-4-chloroimidazole-5-carboxylate (m.p. 154-155°C). NMR (200 MHz, DMSO- d_6): δ 12.75 (br s, 1H), 7.73 (d, 1H), 7.58 (t, 1H), 7.46 (t, 1H), 7.34 (m, 3H), 7.07 (d, 2H), 5.63 (s, 2H), 3.78 (s, 3H), 2.67 (t, 2H), 1.56 (quint., 2H), 1.29 (sext., 2H), 0.83 (t, 3H).

1028

88015687

176
Example 127

Preparation of 1-[(2'-Carboxybiphenyl-4-yl)methyl]-2-butyl-4-chloroimidazole-5-carboxamide

Anhydrous ammonia was bubbled into 40 mL of
5 i-propanol until the solvent was saturated. To this
solution at 25°C was added 0.49 g of powdered sodium
cyanide, then 0.80 g of 1-[(2'-carboxybiphenyl-4-yl)-
methyl]-2-butyl-4-chloroimidazole-5-carboxaldehyde,
and finally 3.48 g of manganese dioxide. This mixture
10 was stirred at 25°C for 65 hours. The reaction
mixture was filtered through Celite®, and the
filtrate concentrated in vacuo. The residue was
dissolved in water, and the aqueous solution was
adjusted to pH 3 using hydrochloric acid and then
15 extracted with methylene chloride. The combined
organic phases were washed with brine, dried over
anhydrous sodium sulfate, filtered, and concentrated.
Column chromatography on silica gel (elution: 0-10%
i-propanol (chloroform) provided 0.22 g of 1-[(2'-
20 carboxybiphenyl-4-yl)methyl]-2-butyl-4-chloroimidazole-
5-carboxamide as a white solid (m.p. 200-202°C). NMR
(200 MHz, DMSO-d₆): δ 12.74 (br s, 1H); 7.71 (d,
2H); 7.56 (t, 1H); 7.48-7.30 (m, 6H); 7.09 (s, 2H);
5.57 (s, 2H); 2.59 (t, 2H); 1.51 (quint., 2H); 1.26
25 (sext., 2H); 0.80 (s, 3H).

Example 128

PART A: Preparation of 1-[(2'-Carbomethoxybiphenyl-4-yl)methyl]-2-butyl-4-chloroimidazole-5-carboxaldehyde

30 A mixture of 2.06 g of 1-[(2'-carbomethoxy-
biphenyl-4-yl)methyl]-2-butyl-4-chloro-5-hydroxymethyl-
imidazole and 3.08 g of activated manganese dioxide in
20 mL of methylene chloride at 25°C was stirred for 40
hours. The reaction mixture was filtered through

1029

88015687

Celite®, and the filtrate concentrated in vacuo.

Column chromatography (elution: ethyl acetate/benzene) provided 1.15 g of 1-[(2'-carboxymethoxybiphenyl-4-yl)methyl]-2-butyl-4-chloroimidazole-5-carboxaldehyde. NMR (200 MHz, CDCl₃) δ 9.76 (s, 1H); 7.83 (d of d, 1H); 7.52 (t of d, 1H); 7.40 (t of d, 1H); 7.31 (d of d, 1H); 7.17 (A₂B₂, 4H); 5.58 (s, 2H); 3.63 (s, 3H); 2.67 (t, 2H); 1.70 (quint., 2H); 1.38 (sext., 2H); 0.90 (t, 3H).

10 PART B: Preparation of 1-[(2'-Carbomethoxybiphenyl-4-yl)methyl]-2-(1-bromobutyl)-4-chloroimidazole-5-carboxaldehyde

A mixture of 1.12 g of 1-[(2'-carbomethoxybiphenyl-4-yl)methyl]-2-butyl-4-chloroimidazole-5-carboxaldehyde and 0.49 g of N-bromosuccinimide in 40 mL of CCl₄ was irradiated (UV-lamp, pyrex filter) for 0.5 hours. The reaction mixture was filtered, and the filtrate was concentrated in vacuo. Column chromatography (elution: ethyl acetate/benzene) afforded 0.54 g of 1-[(2'-carbomethoxybiphenyl-4-yl)methyl]-2-(1-bromobutyl)-4-chloroimidazole-5-carboxaldehyde. NMR (200 MHz, CDCl₃) δ 9.87 (s, 1H); 7.86 (d, 1H); 7.54 (t, 1H); 7.46 (t, 1H); 7.30 (m, 3H); 7.11 (d, 2H); 6.16 (d, 1H); 5.32 (d, 1H); 4.79 (t, 1H); 3.65 (s, 3H); 2.32 (m, 2H); 1.34 (sext., 2H); 0.83 (t, 3H).

30 PART C: Preparation of 1-[(2'-Carbomethoxybiphenyl-4-yl)methyl]-2-(1-trans-butenyl)-4-chloroimidazole-5-carboxaldehyde

A solution of 0.54 g of 1-[(2'-carbomethoxybiphenyl-4-yl)methyl]-2-(1-bromobutyl)-4-chloroimidazole-5-carboxaldehyde and 0.33 mL of 1,8-diazabicyclo[4.5.0]undec-7-ene in 10 mL of

1030

88015687

tetrahydrofuran was stirred at 25°C for 18 hours. the reaction mixture was diluted with diethyl ether, washed with dilute hydrochloric acid, water, and brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. Column chromatography (elution: ethyl acetate/benzene) furnished 0.26 g of 1-[(2'-carbomethoxybiphenyl-4-yl)methyl]-2-(1-trans-butenyl)-4-chloroimidazole-5-carboxaldehyde. NMR (200 MHz, CDCl₃) δ 9.75 (s, 1H); 7.82 (d, 1H); 7.51 (t, 1H); 7.40 (t, 1H); 7.33-7.07 (m, 6H); 6.27 (d, 1H); 5.62 (s, 2H); 3.62 (s, 3H); 2.30 (quint., 2H); 1.09 (t, 3H).

PART D: Preparation of 1-[(2'-Carbomethoxybiphenyl-4-yl)methyl]-2-(1-trans-butenyl)-4-chloro-5-hydroxymethylimidazole

To a solution of 0.26 g of 1-[(2'-carbomethoxybiphenyl-4-yl)methyl]-2-(1-trans-butenyl)-4-chloroimidazole-5-carboxaldehyde in 10 mL of methanol at 0°C was added 0.24 g of sodium borohydride portionwise over 0.5 hours. The mixture was stirred for an additional 0.5 hours at 0°C and then poured into a solution at 10% sodium hydroxide in water. The resulting mixture was extracted with ethyl acetate, and the combined organic phases were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. Column chromatography (elution: ethyl acetate/benzene) provided 0.23 g of 1-[(2'-carbomethoxybiphenyl-4-yl)methyl]-2-(1-trans-butenyl)-4-chloro-5-hydroxymethylimidazole. NMR (200 MHz, CDCl₃) δ 7.84 (d, 1H); 7.53 (t, 1H); 7.40 (t, 1H); 7.29 (m, 3H); 7.08 (d, 2H); 6.86 (d of t, 1H); 6.17 (d, 1H); 5.30 (s, 2H); 4.54 (br s, 2H); 3.63 (s, 3H); 2.23 (quint., 2H); 1.04 (t, 3H).

35

1031

88015687

PART E: Preparation of 1-[(2'-Carboxybiphenyl-4-yl)-methyl]-2-(1-trans-butenyl)-4-chloro-5-hydroxymethylimidazole

This compound was prepared according to the procedure described in Example 85, Part E. From 0.23 g of 1-[(2'-carboxymethoxybiphenyl-4-yl)methyl]-2-(1-trans-butenyl)-4-chloro-5-hydroxymethylimidazole there was obtained 0.16 g of 1-[(2'-carboxybiphenyl)-4-yl)methyl]-2-(1-trans-butenyl)-4-chloro-5-hydroxymethylimidazole (m.p. 198.5-199.5°C). NMR (200 MHz, DMSO-d₆) δ 7.71 (d, 1H); 7.56 (t, 1H); 7.44 (t, 1H); 7.32 (m, 3H); 7.11 (d, 2H); 6.62 (d of t, 1H); 6.39 (d, 1H); 5.38 (s, 2H); 5.33 (br s, 1H); 4.35 (br s, 2H); 2.18 (quint., 2H); 0.99 (t, 3H).

Example 129

Preparation of 1-[(2'-Carboxybiphenyl-4-yl)methyl]-2-(1-trans-butenyl)-4-chloroimidazole-5-carboxaldehyde

This compound was prepared according to the procedure of Example 125. From 0.50 g of 1-[(2'-carboxybiphenyl-4-yl)methyl]-2-(1-trans-butenyl)-4-chloro-5-hydroxymethylimidazole and 2.50 g of manganese dioxide was obtained 0.24 g of 1-[(2'-carboxybiphenyl-4-yl)methyl]-2-(1-trans-butenyl)-4-chloroimidazole-5-carboxaldehyde (m.p. 164-166°C): NMR (200 MHz, DMSO-d₆) δ 12.79 (br s, 1H); 9.70 (s, 1H); 7.72 (d, 1H); 7.57 (t, 1H); 7.46 (t, 1H); 7.33 (m, 3H); 7.15 (d, 2H); 7.01 (d of t, 1H); 6.65 (d, 1H); 5.71 (s, 2H); 2.28 (quint., 2H); 1.04 (t, 3H).

1032


88015687

The compounds in Table 7 were prepared or could be prepared employing the procedures described in Examples 125-129 or by procedures described previously.


Table 7

5

10



15

Ex.
No. R^6 R^7 R^8 


MP (°C)

130

n-butyl

H

CHO

(amorphous^a
solid)


20

131

n-butyl

 CF_3

CHO



132-134


25

132

n-butyl

Cl

CHO



82.7


30

133

n-butyl

 CF_3

CHO











1033

35

88015687

280

Table 7 (continued)

Ex. No.	R ⁶	R ⁷	R ⁸		MP (°C)
5	134 n-butyl	Cl	CONHCH ₃		(solid) ^b
10	135 n-butyl	Cl	CON(CH ₃) ₂		(solid) ^c
15	136 CH ₃ CH=CH-	Cl	CH ₂ OH		
20	137 CH ₃ CH ₂ CH=CH-	CF ₃	CH ₂ OH		
	138 CH ₃ CH ₂ CH=CH-	Cl	CHO		
25	139 CH ₃ CH ₂ CH=CH-	Cl	CH ₂ OH		
30	140 CH ₃ CH ₂ CH=CH-	Cl	CHO		

1034

88015687

- a -NMR (200 MHz, DMSO- d_6) δ 12.76 (br s, 1H); 9.67 (s, 1H); 7.93 (s, 1H); 7.71 (d, 1H); 7.55 (t, 1H); 7.43 (t, 1H); 7.30 (m, 3H); 7.06 (d, 2H); 5.63 (s, 2H); 2.67 (t, 2H); 2.57 (quint., 2H); 2.27 (sext., 2H); 0.81 (t, 3H).
- b -NMR (200 MHz, DMSO- d_6) δ 12.75 (br s, 1H); 8.10 (br quart., 1H); 7.72 (d, 1H); 7.57 (t, 1H); 7.45 (t, 1H); 7.32 (m, 3H); 7.10 (d, 2H); 5.51 (s, 2H); 2.75 (d, 3H); 2.58 (t, 2H); 1.52 (quint., 2H); 1.27 (sext., 2H); 0.81 (t, 3H).
- c -NMR (200 MHz, DMSO- d_6) δ 12.77 (br s, 1H); 7.73 (d, 1H); 7.57 (t, 1H); 7.45 (t, 1H); 7.33 (m, 3H); 7.09 (d, 2H); 5.20 (br s, 2H); 2.83 (s, 3H); 2.73 (t, 2H); 2.66 (s, 3H); 1.63 (quint., 2H); 1.36 (sext., 2H); 0.89 (t, 3H).

1035

88015687

Example 141

PART A: Preparation of 1-[(2'-Aminobiphenyl-4-yl)-
methyl]-2-butyl-4-chloro-5-methoxymethyl-
imidazole

5 A solution of 4.40 g of 1-[(2'-nitrobiphenyl-4-yl)methyl]-2-butyl-4-chloro-5-methoxymethylimidazole, 2.10 g of iron powder, 4.25 mL of glacial acetic acid, and 200 mL of methanol was refluxed for 5 hours. After cooling, the solvent was removed in vacuo, and the residue was dissolved in ethyl acetate. The
10 precipitated iron salts were removed by filtration through Celite®, and the resulting solution was washed with water and brine, dried over anhydrous sodium sulfate and concentrated. Column chromatography on silica gel (elution: 10-30% ethyl acetate/benzene)
15 furnished 2.95 g of 1-[(2'-aminobiphenyl-4-yl)methyl]-2-butyl-4-chloro-5-methoxymethylimidazole; NMR (200 MHz, CDCl₃): δ 7.43 (d, 2H); 7.19-7.04 (m, 4H); 6.80 (m, 2H); 5.19 (s, 2H); 4.33 (s, 2H); 3.70 (br s, 1H); 3.28 (s, 3H); 2.59 (t, 2H); 1.67 (quint., 2H);
20 1.34 (sext., 2H); 0.87 (t, 3H).

PART B: Preparation of 1-[(2'-Trifluoromethanesul-
fonylamidobiphenyl-4-yl)methyl]-2-butyl-
4-chloro-5-methoxymethylimidazole

25 To a solution of 2.95 g of 1-[(2'-aminobiphenyl-4-yl)methyl]-2-butyl-4-chloro-5-methoxymethylimidazole and 1.07 mL of triethylamine in 30 mL of methylene chloride at -78° was added 2.59 mL of trifluoro-
30 methanesulfonic anhydride dropwise at such rate that the reaction temperature remains below -50°. Following the addition, the reaction mixture was allowed to warm slowly to 25°. At the point the mixture was poured into dilute aqueous acetic acid. The resulting
35 suspension was stirred vigorously for several minutes and then extracted with methylene chloride. The

1036 88015687


combined organic phases were washed with water and
brine, dried over anhydrous sodium sulfate, filtered
and concentrated. Column chromatography on silica gel
(elution: 20-50% ethyl acetate/benzene) afforded 0.80
g of 1-[(2'-trifluoromethanesulfonamidobiphenyl-4-yl)-
methyl]-2-butyl-4-chloro-5-methoxymethylimidazole.
m.p. 148-150°; NMR (200 MHz, CDCl₃): δ 7.60 (d,
1H); 7.44-7.27 (m, 5H); 7.07 (d, 2H); 5.20 (s, 2H);
4.29 (s, 2H); 3.27 (s, 3H); 2.57 (t, 2H); 1.65
(quint., 2H); 1.35 (sext., 2H); 0.88 (t, 3H).

Examples 142 to 147 can or could be prepared by
the procedures described in Example 141 using the
appropriate starting material.

1037

88015687

184



Ex. No.	R ⁶	R ⁷	R ⁸	R ¹³	MP (°C)
142	n-butyl	H	CH ₂ OCH ₃		
143	n-hexyl	Cl	CH ₂ OCH ₃		
144	n-butyl	Cl	CH ₂ OH		171-172
145	FCH ₂ CH ₂ CH ₂ CH ₂ -	Cl	CH ₂ OH		
146	HO ₂ CCH ₂ CH ₂ CH ₂ CH ₂ -	Cl	CH ₂ OH		
147	CH ₃ O ₂ CCH ₂ CH ₂ -	Cl	CH ₂ OH		

1038

88015687

Example 149

PART A: Preparation of 2-Butyl-1-[(2'-carbomethoxybiphenyl-4-yl)methyl]-4-chloro-5-(chloromethyl)imidazole·HCl salt

2-Butyl-1-[(2'-carbomethoxybiphenyl-4-yl)methyl]-4-chloro-5-(chloromethyl)imidazole·HCl salt was prepared from 2-butyl-1-[(2'-carbomethoxybiphenyl-4-yl)methyl]-4-chloro-5-(hydroxymethyl)imidazole using the procedure of Example 1, Part B; m.p. 156.0-161.0°. NMR (200 MHz, CDCl_3) δ 7.90 (d, 1H, 7Hz); 7.56 (t, 1H, J= 7Hz); 7.45 (t, 1H, J= 7Hz); 7.43-7.26 (m, 3H); 7.12 (d, 2H, J= 8Hz); 5.47 (s, 2H); 4.48 (s, 2H); 3.70 (s, 3H); 3.14 (t, 2H, J= 7Hz); 1.80 (t of t, 2H, J= 7.7Hz); 1.44 (t of q, 2H, J= 7.7Hz); 0.92 (t, 3H, J= 7Hz). Anal. Calcd. for $\text{C}_{23}\text{H}_{24}\text{Cl}_2\text{N}_2\text{O}_2\cdot\text{HCl}$: C, 59.05; H, 5.39; N, 5.99. Found: C, 58.80; H, 5.48; N, 5.69. Mass Calcd. for $\text{C}_{23}\text{H}_{24}\text{Cl}_2\text{N}_2\text{O}_2$: 430.1215. Found 430.1215.

PART B: Preparation of 5-Azidomethyl-2-n-butyl-1-[(2'-carbomethoxybiphenyl-4-yl)methyl]-4-chloroimidazole

2-Butyl-1-[(2'-carbomethoxybiphenyl-4-yl)methyl]-4-chloro-5-(chloromethyl)imidazole·HCl salt (3.31 g, 7.67 mmol, 1 eq), sodium azide (1.50 g, 23.0 mmol, 3 eq) and DMSO (100 mL) were mixed and stirred overnight. Water was then added (500 mL) and the aqueous extracted with ethyl acetate (3 x 300 mL). The organic layers were dried (MgSO_4) and concentrated to yield 3.48 g of product as an oil. NMR (200 MHz, CDCl_3) δ 7.85 (d, 1H, J= 7Hz); 7.54 (t, 1H, J= 7Hz); 7.40 (t, 1H, J= 7Hz); 7.28 (d, 2H, J= 8Hz); 7.00 (d, 2H, J= 8Hz); 5.20 (s, 2H); 4.23 (s, 2H); 3.67 (s, 3H); 2.63 (t, 2H, J= 7Hz); 1.73 (t of t, 2H, J= 7.7Hz);

- 1039

88015687

1.39 (t of q, 2H, J = 7.7Hz); 0.91 (t, 3H, J = 7Hz).
Mass Calcd. for $C_{23}H_{24}ClN_5O_2$: 438.1697. Found:
438.1669.

5 PART C: Preparation of 5-Aminomethyl-2-butyl-
1-[(2'-carbomethoxybiphenyl-4-yl)methyl]-
4-chloroimidazole

5-Azidomethyl-2-butyl-1-[(2'-carbomethoxybi-
phenyl-4-yl)methyl]-4-chloroimidazole (3.48 g) was
10 hydrogenated at 1 atm in methanol (100 mL) over 10%
palladium/carbon (0.5 g). After 1 hour, the mixture
was filtered through Celite® and the solvent removed
in vacuo to give product (2.80 g) as an oil. NMR (200
MHz, $CDCl_3$) δ 7.84 (d, 1H, J = 7Hz); 7.52 (t, 1H,
J = 7Hz); 7.40 (t, 1H, J = 7Hz); 7.30 (d, 1H, J = 7Hz);
15 7.26 (d, 2H, J = 8Hz); 7.02 (d, 2H, J = 8Hz); 5.27 (s,
2H); 3.74 (s, 2H); 3.65 (s, 3H); 2.60 (t, 2H, J = 7Hz);
1.67 (t of t, 2H, J = 7.7Hz); 1.36 (t of q, 2H, J =
7.7Hz); 0.86 (t, 3H, J = 7Hz). Anal. Calcd. for
20 $C_{23}H_{26}ClN_3O_2 \cdot (DMSO)_{0.5}$: C, 63.91; H, 6.48;
N, 9.32. Found: C, 63.78; H, 6.30; N, 9.14

PART D: Preparation of 5-Aminomethyl-2-butyl-
1-[(2'-carboxybiphenyl-4-yl)methyl]-
25 4-chloroimidazole

5-Aminomethyl-2-butyl-1-[(2'-carbomethoxybi-
phenyl-4-yl)methyl]-4-chloroimidazole (1.64 g, 3.98
mmol, 1 eq), 0.5N KOH in methanol (11.96 mL, 5.98
mmol, 1.5 eq), water (1.0 mL) and methanol (20 mL)
30 were mixed and refluxed under N_2 overnight. The
solution was then brought to neutrality with 1N HCl
and the solvents removed in vacuo. The residue was
taken up in DMF and the salts filtered off. The DMF
was then removed in vacuo to yield 1.76 g of a glass.
35 NMR (200 MHz, $DMSO-d_6$) δ 7.50 (d, 1H, J = 7Hz);

1040

88015687

147

7.40-7.18 (m, 5H); 6.92 (d, 2H, J= 8Hz); 6.50 (bm, 3H); 5.26 (s, 2H); 3.60 (s, 2H); 2.55 (t, 2H, J= 7Hz); 1.51 (t of t, 2H, J= 7.7Hz); 1.27 (t of q, 2H, J= 7.7Hz); 0.81 (t, 3H, J= 7Hz).

5 PART E: Preparation of 2-Butyl-1-[(2'-carboxybiphenyl-4-yl)methyl]-4-chloro-5-(ethoxycarbonylaminomethyl)imidazole

2-Butyl-1-[(2'-carboxybiphenyl-4-yl)methyl]-4-chloro-5-(ethoxycarbonylaminomethyl)imidazole was
10 prepared from 5-aminomethyl-2-n-butyl-1-[(2'-carboxybiphenyl-4-yl)methyl]-4-chloroimidazole using ethyl chloroformate and the Schotten-Baumann procedure described in Example 209. Part B: m.p. 144.0-147.0°. NMR (200 MHz, DMSO-d₆) δ 12.74 (s, 1H); 7.73 (d, 1H, J= 7Hz); 7.63-7.27 (m, 5H); 7.03 (d, 2H, J= 10Hz); 5.27 (s, 2H); 4.60 (bd, 2H, J= 7Hz); 3.90 (q, 2H, J= 7Hz); 3.34 (s, 2H); 2.47 (t, 2H, J= 7Hz); 1.48 (t of t, 2H, J= 7.7Hz); 1.24 (t of q, 2H, J= 7.7Hz); 1.06 (t, 3H, J= 7Hz); 0.78 (t, 3H, J= 7Hz). Anal. Calcd.
20 for C₂₅H₂₈ClN₃O₄·(H₂O)_{0.33}: C, 63.17; H, 6.06; N, 8.83. Found: C, 63.30; H, 6.35; N, 8.44.


Examples 149-159 in Table 9 were prepared or
25 could be prepared using the appropriate chloroformate by the procedure described in Example 148. Parts D and E (the order of which may be interchanged by one skilled in the art) i.e., starting with the amino ester from Part C, reacting it with a chloroformate
30 under Schotten-Baumann type conditions followed by hydrolyzing the ester if necessary.





1041

88015687

1041

Table 9



	Ex. No.	R ⁶	R ⁷	R	R ¹³	MP (°C)
10	149	n-butyl	Cl	C ₆ H ₅	CO ₂ H	198.0-200.0
	150	n-butyl	Cl	CH ₃	CO ₂ H	151.0-155.0
	151	n-butyl	Cl	CH ₂ CH ₂ CH ₃	CO ₂ H	115.5-117.0
	152	n-butyl	Cl	CH ₂ (CH ₃) ₂	CO ₂ H	135.5-138.0
15	153	n-butyl	Cl	CH ₂ CH ₂ CH ₂ CH ₃	CO ₂ H	123.0-125.0
	154	n-butyl	Cl	1-adamantyl	CO ₂ H	170.0-172.0
	155	n-propyl	Cl	CH ₃	CO ₂ H	
20	156	n-butyl	Cl	CH ₃		202.0-204.5
	157	n-butyl	Cl	(CH ₂) ₂ CH ₃		
25	158	n-propyl	Cl	CH ₃		
30	159	n-propyl	H	CH ₂ CH ₃		

1042


35

88015687

142

Examples 160-164 in Table 10 were prepared or could be prepared from 2-n-butyl-1-[(2'-carbomethoxybiphenyl-4-yl)methyl]-5-chloro-4-(hydroxymethyl)imidazole using the procedures in Example 148.

Table 10



Ex. No.	R^6	R^8	R	R^{13}	MP(°C)
15 160	n-butyl	Cl	CH ₃	COOH	200-205
161	n-butyl	Cl	CH ₂ CH ₃	COOH	
162	n-butyl	Cl	CH ₂ CH ₂ CH ₃	COOH	166.5-169.5
20 163	n-butyl	Cl	CH ₂ CH ₂ CH ₂ CH ₃	COOH	
164	n-butyl	Cl	CH(CH ₃) ₂	COOH	

1043

88015687

EXAMPLE 165

PART A: Preparation of 2-n-Butyl-1-[(2'-carbomethoxybiphenyl-4-yl)methyl]-4-chloro-5-(1-naphthylaminocarbonylaminomethyl)imidazole

5 5-Aminomethyl-2-butyl-1-[(2'-carbomethoxybiphenyl-4-yl)methyl]-4-chloroimidazole (1.00 g, 2.4 mmol, 1 eq) and 1-naphthyl isocyanate (0.35 mL, 2.4 mmol, 1 eq), were mixed and stirred in chloroform at room temperature for 3 days. The solvent was removed
10 in vacuo and the residue was purified by flash chromatography over silica gel in 1:1 hexane/ethyl acetate to yield 770 mg of a white glass. NMR (200 MHz, CDCl_3) δ 7.83 (d, 3H, J= 6Hz); 7.67 (d, 1H, J= 6Hz); 7.56-7.18 (m, 9H); 6.97 (d, 2H, J= 7Hz); 6.74 (s, 1H); 5.27 (s, 2H); 4.74 (s, 1H); 4.39 (d, 2H, J= 7Hz); 3.58 (s, 3H); 2.60 (t, 2H, J= 7Hz); 1.43-1.21 (m, 4H); 0.85 (t, 3H, J= 7Hz).

PART B: Preparation of 2-n-Butyl-1-[(2'-carboxybiphenyl-4-yl)methyl]-4-chloro-5-(1-naphthylaminocarbonylaminomethyl)-
20 imidazole

The title compound was prepared from 2-n-butyl-1-[(2'-carbomethoxybiphenyl-4-yl)methyl]-4-chloro-5-(1-naphthylaminocarbonylaminomethyl)imidazole by the
25 hydrolysis procedure described in Example 148. Part D. Work-up yielded 380 mg of white crystalline solid; m.p. 169-175°. NMR (200 MHz, $\text{DMSO}-d_6$) δ 8.45 (s, 1H); 8.05-7.03 (m, 15H); 6.97 (s, 1H); 5.34 (s, 2H); 4.30 (d, 2H, J= 5Hz); 2.52 (t, 2H, J= 7Hz); 1.48 (t of t, 2H, J= 7.7Hz); 1.21 (t of q, 2H, J= 7.7Hz); 0.85 (t, 3H, J= 7Hz). Anal. Calcd. for $\text{C}_{33}\text{H}_{31}\text{ClN}_4\text{O}_3 \cdot (\text{H}_2\text{O})_{0.5}$: C, 68.77; H, 5.60; N, 9.70. Found: C, 68.88; H, 5.67; N, 9.70.

35

1044

88015687

E

Examples 166-172 in Table 11 were prepared or could be prepared using the appropriate isocyanate by the procedure described in Example 165.

5

10

15

20

25

30


1045

88015687

35

193
Table 11

5



10

Ex. No.	R ⁶	R ⁸	R	R ¹³	MP (°C)
166	n-Bu	Cl	CH ₃	CO ₂ H	187-193
15 167	n-Bu	Cl	CH ₂ CH ₃	CO ₂ H	
168	n-Bu	Cl	CH ₂ CH ₂ CH ₃	CO H	
169	n-Bu	Cl	CH ₂ CH ₂ CH ₂ CH ₃	CO ₂ H	
170	n-Bu	Cl	CH(CH ₃) ₂	CO H	
20 171	n-Bu	Cl		CO ₂ H	163-166
172	n-Bu	Cl	1-adamantyl		

25

30

1046

88015687

35

Ba

Example 171

Preparation of 2-n-Butyl-4-chloro-5-methoxymethyl-1-[(2'-((tetrazol-5-yl)aminocarbonyl)biphenyl-4-yl)-methyl]imidazole

5 2-n-Butyl-1-[(2'-carboxybiphenyl-4-yl)methyl]-4-chloro-5-(methoxymethyl)imidazole (1.0 g) was first converted to the corresponding acid chloride and then coupled to 5-aminotetrazole by the procedure in Example 78, Part C to yield 0.87 g of a yellow glass.

10 Flash chromatography in 100% ethyl acetate over silica gel yielded 77.1 mg of a white solid; m.p. 169-173°. NMR (200 MHz, CDCl_3 , $\text{DMSO}-d_6$) δ 12.0 (br s, 1H); 7.73-7.30 (m, 6H); 7.00 (d, 2H, $J = 7\text{Hz}$); 5.18 (s, 2H); 4.23 (s, 2H); 2.55 (t, 2H, $J = 7\text{Hz}$) 1.63 (t of t, 2H, $J = 7.7\text{Hz}$); 1.31 (t of q, 2H, $J = 7.7\text{Hz}$); 0.84 (t, 3H, $J = 7\text{Hz}$). Anal. Calcd. for $\text{C}_{24}\text{H}_{26}\text{ClN}_7\text{O}_2 \cdot (\text{H}_2\text{O})_2$: C, 55.87; H, 5.86. Found: C, 56.01; H, 6.01.

15

20

25

30

35

- 1047

88015687

Example 174

PART A: Preparation of 2-n-Butyl-4-chloro-1-[(2'-(hydroxymethyl)biphenyl-4-yl)methyl]-5-(methoxymethyl)imidazole

5 2-n-Butyl-1-[2'-carbomethoxybiphenyl-4-yl)-methyl]4-chloro-5-(methoxymethyl)imidazole (5.62 g, 13 mmol, 1 eq) was dissolved in THF (50 mL) and to it was slowly added a 1M lithium aluminum hydride solution in THF (39.5 mL, 39 mmol, 3 eq). The resultant mixture
10 was refluxed under N₂ for 2 hours and worked up according to Fieser and Fieser, V.1, p. 584 (Steinhardt procedure) to yield 4.68 g of a light yellow oil which slowly crystallized. NMR (200 MHz, CDCl₃) δ 7.57 (bd, 1H, J= 7Hz); 7.47-7.20 (m, 5H);
15 7.03 (d, 2H, J= 9Hz); 5.18 (s, 2H); 4.58 (s, 2H); 4.32 (s, 2H); 3.28 (s, 3H); 2.60 (t, 2H, J= 7Hz); 1.67 (t of t, 2H, J= 7, 7Hz); 1.35 (t of q, 2H, J= 7.7Hz); 0.86 (t, 3H, J= 7Hz). Anal. Calcd. for C₂₃H₂₇ClN₂O₂: C, 69.25; H, 6.82; Cl, 8.89. Found: C, 69.42; H, 6.87; Cl, 8.65.

20 PART B: Preparation of 2-n-Butyl-4-chloro-1-[(2'-(cyanomethyl)biphenyl-4-yl)methyl]-5-(methoxymethyl)imidazole

25 2-n-Butyl-4-chloro-1-[(2'-(hydroxymethyl)-biphenyl-4-yl)methyl-5-(methoxymethyl)imidazole (4.68 g) was converted to the title cyanomethyl compound by the procedure described in Example 1, Part B. Work up yielded 5.20 g of a brown oil which was further
30 reacted with purification. NMR (200 MHz, CDCl₃) δ 7.54 (m, 1H); 7.40 (m, 2H); 7.28 (m, 3H); 7.08 (d, 2H, J= 10Hz); 5.23 (s, 2H); 4.33 (s, 2H); 3.63 (s, 2H); 3.30 (s, 3H); 2.60 (t, 2H, J= 7Hz); 1.70 (t of t, 2H, J= 7.7Hz); 1.37 (t of q, 2H, J= 7.7Hz); 0.90 (t, 3H, J= 7Hz). Mass Calcd. for C₂₄H₂₆ClN₃O:
35 407.1764. Found: 407.1778.

1048 88015687

152

PART C: Preparation of 2-n-Butyl-4-chloro-5-methoxymethyl-1-[(2'-((tetrazol-5-yl)methyl)biphenyl-4-yl)methyl]imidazole

2-n-Butyl-4-chloro-1-[(2'-(cyanomethyl)biphenyl-4-yl)methyl]-5-(methoxymethyl)imidazole (5.20 g) was converted to the above tetrazole in 2 days using the procedure of Example 90, Part C. Work-up and flash chromatography over silica gel eluting with a gradient solvent system of 1:1 hexane/ethyl acetate to 1:1 ethyl acetate/isopropanol yielded 3.13 g of a light yellow solid; m.p. 149.0-152.5°. NMR (200 MHz, CDCl₃) δ 7.37-7.15 (m, 6H); 6.96 (d, 2H, J = 9Hz); 5.18 (s, 2H); 4.30 (s, 2H); 4.24 (s, 2H); 3.27 (s, 3H); 2.57 (t, 2H, J = 7Hz); 1.56 (t of t, 2H, J = 7.7Hz); 1.28 (t of q, 2H, J = 7.7Hz); 0.77 (t, 3H, J = 7Hz). Anal. Calcd. for C₂₄H₂₇ClN₆O: C, 63.97; H, 6.03; Cl, 7.86. Found: C, 63.79; H, 6.04; Cl, 7.70.

Example 175

Preparation of 2-n-Butyl-1-[(2'-(carboxymethyl)biphenyl-4-yl)methyl]-4-chloro-5-(hydroxymethyl)imidazole·dicyclohexylamine salt

2-n-Butyl-4-chloro-1-[(2'-(cyanomethyl)biphenyl-4-yl)methyl]-5-(methoxymethyl)imidazole (2.60 g) and a 1:1 mixture of concentrated aqueous HCl and glacial acetic acid (50 mL) were mixed together and then refluxed for 6 hours. The solvents were removed in vacuo and water (200 mL) was added to the residue. The pH was adjusted to 3 with concentrated NH₄OH and this aqueous mixture was extracted with ethyl acetate (3 x 200 mL). The organic layers were combined, dried (MgSO₄) and the solvent removed in vacuo to yield an oil. Subsequent flash chromatography in 60:40 ethyl acetate/hexane to 100% isopropanol yielded 1.07 g of a glass. This product was dissolved in acetone and

dicyclohexylamine was added (1 eq). A gum precipitated which was redissolved with more acetone (total of 75 mL) and heat. Upon cooling, solid precipitate was obtained (291 mg); m.p. 135.0-137.0. NMR shows $-OCH_3$ to be missing. NMR (200 MHz, $CDCl_3$) δ 7.43-7.13 (m, 6H); 6.95 (d, 2H, $J=8$ Hz); 5.20 (s, 2H) 4.46 (s, 2H); 3.45 (s, 2H); 2.76 (m, 2H); 2.60 (t, 2H, $J=7$ Hz); 2.00-1.03 (m, 24H); 0.87 (t, 3H, $J=7$ Hz). Mass Calcd. for $C_{23}H_{25}ClN_2O_3$: 412.1554. Found: 412.1544.

Example 176

PART A: Preparation of 2-n-Butyl-4-chloro-1-[(2'-(hydrazido)biphenyl-4-yl)methyl]-5-(methoxymethyl)imidazole

2-n-Butyl-1-[(2'-carboxymethoxybiphenyl-4-yl)-methyl]-4-chloro-5-(methoxymethyl)imidazole (2.00 g, 4.7 mmol, 1 eq), hydrazine (1.5 mL, 46.8 mmol, 10 eq) and methanol (30 mL) were mixed together and then refluxed for 3 days after which 1.5 mL more of hydrazine was added and the reaction refluxed for another day. More hydrazine (1.5 mL) was again added and the reaction was refluxed for an additional day. The reaction was worked up by first removing the hydrazine and methanol in vacuo, following by taking up the residue in ethyl acetate (200 mL) and washing it with water (3 x 100 mL). The organic layer was dried ($MgSO_4$) and the solvent removed in vacuo to yield 1.37 g of a white glass. NMR ($CDCl_3$, 200 MHz.) δ 7.67-7.31 (m, 4H); 7.40 (d, 2H, $J=9$ Hz); 7.03 (d, 2H, $J=9$ Hz); 7.56 (bs, 1H); 5.17 (s, 2H); 4.27 (s, 2H); 3.25 (s, 3H); 2.57 (t, 2H, $J=7$ Hz); 1.70 (t of t, 2H, 7.7Hz); 1.34 (t of q, 2H, $J=7.7$ Hz); 0.86 (t, 3H, $J=7$ Hz). Anal. Calcd. for $C_{23}H_{27}ClN_4O_2$:

1050

88015687

122

C. 64.70; H. 6.37; N. 13.12. Found: C. 64.47; H. 6.35; N. 12.85.

PART B: Preparation of 2-n-Butyl-4-chloro-5-methoxy-
methyl-1-[4-(2-(trifluoromethylsulfonylhydra-
zido)biphenyl-4-yl)methyl]imidazole

A solution of triflic anhydride (0.42 mL, 2.5 mmol, 3.5 eq) in methylene chloride (2 mL) was slowly dripped into a stirred solution at -78°C of 2-n-butyl-4-chloro-1-[(2'-(hydrazido)biphenyl-4-yl)methyl]-5-(methoxymethyl)imidazole (0.71 g, 1.7 mmol, 1.0 eq) and triethylamine (0.35 mL, 2.5 mmol, 1.5 eq) in methylene chloride (5 mL). The solution was stirred at -78°C for 1 hour and then allowed to warm to room temperature. After 2 hours at room temperature, water (100 mL) was added, the pH adjusted to 5 and the aqueous layer extracted with ethyl acetate (3 x 100 mL). The organic layers were dried (MgSO₄), the solvent removed in vacuo, and the residue flash chromatographed over silica gel beginning in 1:1 hexane/ethyl acetate and finishing in 100% ethyl acetate to yield 380 mg of a light yellow glass. NMR (200 MHz, CDCl₃) δ 7.82-7.15 (m, 8H); 6.94 (d, 2H, J = 8Hz); 5.13 (s, 2H); 4.25 (s, 2H); 3.17 (s, 3H); 2.53 (t, 2H, J = 7Hz); 1.69 (t of t, 2H, J = 7.7Hz); 1.27 (t of q, 2H, J = 7.7Hz); 0.81 (t, 3H, J = 7Hz). Fast Atom Bombardment Mass Spectrum: Mass Calcd. for C₂₄H₂₆ClF₃N₄O₄S: 559.15. Found: 559.12.

Example 177

PART A: Preparation of 4'-Methylbiphenyl-2-carboxaldehyde

Methyl 4'-methylbiphenyl-2-carboxylate (20.00 g, 88 mmol, 1 eq) was dissolved in dry toluene (250 mL)

- 1051

88015687

and cooled to -78° : Diisobutylaluminum hydride (1.0 M in toluene, 220.0 mL, 220 mmol, 2.2 eq) was then dripped in slowly over 25 minutes keeping the temperature under -70° . When the addition was complete, the mixture was stirred at -78° for 15 minutes and then methanol (10 mL) was added cautiously. When gas evolution was complete, the mixture was poured into a solution of Rochelle salt (100 mL of saturated solution plus 600 mL water). The mixture was stirred or shaken until an extractable solution was obtained. The layers were separated and the aqueous layer extracted with ether (2 x 200 mL). The organic layers were combined, dried ($MgSO_4$) and the solvent removed in vacuo to yield 16.7 g of a light yellow oil. NMR (200 MHz, $CDCl_3$) δ 7.56-7.16 (m, 8H); 4.59 (s, 2H); 2.40 (s, 3H); 1.74 (s, 1H). This oil (16.7 g, 84 mmol, 1 eq) was subsequently oxidized by dissolving in methylene chloride (100 mL) and stirring with manganese dioxide (7.34 g, 84 mmol, 1 eq). After stirring for one day at room temperature, more manganese dioxide (14.68 g, 168 mmol, 2 eq) was added. The next day, 14.68 g more of manganese dioxide was again added. After another day of stirring, the reaction was filtered through Celite® and the filtrate evaporated to an oil. The oil was chromatographed in 9:1 hexane/ethyl acetate over silica gel to yield 13.4 g of a light yellow opaque oil. The above oxidation can also be performed using pyridinium chlorochromate. NMR ($CDCl_3$, 200 MHz) δ 9.98 (s, 1H); 8.01 (d, 1H, $J = 7$ Hz); 7.64 (t, 1H, $J = 7$ Hz); 7.53-7.38 (m, 2H); 7.28-7.17 (m, 4H); 2.43 (s, 3H). Mass Calcd. for $C_{14}H_{12}O$: 196.0888. Found: 196.0881.

1032

88015687

PART B: Preparation of 4'-Methyl-2-(2-nitroethen-1-yl)biphenyl

4'-Methylbiphenyl-2-carboxaldehyde (13.21 g, 67.3 mmol (1.0 eq), nitromethane (4.74 mL, 87.5 mmol, 1.3 eq), ammonium acetate (2.07 g, 26.0 mmol, 0.4 eq) and glacial acetic acid (30 mL) were mixed and refluxed for 2 days, at which time more nitromethane (4.74 mL) and ammonium acetate (2.07 g) were added and the reaction was refluxed for an additional 5 hours. The reaction mixture was poured into ice water (300 mL) and extracted with ethyl acetate (300 mL). The ethyl acetate layer was washed with water (3 x 200 mL), the organic layer dried (MgSO_4), the solvent removed in vacuo and the residue chromatographed in 1:1 hexane/toluene to yield 11.22 g of a light yellow oil which crystallized. The product was recrystallized from methylcyclohexane to yield 8.47 g of yellow crystals: m.p. 64.0-65.0°. NMR (200 MHz, CDCl_3) δ 8.04 (d, 1H, J= 13Hz); 7.69 (d, 1H, J= 9Hz); 7.59-7.37 (m, 4H); 7.50 (d, 1H, J= 13 Hz); 7.27 (d, 2H, J= 7Hz); 7.19 (d, 2H, J= 7Hz); 2.41 (s, 3H). Anal. Calcd. for $\text{C}_{15}\text{H}_{13}\text{NO}_2$: C, 75.30; H, 5.48; N, 5.85. Found: C, 75.32; H, 5.56; N, 5.58.

PART C: Preparation of 4'-methyl-2-(1,2,3-triazol-4-yl)biphenyl

4'-Methyl-2-(2-nitroethen-1-yl)biphenyl (6.58 g, 27.5 mmol, 1 eq), sodium azide (5.40 g, 82.3 mmol, 3 eq), and dimethylsulfoxide (minimum to dissolve everything) were mixed together and stirred at room temperature for 4.5 hours. Ethyl acetate (500 mL) was then added and the organic phase washed with water (3 x 400 mL). The organic layer was dried (MgSO_4) and the solvent removed in vacuo to yield 6.54 g of an

orange glass. Chromatography in 75:25 hexane/ethyl acetate yielded 2.87 g of of a yellow glass. NMR (200 MHz, CDCl_3) δ 7.83 (m, 1H); 7.51-7.32 (m, 3H); 7.18 (d, 2H, $J = 8\text{Hz}$); 7.13 (d, 2H, $J = 8\text{Hz}$); 7.03 (s, 1H); 2.38 (s, 3H). Mass Calcd. for $\text{C}_{15}\text{H}_{13}\text{N}_3$: 235.1110. Found: 235.1111.

PART D: Preparation of 4'-Methyl-2-(N-(triphenylmethyl)-1,2,3-triazol-4-yl)biphenyl

4'-Methyl-2-(1,2,3-triazol-4-yl)biphenyl (2.61 g, 11 mmol, 1.0 eq), triethylamine (1.69 mL, 12 mmol, 1 eq), tritylbromide (3.88 g, 12 mmol, 1 eq) and methylene chloride (30 mL) were mixed and stirred at 0°C and then allowed to warm to room temperature. After 1 hour, ethyl acetate was added (200 mL) and the organic phase was washed with water (3 x 200 mL). The organic layer was dried (MgSO_4) and the solvent removed in vacuo to yield 5.15 g of a yellow solid. This product was recrystallized from methycyclohexane to give 3.26 g of off-white crystals; m.p. $181.0\text{--}182.5^\circ$. NMR (200 MHz, CDCl_3) δ 8.18 (d, 1H, $J = 7\text{Hz}$); 7.50-7.16 (m, 12H); 7.05-6.89 (m, 10 Hz); 6.47 (s, 1H); 2.54 (s, 3H). Anal. Calcd. for $\text{C}_{34}\text{H}_{27}\text{N}_3$: C, 85.50; H, 5.70; N, 8.80. Found: C, 86.60; H, 5.80; N, 8.94.

PART E: Preparation of 2-n-Butyl-4-chloro-5-hydroxymethyl-1-[(2'-(N-(triphenylmethyl)-1,2,3-triazol-4-yl)biphenyl-4-yl)methyl]imidazole

4'-Methyl-2-(N-(triphenylmethyl)-1,2,3-triazol-4-yl)biphenyl (3.14 g, 6.57 mmoles) was brominated in the benzylic position by the procedure in Example 85, Part B, using benzoylperoxide instead of AIBN as radical initiator. Filtration of succinimide and evaporation yielded 4.45 g of a crude oil which was used as is.

1054

88015687

202

NMR (200 MHz, CDCl_3) δ CH_2Br , 4.41. This bromide (4.33 g, approx. 7.8 mmol, 1 eq) was alkylated onto 2-n-butyl-4-chloro-5-(hydroxymethyl)imidazole by the procedure described in Example 1, Part A. Flash chromatography in 75:25 hexane/ethyl acetate over silica gel yielded a yellow solid (0.67 g) which was recrystallized from carbon tetrachloride to yield 447 mg of white crystals; m.p. 173.0-176.5°. NMR (CDCl_3 , 200 MHz) δ 8.03 (d, 1H, J = 9Hz); 7.51-7.14 (m, 14H); 6.98 (m, 6H); 6.86 (d, 2H, J = 9Hz); 6.63 (s, 1H); 5.15 (s, 2H); 4.33 (s, 2H); 2.53 (t, 2H, J = 7Hz); 1.15 (t of t, 2H, J = 7.7Hz); 1.32 (t of q, 2H, J = 7.7Hz); 0.87 (t, 3H, J = 7Hz). Mass Calcd. for $\text{C}_{42}\text{H}_{38}\text{ClN}_5\text{O}$: 663.2765. Found: 663.2762.

PART F: Preparation of 2-n-Butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1,2,3-triazol-4-yl)biphenyl-4-yl)methyl]imidazole

2-n-Butyl-4-chloro-5-hydroxymethyl-1-[(2'-(N-(triphenylmethyl)triazol-4-yl)biphenyl-4-yl)methyl]imidazole (408 mg, 0.6 mmol, 1 eq), 1,4-dioxane (5 mL), water (1 mL) and 4.0 N HCl in dioxane (0.46 mL, 1.8 mmol, 3 eq) were mixed and stirred at room temperature. After 2 hours, water was added (200 mL), and the aqueous layer extracted with ethyl acetate (3 x 200 mL). The organic layers were dried (MgSO_4) and the solvent removed in vacuo to yield 260 mg of an off-white glass. Flash chromatography of the product in 100% ethyl acetate over silica gel yielded 140 mg of a white glass. NMR (200 MHz, CDCl_3) δ 7.82 (m, 1H); 7.50-7.25 (m, 3H); 7.17 (d, 2H, J = 9Hz); 6.98 (d, 2H, J = 9Hz); 6.95 (s, 1H); 5.23 (s, 2H); 4.52 (s, 2H); 2.58 (t, 2H, J = 7Hz); 1.63 (t of t, 2H, J = 7.7Hz); 1.30 (t of q, 2H, J = 7.7Hz); 0.82 (t, 3H, J = 7Hz). Mass Calcd. for $\text{C}_{23}\text{H}_{24}\text{ClN}_5\text{O}$: 421.1669. Found: 421.1670.

1055 88015687

Examples 178 and 179PART A: Preparation of Ethyl 3-(4-methylphenyl)-3-oxo-2-(allyl)propanoateEthyl 3-(4-methylphenyl)-3-oxopropanoate

(prepared as described in W. Wierenga and H. I. Skulnick, J. Org. Chem. (1979), 44, 310) (63.66 g, 309 mmol, 1 eq) was added to a freshly prepared sodium ethoxide solution (Na, 7.43 g, 323 mmol, 1.05 eq; EtOH, 250 mL). The ethanol was removed in vacuo and the residue was dissolved in DMF (250 mL). Allyl bromide (29.3 mL, 338 mmol, 1.1 eq) followed by sodium iodide (4.56 g, 304 mmol, 1 eq) were then added and the contents stirred overnight at room temperature. The DMF was removed in vacuo, water (250 mL) was added and the aqueous layer extracted with ethyl acetate (3 x 200 mL). The organic layers were dried (MgSO₄) and the solvent removed in vacuo to yield 74.21 g of an amber oil. NMR (200 MHz, CDCl₃) δ 7.81 (d, 2H, J = 10 Hz); 7.30 (d, 2H, J = 10 Hz); 5.96-5.72 (m, 1H); 5.21-5.00 (m, 2H); 4.41 (t, 1H, J = 7 Hz); 4.16 (q, 2H, J = 7 Hz); 2.78 (t, 2H, J = 7 Hz); 2.42 (s, 3H); 1.18 (t, 3H, J = 7 Hz). Anal. Calcd. for C₁₅H₁₈O₃: C, 73.15; H, 7.37. Found: C, 73.10; H, 7.38.

PART B: Preparation of 3-Carboethoxy-4-(4-methylphenyl)-4-(oxo)butanal

Ethyl 3-(4-methylphenyl)-3-oxo-2-(allyl)propanoate (74.21 g, 301 mmol, 1.0 eq), osmium tetroxide (100 mg, cat.), sodium metaperiodate (141.8 g, 663 mmol, 2.2 eq), ether (500 mL) and water (1 L) were mixed and stirred at room temperature. After 24 hours, an additional 110 mg of OsO₄ was added and after another 24 hours, 200 mg more of

1056

88015687

204
OsO₄ was added together with sodium metaperiodate
(190 g, 888 mmol, 3.0 eq). After 4 days, the layers
were separated and the ether layer washed with aqueous
sodium bisulfite (1 x 500 mL) followed by brine (1 x
300 mL). The ether layer was dried (MgSO₄) and the
solvent removed in vacuo to yield 64.99 g of a dark
brown oil. This oil was flash chromatographed over
silica gel in 4:1 hexane/ethyl acetate to yield 37.5 g
of an amber oil. NMR (200 MHz, CDCl₃) δ 9.79 (s,
1H); 7.93 (d, 2H, J= 9Hz); 7.27 (d, 2H, J= 9Hz); 4.87
(t, 1H, J= 7Hz); 4.13 (q, 2H, J= 7Hz); 3.37-3.08 (AB
multiplet, 2H); 2.40 (s, 3H); 1.14 (t, 3H, J= 7Hz).
Anal. Calcd. for C₁₄H₁₆O₄: C, 67.73; H, 6.50.
Found: C, 67.53; H, 6.54.

PART C: Preparation of 3-Carboethoxy-2-(4-methyl-
phenyl)furan

Ethyl 3-Carboethoxy-4-(4-methylphenyl)-4-(oxo)-
butanal (10.00 g), trifluoroacetic anhydride (50 mL)
and trifluoroacetic acid (2 drops) were mixed and
stirred at 0° over ice and allowed to warm to room
temperature. After 3 hours, more trifluoroacetic
anhydride (50 mL) together with trifluoroacetic acid
(2 drops) were added at room temperature. The next
day, the solvent was removed in vacuo and the residue
partitioned between 1 N NaOH (200 mL) and ethyl
acetate (200 mL). The layers were separated and the
organic layer washed with 1 N NaOH (2 x 200 mL). The
organic layer was dried (MgSO₄) and the solvent
removed in vacuo to yield a brown oil (9.95 g) which
was flash chromatographed in 99:1 hexane/ethyl acetate
to yield 2.57 g of an off-white solid; m.p.
79.0-80.5°. NMR (200 MHz, CDCl₃) δ 7.88 (d, 2H,
J= 9Hz); 7.42 (d, 1H, J= 2Hz); 7.26 (d, 2H, J= 9Hz);

1057

88015687

6.83 (d, 1H, J=2Hz); 4.34 (q, 2H, J= 7Hz); 2.40 (s, 3H); 1.34 (t, 3H, J= 7Hz). Anal. Calcd. for $C_{14}H_{14}O_3$: C, 73.03; H, 6.13. Found: C, 73.52; H, 6.30.

5 PART D: Preparation of 2-n-Butyl-1-[4-(3-carboxyfuran-2-yl)benzyl]-4-chloro-5-(hydroxymethyl)-imidazole (isomer A) and 2-n-butyl-1-[4-(3-carboxyfuran-2-yl)benzyl]-5-chloro-4-(hydroxymethyl)imidazole (isomer B)

10 3-Carboethoxy-2-(4-methylphenyl)furan was brominated, alkylated, and saponified by the procedures described in Example 85, Parts B, C, and E.

Isomer A, the faster eluting isomer, was recrystallized from acetonitrile; m.p. 158.5-160.0°. 15 NMR (200 MHz, DMSO- d_6) δ 12.80 (bm, 1H); 7.92 (d, 2H, J= 9Hz); 7.82 (d, 1H, J= 2Hz); 7.17 (d, 2H, J= 9Hz); 6.84 (d, 1H, J= 2Hz); 5.30 (s, 2H), 5.30 (m, 1H); 4.34 (s, 2H); 2.47 (t, 2H, J= 7Hz); 1.47 (t of t, 2H, J = 7.7Hz); 1.24 (t of q, 2H, J= 7.7Hz); 0.74 (t, 20 3H, J = 7Hz). Anal. Calcd. for $C_{20}H_{21}ClN_2O_4$: C, 61.78; H, 5.44; N, 9.12. Found: C, 61.66; H, 5.39; N, 9.09.

Isomer B was recrystallized from nitromethane/ 25 acetonitrile; m.p. 118.5-120.5°. NMR (200 MHz, DMSO- d_6) δ 12.89 (bm, 1H); 7.92 (d, 2H, J= 9Hz); 7.82 (d, 1H, J= 2Hz); 7.13 (d, 2H, J= 9Hz); 6.83 (d, 1H, J= 2Hz); 5.23 (s, 2H); 4.93 (m, 1H) 4.29 (d, 2H, J= 7Hz); 2.57 (t, 2H, J= 7Hz); 1.53 (t of t, 2H, J = 7.7Hz); 1.27 (t of q, 2H, J= 7.7Hz); 0.77 (t, 3H, J= 7Hz). 30 Mass Calcd. for $C_{20}H_{21}ClN_2O_4$: 388.1190. Found: 388.1171.

1058

35

88015687

202

5

10

Ex.
No.

R⁶

R⁷

R⁸

MP (°C)

185 n butyl

Cl CH₂OH

166-167

15

186 n-butyl

Cl CH₂OH

20

187 n-butyl

Cl CH₂OH

25

188 n-propyl

H CH₂OH

189 n-propyl

Cl CH₂OH

30

190 CH₂OCH₂CH₂CH₂

Cl CH₂OH

35

191 n butyl

Cl CH₂OH

1068

88015687

1068 88015687

22

Example 180

PART A: Preparation of 1-[(2'-Carbomethoxybiphenyl-4-yl)methyl]-2-butyl-4-chloro-5-(2-methoxyethoxymethoxymethyl)imidazole

To a solution of 7.50 mL of 1.6 M n-butyllithium/hexane in 50 mL of tetrahydrofuran at 0° was added dropwise 1.50 mL of t-butanol. To this solution was added 4.52 g of 1-[(2'-carbomethoxybiphenyl-4-yl)methyl]-2-butyl-4-chloro-5-hydroxymethylimidazole followed by 1.50 mL of 2-methoxyethoxymethyl chloride. The resulting solution was stirred at 25° for 16 hours. The mixture was diluted with diethyl ether, washed with water and brine, dried over anhydrous sodium sulfate, filtered and concentrated. Column chromatography afforded 3.50 g of 1-[(2'-carbomethoxybiphenyl-4-yl)methyl]-2-butyl-4-chloro-5-(2-methoxyethoxymethoxymethyl)imidazole. NMR (200 MHz, CDCl₃) δ 7.83 (d, 1H); 7.52 (t, 1H); 7.40 (t, 1H); 7.28 (m, 3H); 7.00 (d, 1H); 5.19 (s, 2H); 4.68 (s, 2H); 4.48 (s, 2H); 3.67 (m, 2H); 3.64 (s, 3H); 3.54 (m, 2H); 3.37 (s, 3H); 2.58 (t, 2H); 1.67 (quint., 2H); 1.34 (sext., 2H); 0.88 (t, 3H).

PART B: Preparation of 1-[(2'-Carboxybiphenyl-4-yl)methyl]-2-butyl-4-chloro-5-(2-methoxyethoxymethoxymethyl)imidazole

A solution of 3.15 g of 1-[(2'-carbomethoxybiphenyl-4-yl)methyl]-2-butyl-4-chloro-5-(2-methoxyethoxymethoxymethyl)imidazole and 2.77 g of potassium methanethiolate in 125 mL of dimethylformamide was stirred at 125° for 4 hours. After cooling the solvent was removed in vacuo, and the residue was dissolved in water. The resulting aqueous solution was washed with diethyl ether, adjusted to pH 3

1059

88015687

employing 10% hydrochloric acid, and extracted with methylene chloride. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was recrystallized from chlorobutane to afford 2.45 g of 1-[(2'-carboxybiphenyl-4-yl)methyl]-2-butyl-4-chloro-5-(2-methoxyethoxymethoxymethyl)imidazole. NMR (200 MHz, CDCl_3) δ 7.95 (d, 1H); 7.57 (t, 1H); 7.46 (t, 1H); 7.38 (m, 3H); 7.05 (d, 2H); 5.22 (s, 2H); 4.64 (s, 2H); 4.48 (s, 2H); 3.58 (m, 4H); 3.40 (s, 3H); 2.54 (t, 2H); 1.60 (quint., 2H); 1.32 (sext., 2H); 0.84 (t, 3H).

PART C: Preparation of 1-[(2'-Methoxyaminocarbonyl-biphenyl-4-yl)methyl]-2-butyl-4-chloro-5-(2-methoxyethoxymethoxymethyl)imidazole

A solution of 0.24 ml of oxalyl chloride in 5 mL of chloroform was added dropwise to a solution of 1 mL of dimethylformamide in 4 mL of chloroform at -20° . After this solution had been stirred at -20° for 20 minutes, 0.28 mL of N-methylmorpholine was added, followed by 1.21 g of 1-[(2'-carboxybiphenyl-4-yl)methyl]-2-butyl-4-chloro-5-(2-methoxyethoxymethoxymethyl)imidazole. After another 20 minutes at -20° , 0.55 mL of N-methylmorpholine and 1.35 mL of methoxylamine were added to the mixture. The reaction mixture was warmed slowly to 25° , stirred at 25° for 4 hours, and finally refluxed for 40 hours. After cooling the mixture was diluted with ethyl acetate. The resulting solution was washed with 10% hydrochloric acid, water, 10% sodium bicarbonate solution and brine. Finally the solution was dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. Column chromatography

1060

88015687

207

(elution: methanol/chloroform) furnished 0.21 g of 1-[(2'-methoxyaminocarbonylbiphenyl-4-yl)methyl]-2-butyl-4-chloro-5-(2-methoxyethoxymethoxymethyl)imidazole. NMR (200 MHz, CDCl_3) δ 7.85 (s, 1H); 7.63 (d, 1H); 7.53-7.33 (m, 5H); 7.05 (d, 2H); 5.20 (s, 2H); 4.67 (s, 2H); 4.47 (s, 2H); 3.63 (m, 5H); 3.55 (m, 2H); 3.36 (s, 3H); 2.56 (t, 2H); 1.67 (m, 2H); 1.32 (m, 2H); 0.87 (t, 3H).

10 PART D: Preparation of 1-[(2'-Methoxyaminocarbonylbiphenyl-4-yl)methyl]-2-butyl-4-chloro-5-hydroxymethylimidazole

A solution of 0.20 g of 1-[(2'-methoxyaminocarbonylbiphenyl-4-yl)methyl]-2-butyl-4-chloro-5-(2-methoxyethoxymethoxymethyl)imidazole in 60 ml of 1.5 M aqueous tetrafluoroboric acid/acetonitrile was stirred for 20 hours at 25°. The reaction mixture was poured into dilute sodium bicarbonate solution, and the resulting mixture was extracted with diethyl ether. The combined organic phases were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated. Column chromatography (elution: methanol/chloroform) provided 0.11 g of 1-[(2'-methoxyaminocarbonylbiphenyl-4-yl)methyl]-2-butyl-4-chloro-5-hydroxymethylimidazole. NMR (200 MHz, CDCl_3) δ 11.31 (br s, 1H); 7.48 (m, 1H); 7.41-7.33 (m, 5H); 7.09 (d, 2H); 5.27 (br s, 3H); 4.32 (d, 2H); 3.44 (s, 3H); 2.49 (t, 2H); 1.48 (quint., 2H); 1.25 (sext., 2H); 0.80 (t, 3H).


30 The following compounds were prepared according to the procedures described in the above example.

1061

88015687


NMR (200 MHz, DMSO- d_6)

Example 181



δ 11.29 (br s, 1H),
7.48 (m, 1H), 7.33 (m,
10H), 7.09 (d, 2H),
5.27 (d, 2H), 4.67 (s,
2H), 4.31 (s, 2H), 2.47
(t, 2H), 1.46 (quint.,
2H), 1.21 (sext., 2H),
0.76 (t, 3H).

Example 182



δ 10.81 (br s, 1H),
9.02 (br s, 1H), 7.55-
7.35 (m, 6H), 7.11 (d,
2H), 5.28 (br s, 3H),
4.34 (d, 2H), 2.50 (t,
2H), 1.49 (quint., 2H),
1.25 (sext., 2H), 0.78
(t, 3H).

Example 183

25

PART A: Preparation of 1-[(2'-Aminobiphenyl-4-yl)methyl]-2-butyl-4-chloro-5-hydroxymethylimidazole

30

This compound was prepared according to the procedure described in Example 141, Part A. From 3.30 g of 1-[(2'-nitrobiphenyl-4-yl)methyl]-2-butyl-4-chloro-5-hydroxymethylimidazole, 1.60 g of iron powder, 3.20 ml of acetic acid, and 160 mL of methanol there was obtained 2.05 g of 1-[(2'-aminobiphenyl-4-

1062

88015687

yl)methyl]-2-butyl-4-chloro-5-hydroxymethylimidazole.
 NMR (200 MHz, CDCl₃) δ 7.45 (d, 2H); 7.23-7.08 (m, 4H); 6.89-6.77 (m, 2H); 5.27 (s, 2H); 4.55 (br s, 2H); 2.62 (t, 2H); 1.69 (quint., 2H); 1.37 (sext., 2H); 0.88 (t, 3H).

PART B: Preparation of 1-[(2'-Aminobiphenyl-4-yl)methyl]-2-butyl-4-chloro-5-(2-methoxyethoxymethoxymethyl)imidazole

This compound was prepared according to the procedure described in Example 180, Part A. From 2.03 g of 1-[(2'-aminobiphenyl-4-yl)methyl]-2-butyl-4-chloro-5-hydroxymethylimidazole, 3.75 mL of 1.6 M n-butyllithium/hexane, 0.75 mL of t-butanol, 0.75 mL of 2-methoxyethoxymethyl chloride, and 25 mL of tetrahydrofuran there was obtained 0.84 g of 1-[(2'-aminobiphenyl-4-yl)methyl]-2-butyl-4-chloro-5-(2-methoxyethoxymethoxymethyl)imidazole. NMR (200 MHz, CDCl₃) δ 7.42 (d, 2H); 7.19-7.03 (m, 4H); 6.86 (m, 2H); 5.20 (s, 2H); 4.69 (m, 2H); 4.49 (m, 2H); 3.67 (m, 2H); 3.54 (m, 2H); 3.37 (s, 3H); 2.59 (t, 2H); 1.67 (quint., 2H); 1.34 (sext., 2H); 0.87 (t, 3H).

PART C: Preparation of 1-[(2'-Trifluoroacetamido-biphenyl-4-yl)methyl]-2-butyl-4-chloro-5-(2-methoxyethoxymethoxymethyl)imidazole

To a solution of 0.84 g of 1-[(2'-aminobiphenyl-4-yl)methyl]-2-butyl-4-chloro-5-(2-methoxyethoxymethoxymethyl)imidazole, 0.23 g of 4-dimethylaminopyridine, 1.28 mL of triethylamine, and 10 mL of tetrahydrofuran at 25° was added dropwise 1.30 mL of trifluoroacetic anhydride. The reaction mixture was stirred at 25° for 4 hours and then was poured into

1063

88015687

water. The resulting solution was adjusted to pH 4 using 10% hydrochloric acid and extracted with diethyl ether. The combined organic phases were washed with water and brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. Column chromatography afforded 0.96 g of 1-[(2'-trifluoroacetamidobiphenyl-4-yl)methyl]-2-butyl-4-chloro-5-(2-methoxyethoxymethoxymethyl)-imidazole. NMR (200 MHz, CDCl₃) δ 8.22 (d, 1H); 7.89 (br s, 1H); 7.44 (m, 1H); 7.36-7.29 (m, 4H); 7.12 (d, 2H); 5.23 (s, 2H); 4.68 (s, 2H); 4.49 (s, 2H); 3.65 (m, 2H); 3.54 (m, 2H); 3.37 (s, 3H); 2.56 (t, 2H); 1.67 (quint., 2H); 1.34 (sext., 2H); 0.87 (t, 3H).

PART D: Preparation of 1-[(2'-Trifluoroacetamidobiphenyl-4-yl)methyl]-2-butyl-4-chloro-5-hydroxymethylimidazole

This compound was prepared according to the procedure described in Example 180, Part D. From 0.96 g of 1-[(2'-trifluoroacetamidobiphenyl-4-yl)methyl]-2-butyl-4-chloro-5-(2-methoxyethoxymethoxymethyl)-imidazole there was obtained 0.35 g of 1-[(2'-trifluoroacetamidobiphenyl-4-yl)methyl]-2-butyl-4-chloro-5-hydroxymethylimidazole. NMR (200 MHz, CDCl₃) δ 8.24 (d, 1H); 7.89 (br s, 1H); 7.46 (m, 1H); 7.32 (m, 4H); 7.15 (d, 2H); 5.30 (s, 2H); 4.55 (d, 2H); 2.60 (t, 2H); 1.67 (br t, 1H); 1.70 (quint., 2H); 1.36 (sext., 2H); 0.88 (t, 3H).

1064

88015687

Example 184PART A: Preparation of 2-(4-Methylphenoxy)-benzoic acid

To a solution of 5.95 g of p-cresol and 7.83 g of 2-chlorobenzoic in 50 mL of dimethylformamide at 25°
5 was added, in portions, 14.50 g of anhydrous potassium carbonate. The resulting mixture was heated to 80°, and 0.10 g of copper(I) iodide was added. The reaction mixture then was refluxed for 16 hours. While
10 still hot the mixture was poured onto water-ice. The resulting suspension was filtered, and the filtrate was adjusted to pH 3.0 using aqueous hydrochloric acid. The precipitate was recovered by filtration. The crude solid was dissolved in an aqueous sodium
15 hydroxide solution. This solution was acidified to pH 6.0 using hydrochloric acid, filtered, and then acidified to pH 3.0. Filtration provided 5.67 g of 2-(4-methylphenoxy)benzoic acid which was employed in the following reaction without further purification.
20 NMR (200 MHz, CDCl₃): δ 8.15 (d of d, 1H); 7.42 (d of d of d, 1H); 7.23-7.12 (m, 3H); 6.97 (d, 2H); 6.80 (d, 1H); 2.37 (s, 3H).

PART B: Preparation of Methyl 2-(4-methylphenoxy)-benzoate

25 A solution of 37.70 g of 2-(4-methylphenoxy)-benzoic acid was 12.0 mL of concentrated sulfuric acid in 500 mL of methanol was refluxed for 14 hours. After cooling, the reaction mixture was concentrated in vacuo
30 and the residue was added to a mixture of methylene chloride and water. The organic phase was separated, washed with saturated sodium bicarbonate solution and brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was kugelrohr
35 distilled (120-135°/0.025 torr) to furnish 35.08 g of

1065

88015687

7R

methyl 2-(4-methylphenoxy)benzoate, m.p. 31-34°. NMR (200 MHz, CDCl₃) δ 7.87 (d of d, 1H); 7.39 (t of d, 1H); 7.11 (m, 3H); 6.88 (m, 3H); 3.81 (s, 3H); 2.30 (s, 3H).

5 PART C: Preparation of Methyl 2-(4-bromomethylphenoxy)benzoate

A solution of 35.08 g of methyl 2-(4-methylphenoxy)benzoate, 25.7 g of N-bromosuccinimide, 0.57 g of azobisisobutyronitrile, and 1200 mL of carbon tetrachloride was refluxed for 3 hours. After cooling to room temperature the resulting suspension was filtered and then concentrated in vacuo to provide 4.51 g of crude methyl 2-(4-bromomethylphenoxy)benzoate which was used in a subsequent reaction without further purification: NMR (200 MHz, CDCl₃): δ 7.92 (d of d, 1H); 7.45 (t of d, 1H); 7.16 (m, 3H); 6.90 (m, 3H); 4.49 (s, 2H); 3.83 (s, 3H).

20 PART D: Preparation of 2-Butyl-4-chloro-1-[4-(2-carbomethoxyphenoxy)benzyl]-5-hydroxymethylimidazole

To a suspension of 7.51 g of sodium methoxide in 100 mL of dimethylformamide at 25° was added a solution of 26.50 g of 2-butyl-4(5)-chloro-5(4)-hydroxymethylimidazole in 100 mL of DMF. The resulting mixture was stirred at 25° for 0.25 hours; to this mixture was added dropwise a solution of 45.1 g of methyl 2-(4-bromomethylphenoxy)benzoate in 100 mL of DMF. Finally, the reaction mixture was stirred at 40° for 4 hours. After cooling to 25°, the solvent was removed in vacuo. The residue was dissolved in ethyl acetate, and this solution was washed with water and brine, dried over anhydrous sodium sulfate, filtered, and concentrated. Column chromatography on silica gel

1066 88015687

214

(elution: 10-25% ethyl acetate/benzene) afforded 7.80 g of 2-butyl-4-chloro-1-[4-(2-carbomethoxyphenoxy)-benzyl]-5-hydroxymethylimidazole. NMR (200 MHz, CDCl₃) δ 7.92 (d, 1H); 7.48 (t, 1H); 7.21 (t, 1H); 6.93 (m, 5H); 5.21 (s, 2H); 4.48 (s, 2H); 3.79 (s, 3H); 2.56 (t, 2H); 1.65 (quint., 2H); 1.34 (sext., 2H); 0.88 (t, 3H).

PART E: Preparation of 2-Butyl-4-chloro-1-[4-(2-carboxyphenoxy)benzyl]-5-hydroxymethylimidazole

A solution of 7.70 g of 1-[4-(2-carbomethoxyphenoxy)benzyl]-2-butyl-4-chloro-5-hydroxymethylimidazole in 250 mL of ethanol and 125 mL of 10% aqueous sodium hydroxide was refluxed for 5 hours. After cooling, the reaction mixture was filtered, and the solvent was removed in vacuo. The residue was dissolved in water, and the solution was acidified to pH 3.5 using hydrochloric acid. The precipitated solid was recovered by filtration and recrystallized from acetone to furnish 6.52 g of 2-butyl-4-chloro-1-[4-(2-carboxyphenoxy)benzyl]-5-hydroxymethylimidazole, m.p. 178-180°. NMR (200 MHz, DMSO) δ 7.79 (d, 1H); 7.53 (t, 1H); 7.23 (t, 1H); 7.07 (d, 2H); 6.94 (d, 1H); 6.87 (d, 2H); 5.18 (s, 2H); 4.32 (s, 2H); 2.47 (t, 2H); 1.46 (quint., 2H); 1.23 (sext., 2H); 0.78 (t, 3H).

The following compounds have been or could be prepared by the above procedures.

1067

88015687

Example 192**PART A: Preparation of 1-(4-Benzyloxybenzyl)-2-butyl-4-chloro-5-hydroxymethylimidazole**

To a suspension of 1.43 g of sodium methoxide in 20 mL of dimethylformamide at 25° was added a solution of 5.00 g of 2-butyl-4(5)-chloro-5(4)-hydroxymethylimidazole in 15 mL of dimethylformamide (DMF). The resulting mixture was stirred at 25° for 0.25 hours, and then to this mixture was added dropwise a solution of 4-benzyloxybenzyl chloride in 15 mL of DMF. Finally, the reaction mixture was stirred at 40°, the solvent was removed in vacuo. The residue was dissolved in ethyl acetate, and this solution was washed with water and brine, dried over anhydrous sodium sulfate, filtered, and concentrated. Column chromatography on silica gel (elution: 10-25% ethyl acetate/benzene) afforded 3.27 g of 1-(4-benzyloxybenzyl)-2-butyl-4-chloro-5-hydroxymethylimidazole: m.p. 115-116°; NMR (200 MHz, CDCl₃): δ 7.39 (m, 5H); 6.94 (s, 4H); 5.15 (s, 2H); 5.04 (s, 2H); 4.47 (bs, 2H); 2.56 (t, 2H); 2.07 (bs, 1H); 1.63 (quint., 2H); 1.32 (sext., 2H); 0.87 (t, 3H).

PART B: Preparation of 1-(4-Hydroxybenzyl)-2-butyl-4-chloro-5-hydroxymethylimidazole

A mixture of 0.50 g of 1-(4-benzyloxybenzyl)-2-butyl-4-chloro-5-hydroxymethylimidazole, 0.50 g of 10% palladium/carbon and 40 mL of tetrahydrofuran was stirred at room temperature under hydrogen gas (1 atm.) for 6 hours. The mixture was filtered through Celite® under nitrogen, and the resulting solution was concentrated in vacuo. The crude product was extracted with hot chloroform. After cooling, the chloroform mixture was concentrated in vacuo, and the

1069

88015687

resulting solid was washed with hexane to afford 0.16 g of 1-(4-hydroxybenzyl)-2-butyl-4-chloro-5-hydroxymethylimidazole; NMR (200 MHz, DMSO- d_6): δ 9.43 (s, 1H); 6.81 (A₂B₂, 4H); 5.21 (t, 1H); 5.10 (s, 2H); 4.33 (d, 2H); 2.47 (t, 2H); 1.44 (quint 2H); 1.23 (sext., 2H); 0.79 (t, 3H).

PART C: Preparation of 1-[4-(2-Cyanobenzoyloxy)benzyl]-
2-butyl-4-chloro-5-hydroxymethylimidazole

To a solution of 1.00 g of 1-(4-hydroxybenzyl)-2-butyl-4-chloro-5-hydroxymethylimidazole in 15 mL of DMF at 25° was added 0.185 g of sodium methylate, and the resulting mixture was stirred at 25° for 0.25 hours. To this mixture was then added a solution of 0.80 g of α -bromo-*p*-tolunitrile in 5 mL of DMF. The reaction mixture was stirred at 25° for 16 hours. The solvent was removed in vacuo, and the residue dissolved in ethyl acetate. This solution was washed with water and brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. Column chromatography on silica gel (elution: 10-25% ethyl acetate/benzene) provided 0.76 g of 1-[4-(2-cyanobenzoyloxy)benzyl]-2-butyl-4-chloro-5-hydroxymethylimidazole; NMR (200 MHz, CDCl₃): δ 7.73-7.59 (m, 3H); 7.44 (m, 1H); 6.96 (s, 4H); 5.23 (s, 2H); 5.14 (s, 2H); 4.50 (d, 2H); 2.57 (t, 2H); 1.66 (quint., 2H); 1.33 (sext., 2H); 0.87 (t, 3H).

PART D: 1-[4-(2-Cyanobenzoyloxy)benzyl]-2-butyl-4-chloro-5-cyanomethylimidazole

To a solution of 0.76 g of 1-[4-(2-cyanobenzoyloxy)benzyl]-2-butyl-4-chloro-5-hydroxymethylimidazole in 20 mL of chloroform at 25° was added dropwise 0.95 mL of thionyl chloride and the mixture was stirred at 25° for 2 hours. The solvent was removed in vacuo.

1070

88015687

The residue was dissolved in 20 mL of toluene, and then the toluene was removed in vacuo. Finally, the residue was dissolved in 10 mL of dimethyl sulfoxide, and the resulting solution was added to a solution of 0.71 g of sodium cyanide in 10 mL of dimethylsulfoxide. The mixture was stirred at 25° for 1 hour and then poured into water. This emulsion was extracted with ethyl acetate; and the combined organic phases were washed with water and brine, dried over anhydrous sodium sulfate, filtered, and concentrated. Column chromatography on silica gel (elution 0-25% ethyl acetate/benzene) afforded 0.67 g of 1-[4-(2-cyanobenzyloxy)benzyl]-2-butyl-4-chloro-5-cyanomethylimidazole; NMR (200 MHz, CDCl₃): δ 7.79-7.60 (m, 3H); 7.47 (m, 1H); 7.00 (s, 4H); 5.24 (s, 2H); 5.14 (s, 2H); 3.46 (s, 2H); 2.66 (t, 2H); 1.71 (quint., 2H); 1.40 (sext., 2H); 0.92 (t, 3H).

PART E: 1-[4-(2-Carboxybenzyloxy)benzyl]-2-butyl-4-chloroimidazole-5-acetic acid

A solution of 0.65 g of 1-[4-(2-cyanobenzyloxy)benzyl]-2-butyl-4-chloro-5-cyanomethylimidazole in 20 mL of ethylene glycol and 10 mL of 10% aqueous sodium hydroxide was refluxed for 14 hours. After cooling, the reaction mixture was filtered, and the solvent was removed in vacuo. The residue was dissolved in water, and the solution was acidified to pH 3.5 using hydrochloric acid. The precipitated solid was recovered by filtration and recrystallized from aqueous ethanol to furnish 0.21 g of 1-[4-(2-carboxybenzyloxy)benzyl]-2-butyl-4-chloroimidazole-5-acetic acid, m.p. 170-172°; NMR (200 MHz, DMSO-d₆): δ 12.9 (bs, 2H); 7.94 (d, 1H); 7.61 (d, 1H); 7.60 (t, 1H); 7.46 (t, 1H); 6.99 (s, 4H); 5.45 (s, 2H); 5.11 (s, 2H); 3.49 (s, 2H); 2.52 (t, 2H); 1.48 (quint., 2H); 1.24 (sext., 2H); 0.82 (t, 3H).

- 1071

88C 5687

Example 193**PART A: Preparation of 1-(4-Hydroxybenzyl)-2-butyl-5-hydroxymethylimidazole**

A mixture of 1.00 g of 10% palladium/carbon and 1.00 g of 1-(4-benzyloxybenzyl)-2-butyl-4-chloro-5-hydroxymethyl imidazole in 20 mL of methanol was stirred at 25° for five minutes. Hydrogen gas was bubbled into the solution, and the mixture was stirred under hydrogen gas (1 atm.) at 25° for 2 hours. The mixture was filtered, and the resulting solution concentrated in vacuo to furnish 0.75 g of 1-(4-hydroxybenzyl)-2-butyl-5-hydroxymethylimidazole: NMR (200 MHz, DMSO-d₆): δ 9.75 (bs, 1H); 7.55 (s, 1H); 6.91 (A₂B₂, 4H); 5.80 (bs, 1H); 5.35 (s, 2H); 4.45 (s, 2H); 2.89 (t, 2H); 1.44 (quint, 2H); 1.21 (sext., 2H); 0.80 (t, 3H).

PART B: Preparation of 1-[4-(2-Carboxybenzyloxy)benzyl]-2-butyl-5-hydroxymethylimidazole

The title compound was prepared from 1-(4-hydroxybenzyl)-2-butyl-5-hydroxymethylimidazole using the alkylation and hydrolysis procedures described in Example 192, Parts C and E, m.p. 115-116°; NMR (200 MHz, DMSO-d₆): δ 7.92 (d, 1H); 7.59 (m, 2H); 7.43 (m, 1H); 6.95 (A₂B₂, 4H); 6.74 (s, 1H); 5.40 (s, 2H); 5.11 (s, 2H); 4.31 (s, 2H); 2.48 (t, 2H); 1.47 (quint., 2H); 1.23 (sext., 2H); 0.77 (t, 3H).

Example 194**PART A: Preparation of 1-[4-(2-Cyanobenzyloxy)benzyl]-2-butyl-4-chloro-5-methoxymethylimidazole**

To a solution of 0.29 g of 1-[4-(2-cyanobenzyl-oxy)benzyl]-2-butyl-4-chloro-5-hydroxymethylimidazole in 8.0 mL of dimethyl sulfoxide at 25° was added 0.93 g of potassium t-butoxide followed by 0.060 mL of

1072

88015687

methyl iodide. The reaction mixture was stirred at 25° for 2.5 hours and then was poured into water. The aqueous emulsion was extracted with ethyl acetate; the organic phases were combined and washed with water and brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. Column chromatography on silica gel (elution: 5-25% ethyl acetate/benzene) furnished 0.17 g of 1-[4-(2-cyanobenzyloxy)benzyl]-2-butyl-4-chloro-5-methoxymethylimidazole; NMR (200 MHz, CDCl₃): δ 7.72-7.57 (m, 3H); 7.43 (m, 1H); 6.94 (s, 4H); 5.22 (s, 2H); 5.04 (s, 2H); 4.27 (s, 2H); 3.26 (s, 3H); 2.56 (t, 2H); 1.65 (quint., 2H); 1.33 (sext., 2H); 0.88 (t, 3H).

15 PART B: Preparation of 1-[4-(2-Carboxybenzyloxy)-benzyl]-2-butyl-4-chloro-5-methoxymethyl-imidazole


The title compound was prepared from 1-[4-(2-cyanobenzyloxy)benzyl]-2-butyl-4-chloro-5-methoxymethylimidazole via the hydrolysis procedure described in Example 192, Part E; NMR (200 MHz, DMSO-d₆): δ 7.91 (d, 1H); 7.57 (m, 2H); 7.42 (m, 1H); 6.97 (A₂B₂, 4H); 5.41 (s, 2H); 5.09 (s, 2H); 4.27 (3, 2H); 3.17 (s, 3H); 2.47 (t, 2H); 1.44 (quint, 2H); 1.21 (sext., 2H); 0.79 (t, 3H).

The compounds shown in Table 13 where X = -OCH₂- were prepared or could be prepared employing the above procedures of Examples 192-194 and procedures previously described.









1073

88015687

5



10

Ex. No.	R ⁶	R ⁷	R ⁸		MP (°C)
195	n-butyl	Cl	CH ₂ OH	4-OCH ₂ - 	(oil) ^a
196	n-butyl	Cl	CH ₂ OH	3-OCH ₂ - 	
197	n-butyl	Cl	CH ₂ OCH ₂ CH ₃	4-OCH ₂ - 	
198	n-butyl	Cl	CH ₂ OCH ₂ C ₆ H ₅	4-OCH ₂ - 	
199	n-butyl	Cl	CH ₂ O ^O CCH ₃	4-OCH ₂ - 	(oil) ^b
200	CH ₃ OCH ₂ CH ₂ - F F	Cl	CH ₂ OH	4-OCH ₂ - 	
201	n propyl	CF ₃	CH ₂ OH	4-OCH ₂ - 	

35

1074

88015687

a NMR (200 MHz, DMSO- d_6): δ 7.91 (d, 1H);
7.58 (m, 2H); 7.42 (m, 1H); 6.98 (A_2B_2 ,
4H); 5.42 (s, 2H); 5.15 (s, 2H); 4.32 (s,
2H); 2.48 (t, 2H); 1.44 (quint., 2H); 1.23
(sext., 2H); 0.79 (t, 3H).

b NMR (200 MHz, $CDCl_3$): δ 8.13 (d, 1H);
7.75 (d, 1H); 7.58 (t, 1H); 7.39 (t, 1H);
6.88 (A_2B_2 , 4H); 5.51 (s, 2H); 5.04 (s,
2H); 4.95 (s, 2H); 2.60 (t, 2H); 1.83 (s,
3H); 1.65 (quint., 2H); 1.32 (sext., 2H);
0.85 (t, 3H).

Example 202

PART A: Methyl 2-[4-(Bromomethyl)benzoyl]benzoate

Methyl 2-toluybenzoate (CA reg. # 6424-25-5:
available by simple esterification of commercially
available 2-toluybenzoic acid) (10.00 g, 39.3 mmol,
1 eq), N-bromosuccinimide (7.00 g, 39.3 mmol, 1 eq),
benzoyl peroxide (1.0 g) and 100 mL carbon tetra-
chloride were mixed and refluxed overnight (peroxide
added last). The mixture was filtered and 250 mL of a
100 g/l aqueous solution of sodium bisulfite solution
was added. The layers were separated and the organic
layer was dried ($MgSO_4$) and concentrated. The brown
solid residue was recrystallized from ether/hexane to
give 6.47 g of product; m.p. 88.2-91.5°. NMR (200 MHz,
 $CDCl_3$) δ 8.07 (d, 1H, $J = 7$ Hz); 7.82-7.07 (m, 7H); 4.50
(s, 2H); 3.67 (s, 3H). Anal. Calcd. for $C_{16}H_{13}O_3Br$:
C, 57.68; H, 3.93; Br, 23.98. Found: C, 57.84; H,
4.04; Br 23.99. Mass Calcd. for $C_{16}H_{13}O_3Br$:
332.0048. Found: 332.0033.

1075

88015687

PART B: Preparation of 2-Butyl-1-[4-(2-carbomethoxybenzoyl)benzyl]-4-chloro-5-hydroxymethylimidazole

To a solution of 2-butyl-4-chloro-5-(hydroxymethyl)imidazole (11.12 g, 54 mmol, 1 eq) in 200 mL methanol was added dropwise a freshly prepared sodium methoxide solution (1.36 g Na, 59 mmol, 1.1 eq in 50 mL MeOH). After stirring for 0.5 hours, the methanol was removed in vacuo and the resultant glass was dissolved in 200 mL DMP. To this mixture was added a solution of methyl 2-[4-(bromomethyl)benzoyl]benzoate (18.00 g, 59 mmol, 1.1 eq) in DMP and the entire contents was stirred overnight under N_2 at room temperature. The solvent was then removed in vacuo and the residue dissolved in 500 mL ethyl acetate and 500 mL H_2O . The layers were separated and the aqueous layer was extracted twice with 500 mL portions of ethyl acetate. The organic layers were dried and concentrated and the crude product flash chromatographed to separate the two regioisomers in 60:40 hexane/ethyl acetate over silica gel. The faster moving isomer was isolated to yield 14.72 g of a glassy solid. NMR (200 MHz, $CDCl_3$) δ 8.03 (d, 1H, J= 7Hz); 7.67 (m, 4H); 7.36 (d, 1H, J= 7Hz); 7.05 (d, 2H, J= 7Hz); 5.28 (s, 2H); 4.43 (s, 2H); 3.63 (s, 3H); 2.53 (t, 2H, J= 7Hz); 1.60 (t of t, 2H, J= 7.7Hz); 1.30 (t of q, 2H, J= 7.7Hz); 0.87 (t, 3H, J= 7Hz). Mass Calcd. for $C_{25}H_{26}ClF_3N_4O_5S$: 586.1264. Found: 586.1285.

1076

88015687

PART C: 2-Butyl-1-[4-(2-Carboxybenzoyl)benzyl]-4-
chloro-5-(hydroxymethyl)imidazole

2-Butyl-1-[4-(2-carbomethoxybenzoyl)benzyl]-4-
chloro-5-hydroxymethylimidazole (500 mg, 1.13 mmol,
1 eq), 0.5 N KOH in methanol (2.27 mL, 1.14 mmol, 1
eq), and 0.5 mL of H₂O were mixed and stirred.
After 6 hours, water (50 mL) was added and the pH was
lowered to 3-5 with conc. HCl. The aqueous mixture
was extracted with ethyl acetate (3 x 50 mL) and the
organic layers were dried (MgSO₄) and concentrated
to give 200 mg of product: m.p. 90.0-95.0°. NMR (200
MHz, CDCl₃) δ 8.05 (d, 1H, J= 7Hz); 7.48-7.75 (m,
4H); 7.37 (d, 1H, J= 7Hz); 7.00 (d, 2H, J= 7Hz); 5.20
(s, 2H); 4.40 (s, 2H); 2.45 (t, 2H, J= 7Hz); 1.50 (t
of t, 2H, J= 7Hz); 1.25 (t of q, 2H, J= 7Hz); 0.79 (t,
3H, J= 7Hz). Anal. Calcd. for C₂₃H₂₃ClN₂O₄·(CH₃OH): C,
62.81; H, 5.93; Found: C, 62.95; H, 5.99. Mass spec-
trum shows M-H₂O. Mass Calcd. for C₂₃H₂₃ClN₂O₄-H₂O:
408.1235. Found: 408.1228.

Example 203

Preparation of 2-n-Butyl-1-[4-(2-carboxybenzoyl)-
benzyl-4-hydroxymethyl-5-chlorimidazole

Using the procedure of Example 202, 2-n-butyl-1-
[4-(2-carboxybenzoyl)benzyl]-4-hydroxymethyl-5-chloro-
imidazole was prepared from 2-n-butyl-1-[4-(2-carbo-
methoxybenzoyl)benzyl]-4-hydroxymethyl-5-chloro-
imidazole, m.p. 214.0-216.0°. NMR (200 MHz, CDCl₃ +
DMSO-d₆) δ 8.07 (d, 1H, J= 7.7Hz); 7.32 (d, 1H, J=
7Hz); 7.10 (d, 2H, J= 7Hz); 5.19 (s, 2H); 4.50 (s,
2H); 2.61 (t, 2H, J= 7Hz); 1.63 (t of t, 2H, J=
7.7Hz); 1.33 (t of q, 2H, J= 7.7Hz); 0.87 (t, 3H, J=
7Hz). Titration of the product with 1.000 N NaOH
showed the presence of exactly one acidic
functionality. Anal. Calcd. for C₂₃H₂₃ClN₂O₄:

1077

88015687

C. 64.71; H. 5.43; N. 6.56. Found: C, 64.75; H, 5.30; N, 6.65.

Example 204

5 PART A: Preparation of 2-Butyl-1-[4-(2-carbomethoxybenzoyl)benzyl]-4-chloro-5-(chloromethyl)-imidazole, hydrochloride salt

2-Butyl-1-[4-(2-carbomethoxybenzoyl)benzyl]-4-chloro-5-hydroxymethylimidazole (5.00 g, 11.3 mmol, 1 eq) was dissolved in 50 mL chloroform and to this
10 solution was dropwise added thionyl chloride (4.13 mL, 56.6 mmol, 5 eq) with stirring at room temperature. After 4 hours, the solvent and excess thionyl chloride were removed by rotary evaporation. Toluene (100 mL) was added to the residue and the solvent again removed
15 by rotary evaporation. Toluene was again added and while evaporating the second time, product crystallized from solution yielding 2.91 g of a white solid; m.p. 139.0-143.5°. NMR (200 MHz, CDCl₃) δ 8.07 (d, 1H, J = 7Hz); 7.80 (d, 2H, J = 10Hz); 7.68 (t, 1H, J = 7Hz);
20 7.58 (t, 1H, J = 7Hz); 7.35 (d, 1H, J = 7Hz); 7.13 (d, 2H, J = 10Hz); 5.43 (s, 2H); 4.42 (s, 2H); 3.67 (s, 3H); 2.96 (m, 2H); 1.75 (m, 2H); 1.39 (m, 2H); 0.88 (t, 2H, J = 7Hz). Mass Calcd. for C₂₄H₂₄Cl₂N₂O₃: 458.1162. Found: 458.1160.
25

PART B: 2-Butyl-1-[4-(2-Carbomethoxybenzoyl)benzyl]-4-chloro-5-((1,2,4-triazol-1-yl)methyl)imidazole

2-Butyl-1-[4-(2-carbomethoxybenzoyl)benzyl]-4-chloro-5-chloromethylimidazole·HCl salt (1.00 g, 2.06 mmol, 1.0 eq), potassium triazolidine (0.26 g, 2.39 mmol, 1.1 eq) and DMF (50 mL) were mixed and heated at 90°
30 under N₂ overnight. The reaction was worked up by

35

1078


88015687

removing the solvent in vacuo, taking up the residue in water (200 mL) and ethyl acetate (200 mL), separating the layers and extracting the aqueous with ethyl acetate (2 x 200 mL). The organic layers were dried (MgSO_4) and concentrated; the residue was flash chromatographed over silica gel in 100% ethyl acetate to give 780 mg of a white glassy solid. NMR (200 MHz, CDCl_3) δ 8.05 (s, 1H); 8.05 (d, 1H, $J = 7\text{Hz}$); 7.83 (s, 1H); 7.74 (d, 2H, $J = 10\text{Hz}$); 7.66 (t, 1H, $J = 7\text{Hz}$); 7.58 (t, 1H, $J = 7\text{Hz}$); 7.33 (d, 1H, $J = 7\text{Hz}$); 6.98 (d, 2H, $J = 7\text{Hz}$); 5.37 (s, 2H); 5.15 (s, 2H); 3.69 (s, 3H); 2.56 (t, 2H, $J = 7\text{Hz}$); 1.73 (m, 2H); 1.36 (t of q, 2H, $J = 7.7\text{Hz}$); 0.87 (t, 3H, $J = 7\text{Hz}$). Mass Calcd. for $\text{C}_{26}\text{H}_{26}\text{ClN}_5\text{O}_3$: 491.1722. Found: 491.1816.

The following intermediates were prepared by the above procedure using the appropriate nucleophile, imidazole starting material, and solvent.

1079

88015687



	<u>R⁶</u>	<u>R⁷</u>	<u>R⁸</u>	<u>R</u>	<u>MP (°C)</u>
5					
10	n-butyl	Cl	CH ₂ -N		(oil) ^a
	n-butyl	Cl	CH ₂ N ₃		127.0-129.5
15	n-butyl	Cl	CH ₂ CN		(oil) ^b
20	n-butyl	Cl	CH ₂ OCH ₃		(solid) ^c
25	<p>a NMR (200 MHz, CDCl₃) δ 8.05 (d, 1H, J= 7Hz); 7.72 (d, 2H, J= 8Hz); 7.65 (t, 1H, J= 7Hz); 7.56 (t, 1H, J= 7Hz); 7.36 (d, 1H, J= 7Hz); 7.33 (bs, 1H); 7.00 (bs, 1H); 6.89 (d, 2H, J= 8Hz); 6.78 (bs, 1H); 4.91 (s, 2H); 4.88 (s, 2H); 3.67 (s, 3H); 2.54 (t, 2H, J= 7Hz); 1.65 (t of t, 2H, J= 7.7Hz); 1.33 (t of q, 2H, J= 7.7Hz); 0.85 (t, 3H, J= 7Hz).</p> <p>b NMR (200 MHz, CDCl₃) δ 8.05 (d, 1H, J= 7Hz); 7.76 (d, 2H, J= 10Hz); 7.64 (t, 1H, J= 7Hz); 7.56 (t, 1H, J= 7Hz); 7.36 (d, 1H, J= 7Hz); 7.06 (d, 2H, J= 10Hz); 5.24 (s, 2H); 3.66 (s, 3H); 3.47 (s, 2H); 2.63 (t, 2H, J= 7Hz); 1.70 (t of t, 2H, J= 7.7Hz); 1.37 (t of q, 2H, J= 7. Hz); 0.89 (t, 3H, J= 7Hz).</p>				
30					
35					

1080 88015687

277

c NMR (200 MHz, CDCl_3) δ 8.05 (d, 1H, J= 8Hz); 7.72 (d, 2H, J= 8Hz); 7.61 (m, 2H); 7.38 (d, 1H, J= 7Hz); 7.04 (d, 2H, J= 7Hz); 5.20 (s, 2H); 4.26 (s, 2H); 3.63 (s, 3H); 3.21 (s, 3H); 2.50 (t, 2H, J= 7Hz); 1.65 (m, 2H); 1.29 (m, 2H); 0.84 (t, 3H, J= 7Hz).


PART C: 2-Butyl-1-[4-(2-Carboxybenzoyl)benzyl]-4-chloro-5-((1,2,4-triazol-1-yl)methyl)imidazole


10 2-Butyl-1-[4-(2-carbomethoxybenzoyl)benzyl]-4-chloro-5-((1,2,4-triazol-1-yl)methyl)imidazole (780 mg, 1.59 mmol, 1 eq), 0.5 N KOH in MeOH (6.34 mL, 3.17 mmol, 2 eq) and methanol (20 mL) were mixed and stirred at 20° under N_2 . After 2.5 hours, one more equivalent of 0.5 N KOH in MeOH was added. After 15 seven hours, the solution was acidified to a pH of 4 with 1 N HCl, and 200 mL each of ethyl acetate and water was added. The layers were separated and the aqueous layer was extracted with ethyl acetate (2 x 20 200 mL). The organic layers were dried (MgSO_4) and concentrated to give 640 mg of a white glassy solid; m.p. 180.0-188.0°. NMR (200 MHz, CDCl_3) δ 7.94 (d, 1H, J= 7Hz); 7.74 (s, 1H); 7.65 (s, 1H); 7.55 (d, 2H, J= 7Hz); 7.70-7.50 (m, 3H); 6.67 (d, 2H, J= 7Hz); 5.34 (s, 2H); 5.14 (s, 2H); 2.64 (t, 2H, J= 7Hz); 1.74 (t of t, 2H, J= 7.7Hz); 1.36 (t of q, 2H, J= 7.7Hz); 0.89 (t, 3H, J= 7Hz). Anal. Calcd. for $\text{C}_{25}\text{H}_{24}\text{ClN}_5\text{O}_3 \cdot 2\text{EtOAc}$: C, 61.53; H, 5.70; N, 12.37. Found: C, 61.72; H, 5.19, N, 12.27.

30 Examples 205-207 in Table 14 were prepared by the procedure described in Example 203, Part C using the appropriate imidazole starting materials.

1081

88015687

229
Table 14

Ex. No.	R ⁶	R ⁷	R ⁸	R ¹³	MP (°C)
205	n-butyl	Cl	CH ₂ -N 	CO ₂ H	(oil) ^a
206	n-butyl	Cl	CH ₂ N ₃	CO ₂ H	188.0-190.0
207	n-butyl	Cl	CH ₂ OCH ₃	CO ₂ H	210.0-211.5

^a NMR (200 MHz, CDCl₃/D₂O exchange) δ
 9.67 (s, 1H); 7.98 (d, 1H, J= 7Hz); 7.63 (t, 1H, J= 7Hz); 7.55 (t, 2H, J= 7Hz); 7.41 (d, 2H, J= 10Hz); 7.41 (d, 1H, J= 7Hz); 7.09 (s, 1H); 7.08 (s, 1H); 6.70 (d, 2H, J= 10Hz); 5.65 (s, 2H); 5.58 (s, 2H); 2.59 (t, 2H, J= 7Hz); 1.71 (t of t, 2H, J= 7.7Hz); 1.36 (t of q, 2H, J= 7.7Hz); 0.87 (t, 3H, J= 7Hz).

Example 208

PART A: Preparation of 2-Butyl-1-[4-(2-carbomethoxybenzoyl)benzyl]-4-chloro-5-[(1H-tetrazol-5-yl)methyl]imidazole

The title compound was prepared from 2-butyl-1-[4-(2-carbomethoxybenzoyl)benzyl]-4-chloro-5-(cyano-methyl)imidazole by the procedure described in Example

1082

88015687

230
26; NMR (200 MHz, DMSO- d_6) δ 8.00 (d, 1H, J = 7Hz); 7.78 (t, 1H, J = 7Hz); 7.70 (t, 1H, J = 7Hz); 7.50 (d, 2H, J = 8Hz); 7.46 (d, 1H, J = 7Hz); 7.05 (d, 2H, J = 8Hz); 5.35 (s, 2H); 4.20 (s, 2H); 3.57 (s, 3H); 2.52 (t, 2H, J = 7Hz); 1.52 (t of t, 2H, J = 7.7Hz); 1.27 (t of q, 2H, J = 7.7Hz); 0.70 (t, 3H, J = 7Hz). Anal. Calcd. for $C_{25}H_{25}ClN_6O_3$: C, 60.91; H, 5.11; N, 17.05. Found: C, 60.84; H, 5.12; N, 16.71. Mass Calcd. for $C_{25}H_{25}ClN_6O_3$: 492.1686. Found: 492.1614.

10 PART B: Preparation of 2-Butyl-1-[4-(2-carboxy-benzoyl)benzyl]-4-chloro-5-[(1H-tetrazol-5-yl)methyl]imidazole

15 The title compound was prepared from 2-butyl-1-[4-(2-carbomethoxybenzoyl)benzyl]-4-chloro-5-[(1H-tetrazol-5-yl)methyl]imidazole by the procedure described in Example 202, Part C; m.p. 228.0-229.5°. NMR (200 MHz, DMSO- d_6) δ 7.98 (d, 1H, J = 7Hz); 7.73 (t, 1H, J = 7Hz); 7.69 (t, 1H, J = 7Hz); 7.55 (d, 2H, J = 8Hz); 7.38 (d, 1H, J = 7Hz); 7.05 (d, 2H, J = 8Hz); 20 5.32 (s, 2H); 4.16 (s, 2H); 2.50 (t, 2H, J = 7Hz); 1.50 (t of t, 2H, J = 7.7Hz); 1.24 (t of q, 2H, J = 7.7Hz); 0.80 (t, 3H, J = 7Hz). Anal. Calcd. for $C_{24}H_{23}ClN_6O_3$: C, 60.19; H, 4.84; N, 17.55. Found: C, 59.73; H, 4.61; 25 N, 17.82.

Example 209

PART A: Preparation of 5-Aminomethyl-2-n-butyl-1-[4-(2-carbomethoxybenzoyl)benzyl]-4-chloroimidazole, chromium salt

30 5-Azidomethyl-2-n-butyl-1-[4-(2-carbomethoxybenzoyl)benzyl]-4-chloroimidazole (4.24 g, 9.1 mmol, 1 eq), chromium (II) chloride (6.75 g, 54.7 mmol, 6 eq), acetone (40 mL) and water (13 mL) were mixed

35 • 1083 •

88015687

and stirred (the chromium (II) chloride being added last). After N_2 evolution had stopped, the reaction mixture was diluted with saturated aqueous sodium bicarbonate (250 mL) and extracted with ethyl acetate (3 x 250 mL). The organic layers were dried ($MgSO_4$) and concentrated to give solids which after washing with ether gave 2.92 g of white solid (chromium salt of the product); m.p. 178.5-181.0°. NMR (200 MHz, $CDCl_3/DMSO-d_6$) δ 8.85 (bs, 1H); 8.05 (d, 1H, $J=7$ Hz); 7.57-7.25 (m, 4H); 7.36 (d, 1H, $J=7$ Hz); 7.06 (bd, 2H, $J=7$ Hz); 5.67 (bs, 2H); 3.85 (bs, 2H); 3.67 (s, 3H); 2.60 (t, 2H, $J=7$ Hz); 1.68 (m, 2H); 1.37 (t of q, 2H, $J=7.7$ Hz); 0.89 (t, 3H, $J=7$ Hz). Mass Calcd. for $C_{24}H_{26}ClN_3O_3$: 439.1663. Found: 439.1663. Anal. Calcd. for $Cr(C_{24}H_{26}ClN_3O_3)_2$: C, 61.87; H, 5.62; N, 9.02. Found: C, 61.46; H, 5.59; N, 8.54.

PART B: Preparation of 2-Butyl-4-chloro-1-[4-(2-carbomethoxybenzoyl)benzyl]-5-(methoxycarbonylaminomethyl)imidazole

5-Aminomethyl-2-butyl-1-[4-(2-carbomethoxybenzoyl)benzyl]-4-chloroimidazole (chromium salt) (500 mg, 1.14 mmol, 1 eq) was dissolved in a mixture of 1.00 N NaOH (1.14 mL, 1.14 mmol, 1 eq) and H_2O (10 mL). Tetrahydrofuran may be added to assist solvation. The solution was cooled to 0° when methyl chloroformate (0.176 mL, 2.28 mmol, 2 eq) in THF (5 mL) was slowly dripped in, in five equal portions, alternating with five portions of 1.00 N NaOH (total of 1.14 mL, 1.14 mmol, 1 eq). When the addition was complete, the mixture was stirred at room temperature for 4 hours. Water (100 mL) was added and the pH adjusted to 5 with 1N HCl. The aqueous was extracted with ethyl acetate (3 x 100 mL), the organic layers

1084

88015687

dried (MgEO_4) and stripped to give a white glass
(560 mg). Flash chromatography in 100% ethyl acetate
to 100% isopropanol yielded 280 mg of product as an
oil. NMR (200 MHz, CDCl_3) δ 8.10 (d, 1H, $J = 7\text{Hz}$);
7.75 (d, 2H, $J = 7\text{Hz}$); 7.75-7.56 (m, 2H); 7.39 (d, 1H,
5 $J = 7\text{Hz}$); 7.02 (d, 2H, $J = 7\text{Hz}$); 5.32 (s, 2H); 4.83 (m,
1H); 4.28 (d, 2H, $J = 7\text{Hz}$); 3.70 (s, 3H); 3.57 (s, 3H);
2.58 (t, 2H, $J = 7\text{Hz}$); 1.72 (t of t, 2H, $J = 7.7\text{Hz}$);
1.37 (t of q, 2H, $J = 7.7\text{Hz}$); 0.92 (t, 3H, $J = 7\text{Hz}$).
10 Mass Calcd. for $\text{C}_{26}\text{H}_{28}\text{ClN}_3\text{O}_5$: 497.1717.
Found: 497.1699.

The following intermediates were prepared or
could be prepared by the procedure described in
Example 209, Part B from the corresponding
15 5-(aminoalkyl)imidazole intermediate and the
appropriate chloroformate or sulfonyl chloride.

20

25


30

1085

35

88015687

5



	<u>R¹</u>	<u>R⁶</u>	<u>R⁷</u>	<u>R⁸</u>	<u>MP (°C)</u>
10		n-butyl	Cl		
15		n-butyl	Cl		
20		n-butyl	Cl		
25		n-butyl	Cl		
30		n-butyl	Cl		
35		n-butyl	Cl		163.0-168.0

1086

88015687

PART C: Preparation of 2-Butyl-4-chloro-1-[4-(2-carboxybenzoyl)benzyl]-5-(methoxycarbonylaminomethyl)imidazole

Using the procedure of Example 202, Part C (with or without refluxing), 2-butyl-1-[4-(2-carboxybenzoyl)benzyl]-4-chloro-5-(methoxycarbonylaminomethyl)imidazole was prepared from 2-butyl-1-[4-(2-carbomethoxybenzoyl)benzyl]-4-chloro-5-(methoxycarbonylamino-

methyl)imidazole; mp = sublimes. NMR (200 MHz, DMSO-d₆) δ 13.17 (bm, 1H); 7.97 (d, 1H, J = 7Hz); 7.71 (t, 1H, J = 7Hz); 7.63 (t, 1H, J = 7Hz); 7.56 (d, 2H, J = 10Hz); 7.50 (m, 1H); 7.36 (d, 1H, J = 7Hz); 7.03 (d, 2H, J = 10Hz); 5.31 (s, 2H); 4.06 (d, 2H, J = 7Hz); 2.46 (t, 2H, J = 7Hz); 1.48 (t of t, 2H, J = 7.7Hz);


1.22 (t of q, 2H, J = 7.7Hz); 0.78 (t, 3H, J = 7Hz).

Anal. Calcd. for C₂₅H₂₆ClN₃O₅: C, 62.05; H, 5.42; N, 8.68. Found: C, 61.97; H, 5.58; N, 8.40. Mass Calcd. for C₂₅H₂₆ClN₃O₅: 483.1561. Found: 483.1560.

Examples 210-216 in Table 15 were prepared or could be prepared by the procedure described in Example 209, Part C using the appropriate starting material.

1087

88015687



10

Ex. No.	<u>R¹³</u>	<u>R⁶</u>	<u>R⁷</u>	<u>R⁸</u>	MP (°C)
210	CO ₂ H	n-butyl	Cl	CH ₂ NHCOCH ₂ CH ₃	
211	CO ₂ H	n-butyl	Cl	CH ₂ NHCOCH ₂ CH ₂ CH ₃	
212	CO ₂ H	n-butyl	Cl	CH ₂ NHC(O)CH(CH ₃) ₂	
213	CO ₂ H	n-butyl	Cl	CH ₂ NHCOCH ₂ CH ₂ CH ₂ CH ₃	
214	CO ₂ H	n-butyl	Cl	CH ₂ NHCOC ₆ H ₅	
215	CO ₂ H	n-butyl	Cl	CH ₂ NHSC ₂ H ₅	(oil) ^a
216	CO ₂ H	n-butyl	Cl	CH ₂ NHCOCH ₂ C ₆ H ₅	

30

^a NMR (200 MHz, CDCl₃) δ 7.97 (d, 1H, J = 7 Hz); 7.71-7.50 (m, 4H); 7.45 (d, 1H, J = 7 Hz); 6.95 (d, 2H, J = 8 Hz); 5.23 (s, 2H); 4.15 (s, 2H); 2.57 (t, 2H, J = 7 Hz); 1.67 (t of t, 2H, J = 7.7 Hz); 1.36 (t of q, 2H, J = 7.7 Hz); 0.87 (t, 3H, J = 7 Hz).

35

1088

88015687

235

Example 217

PART A: Preparation of 2-Butyl-1-[4-(2-carbomethoxybenzoyl)benzyl]-4-chloro-5-[(trifluoromethylsulfonamido)methyl]imidazole

5 Triflic anhydride (0.21 mL, 1.25 mmol, 1.1 eq) was slowly added to a pyridine (20 mL) solution of the chromium salt of 5-aminomethyl-2-butyl-1-[4-(2-carbomethoxybenzoyl)benzyl]-4-chloroimidazole (0.50 g, 1.1 mmol, 1.0 eq) at 0°C. The solution was
10 allowed to warm to room temperature. After 1.5 hour, 1.5 equivalents of triflic anhydride were added at 0°. After an additional 4 hours at room temperature, water (200 mL) was added and the pH adjusted to 5. The aqueous was extracted with ethyl acetate (3 x 100
15 mL) and the organic layers dried (MgSO₄) and concentrated to yield 150 mg of a yellow oil which was used as is for the subsequent hydrolysis step. NMR (200 MHz, CDCl₃) δ 8.33 (bm, 1H); 7.96 (d, 1H, J= 7Hz); 7.64 (d, 2H, J= 10Hz); 7.56 (t, 1H, J= 7Hz); 7.48 (t, 1H, J= 7Hz); 7.28 (d, 1H, J= 7Hz);
20 6.92 (d, 2H, J= 10Hz); 5.21 (s, 2H); 4.14 (s, 2H); 3.17 (s, 3H); 2.48 (t, 2H, J= 7Hz); 1.55 (t of t, 2H, J= 7.7Hz); 1.24 (m, 2H); 0.79 (t, 3H, J= 7Hz).

25 PART B: Preparation of 2-Butyl-1-[4-(2-carboxybenzoyl)benzyl]-4-chloro-5-[(trifluoromethylsulfonamido)methyl]imidazole

2-Butyl-1-[4-(2-carbomethoxybenzoyl)benzyl]-4-chloro-5-[(trifluoromethylsulfonamido)methyl]imidazole
30 (150 mg, 0.26 mmol, 1 eq), 1.000 N NaOH (0.55 mL, 0.55 mmol, 2.1 eq), methanol (20 mL), and water (0.5 mL) were mixed and stirred for 5 hours at room temperature under N₂. The solvent was removed in vacuo. Water (50 mL) was added and the pH was

35 1089

88015687

adjusted to 4 with 1 N HCl. Tan solids precipitated. These were collected and dried to yield 89 mg. NMR (200 MHz, DMSO- d_6) δ 7.98 (d, 1H, J= 7Hz); 7.70 (t, 1H, J= 7Hz); 7.68 (t, 1H, J= 7Hz); 7.63 (d, 2H, J= 10Hz); 7.37 (d, 1H, J= 7Hz); 7.10 (d, 2H, J= 10Hz); 5.34 (s, 2H); 4.20 (s, 2H); 2.50 (t, 2H, J= 7Hz); 1.49 (t of t, 2H, J= 7.7Hz); 1.27 (t of q, 2H, J= 7.7Hz); 0.80 (t, 3H, J= 7Hz). Mass calcd. for $C_{24}H_{23}ClF_3N_3O_5S$: 557.0999. Found: 557.0988

Example 218

PART A: Preparation of 2-Butyl-1-[4-(2-carbomethoxybenzoyl)benzyl]-5-[(4-carbomethoxy-1,2,3-triazol-1-yl)methyl]-4-chloroimidazole and 2-butyl-1-[4-(2-carbomethoxybenzoyl)benzyl]-5-[(5-carbomethoxy-1,2,3-triazol-1-yl)methyl]-4-chloroimidazole

5-Azidomethyl-2-butyl-4-chloro-1-[4-(2-carbomethoxybenzoyl)benzyl]imidazole (0.50 g, 1.07 mmol, 1 eq), methyl propiolate (0.95 mL, 10.7 mmol, 10 eq) and toluene (20 mL) were mixed and refluxed under N_2 for 3 hours. The reaction mixture was concentrated and the residue flash chromatographed over silica gel in 75:25 hexane/ethyl acetate. The two regioisomers were separated to give 10 mg of the faster eluting isomer as a glass and 330 mg of the slower as a solid. The slower isomer could be further purified by washing with ethyl acetate to give 190 mg of white crystalline solid. Faster eluting isomer: NMR (200 MHz, $CDCl_3$) δ 8.06 (d, 1H, J= 8Hz); 7.96 (s, 1H); 7.73-7.54 (m, 4H); 7.37 (d, 1H, J= 8Hz); 6.86 (d, 2H, J= 8Hz); 5.76 (s, 2H); 5.41 (s, 2H); 3.90 (s, 3H); 3.68 (s, 3H); 2.56 (t, 2H, J= 7Hz); 1.67 (t of t, 2H, J= 7.7Hz); 1.35

35

1090

88015687

ZFR

(t of q, 2H, J= 7.7Hz): 0.86 (t, 2H, J= 7Hz). Mass
calcd. for $C_{28}H_{28}N_5O_5Cl$: 549.1778. Found: 549.1860.
Slower eluting isomer: m.p. 163.5-167.0°; NMR (200
MHz, $CDCl_3$) δ 8.06 (d, 1H, J= 8Hz); 8.00 (s, 1H);
5 7.72 (d, 2H, J= 8Hz); 7.72-7.55 (m, 2H); 7.41 (d, 1H,
J= 7Hz); 6.96 (d, 2H, J= 8Hz); 5.40 (s, 2H); 5.23 (s,
2H); 3.95 (s, 3H); 3.69 (s, 3H); 2.58 (t, 2H, J= 7Hz);
1.70 (t of t, 2H, J= 7.7Hz); 1.38 (t of q, 2H, J=
7.7Hz); 0.89 (t, 3H, J= 7Hz). Mass calcd. for
10 $C_{28}H_{28}N_5O_5Cl$: 549.1778. Found: 549.1763.

The intermediates shown below were prepared or
could be prepared by the procedure described in
Example 218, Part A using the appropriate starting
15 materials.

20

25


30

- 1091

35

88015687

258



5

10

15

20

25

30

35

<u>R⁶</u>	<u>R⁷</u>	<u>R⁸</u>	<u>R¹³</u>	<u>MP(°C)</u>
n-butyl	Cl		CO ₂ CH ₃	(oil) ^a (mixture of 2 regio- isomers)
n-butyl	Cl		CO ₂ CH ₃	
n-butyl	Cl		NHSO ₂ CF ₃	
n-butyl	Cl		NHSO ₂ CF ₃	
n-butyl	Cl		NHSO ₂ CF ₃	
n-propyl	H		NHSO ₂ CF ₃	
n-propyl	H		NHSO ₂ CF ₃	

1092

88015687

722

- a NMR (200 MHz, CDCl_3) shows a mixture of 2 regioisomers: δ 8.08 (d, 1H, $J = 8\text{Hz}$); 7.80-7.55 (m, 4H); 7.44-7.34 (m, 1H); 7.28 (s, 1H); 7.00-6.88 (m, 2H); 5.40 (s, 0.5 x 2H); 5.32 (s, 0.5 x 4H); 5.29 (s, 0.5 x 2H); 3.71 (s, 0.5 x 3H); 3.69 (s, 0.5 x 3H); 2.75-2.48 (m, 4H); 1.80-1.21 (m, 8H); 1.00-0.81 (m, 6H).

- 10 PART B: Preparation of 2-Butyl-1-[4-(2-carboxybenzoyl)benzyl]-5-[(4-carboxy-1,2,3-triazol-1-yl)methyl]-4-chloroimidazole and 2-butyl-1-[4-(2-carboxybenzoyl)benzyl]-5-[(5-carboxy-1,2,3-triazol-1-yl)methyl]-4-chloroimidazole


- 15 The slower eluting isomer in Example 218, Part A (190 mg, 0.35 mmol, 1 eq), 0.5 N KOH in methanol (2.76 mL, 1.39 mmol, 4 eq) and 5 mL of water were mixed and refluxed overnight under N_2 . Water (50 mL) was added and the pH adjusted to 5. The aqueous mixture was extracted with ethyl acetate (3 x 50 mL), the organic fractions dried (MgSO_4) and concentrated to give a residue which was triturated with ether yielding 160 mg of solid product. NMR (200 MHz, $\text{DMSO}-d_6 + \text{py}-d_5$) δ 8.20 (d, 1H, $J = 8\text{Hz}$); 7.86-7.63 (m, 4H); 7.57 (d, 1H, $J = 8\text{Hz}$); 7.43 (s, 1H); 7.04 (d, 2H, $J = 10\text{Hz}$); 6.84 (s, 2H); 6.63 (s, 2H); 2.62 (t, 2H, $J = 7\text{Hz}$); 1.65 (t of t, 2H, $J = 7.7\text{Hz}$); 1.30 (t of q, 2H, $J = 7.7\text{Hz}$); 0.81 (t, 3H, $J = 7\text{Hz}$). Mass calcd. for $\text{C}_{26}\text{H}_{24}\text{N}_5\text{O}_5\text{Cl}-\text{CO}_2$: 477.1567. Found: 477.1593.

- 30 The faster eluting isomer in Example 218, Part A was hydrolyzed in a similar fashion except that upon acidification in the work-up, solid product precipitated, m.p. 149.0-152.5°. NMR (200 MHz, $\text{DMSO}-d_6$) δ 8.02 (s, 1H); 8.02 (d, 2H, $J = 7\text{Hz}$); 7.74 (t, 1H, $J =$

7Hz); 7.66 (t, 1H, J = 7Hz); 7.50 (d, 2H, J = 7Hz); 7.37 (d, 1H, J = 7Hz); 6.92 (d, 2H, J = 7Hz); 5.83 (s, 2H); 5.42 (s, 2H); 2.52 (t, 2H, J = 7Hz); 1.55 (t of t, 2H, J = 7Hz); 1.28 (t of q, 2H, J = 7.7Hz); 0.78 (t, 3H, J = 7Hz). Mass calcd. for $C_{26}H_{24}N_5O_5Cl-CO_2$: 477.1567. Found: 477.1479.

Examples in Table 16 were prepared or could be prepared by the procedure described in Example 218, Part B.

Table 16



Ex. No.	R ⁶	R ⁷	R ⁸	R ¹³	MP (°C)
219	n-butyl	Cl		CO ₂ H	(oil) ^a (2 regio-isomers)
220	n-butyl	Cl		CO ₂ H	
221	n-butyl	Cl		NHSO ₂ CF ₃	
222	n-butyl	Cl		NHSO ₂ CF ₃	
1094					

88015687

- a NMR (200 MHz, CDCl_3) δ 8.03 (m, 1H);
 7.77-7.42 (m, 5H); 7.33 (s, 1H); 5.36 (s,
 2H); 5.26 (s, 2H); 2.68-2.45 (m, 4H);
 1.82-1.48 (m, 4H); 1.42-1.20 (m, 4H);
 1.00-0.80 (m, 6H).

5

Example 223

PART A: Preparation of 1-(4-Formylbenzyl)-2-butyl-4-chloro-5-hydroxymethylimidazole

- 10 To a solution of 5.05 g of 1-(4-cyanobenzyl)-2-butyl-4-chloro-5-hydroxymethylimidazole in 350 mL of benzene at 25° was added dropwise 22.8 mL of diisobutylaluminum hydride (0.15 M in toluene). The mixture was warmed to 45° and stirred for 16 hours.
- 15 After cooling, the reaction mixture was poured in ice-cold 20% aqueous sulfuric acid. This solution was allowed to warm to 25° and then stirred for 2 hours. The solution was cooled to 0°, neutralized using aqueous sodium hydroxide and extracted with ethyl
- 20 acetate. The combined organic phases were washed with water and brine, dried over anhydrous sodium sulfate, filtered, and concentrated. Column chromatography on silica gel (elution: 0-20% ethyl acetate/benzene) provided 3.60 g of 1-(4-formyl-
- 25 benzyl)-2-butyl-4-chloro-5-hydroxymethylimidazole; NMR (200 MHz, CDCl_3) δ : 9.96 (s, 1H); 7.47 (A_2M_2 , 4H); 5.26 (s, 2H); 4.42 (s, 2H); 2.54 (t, 2H); 1.64 (quint., 2H); 1.32 (sext., 2H); 0.86 (t, 3H).

- 30 PART B: Preparation of 1-[(2'-Cyano-trans-stilben-4-yl)methyl]-2-butyl-4-chloro-5-hydroxymethylimidazole

To a solution of 0.98 g of α -bromo-p-toluonitrile in 25 mL of dimethylformamide at 25° was added
 35 1.40 g of triphenylphosphine. The mixture was stirred

- 1095

88015687

at 80° for 3 hours, then treated with 1.53 g of 1-(4-formylbenzyl)-2-butyl-4-chloro-5-hydroxymethylimidazole, followed immediately by 0.54 g of sodium methoxide, and the mixture was diluted with water and extracted with benzene. The organic phases were combined and washed with water and brine, dried over anhydrous sodium sulfate, filtered, and concentrated. Column chromatography on silica gel (elution: 0-20% ethyl acetate/benzene) afforded 0.45 g of 1-[(2'-cyano-trans-stilben-4-yl)methyl]-2-butyl-4-chloro-5-hydroxymethylimidazole; NMR (200 MHz, CDCl₃): δ 8.01 (d, 1H); 7.85 (d, 1H); 7.73 (t, 1H); 7.47 (t, 1H); 7.44 (AB, 2H, J=16.3); 7.38 (A₂B₂, 4H); 5.28 (s, 2H); 5.24 (t, 1H); 4.34 (d, 2H); 2.49 (t, 2H); 1.47 (quint., 2H); 1.24 (sext., 2H); 0.79 (t, 3H).

PART C: 1-[(2'-Carboxy-trans-stilben-4-yl)methyl]-2-butyl-4-chloro-5-hydroxymethylimidazole

A solution of 0.40 g of 1-[(2'-cyano-trans-stilben-4-yl)methyl]-2-butyl-4-chloro-5-hydroxymethylimidazole in 20 mL of ethylene glycol and 12 mL of 10% aqueous sodium hydroxide was refluxed for 5.5 hours. After cooling, the reaction mixture was filtered, and the solvent was removed in vacuo. The residue was dissolved in water, and the solution was acidified to pH 3.5 using hydrochloric acid and the resulting emulsion was extracted with chloroform. The combined organic phases were washed with saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, filtered and concentrated. Column chromatography on silica gel (elution: 5% methanol/chloroform) afforded 0.12 g of 1-[(2'-carboxy-trans-stilben-4-yl)methyl]-2-butyl-4-chloro-5-hydroxymethylimidazole; NMR (200 MHz, CDCl₃): δ 8.08-8.00 (m, 2H); 7.71 (d, 1H); 7.57-7.47 (m, 3H); 7.34 (t, 1H); 7.01-6.92 (m,

3H); 5.21 (s, 2H); 4.50 (s, 2H); 2.60 (t, 2H); 1.62
(quint, 2H); 1.31 (sext., 2H); 0.03 (t, 3H).

Example 224

5 PART A: Preparation of N-(4-Benzyloxybenzyl)glycine
ethyl ester

To a suspension of 11.0 g of glycine ethyl ester
hydrochloride in 100 mL of dimethylformamide at 25° was
added 22.0 mL of triethylamine. To the resulting milky
10 suspension was added 9.08 g of 4-benzyloxybenzyl
chloride in 50 mL of DMF dropwise over 0.5 hour. The
mixture was stirred for 16 hours at 25°. The reaction
mixture was diluted with diethyl ether and then fil-
tered to remove the precipitated triethylamine hydro-
15 chloride. The resulting solution was concentrated in
vacuo, and the residue was dissolved in ethyl acetate.
The solution was washed with water and brine, dried
over anhydrous sodium sulfate, filtered, and concen-
trated. Kugelrohr distillation provided 5.90 g of
20 N-(4-benzyloxybenzyl)glycine ethyl ester [bp 160-180°
(0.015 torr.)]; NMR (200 MHz, CDCl₃): δ 7.43-7.27 (m,
5H); 7.06 (A₂B₂, 4H); 5.01 (s, 2H); 4.14 (quart., 2H);
3.71 (s, 2H); 3.36 (s, 3H); 2.01 (bs, 1H); 1.24 (t,
3H).

25

PART B: Preparation of N-(4-Benzyloxybenzyl)-N-formyl-
glycine ethyl ester

A solution of 5.83 g of N-(4-benzyloxybenzyl)-
glycine ethyl ester, 0.86 mL of formic acid, and 20 mL
30 of xylene was refluxed for 2 hours using a Dean-Stark
trap to remove the water produced in the reaction.
After cooling, the reaction mixture was washed with
20% aqueous formic acid, water, saturated sodium
bicarbonate solution, water, and brine. Finally the
35 mixture was dried over anhydrous sodium sulfate.

filtered, and the filtrate was concentrated to furnish 6.23 g of crude N-(4-benzyloxybenzyl)-N-formyl glycine ethyl ester, used in the following reaction without further purification.

5

PART C: Preparation of 1-(4-Benzyloxybenzyl)-5-carbomethoxy-2-(3H)-imidazolethione

To a suspension of 1.10 g of sodium methoxide in 35 mL of tetrahydrofuran at 10° there was added in one
10 portion, a solution of 6.23 g of N-(4-benzyloxybenzyl)-N-formyl glycine ethyl ester and 3.46 mL of methyl formate in 15 mL of THF. The mixture was stirred at 10° for 1 hour and then at 25° for 16 hours. The solvent was removed in vacuo and the residue dissolved
15 in 36 mL of methanol. To this solution was added 3.57 mL of conc. hydrochloric acid, and the mixture was stirred at 40° for 0.5 hour. A solution of 2.80 g of potassium thiocyanate in 6 mL of water was added, and the resulting mixture was stirred for 16 hours at
20 40°. Finally, 40 mL of water was added, and the mixture was allowed to cool to 25°. The precipitated solid was recovered by filtration to afford 3.60 g of 1-(4-benzyloxybenzyl)-5-carbomethoxy-2(3H)-imidazolethione; NMR (200 MHz, CDCl₃): δ 11.25 (bs, 1H);
25 8.05 (s, 1H); 7.39 (m, 5H); 7.03 (A₂B₂, 4H); 5.06 (s, 2H); 4.56 (s, 2H); 3.81 (s, 3H).

PART D: Preparation of 1-(4-Benzyloxybenzyl)-2-propylthio-5-carboethoxyimidazole

To 60 mL of ethanol at 25° was added portionwise
30 0.30 g of sodium metal. After the sodium metal has reacted 3.54 g of 1-(4-benzyloxybenzyl)-5-carbomethoxy-2-(3H)-imidazolethione was added followed immediately by 2.24 mL of 1-iodopropane, and the mixture was
35 stirred at 24° for 3 hours. At this point, the


1098

88015687

232

solvent was removed in vacuo, and the residue was dissolved in methylene chloride. This solution was washed with water and brine, dried over anhydrous sodium sulfate, filtered, and concentrated to furnish 3.46 g of crude 1-(4-benzyloxybenzyl)-2-propylthio-5-carboethoxyimidazole, used in a subsequent reaction without further purification; NMR (200 MHz, CDCl_3): δ 7.77 (s, 1H); 7.45-7.32 (m, 5H); 7.03 (A_2B_2 , 4H); 5.49 (s, 2H); 5.03 (s, 2H); 4.28 (quart., 2H); 3.20 (t, 2H); 1.32 (t, 3H); 1.02 (t, 3H).

The following intermediates were prepared or could be prepared employing the above procedure.







R^6	R^7	R^8
$n\text{-C}_6\text{H}_{13}\text{S-}$	H	$\text{CO}_2\text{CH}_2\text{CH}_3$
$n\text{-C}_4\text{H}_9\text{S-}$	H	$\text{CO}_2\text{CH}_2\text{CH}_3$

30 PART E: Preparation of 1-(4-Benzyloxybenzyl)-2-propylthio-5-hydroxymethylimidazole

A solution of 2.05 g of 1-(4-benzyloxybenzyl)-2-propylthio-5-carboethoxyimidazole in 10 mL of tetrahydrofuran was added dropwise to 10 mL of 1M lithium aluminum hydride in THF at 0° such that the reaction

temperature remained below 5°. The resulting solution then was stirred at 0° for 1 hour. At this point, the reaction mixture was quenched by sequential dropwise addition of 0.40 mL of water, 0.40 mL of 15% aqueous sodium hydride, and 1.20 mL of water. The resulting suspension was filtered employing diethyl ether, and the filtrate was concentrated to furnish 1.55 g of 1-(4-benzyloxybenzyl)-2-propylthio-5-hydroxymethyl-imidazole; NMR (200 MHz, CDCl₃): δ 7.41-7.29 (m, 5H); 7.03-6.86 (m, 5H); 5.22 (s, 2H); 5.01 (s, 2H); 4.45 (s, 2H); 3.01 (t, 2H); 2.32 (bs, 1H); 1.66 (sext., 2H); 0.97 (t, 3H).

The intermediates shown below were prepared or could be prepared employing the above procedure.



1100





88015687

247

PART F: Preparation of 1-(4-Hydroxybenzyl)-2-propylthio-5-hydroxymethylimidazole

A solution of 1.40 g of 1-(4-benzyloxybenzyl)-2-propylthio-5-hydroxymethylimidazole in 15 mL of trifluoroacetic acid was refluxed for 0.25 hour. After cooling, the reaction was poured into water containing an excess of sodium bicarbonate, and the resulting emulsion was extracted with ethyl acetate. The combined organic phases were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated. Column chromatography on silica gel (elution: 0-5% methanol/chloroform) afforded 0.28 g of 1-(4-hydroxybenzyl)-2-propylthio-5-hydroxymethylimidazole; NMR (200 MHz, DMSO- d_6): δ 9.41 (s, 1H); 6.88 (s, 1H); 6.79 (A₂B₂, 4H); 5.14 (t, 1H); 5.07 (s, 2H); 4.33 (d, 2H); 2.89 (t, 2H); 1.54 (sext., 2H); 0.88 (t, 3H).

These intermediates were prepared or could be prepared employing the above procedure.




1101

88015687

STEP G: Preparation of 1-[4-(2-Cyanobenzoyloxy)benzyl]-
2-propylthio-5-hydroxymethylimidazole

The title compound was prepared from 1-(4-hydroxybenzyl)-2-propylthio-5-hydroxymethylimidazole using the procedure described in Example 192, Part C; NMR (200 MHz, CDCl₃): δ 7.66 (m, 3H); 7.43 (m, 1H); 7.03 (s, 1H); 6.99 (A₂B₂, 4H); 5.23 (s, 2H); 5.22 (s, 2H); 4.47 (s, 2H); 3.04 (t, 2H); 1.69 (sext., 2H); 0.98 (t, 3H).

The following 2-mercaptoimidazoles shown below were prepared by the procedure illustrated above.



STEP H: Preparation of 1-[4-(2-Carboxybenzyloxy)-
benzyl]-2-propylthio-5-hydroxymethylimidazole

30 A solution of 0.23 g of 1[4-(2-cyanobenzoyloxy)-benzyl]-2-propylthio-5-hydroxymethylimidazole in 17 mL of ethylene glycol and 7 mL of 10% aqueous sodium hydroxide was refluxed for 14 hours. After cooling, the reaction mixture was filtered, and the solvent was

35

1102

88015687


750

removed in vacuo. The residue was dissolved in water, and the solution was acidified to pH 3.5 using hydrochloric acid. The precipitated solid was recovered by filtration and recrystallized from aqueous ethanol to furnish 0.094 g of 1-[4-(2-carboxybenzyloxy)benzyl]-2-propylthio-5-hydroxymethylimidazole; NMR (200 MHz, DMSO- d_6): δ 13.12 (bs, 1H); 7.93 (d, 1H); 7.58 (m, 2H); 7.45 (m, 1H); 6.99 (A₂B₂, 4H); 6.98 (s, 1H); 5.42 (s, 2H); 5.25 (bs, 1H); 5.17 (s, 2H); 4.35 (s, 2H); 2.92 (t, 2H); 1.55 (sext., 2H); 0.89 (t, 3H).

The following 2-mercaptoimidazoles of Table 17 were prepared or could be prepared by the procedure illustrated above.


Table 17

15




20

25

Ex.
NO.R⁶R⁷R⁸225 n-C₆H₁₃S-


H

CH₂OH

30

226 n-C₄H₉S-

H

CH₂OH

1103

35

88015687

256

Example 227PART A: Preparation of 1-(4-Nitrobenzyl)-2-butyl-4-chloroimidazole-5-aldehyde

A mixture of 1 g of 1-(4-nitrobenzyl)-2-butyl-4-chloro-5-hydroxymethyl imidazole and 5 g of activated MnO_2 in CH_2Cl_2 was stirred at room temperature for 16 hours. The reaction mixture was filtered through celite and the filtrate was concentrated to give a thick oil which was purified by flash column chromatography on silica gel (Hexane:ethyl acetate=1.5:1 elution). The desired compound was obtained as a colorless solid, 0.76 g; m.p. 88-89°; NMR (200 MHz, CDCl_3): δ 9.74 (d, 1H); 5.64 (s, 2H); 2.63 (t, 3H, J=7.4 Hz); 1.68 (m, 2H); 1.34 (m, 2H); 0.89 (t, 3H, J=7.3 Hz).

PART B: Preparation of 3-[1-(4-Nitrobenzyl)-2-butyl-4-chloroimidazol-5-yl]propenoic acid, ethyl ester, E and Z isomers

A mixture of 1.2 g of 1-(4-nitrobenzyl)-2-butyl-4-chloroimidazole-5-aldehyde and 1.5 g of (carboxymethylene)triphenylphosphorane in 50 mL of benzene was refluxed for 2 hours. The reaction mixture was concentrated and the residue was purified by flash column chromatography on silica gel (Hexane:EtOAc=3:1 elution). The major product, the E isomer, was eluted first and was obtained as a thick oil initially which solidified to give an amorphous solid, 1.2 g. The minor product, the Z isomer was eluted next and was isolated as a thick liquid, 85 mg. E isomer: NMR (200 MHz, CDCl_3): 7.3 and 6.53 (d, 2H, J=16 Hz); 5.3 (s, 2H); 2.62 (t, 2H, J=7.3 Hz); 1.69 (m, 2H); 1.28 (m, 5H); 0.89 (t, 3H, J=7.3 Hz). Z isomer: NMR (200 MHz, CDCl_3): (key peaks only) δ 6.45 and 6.02 (d, 2H, J=11.8 Hz); 5.17 (s, 2H).

PART C: Preparation of 3-[1-(4-Nitrobenzyl)-2-butyl-4-chloroimidazol-5-yl]propen-1-ol, E isomer

A solution of 0.5 g of 3-[1-(4-nitrobenzyl)-2-butyl-4-chloroimidazol-5-yl]propenoic acid, ethyl ester, E isomer in 20 mL of THF was cooled with an ice bath. 1.7 mL of 1.5 M diisopropylaluminum hydride (in toluene) was added slowly. The cooling bath was removed and the reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was then quenched with 3 mL of conc. NH_4Cl solution and the mixture was stirred for an additional 30 minutes. During this period an extensive gel-like material formed. The reaction mixture was further diluted with ether and filtered through celite. The filtrate was concentrated and the crude product was purified by flash column chromatography on silica gel (Hexane: EtOAc=1:1 elution). The desired compound was obtained as a thick liquid; NMR (200 MHz, CDCl_3): δ 6.5-6.15 (m, 2H); 5.21 (s, 2H); 4.25 (d, 2H, $J=4.5$ Hz); 2.35 (t, 3H, $J=7.4$ Hz); 1.68 (m, 2H); 1.34 (m, 2H); 0.86 (t, 3H, $J=7.4$ Hz).

PART D: Preparation of 3-[1-(4-Aminobenzyl)-2-butyl-4-chloroimidazol-5-yl]propen-1-ol, E isomer

A mixture of 0.2 g of 3-[1-(4-nitrobenzyl)-2-butyl-4-chloroimidazol-5-yl]propen-1-ol, 0.15 g of iron and 0.3 mL of glacial acetic acid in 10 mL of absolute ethanol was refluxed for 1 hour. The reaction mixture was concentrated to dryness and the residue was dissolved in 20 mL of water and the solution was made basic to pH 8 by adding K_2CO_3 . The mixture was then extracted with ethyl acetate and the ethyl acetate layer was washed with water. The organic layer was concentrated to give a crude product which was purified by flash silica gel column chromatography

1105

88015687

(ethyl acetate elution). A pure product was obtained as an amorphous solid; NMR (200 MHz, CDCl_3): δ 6.76 and 6.62 (dd, 4H, $J=8.5$ Hz): 6.42-6.22 (m, 2H): 2.57 (t, 2H, $J=7.3$ Hz): 1.65 (m, 2H): 1.33 (m, 2H): 0.87 (t, 2H, $J=7.3$ Hz).

PART E: Preparation of 3-[1-(4-(2-Carboxybenzamido)-benzyl)-2-butyl-4-chloroimidazol-5-yl]-propen-1-ol, E isomer

To a solution of 95 mg of 3-[1-(4-aminobenzyl)-2-butyl-4-chloroimidazol-5-yl]propen-1-ol in 2 mL of CHCl_3 was added 45 mg of phthalic anhydride and the mixture was stirred at room temperature for 1 hour. During this period of time the initially clear solution became turbid and produced solid. The reaction mixture was diluted with 2 mL of ether and the solid was collected by filtration and washed with ether. The desired product was obtained as a tan solid, 115 mg, m.p. 150-151°; NMR (10% $\text{DMSO}-d_6/\text{CDCl}_3$): δ 9.94 (s, 1H): 7.71 and 6.93 (d, 4H, $J=8.3$ Hz): 6.36 (m, 2H): 5.1 (s, 2H): 4.18 (d, 2H, $J=3.9$ Hz): 2.6 (t, 3H, $J=7.4$ Hz): 1.68 (m, 2H): 1.34 (m, 2H): 0.89 (t, 3H, $J=7.4$ Hz).

Example 228

PART A: Preparation of 3-[2-Butyl-4-chloro-1-(4-aminobenzyl)imidazol-5-yl]propenoic acid ethyl ester, E isomer

A mixture of 0.5 g of 3-[2-butyl-4-chloro-1-(4-nitrobenzyl)imidazol-5-yl]propenoic acid ethyl ester (E isomer) prepared from Part B of Example 227, 1 g of iron and 2 mL of glacial acetic acid in 30 mL of absolute ethanol was refluxed for 1 hour. The reaction mixture was concentrated to dryness and the residue was dissolved in 50 mL of H_2O . The aqueous

1106

88015687

AD

solution was adjusted to pH 8 by K_2CO_3 and was extracted with ethyl acetate. The crude product obtained upon concentration of the ethyl acetate extract was purified by flash silica gel column chromatography (hexane:ethyl acetate-1:1 elution). The desired compound was obtained as a thick colorless oil. 0.35 g.

10 PART B: Preparation of 3-[2-Butyl-4-chloro-1-(4-(2-carboxybenzamido)benzyl)imidazol-5-yl]-propenoic acid ethyl ester, E isomer

A mixture of 361 mg of the aniline derivative obtained from Part A and 150 mg of phthalic anhydride in 3 mL of chloroform was stirred at room temperature for 1 hour. The reaction mixture was concentrated and the residue was triturated in ethyl ether. The resulting solid was collected and dried to give a colorless solid, 450 mg, m.p. 180-181°. NMR ($CDCl_3$, 5% DMSO- d_6) δ 0.91 (t, 3H, J= 7.1Hz); 1.1-1.4 (m, 5H); 1.60 (q, 2H, J= 7.3Hz); 2.71 (t, 2H, J= 8.4Hz); 4.17 (q, 2H, J= 7.3Hz); 5.23 (s, 2H); 6.46 + 7.38 (d each, 2H, J= 16.1Hz); 6.0-8.0 (m, 8H), 10.2 (s, 1H).

Example 229

25 PART A: Preparation of 1-(2'-Carbomethoxybiphenyl-4-yl)methyl-2-butyl-4-chloroimidazole-5-carboxaldehyde

A mixture of 0.68 g of the hydroxymethyl precursor prepared in Example 85, Part C and 3.4 g of activated MnO_2 in 30 mL of $CHCl_3$ was stirred at room temperature for 4 hours. The reaction mixture was then filtered through celite and the filtrate was concentrated to give a thick oily residue which was purified by flash chromatography on silica gel (hexane:ethyl acetate-2:1 elution). The desired

aldehyde was obtained as a thick colorless oil, 0.5 g;
NMR (CDCl_3): 9.78 (s, 1H); 5.6 (s, 2H); 3.63 (s,
3H); 2.63 (t, 3H, $J=7.4$ Hz); 1.68 (m, 2H); 1.34 (m,
2H); 0.89 (t, 3H, $J=7.4$ Hz).

5

PART B: 4-[1-(2'-Carbomethoxybiphenyl-4-yl)methyl-
2-butyl-4-chloroimidazol-5-yl]-3-buten-2-
one, E isomer

A mixture of 0.5 g of 1-(2'-carbomethoxybi-
10 phenyl-4-yl)methyl-2-butyl-4-chloroimidazole-5-
carboxaldehyde and .04 g of 1-triphenylphosphoran-
ylidene-2-propanone in 20 mL of benzene was refluxed
for 16 hours. The reaction mixture was concentrated
to give an oily residue which was purified by flash
15 chromatography on silica gel (hexane:ethyl acetate-1:1
elution). The desired compound was obtained as a
thick yellowish liquid, 0.46 g; NMR (200 MHz, CDCl_3):
 δ 7.9-6.8 (m, 10H); 5.24 (s, 2H); 3.62 (s, 3H); 3.62
(s, 3H); 2.69 (t, 2H, $J=7.4$ Hz); 2.26 (s, 3H); 1.72
20 (m, 2H); 1.38 (m, 2H); 0.91 (t, 3H, $J=7.4$ Hz).

PART C: Preparation of 4-[1-(2'-Carbomethoxybi-
phenyl-4-yl)methyl-2-butyl-4-chloro-
imidazol-5-yl]-3-buten-2-ol, E isomer

25 A solution of 0.45 g of the compound prepared in
Part B in 5 mL of methanol was cooled with ice and
0.2 g of NaBH_4 was added portionwise. After all the
 NaBH_4 was added the reaction mixture was stirred for
10 minutes. The reaction mixture was concentrated to
30 dryness and the residue was treated with 3 mL of satd.
 NH_4Cl and the mixture was stirred at room temperature
for 10 min. The mixture was then extracted with ethyl
acetate and the ethyl acetate extract was concentrated
to give a thick liquid, 0.45 g; NMR (200 MHz, CDCl_3):
35 6.45-6.15 (m, 2H.); 5.16 (s, 2H); 4.34 (m, 1H.); 3.67
(s, 3H).

- 1108

88015687

Example 220

PART A: Preparation of 1-(4-nitrobenzyl)-2-butyl-4-chloro-5-(2-phenylethen-1-yl)imidazole, E isomer

- 5 A solution of 0.4 g of benzyltriphenylphosphonium chloride in 20 mL of dried THF was cooled to -30°. To the above solution was added 0.65 mL of 1.6 M n-BuLi dropwise. As the BuLi was added the solution turned to deep orange color. After stirring for 10 min. at -30°, 0.32 g of 1-(4-nitrobenzyl)-2-butyl-4-chloroimidazole-5-aldehyde was added and the reaction mixture was allowed to warm up to room temperature and stirred at room temperature for 2 hours. The reaction mixture was quenched with 2 mL of saturated NH₄Cl solution and diluted with ethyl acetate, and the ethyl acetate solution was washed with water and a brine solution. Evaporation gave a thick oily residue which was purified by the flash silica gel column chromatography (hexane:ethyl acetate-3:1 elution) to give a thick yellow oil. 0.39 g.

PART B: Preparation of 1-[4-(2-Carboxybenzamido)-benzyl]-2-butyl-4-chloro-5-(2-phenylethen-1-yl)imidazole, E isomer

- 25 The compound was prepared from the compound of Part A by the procedure described in Example 227. Parts D and E; m.p. 111-113° (dec).

Example 231

- 30 PART A: Preparation of 3-[2-Butyl-4-chloro-1-(4-nitrobenzyl)imidazol-5-yl]-3-propen-1-ol acetate, E isomer

A mixture of 1 g of 3-[1-(4-nitrobenzyl)-2-butyl-4-chloroimidazol-5-yl]propen-1-ol obtained from Part C of Example 227, 1 mL of acetic anhydride and 2 mL of

1109

88015687

pyridine in 20 mL of CH_2Cl_2 was stirred at room temperature for 16 hours. The reaction mixture was diluted with 100 mL of ethyl acetate and the organic layer was washed with H_2O . The crude product obtained upon concentration of the organic layer was purified by flash silica gel chromatography (hexane: ethyl acetate=1:1 elution) to give the desired acetate as a thick colorless oil. 0.95 g.

10 PART B: Preparation of 3-[2-Butyl-4-chloro-1-(4-aminobenzyl)imidazol-5-yl]-3-propen-1-ol acetate, E isomer

The nitro compound obtained from Part A was reduced to the amino compound by the conditions described in Part D of Example 227. The desired compound was obtained as a colorless thick oil.

20 PART C: Preparation of 3-[2-Butyl-4-chloro-1-(4-(2-carboxybenzamido)benzyl)imidazol-5-yl]-3-propen-1-ol acetate, E isomer

The phthalamic acid derivative was obtained from the aniline derivative obtained from Part B and phthalic anhydride by the method described in Part E of Example 227. The desired compound was obtained as a colorless solid, m.p. 84-87°.

NMR (CDCl_3) δ 0.91 (t, 3H, J= 7.1Hz): 1.2 (m, 2H): 1.7 (m, 2H): 2.0 (s, 3H): 2.7 (t, 2H, J= 7.4Hz): 4.57 (d, 2H, J= 5.4Hz): 5.06 (s, 2H): 6.24 (m, 2H): 6.9-8.0 (m, 8H): 8.8 (s, 1H).

1110

88015687

Example 232

Preparation of 3-[1-(4-((N-Trifluoromethanesulfonyl)-anthranilamido)benzyl)-2-butyl-4-chloroimidazol-5-yl]-3-propen-1-ol acetate, E isomer

- 5 A mixture of 0.72 g of 3-[2-butyl-4-chloro-1-(4-aminobenzyl)imidazol-5-yl]-3-propen-1-ol acetate obtained from Example 231, Part B and 0.6 mL of triethylamine in 20 mL of CH_2Cl_2 was cooled with an ice bath. To this solution was added 0.6 g of p-(tri-
- 10 fluoromethanesulfonamido)benzoyl chloride dropwise and the reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was then diluted with 100 mL of ethyl acetate, and the ethyl acetate solution was washed with water, dried over Na_2SO_4 and
- 15 concentrated to give a crude product which was purified by a flash silica gel column chromatography (3% acetonitrile in ethyl acetate) to give the desired compound as a solid, 1.05 g, m.p. 156-158°; NMR (200 MHz, CDCl_3): δ 12.9 (bs, 1H); 8.12-6.91 (m); 6.3 (s);
- 20 5.09 (s); 4.61 (d, 2H, $J=4.5$ Hz); 2.04 (s, 3H).

Example 233

Preparation of 3-[1-(4-((N-trifluoromethanesulfonyl)-anthranilamido)benzyl)-2-butyl-4-chloroimidazol-5-yl]-propen-1-ol, E isomer

- 25 A mixture of 0.9 g of the compound of Example 232 and 3 mL of 1N NaOH in 6 mL of methanol was stirred at room temperature for 16 hours. The reaction mixture was diluted with 50 mL of water and the aqueous solution was acidified to a pH of 3 with 1N HCl to produce
- 30 extensive solids which were collected and washed with water. The solids were then dried in vacuo to give 0.85 g of the desired product, m.p. 129-131°; NMR (200 MHz, 5% $\text{DMSO}-d_6/\text{CDCl}_3$): δ 11.15 (bs, 1H); 8.02-6.95 (m, 8H); 6.5-6.3 (m, 2H); 5.13 (s, 2H); 4.19 (d, 2H, $J=3.5$ Hz).
- 35

1111

88015687

Example 224

PART A: Preparation of 3-[2-Butyl-4-chloro-1-(4-nitrobenzyl)imidazol-5-yl]-2-(carboethoxy)-propanoic acid, ethyl ester

5 The sodium salt of diethyl malonate was generated from 2.5 g of NaH (50% oil dispersion) and 8 mL of diethyl malonate in 100 mL of dried DMF with ice cooling. To the above solution was added 5 g of the chloromethyl compound and the mixture was stirred at
10 room temperature for 3 hours. The reaction mixture was stirred at room temperature for 3 hours. The reaction mixture was concentrated and the residue was diluted with 100 mL of water. The aqueous layer was acidified to a pH of 6 by 1N HCl and the product was
15 extracted with ethyl acetate. The crude product was purified by column chromatography (Hexane:EtOAc=2:1 elution) which afforded the product as a thick yellow oil. 2.8 g.

20 PART B: Preparation of 3-[2-Butyl-4-chloro-1-(4-nitrobenzyl)imidazol-5-yl]propanoic acid methyl ester

A mixture of 0.5 g of the compound from Part A in 20 mL of 3N HCl was refluxed for 2 hours. The
25 reaction mixture was cooled and neutralized to a pH of 6 with 4N NaOH solution. The resulting gummy solids were extracted into ethyl acetate and concentrated to give a thick yellow oil. 0.5 g. The propionic acid derivative was dissolved in ethyl ether and was
30 treated with diazomethane in ethyl ether to give a crude methyl ester which was purified by column chromatography (hexane:ethyl acetate=1:1) which afforded the product as a waxy solid. 0.34 g.

PART C: Preparation of 3-[2-Butyl-4-chloro-1-(4-(2-carboxybenzamido)benzyl)imidazol-5-yl]-
propanoic acid methyl ester

The nitro compound of Part B was reduced to the
5 corresponding amino compound by methods previously
described. A mixture of 17 mg of the amino compound
and 7.5 g of phthalic anhydride in 1 mL of CHCl₃ was
stirred at room temperature for 1 hour. The reaction
mixture was concentrated to dryness and the residue
10 was triturated with ether. The resulting solids were
collected and washed with ether. The pure product was
obtained as a colorless solid. 20 mg. m.p. 150.5-151.5°
(dec.).

15 Example 235

Preparation of 3-[2-Butyl-4-chloro-1-(4-((N-trifluoro-
methanesulfonyl)anthranilamido)benzyl)imidazol-5-yl]-
propanoic acid methyl ester

Reaction between the amino compound of Example
20 234, Part C and o-(trifluoromethanesulfonamido)benzoyl
chloride using the conditions described in Example 232
produced the title compound as a solid. m.p. 168-172°.

Example 236

25 PART A: Preparation of 3-[1-(4-Nitrobenzyl)-2-
butyl-4-chloroimidazol-5-yl]propanoic acid,
N,N-dimethylamide

To a solution of 0.7 g of propionic acid from
Part B of Example 234 in 20 mL of methylene chloride
30 was added 0.5 mL of pyridine. 0.16 g of dimethylamine
HCl salt and 0.42 g of dicyclohexylcarbodiimide. The
mixture was then stirred at room temperature for 16
hours. At the end of the reaction the mixture was
filtered through celite and the filtrate was concen-
35 trated to give a thick oily product. Thus obtained

1113

88015687

crude product was purified by flash column chromatography (100% elution) to give a pure product as a thick colorless oil, 0.68 g: NMR (200 MHz, CDCl_3) δ 2.89 (s, 3H); 2.93 (s, 3H); 5.43 (s, 2H).

5

PART B: Preparation of 3-[1-(4-Aminobenzyl)-2-butyl-4-chloroimidazol-5-yl]propanoic acid, N,N-dimethylamide

10 The nitro compound from Part A was reduced by the same method described in Part D of Example 227 to give the amino compound as a solid, m.p. 146-148°.

15 PART C: Preparation of 3-[2-Butyl-4-chloro-1-(4-((N-trifluoromethanesulfonyl)anthranilamido)-benzyl)imidazol-5-yl]propanoic acid, N,N-dimethylamine amide

20 The amino compound from Part B was treated with *o*-(trifluoromethanesulfonamido)benzoyl chloride as described in Example 232 to give the trifluoromethyl-sulfonamide product, m.p. 106-108°.

PART D: Preparation of 3-[2-Butyl-4-chloro-1-(4-(2-carboxybenzamido)benzyl)imidazol-5-yl]-propanoic acid, N,N-dimethylamine amide

25 The amino compound from Part B was reacted with phthalic anhydride as described in Part E of Example 227 to give the phthalamic acid derivative, m.p. 139-142°.

30

1114

35

88015687

Example 237

PART A: Preparation of 3-[1-(4-Nitrobenzyl)-2-butyl-4-chloroimidazol-5-yl]-2-carboethoxy-2-methylpropanoic acid, ethyl ester

- 5 A solution of 2 g of the malonate derivative obtained from Part A of Example 234 in 10 mL of dried DMP was cooled with ice. To the solution was added 0.22 g of NaH (50% oil dispersion) and the solution was stirred for 5 minutes before adding 0.3 mL of
- 10 methyl iodide. The reaction mixture then stirred at room temperature for 2 hours. The reaction mixture was diluted with 400 mL of ethyl acetate and the organic layer was washed with H₂O and brine. The crude product obtained upon concentration of the
- 15 organic layer was purified by flash silica gel column chromatography (hexane:ethyl acetate=1:1 elution) to give a pure compound as a thick colorless oil, 1.8 g.

PART B: Preparation of 3-[1-(4-Nitrobenzyl)-2-butyl-4-chloroimidazol-5-yl]-2-methylpropanoic acid

- 20 The malonate derivative from Part A was subjected to the hydrolysis-decarboxylation condition as described in Part B of Example 234. The desired compound was obtained as a thick yellowish liquid.

25 PART C: Preparation of 3-[1-(4-Nitrobenzyl)-2-butyl-4-chloroimidazol-5-yl]-2-methylpropanoic acid, isopropyl ester

- A mixture of 0.38 g of the acid from Part B, 1 mL of isopropyl alcohol and 0.22 g of dicyclohexylcarbodiimide in 10 mL of CH₂Cl₂ was stirred at room temperature for 16 hours. The reaction mixture was concentrated and the residue was taken into ethyl acetate. Insoluble material was filtered off and the
- 35 filtrate was concentrated to give a crude product which

1115

88015687

was purified by column chromatography (hexane:ethyl acetate-2:1 elution) to give the desired compound as a thick colorless oil, 0.36 g.

5 PART D: Preparation of 3-[1-(4-((N-trifluoromethanesulfonyl)anthranilamido)benzyl)-2-methyl-
propanoic acid, isopropyl ester

The title compound was prepared from the ester of Part C by the methods described in Parts B and C of
10 Example 236; m.p. 132-135°.

Examples 238 and 239

PART A: Preparation of d and l 3-[1-(4-Nitrobenzyl)-
2-butyl-4-chloroimidazol-5-yl]-2-methyl-
15 propanoic acid, d-(+)- α -methylbenzylamide

A mixture of 0.71 g of the propionic acid derivative from Part B of Example 237, 0.25 mL of d-(+)- α -methylbenzylamine and 0.4 g of dicyclohexylcarbodiimide in 50 mL of CH_2Cl_2 was stirred at room
20 temperature for 16 hours. The reaction mixture was concentrated and residue was dissolved in 100 mL of ethyl acetate. Insoluble material was filtered off through celite and the filtrate was concentrated to give a crude product which was purified by silica gel
25 column chromatography (hexane:ethyl acetate-2:1 elution). Two diastereoisomers were separated as a thick colorless oil, 0.37 g each.

PART B: Preparation of d and l 3-[1-(4-Aminobenzyl)-
30 2-butyl-4-chloroimidazol-5-yl]-2-methyl-
propanoic acid, d-(+)- α -methylbenzylamide

The nitro compound from Part A was reduced by the same method described in Part D of Example 227 to give the amino compound as a thick colorless oil.

35

1116

88015687

PART C: Preparation of d and l 3-[1-(4-(2-Carboxybenzamido)benzyl-2-butyl-4-chloroimidazole-5-yl)-2-methylpropanoic acid, d-(+)- α -methylbenzylamide

5 Each diastereoisomer of the amino compound from Part B was reacted with phthalic anhydride separately as described in Part E of Example 227, to give the phthalamic acid derivatives, m.p. 188-189.5° and 201-202°, respectively.

10

Example 240

Preparation of 1-[(2'-Carboxybiphenyl-4-yl)methyl]-2-butyl-4-chloroimidazole-5-carboxylic acid

15 To a solution of 1.03 g of 1-[(2'-carboxymethoxybiphenyl-4-yl)methyl]-2-butyl-4-chloro-5-hydroxymethylimidazole in 10 mL of anhydrous acetic acid at 25° was added a solution of 0.62 g of chromium trioxide in 10 mL of water. The mixture was stirred at 25° for 15 minutes and then poured into water. The precipitated
20 solids were recovered by filtration and then dissolved in 50 mL of 1.0 N aqueous sodium hydroxide solution. The alkaline solution was allowed to stand at 25° overnight and then was acidified to pH 3 with 10% aqueous hydrochloric acid. The precipitated solid was
25 recovered by filtration and recrystallized from ethyl acetate to afford 0.10 g of 1-[(2'-carboxybiphenyl-4-yl)methyl]-2-butyl-4-chloroimidazole-5-carboxylic acid (m.p. 186-187° (decomp.)). NMR (DMSO- d_6) δ 12.97 (br s, 2H); 7.68 (d, 1H); 7.53 (t, 1H); 7.41 (t, 1H); 7.34
30 (d, 1H); 7.28 (d, 2H); 7.02 (d, 2H); 5.61 (s, 2H); 2.60 (t, 2H); 1.53 (quint., 2H); 1.27 (sext., 2H); 0.81 (t, 3H).

35 Examples 241-264 were prepared using procedures illustrated in Examples 227-240.


1117

88015687

265

Table 18

5


















Ex. No.	R ⁶	R ⁷	R ⁸	R ¹³	MP (°C)
241	n-butyl	Cl			115-120
242	n-butyl	Cl			171.5-172.5
243	n-butyl	Cl			160-162
244	n-butyl	Cl	$(CH_2)_2COCH_3$		164-162
245	n-propyl	Cl	$CH_2CH_2CO_2CH_3$		
246	n-butyl	Cl	$CH_2CH(CH_3)CO_2CH(CH_3)_2$		123-125
247	n-butyl	Cl	$(CH_2)_3OAc$		124-127

1118

88015687

Table 18 (continued)









Ex. No.	R ⁶	R ⁷	R ⁸	R ¹³	MP (°C)
5 248	n-butyl	Cl	(CH ₂) ₃ OAc		64-67
10 249	n-butyl	Cl			142-144
15 250	n-butyl	Cl			63-64.5
20 251	n-butyl	Cl			
25 252	n-butyl	Cl	CO ₂ H		
30 253	n-pentyl	H	CO ₂ H		
35 254	n-propyl	H			
255	n-propyl	Cl			
256	n propyl	Cl			

1119

88015687

2A

267
Table 1B (continued)


Ex. No.	R ⁶	R ⁷	R ⁸	R ¹³	MP (°C)
5	257	n butyl	Cl		
10	258	n-butyl	Cl		
15	259	n-butyl	Cl		
20	260	n-butyl	Cl		
	261	n-butyl	Cl		
25	262	n-butyl	Cl		
30	263	n-butyl	Cl		
35	264	n butyl	Cl		75-76.5

1120

88015687

78

Table 18 (continued)

Ex. No.	R ⁶	R ⁷	R ⁸	R ¹³	MP(°C)
5	265	n-butyl	Cl	CH ₂ CH ₂ CH ₂ CO ₂ H	83-85
					

Example 266

- 10 PART A: Preparation of 2-(But-1-en-1-yl)-5-t-butyl-5-(dimethylsilyloxymethyl)-1-[(2'-carboxymethoxybiphenyl-4-yl)methyl]-4-chloroimidazole

- 15 2-(But-1-en-1-yl)-1-[(2'-carboxymethoxybiphenyl-4-yl)methyl]-4-chloro-5-(hydroxymethyl)-imidazole (1.4 g), t-butyl-dimethylsilyl chloride (0.55 g), and imidazole (0.5 g) were mixed and stirred in DMF (5 mL) for 18 hours at room temperature. Dilution with ethyl acetate and washing
- 20 the organic phase with water followed by drying (MgSO₄), evaporation of the solvent in vacuo, and flash chromatography in 3:1 hexane/ethyl acetate yielded 1.5 g of a clear oil. NMR (200 MHz, CDCl₃)
- 25 δ 7.83 (d, 1H); 7.52 (t, 1H); 7.40 (t, 1H); 7.33-7.24 (m, 3H); 7.08 (d, 2H); 6.83 (d of t, 1H); 6.13 (d, 1H); 5.30 (s, 2H); 4.57 (s, 2H); 3.64 (s, 3H); 2.21 (quint., 2H); 1.04 (t, 3H); 0.86 (s, 9H); 0.05 (s, 6H).

- 30 PART B: Preparation of 5-t-Butyl-5-(dimethylsilyloxymethyl)-1-[(2'-carboxymethoxybiphenyl-4-yl)methyl]-4-chloroimidazole-2-carboxaldehyde

2-(But-1-en-1-yl)-5-(t-butyl-dimethylsilyloxymethyl)-1-[(2-carboxymethoxybiphenyl-4-yl)methyl]-4-

35

1121

88015687

chlorimidazole (262 mg) was reacted with osmium tetroxide and sodium periodate by the procedure described in Example 178, Part B for 1.5 hours at room temperature. Work-up and flash chromatography
5 in 3:1 hexane/ethyl acetate yielded 200 mg of an amorphous solid. NMR (200 MHz, CDCl₃) δ 9.74 (s, 1H); 7.84 (d, 1H), 7.54 (t, 1H), 7.43 (t, 1H), 7.34-7.25 (m, 3H), 7.16 (d, 2H) 5.83 (s, 2H), 4.65 (s, 2H), 3.64 (s, 3H), 0.90 (s, 9H), 0.09 (s, 6H).

10

PART C: Preparation of 5-t-Butyldimethylsilyloxymethyl-1-[(2'-carbomethoxybiphenyl-4-yl)-methyl]-4-chloro-2-(cis-pent-1-en-1-yl)-imidazole

15

5-t-Butyldimethylsilyloxymethyl-1-[(2'-carbomethoxybiphenyl-4-yl)methyl]-4-chloroimidazole-2-carboxaldehyde (200 mg) was added all at once to a solution of n-butyltriphenylphosphonium bromide (0.26 g) and potassium t-butoxide (70 mg) in THF at 0°C.

20

The reaction mixture was stirred at room temperature for 15 minutes when it was quenched with saturated aqueous ammonium chloride solution. The mixture was extracted with ethyl acetate, the organic layers washed with water, dried (MgSO₄) and the solvent

25

removed in vacuo. The residue was flash chromatographed in hexane/ethyl acetate (5:1) to yield 100 mg of an oil. NMR (200 MHz, CDCl₃) δ 7.85 (d, 1H), 7.54 (t, 1H), 7.42 (t, 1H), 7.35-7.24 (m, 3H), 7.07 (d, 2H), 6.07 (d, 1H), 5.87 (d of t, 1H), 5.28 (s, 2H), 4.59 (s, 2H), 3.64 (s, 3H), 2.69 (quart., 2H), 1.46 (sext., 2H), 0.91 (t, 3H), 0.86 (s, 9H), 0.05 (s, 6H).

30

1122

35

88015687

209

PART D: Preparation of 1-[(2'-Carbomethoxybiphenyl-4-yl)methyl]-4-chloro-5-hydroxymethyl-2-(cis-pent-1-en-1-yl)imidazole

5-t-Butyldimethylsilyloxymethyl-1-[(2'-carbo-
5 methoxybiphenyl-4-yl)methyl]-4-chloro-2-(cis-pent-1-en-1-yl)imidazole (100 mg) was desilylated with fluoride by procedures familiar to one skilled in the art. Flash chromatography in 1:1 hexane/ethyl acetate yielded 65 mg of a viscous, colorless oil.
10 NMR (200 MHz, CDCl₃) δ 7.85 (d, 1H), 7.55 (t, 1H), 7.42 (t, 1H), 7.28 (m, 3H), 7.05 (d, 2H), 6.11 (d, 1H), 5.92 (d of t, 1H), 5.30 (s, 2H), 4.57 (d, 2H), 3.64 (s, 3H), 2.69 (quart., 2H), 1.62 (t, 1H), 1.47 (sext., 2H), 0.92 (t, 1H).

15

PART E: Preparation of 1-[(2-Carboxybiphenyl-4-yl)-methyl]-4-chloro-5-hydroxymethyl-2-(cis-pent-1-en-1-yl)imidazole

1-[2'-Carbomethoxybiphenyl-4-yl)methyl]-4-
20 chloro-5-hydroxymethyl-2-(cis-pent-1-en-1-yl)imidazole (65 mg) was hydrolyzed by a procedure similar to that found in Example 85, Part E. Work-up yielded 45 mg of colorless solids; m.p. 148-150°. NMR (200 MHz, DMSO-d₆) δ 7.77 (d, 1H); 7.50 (t,
25 1H); 7.38 (t, 1H); 7.33 (m, 3H); 7.08 (d, 2H); 6.10 (d, 1H); 5.84 (d of t, 1H); 5.32 (s, 2H); 4.47 (s, 2H); 2.65 (quart., 2H), 1.45 (sext., 2H); 0.92 (t, 3H).

30

Table 19 further illustrates compounds which were made or could be made by the methods described in the specification.

1123


35

88015687

220

Table 19

5



10

Ex. No.	Σ	R^6	R^7	R^8	R^{13}	MP (°C)
267	1	n-butyl	Cl	CH ₂ OH		
268	1	n-propyl	H	CH ₂ OH		
269	1	n-butyl	Cl	CH ₂ CO ₂ CH ₃		
270	1	n-pentyl	Cl	CH ₂ OH		
271	1	n-butyl	Cl	CH ₂ NHC(=O)OC ₃ H ₇		
272	2	n-butyl	Cl	CH ₂ OH		
273	1	n-propyl	H	CH ₂ OH		

88015687

42

Table 19 (continued)

Ex. No.	τ	R^6	R^7	R^8	R^{13}	MP (°C)
5	274	1	n-butyl	CF_3	CH_2OH	
10	275	1	n-butyl	Cl	CH_2OH	
15	276	1	n-butyl	H	CH_2OH	
	276	1	n-hexyl	Cl	$CH_2NHCO_2CH_3$	
20	278	1	n-butyl	Cl	CH_2OH	
25	279	1	n-butyl	Cl	CH_2OH	
30	280	0	n-butyl	Cl	CH_2OH	
35	281	1	n-propyl	Cl	CH_2OH	








1125

1125

88015687

272











Table 19 (continued)

Ex. No.	<u>5</u>	<u>R⁶</u>	<u>R⁷</u>	<u>R⁸</u>	<u>R¹³</u>	MP (°C)
5	282	1	n-butyl	Cl	CH ₂ OH	
10	283	1	n-butyl	Cl	CH ₂ OH	
15	284	1	n-hexyl	H	CH ₂ OH	
	285	1	n-butyl	Cl	CH ₂ OH	
20						
25	286	1	n-propyl	H	CH ₂ OH	
30	287	1	n-butyl	Cl	(CH ₂) ₂ F	
			1126			
35	288	1	n-butyl	Cl	CH ₂ OCONHCH ₃	

88015687










24

Table 19 (continued)

Ex. No.	E	R ⁶	R ⁷	R ⁸	R ¹³	mp (°C)
5	289	1	n-butyl	Cl	$\text{CH}_2\text{OCNHCCH}_3$ 	
10	290	1	n-propyl	H	$\text{CH}_2\text{NHCOCH}_2\text{CH}_2\text{CH}_3$ 	
	291	1	n-pentyl	H	$\text{CH}_2\text{NHCNHCCH}_3$ 	
15	292	1	n-butyl	Cl	$(\text{CH}_2)_3\text{F}$ 	181-182.5
20	293	1	n-butyl	Cl	CH_2ONO_2 	
25	293	1	n-butyl	Cl	 	
	295	1	n-butyl	Cl	CH_2OH 	
30	296	1	n-butyl	Cl	CH_2OH 	
35	1127					
	297	1	n-butyl	Cl	CH_2OH 	

88015687









Table 19 (continued)

Ex. No.	E	R ⁶	R ⁷	R ⁸	R ¹³	MP (°C)
5	298	1	n-butyl	Cl	CH ₂ OH	4-SCH ₂ - 
10	299	1	n-butyl	Cl	CH ₂ OH	4-CO ₂ H- 
	300	1	n-butyl	Cl	CH ₂ OH	4-NHCH ₂ - 
15	301	1	n-butyl	Cl	CH ₂ OH	4-NHC(CH ₃)C ₆ H ₅ - 
20	302	1	n-propyl	Cl	CH ₂ OH	4-SO ₂ NH ₂ - 
	303	1	n-pentyl	Cl	CH ₂ OH	4-CH ₂ NH- 
25	304	1	n-hexyl	Cl	CH ₂ OH	4-CF=CF- 
30	305	1	n-butyl	Cl	CH ₂ OH	4-CH=CF- 
35	306	1	n-butyl	H	CH ₂ OH	4-CH ₂ CH ₂ - 

1128

88015687

Table 19 (continued)

Ex. No.	R^1	R^2	R^3	R^4	R^5	MP (°C)
5	307	1	n-butyl	Cl	CH ₂ OH	
10	308	1	n-butyl	Cl	CH ₂ OH	
	309	1	n-butyl	Cl	CH ₂ OH	
15	310	1	n-butyl	Cl	CH ₂ OH	
20	311	1	n-butyl	Cl	CH ₂ OH	
25	312	1	n-propyl	H	CH ₂ OH	
30	313	1	n-pentyl	Cl	CH ₂ OH	
	-	1129				
35	314	1	n-butyl	Cl	CH=CHCH ₂ OH	

103-104.5

88015687

Utility

The hormone angiotensin II (AII) produces numerous biological responses (e.g. vasoconstriction) through stimulation of its receptors on cell membranes. For the purpose of identifying compounds such as AII antagonists which are capable of interacting with the AII receptor, a ligand-receptor binding assay was utilized for the initial screen. The assay was carried out according to the method described by [Glossmann et al., J. Biol. Chem., 249, 825 (1974)], but with some modifications. The reaction mixture contained rat adrenal cortical microsomes (source of AII receptor) in Tris buffer and 2 nM of ^3H -AII with or without potential AII antagonist. This mixture was incubated for 1 hour at room temperature and the reaction was subsequently terminated by rapid filtration and rinsing through glass micro-fibre filter. Receptor-bound ^3H -AII trapped in filter was quantitated by scintillation counting. The inhibitory concentration (IC_{50}) of potential AII antagonist which gives 50% displacement of the total specifically bound ^3H -AII is presented as a measure of the affinity of such compound for the AII receptor (see Table 20).

The potential antihypertensive effects of the compounds of this invention may be demonstrated by administering the compounds to awake rats made hypertensive by ligation of the left renal artery [Cangiano et al., J. Pharmacol. Exp. Ther., 208, 310 (1979)]. This procedure increases blood pressure by increasing renin production with consequent elevation of AII levels. Compounds are administered orally at 100 mg/kg and/or intravenously via a cannula in the jugular vein at 10 mg/kg. Arterial blood pressure is continuously measured directly through a carotid artery cannula and recorded using a pressure

1130

88015687

transducer and a polygraph. Blood pressure levels after treatment are compared to pretreatment levels to determine the antihypertensive effects of the compounds (See Table 20).

Table 20

<u>Ex. No.</u>	<u>Angiotensin II Receptor Binding</u>	<u>Antihypertensive Effects in Renal Hypertensive Rats</u>	
		<u>Intravenous Activity¹</u>	<u>Oral Activity²</u>
1	IC ₅₀ (μ molar) 1.80	+	NA
2 (sodium salt)	0.140	+	NA
3 (sodium salt)	0.420		NA
4 (sodium salt)	0.280	+	NA
5 (sodium salt)	0.190		NA
6	5.70	NT	
7	0.420	+	NA
8 (sodium salt)	0.790		NA
9 (sodium salt)	5.80	NT	
10 (sodium salt)	0.190	NT	
11 (sodium salt)	0.380	NA	NA
12 (sodium salt)	0.030	+	NA
13 (sodium salt)	6.90	+	NA
14	3.20	NT	
15 (sodium salt)	9.4	+	NA
16	0.018	+	NA
17 (sodium salt)	0.042	+	NA
18	0.08	+	NA
19 (sodium salt)	1.70	NT	
20 (sodium salt)	5.30	NT	
21 (sodium salt)	2.10	+	NA
25	3.90	NT	
26 (sodium salt)	3.80		NA
27 (sodium salt)	1.20	+	+

• 1131 88015687

Table 20 (continued)

Ex. No.	Angiotensin II Receptor Binding	Antihypertensive Effects in Renal Hypertensive Rats	
	IC ₅₀ (μ molar)	Intravenous Activity ¹	Oral Activity ²
28	8.00	NT	
29	3.10	+	NA
30 (sodium salt)	0.39	+	+
31	0.64		NT
32 (sodium salt)	0.43		NT
33	0.940		NT
35 (sodium salt)	3.40	+	+
36 (sodium salt)	0.19	+	NA
51	2.30	NA	NA
52	1.10		NT
54	7.20	+	
55	0.930	+	NA
56	4.40		NT
57	4.90	+	NA
58	8.30	+	NA
59	3.00	NA	NA
60	1.20		NT
61	5.00		NT
62 (sodium salt)	9.20		NT
63 (sodium salt)	3.70		NA
64	0.620	+	NA
65	0.240	+	NA
66	0.350	+	NA
67	1.10	+	NA
70	2.50	+	NA
71	2.80		NT
72	6.50	+	NA

1132

88015687

Table 20 (continued)

Ex. No.	Angiotensin II Receptor Binding	Antihypertensive Effects in Renal Hypertensive Rats	
	IC ₅₀ (μ molar)	Intravenous Activity ¹	Oral Activity ²
74 (<u>trans</u> compound)	3.90	+	NA
(<u>cis</u> compound)	4.50	+	NA
75 (sodium salt)	7.60	+	+
76 (sodium salt)	2.70	+	NA
77 (sodium salt)	5.70	NA	NA
78 (sodium salt)	8.00	+	+
79 (sodium salt)	0.50	+	NA
80 (sodium salt)	0.50	+	+
81 (sodium salt)	0.57	NA	NA
82	6.10		NT
83	6.40		NT
85	0.49	+	+
86	2.90	+	NA
87	2.50		NT
88	1.30		+
89	0.039	+	+
90 (sodium salt)	0.020	+	+
91	0.26	+	NA
92	0.062	+	
93	0.89	+	NA
94	0.280	+	+
95	1.20	+	NA
96	1.10		NT
97	0.270	+	NA
98 (sodium salt)	0.099	+	+

1133

88015687

Table 20 (continued)

Ex. No.	Angiotensin II Receptor Binding	Antihypertensive Effects in Renal Hypertensive Rats	
	IC ₅₀ (μ molar)	Intravenous Activity ¹	Oral Activity ²
99	0.090	+	+
100	0.090	+	+
102	0.061	+	+
105	0.680	+	+
106	1.90	+	+
107	1.70		NT
108	0.160	+	+
109	0.98	+	+
110	1.30	+	+
113	0.020		NT
114	0.050	+	+
115	0.43	+	+
116	0.26	+	+
117	0.89	+	+
118	0.089	+	+
121	0.330	+	+
123	5.60	+	NA
124	1.80	+	NA
125	0.650	+	+
126	0.340	+	+
127	0.150	+	+
128	0.08	+	+
129	0.330	+	+
130	0.470	+	+
132	0.020	+	+
134	0.180	+	+
135	1.30	+	+
141	0.100	+	+

- 1134

88015687

20

Table 20 (continued)

Ex. No.	Angiotensin II Receptor Binding	Antihypertensive Effects in Renal Hypertensive Rats	
	IC ₅₀ (μ molar)	Intravenous Activity ¹	Oral Activity ²
144	0.083	+	+
148 (sodium salt)	0.200	+	+
149 (sodium salt)	0.450	+	+
150 (sodium salt)	0.200	+	+
151 (sodium salt)	0.560	+	+
152 (sodium salt)	0.250	+	+
153 (sodium salt)	0.200	+	+
154 (sodium salt)	0.60	+	+
156	0.060	+	+
160 (sodium salt)	0.120	+	+
162 (sodium salt)	0.140	+	+
165 (sodium salt)	3.00	+	NA
166 (sodium salt)	0.240	+	NA
171 (sodium salt)	0.600	+	NA
173 (sodium salt)	0.700	+	
174 (sodium salt)	0.300	+	NA
175 (DCHA salt)	1.50	+	NA
176	0.200	+	NA
177	9.60	+	NA
178	4.20	+	+
179	4.40	+	NA
180	2.90	+	NA
181	4.90	+	NA
182	4.10	+	NA
183	6.30	+	NA
184	0.40	+	NA
1135			

88015687

Table 20 (continued)

Ex. No.	Angiotensin II Receptor Binding	Antihypertensive Effects in Renal Hypertensive Rats	
	IC ₅₀ (μ molar)	Intravenous Activity ¹	Oral Activity ²
185	0.400	+	NA
192	2.30		NA
193	0.31	+	NA
194	1.20		NT
195	0.92	+	+
199	1.80		NA
202 (sodium salt)	0.160	+	NA
203 (sodium salt)	0.340	+	+
204 (sodium salt)	1.90	+	NA
205 (sodium salt)	2.50		NT
206 (sodium salt)	1.40		NT
207 (sodium salt)	0.15	+	+
208 (sodium salt)	0.330	+	NA
209 (sodium salt)	0.27		NT
215 (sodium salt)	0.200	+	NA
217 (sodium salt)	2.70		NT
218 (sodium salt)	2.0		NT
219	0.68		NT
223	5.40		NT
224	5.90		NT
227	0.110	+	
22.	0.530		NT
229	2.10	+	+
230	1.60	+	
231	0.076		NT
232	0.510	+	

1136

88015687

Table 20 (continued)

Ex. No.	Angiotensin II Receptor Binding	Antihypertensive Effects in Renal Hypertensive Rats	
	IC ₅₀ (μ molar)	Intravenous Activity ¹	Oral Activity ²
233	0.600	+	+
234	0.064	+	NA
235	0.160	+	NA
236	0.110	+	
237	0.120	+	NA
238	0.110	+	NA
239	0.092	+	
241	0.170	+	
242	0.270	+	
243	0.200		NT
244	0.088	+	
246	0.120	+	
247	0.110		NT
248	0.250	+	
249	0.072	+	NA
250	0.120	+	NA
264	0.250	+	+
265	0.270	+	+
266	2.30	+	
292	0.700	+	+
314	0.630	+	NA

- 1137

88015687

- 1 Significant decrease in blood pressure at 10 mg/kg or less
 - 2 Significant decrease in blood pressure at 100 mg/kg or less
- NA - Not active at 100 mg/kg dosage administered. Although many of the compounds tested were not active orally, they were active intravenously. A few compounds (Examples 10, 51, 59, 77 and 81) did not produce a significant decrease in blood pressure at 10 mg/kg intravenously, but did produce some decrease at that level, and it is expected that they would be active intravenously at a higher dosage, e.g., 30 mg/kg.

NT - Not tested.

1138

88015687

Dosage Forms

The compounds of this invention can be administered for the treatment of hypertension according to the invention by any means that effects contact of the active ingredient compound with the site of action in the body of a warm-blooded animal. For example, administration can be parenteral, i.e., subcutaneous, intravenous, intramuscular, or intra peritoneal. Alternatively, or concurrently, in some cases administration can be by the oral route.

- 10 The compounds can be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents. They can be administered alone, but are generally administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.

For the purpose of this disclosure, a warm-blooded animal is a member of the animal kingdom possessed of a homeostatic mechanism and includes mammals and birds.

- 20 The dosage administered will be dependent on the age, health and weight of the recipient, the extent of disease, kind of concurrent treatment, if any, frequency of treatment and the nature of the effect desired. Usually, a daily dosage of active ingredient compound will be from about 1-500 milligrams per day. Ordinarily, from 10 to 100 milligrams per day in one or more applications is effective to obtain desired results. These dosages are the effective amounts both for treatment of hypertension and for treatment of congestive heart failure, i.e., for lowering blood pressure and for correcting the hemodynamic burden on the heart to relieve the congestion.

- 30 The active ingredient can be administered orally in solid dosage forms, such as capsules, tablets, and powders, or in liquid dosage forms, such as elixirs, syrups, and suspensions. It can also be administered parenterally, in sterile liquid dosage forms.

1139

88015687

Gelatin capsules contain the active ingredient and powdered carriers, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract.

Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance.

In general, water, a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions. Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances. Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents. Also used are citric acid and its salts and sodium EDTA. In addition, parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl- or propylparaben, and chlorobutanol.

Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, A. Osol, a standard reference text in this field.

Useful pharmaceutical dosage-forms for administration of the compounds of this invention can be illustrated as follows:

1140

88015687

Capsules

A large number of unit capsules are prepared by filling standard two-piece hard gelatin capsules each with 100 milligrams of powdered active ingredient, 150 milligrams of lactose, 50 milligrams of cellulose, and 6 milligrams magnesium stearate.

Soft Gelatin Capsules

A mixture of active ingredient in a digestible oil such as soybean oil, cottonseed oil or olive oil is prepared and injected by means of a positive displacement pump into gelatin to form soft gelatin capsules containing 100 milligrams of the active ingredient. The capsules are washed and dried.

Tablets

A large number of tablets are prepared by conventional procedures so that the dosage unit is 100 milligrams of active ingredient, 0.2 milligrams of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 milligrams of microcrystalline cellulose, 11 milligrams of starch and 98.8 milligrams of lactose. Appropriate coatings may be applied to increase palatability or delay absorption.

Injectable

A parenteral composition suitable for administration by injection is prepared by stirring 1.5% by weight of active ingredient in 10% by volume propylene glycol. The solution is made to volume with water for injection and sterilized.

Suspension


An aqueous suspension is prepared for oral administration so that each 5 milliliters contain 100 milligrams of finely divided active ingredient, 100 milligrams of sodium carboxymethyl cellulose, 5 milligrams of sodium benzoate, 1.0 grams of sorbitol solution, U.S.P., and 0.025 milliliters of vanillin.

- 1141

88015687






CLAIMS:

1. An antihypertensive compound of the formula:




(I)

wherein



1142 88015687



25 R^2 is H; Cl; Br; I; F; NO_2 ; alkyl of 1 to 4 carbon atoms; acyloxy of 1 to 4 carbon atoms; alkoxy of 1 to 4 carbon atoms; CO_2H ; CO_2R^9 ; NHSO_2CH_3 ; NHSO_2CF_3 ;

CONHOR^{12} ; SO_2NH_2 ; ; aryl; or furyl;

30 R^3 is H; Cl; Br; I or F; alkyl of 1 to 4 carbon atoms or alkoxy of 1 to 4 carbon atoms;

R^4 is CN, NO_2 or CO_2R^{11} ;

R^5 is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, alkenyl or

35 alkynyl of 2 to 4 carbon atoms;






88015687

1143

R^6 is alkyl of 2 to 10 carbon atoms, alkenyl or
alkynyl of 3 to 10 carbon atoms or the same groups
substituted with F or CO_2R^{14} ; cycloalkyl of 3
to 8 carbon atoms, cycloalkylalkyl, of 4 to 10
carbon atoms; cycloalkylalkenyl or
cycloalkylalkynyl of 5 to 10 carbon atoms;
 $(\text{CH}_2)_6Z(\text{CH}_2)_mR^5$ optionally substituted
with F or CO_2R^{14} ; benzyl or benzyl substituted
on the phenyl ring with 1 or 2 halogens, alkoxy of
1 to 4 carbon atoms, alkyl of 1 to 4 carbon atoms
or nitro;




R^7 is H, F, Cl, Br, I, NO_2 , CF_3 or CN;

R^8 is H, CN, alkyl of 1 to 10 carbon atoms, alkenyl
of 3 to 10 carbon atoms, or the same groups
substituted with F; phenylalkenyl wherein the
aliphatic portion is 2 to 6 carbon atoms;
 $-(\text{CH}_2)_m$ -imidazol-1-yl; $-(\text{CH}_2)_m$ -1,2,3-
triazolyl optionally substituted with one or two
groups selected from CO_2CH_3 or alkyl of 1 to 4
carbon atoms; $-(\text{CH}_2)_m$ -tetrazolyl;



35

1144 88015687




R^{10} is alkyl of 1 to 6 carbon atoms or perfluoro-alkyl of 1 to 6 carbon atoms, 1-adamantyl, 1-naphthyl, 1-(1-naphthyl)ethyl, or $(CH_2)_p C_6H_5$;




R^{11} is H, alkyl of 1 to 6 carbon atoms, cyclo-alkyl of 3 to 6 carbon atoms, phenyl or benzyl;

R^{12} is H, methyl or benzyl;

R^{13} is $-CO_2H$; $-CO_2R^9$; $-CH_2CO_2H$; $-CH_2CO_2R^9$;




$-PO_3H$; $-C(CF_3)_2OH$; $-NHSO_2CH_3$; $-NHSO_2CF_3$; $-NHCOCF_3$;



- 1145

88015687

- R^{14} is H, alkyl or perfluoroalkyl of 1 to 8 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, phenyl or benzyl;
- 5 R^{15} is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, phenyl, benzyl, acyl of 1 to 4 carbon atoms, phenacyl;
- R^{16} is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, $(CH_2)_p C_6H_5$, OR¹⁷, or NR¹⁸R¹⁹;
- 10 R^{17} is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, phenyl or benzyl;
- R^{18} and R^{19} independently are H, alkyl of 1 to 4 carbon atoms, phenyl, benzyl, α -methylbenzyl, or taken together form a ring of the formula




Q is NR²⁰, O or CH₂:

- R^{20} is H, alkyl of 1-4 carbon atoms, or phenyl;
- 20 R^{21} is alkyl of 1 to 6 carbon atoms, -NR²²R²³, or $-CHCH_2CO_2CH_3$;
- NH_2

- R^{22} and R^{23} independently are H, alkyl of 1 to 6 carbon atoms, benzyl, or are taken together as $(CH_2)_u$ where u is 3-6;
- 25 R^{24} is H, CH₃ or -C₆H₅;

- R^{25} is NR²⁷R²⁸, OR²⁸, NHCONH₂, NHCSNH₂.
- 30



R^{26} is hydrogen, alkyl with from 1 to 6 carbon atoms, benzyl, or allyl;

35

1146 88015687

R^{27} and R^{28} are independently hydrogen, alkyl with from 1 to 5 carbon atoms, or phenyl;

R^{29} and R^{30} are independently alkyl of 1-4 carbon atoms or taken together are $-(CH_2)_q-$;

5 R^{31} is H, alkyl of 1 to 4 carbon atoms, $-CH_2CH=CH_2$ or $-CH_2C_6H_4R^{32}$;

R^{32} is H, NO_2 , NH_2 , OH or OCH_3 ;

X is a carbon-carbon single bond, $-CO-$, $-O-$, $-S-$,

10 $-NH-$, $-N-$, $-CON-$, $-NCO-$, $-OCH_2-$, $-CH_2O-$,
 $\begin{matrix} R^{26} & R^{23} & R^{23} \end{matrix}$

$-SCH_2-$, $-CH_2S-$, $-NHC(R^{27})(R^{28})$, $-NR^{23}SO_2-$,

$-SO_2NR^{23}-$, $-C(R^{27})(R^{28})NH-$, $-CH=CH-$, $-CF=CF-$,

15 $-CH=CF-$, $-CF=CH-$, $-CH_2CH_2-$, $-CF_2CF_2-$, Δ .

$\begin{matrix} OR^{14} & OCOR^{17} & NR^{25} & R^{29}O & OR^{30} \\ -CH- & -CH- & -C- & or & -C- \end{matrix}$

Y is O or S;

Z is O, NR^{11} , or S;

20 m is 1 to 5;

n is 1 to 10;

p is 0 to 3;

q is 2 to 3;

r is 0 to 2;

25 s is 0 to 5;

t is 0 or 1;

30 and pharmaceutically acceptable salts of these compounds:


provided that:


(1) the R^1 group is not in the ortho position

1147


35

88015687

(2) when R^1 is . X is a single bond.

and R^{13} is CO_2H , or . then R^{13} must


be in the ortho or meta position; or when R^1 and X are as above and R^{13} is NHSO_2CF_3 or NHSO_2CH_3 , R^{13} must be ortho;

(3) when R^1 is . and X is other than

a single bond, then R^{13} must be ortho except when X = NR^{23}CO and R^{13} is NHSO_2CF_3 or NHSO_2CH_3 , then R^{13} must be ortho or meta;

(4) when R^1 is 4- CO_2H or a salt thereof, R^6 cannot be S-alkyl;

(5) when R^1 is 4- CO_2H or a salt thereof, the substituent on the 4-position of the imidazole cannot be CH_2OH , $\text{CH}_2\text{OCOCH}_3$, or $\text{CH}_2\text{CO}_2\text{H}$;

(6) when R^1 is . X is $-\text{OCH}_2-$.

R^{13} is 2- CO_2H , and R^7 is H then R^6 is not $\text{C}_2\text{H}_5\text{S}$;

1148


88015687

- (7) when R^1 is $-\text{CONH}-\text{C}_6\text{H}_5$ and R^6 is n-hexyl then R^7 and R^8 are not both hydrogen;

- (8) when R^1 is $-\text{NHCO}-\text{C}_6\text{H}_5$, R^6 is not methoxy-benzyl.



- (9) the R^6 group is not $-\text{CH}(\text{F})\text{CH}_2\text{CH}_2\text{CH}_3$ or CH_2OH .

2. A compound of claim 1 having the formula:



(II)

Wherein



- R^6 is alkyl of 3 to 10 carbon atoms, alkenyl of 3 to 10 carbon atoms, alkynyl of 3 to 10 carbon atoms, cycloalkyl of 3 to 8 carbon atoms, benzyl substituted on the phenyl ring with up to two groups selected from alkoxy of 1 to 4 carbon atoms, halogen, alkyl of 1 to 4 carbon atoms, and nitro;

1149

88015687


R^8 is phenylalkenyl wherein the aliphatic portion is 2 to 4 carbon atoms, $-(CH_2)_m$ -imidazol-1-yl, $-(CH_2)_m$ -1,2,3-triazolyl optionally substituted with one or two groups selected from CO_2CH_3 or alkyl of 1 to 4 carbon atoms,

$(CH_2)_m$ -tetrazolyl, $-(CH_2)_nOR^{11}$; $-(CH_2)_nO\overset{O}{\overset{||}{C}}R^{14}$;

10 $-(CH_2)_s\overset{O}{\overset{||}{C}}R^{16}$; $-(CH_2)_s\overset{R^{14}}{\overset{||}{C}}HOR^{15}$;

$-(CH_2)_n\overset{O}{\overset{||}{C}}R^{16}$; $-(CH_2)_nNH\overset{O}{\overset{||}{C}}OR^{10}$; $-(CH_2)_nNH\overset{O}{\overset{||}{C}}SO_2R^{10}$;

15 $-(CH_2)_mF$; $-(CH_2)_m\overset{O}{\overset{||}{C}}R^{16}$;

R^{13} is $-CO_2H$, $-CO_2R^9$, $NHSO_2CF_3$; and  :

20 R^{16} is H, alkyl of 1 to 5 carbon atoms, OR^{17} , or $NR^{18}R^{19}$;

X is carbon-carbon single bond, $-CO-$, $-CON-$, $\overset{R^{23}}{\overset{|}{C}}$.

25 $-CH_2CH_2-$, $\overset{R^{23}}{\overset{|}{C}}-NCO-$, $-OCH_2-$, $-CH_2O-$, $-O-$, $-SCH_2-$, $-CH_2S-$, $-NHCH_2-$, $-CH_2NH-$ or $-CH=CH-$; and

pharmaceutically acceptable salts of these compounds.

30

• 1150

35

88015687

3. A compound of claim 2 wherein:

R^2 is H, alkyl of 1 to 4 carbon atoms, halogen,

or alkoxy of 1 to 4 carbon atoms;

R^6 is alkyl, alkenyl or alkynyl of 3 to 7 carbon atoms;

5 R^7 is H, Cl, Br, I or CF_3 ;

10 R^8 is $-(CH_2)_mOR^{11}$; $-(CH_2)_mO\overset{\overset{O}{\parallel}}{C}R^{14}$; $-CH-CH-\overset{\overset{R^{14}}{\mid}}{C}HOR^{15}$;
 $-(CH_2)_m\overset{\overset{O}{\parallel}}{C}R^{16}$; $-CH_2NH\overset{\overset{O}{\parallel}}{C}OR^{10}$;

15 $-(CH_2)_mNHSO_2R^{10}$; $-CH_2\overset{\overset{N-N}{\parallel}}{\underset{\underset{H}{\mid}}{N}}$: or $-COR^{16}$;

R^{10} is CF_3 , alkyl of 1 to 6 carbon atoms or phenyl;

R^{11} is H, or alkyl of 1 to 4 carbon atoms;

20 R^{13} is CO_2H ; $CO_2CH_2OCOC(CH_3)_3$; $NHSO_2CF_3$

and $\overset{\overset{N-N}{\parallel}}{\underset{\underset{H}{\mid}}{N}}$:

25 R^{14} is H, or alkyl of 1 to 4 carbon atoms;

R^{15} is H, alkyl of 1 to 4 carbon atoms, or acyl of 1 to 4 carbon atoms;

R^{16} is H, alkyl of 1 to 5 carbon atoms; OR^{17} ; or

30  :

m is 1 to 5;

X = single bond, -O-, -CO-, -NHCO-, or -OCH₂-; and pharmaceutically acceptable salts.

35 - 1151

88015687

4. The compounds of claims 1 to 3, selected from 2-Butyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-5-(hydroxymethyl)imidazole, or a pharmaceutically acceptable salt thereof,

5

2-Butyl-4-chloro-1-[(2'-carboxybiphenyl-4-yl)methyl]-5-(hydroxymethyl)imidazole, or a pharmaceutically acceptable salt thereof,

10

2-Butyl-4-chloro-1-[(2'-carboxybiphenyl-4-yl)methyl]-5-[(methoxycarbonyl)aminomethyl]imidazole, or a pharmaceutically acceptable salt thereof,

15

2-Butyl-4-chloro-1-[(2'-carboxybiphenyl-4-yl)methyl]-5-[(propoxycarbonyl)aminomethyl]imidazole, or a pharmaceutically acceptable salt thereof,

20

2-Butyl-4-chloro-1-[(2'-carboxybiphenyl-4-yl)methyl]imidazole-5-carboxaldehyde, or a pharmaceutically acceptable salt thereof,

25

2-Butyl-1-[(2'-carboxybiphenyl-4-yl)methyl]imidazole-5-carboxaldehyde, or a pharmaceutically acceptable salt thereof,

30

2-(1E-Butenyl)-4-chloro-1-[(2'-carboxybiphenyl-4-yl)methyl]-5-(hydroxymethyl)imidazole, or a pharmaceutically acceptable salt thereof,

35

1152

88015687

2-(1E-Butenyl)-4-chloro-1-[(2'-carboxybiphenyl-4-yl)methyl]imidazole-5-carboxaldehyde, or a pharmaceutically acceptable salt thereof,

5

2-propyl-4-chloro-1-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-5-(hydroxymethyl)imidazole, or a pharmaceutically acceptable salt thereof;

10

2-propyl-4-chloro-1-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-carboxaldehyde, or a pharmaceutically acceptable salt thereof;

15

2-butyl-4-chloro-1-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-carboxaldehyde, or a pharmaceutically acceptable salt thereof;

20

2-(1E-butenyl)-4-chloro-1-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-5-hydroxymethyl)imidazole, or a pharmaceutically acceptable salt thereof; and

25

2-(1E-butenyl)-4-chloro-1-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-carboxaldehyde, or a pharmaceutically acceptable salt thereof.

30

5. A pharmaceutical composition comprising a pharmaceutically suitable carrier and at least one compound of Claims 1 to 4.

1153


35

88015687

5

10

6. A process for the preparation of a compound of claims
15 1 to 4 wherein x is 1 which comprises contacting
an imidazole derivative of Formula 1 with a benzyl
derivative of Formula 2 in a solvent in the presence
of a base for about 1 to about 10 hours at a
temperature in the range of about 20°C to the reflux
20 temperature of the solvent to form a benzylimidazole
of Formula 3:



30

1154

35


88015687

wherein each of R^1 , R^2 , R^3 , R^6 , R^7 and R^8 is stable under the reaction conditions and is a group as defined in claim 1 or an intermediate or protected form thereof which can be transformed to such a group and wherein X^1 is halogen, p-toluenesulfonyloxy or methylsulfonyloxy; and thereafter as necessary transforming said intermediate or protected forms of the R groups to R groups as defined in claim 1.

7. Process of claim 6 wherein compounds 1 and 2 are contacted in the presence of a base selected from the group consisting of a metal hydride, MH, a metal alkoxide, MOR, sodium carbonate, potassium carbonate, triethylamine and pyridine, in a dipolar aprotic solvent or, where the base is MOR, the solvent can be an alcohol, ROH, where M is lithium, sodium or potassium and R is methyl, ethyl or t-butyl.

8. Process of claim 6 wherein: R^1 is

20



25

X is a carbon-carbon single bond, -CO-, -O-, -S-, or -NH-;

R^2 and R^3 are each independently H, Cl, Br, I,

CO_2R^{14} , F, NO_2 , alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, aryl or furyl;

R^6 and R^7 are as defined in claim 20;

1155

35

88015687

R^8 is alkyl of 1 to 10 carbon atoms or alkenyl of 3 to 10 carbon atoms, or the same groups substituted with F; phenylalkenyl wherein the aliphatic portion is 2 to 6 carbon atoms; $-(CH_2)_nOR^{11}$;

5 $-(CH_2)_nSR^{15}$; or $-(CH_2)_nCN$;

R^{11} is as defined in Claim 20;

R^{13} is CO_2R^{14} , CN, NO_2 , trialkyltin tetrazole, or trityltetrazole; and

R^{14} and R^{15} are as defined in Claim 20.

10

9. Process of Claim 8 wherein R^{13} is $-CO_2R^{14}$ and the product of Formula 3 is contacted with an alkali in an aqueous alcoholic solvent or with CF_3CO_2H at a temperature in the range of about 20°C to the reflux temperature of the solvent for about 1-24 hours, followed by adjustment of the pH of the mixture to a value in the range of 3 to 7, to convert the product to the corresponding product wherein R^{13} is $-CO_2H$.

20

10. Process of Claim 9 wherein at least one of R^2 , R^3 or R^{13} in Formula 1 is $-CO_2R^{14}$ and is converted to $-CO_2H$.

25

11. Process of Claim 9 wherein R^{14} is t-butyl and the reaction is conducted in CF_3CO_2H .

30

12. Process of Claim 8 wherein R^{13} is $-CN$ and the product of Formula 3 is contacted with (i) a strong acid at reflux temperature of the solvent for about 2-96 hours or (ii) a strong alkali in an alcohol solvent at a temperature in the range of about 20°C and the reflux temperature of the solvent for about 2-96 hours followed by adjustment of the pH to about 3-7, or (iii) sulfuric acid followed by acid

35

1156

88015687

243

or alkali, to convert the product to the corresponding compound wherein R^{13} is $-CO_2H$.

13. Process of Claim 12 wherein at least one of R^2 , R^3 or R^{13} is $-CO_2R^{14}$ and is converted to $-CO_2H$.

14. Process of Claim 12 wherein R^6 is $-(CH_2)_nCN$ and is converted to $-(CH_2)_nCO_2H$ or is $-(CH_2)_nOR^{11}$ and is converted to $(CH_2)_nOH$ when R^{13} is converted to $-CO_2H$.

15. Process of Claim 8 wherein R^{13} is $-CN$ and the product of Formula 3 is contacted with a mixture of equimolar amounts of sodium azide and ammonium chloride in a polar aprotic solvent at a temperature in the range of about $30^\circ C$ to the reflux temperature of the solvent, for about 1 hour to 10 days, to convert the product to the corresponding compound wherein R^{13} is 5-tetrazolyl.

16. Process of Claim 15 wherein R^6 is $-(CH_2)_mCN$ and is converted to $-(CH_2)_m$ -tetrazolyl when R^{13} is converted to 5-tetrazolyl.

17. Method of Claim 8 wherein R^{13} is $-CN$ and the product of Formula 3 is reacted with trialkyltin azide or triaryltin azide followed by acidic or basic hydrolysis to convert the product to the corresponding compound wherein R^{13} is 5-tetrazolyl.

18. Process of Claim 17 wherein R^6 is $-(CH_2)_mCN$ and is converted to $-(CH_2)_m$ -tetrazolyl when R^{13} is converted to 5-tetrazolyl.

19. Process of Claim 8 wherein R^{13} is $-\text{NO}_2$ and the product of Formula 3 is contacted with a reducing agent to form a second intermediate of Formula 3 in which R^{13} is NH_2 , and the latter is contacted with an anhydride $(\text{CH}_3\text{SO}_2)_2\text{O}$ or $(\text{CF}_3\text{SO}_2)_2\text{O}$ or a chloride $\text{CH}_3\text{SO}_2\text{Cl}$ or $\text{CF}_3\text{SO}_2\text{Cl}$ of sulfonic acid in a solvent to produce a compound in which R^{13} is $-\text{NHSO}_2\text{CH}_3$ or $-\text{NHSO}_2\text{CF}_3$.
20. Process of Claim 19 wherein at least one of R^2 , R^3 , or R^{13} is $-\text{NO}_2$ and is converted to $-\text{NHSO}_2\text{CH}_3$ or $-\text{NHSO}_2\text{CF}_3$.
21. Process of Claim 9 or 12 wherein the compound of Formula 3 with $R^{13} = \text{CO}_2\text{H}$ either
- (a) is contacted with about 1-4 equivalents of thionyl chloride in excess thionyl chloride or another solvent at a temperature in the range of about 20°C to the reflux temperature of the solvent for a period of about 5 minutes to about 2 hours to form an intermediate of Formula 3 wherein R^{13} is COCl , and the latter is contacted with about 2-10 equivalents of hydroxylamine derivative $\text{H}_2\text{NOR}^{12}$ in excess hydroxylamine derivative $\text{H}_2\text{NOR}^{12}$ or other solvent, at a temperature in the range of about $25-80^\circ\text{C}$ for about 2-18 hours, or
- (b) is contacted the hydroxylamine derivative $\text{H}_2\text{NOR}^{12}$, dicyclohexylcarbodiimide and 1-hydroxybenzotriazole in a solvent at a temperature in the range of about $0-30^\circ\text{C}$ for about 1-24 hours; to provide a compound in which R^{13} is CONHOR^{12} .


1158

35

88015687

305

22. Process of Claim 6 wherein: R^1 is



X is a carbon-carbon single bond, -CO-, -O-, -S-, or

10 -NH-;

R^2 , R^3 , R^6 and R^7 are as defined in Claim 15;

and

R^8 is $(CH_2)_nOR^{11}$, $(CH_2)_nOCOR^{14}$,

$(CH_2)_nCH(OH)R^{16}$, $(CH_2)_nCOR^{16}$

15 $(CH_2)_nCl$, $(CH_2)_nCN$, CHO.

23. Process of Claim 22 wherein R^8 is

$(CH_2)_nOH$ and the product of Formula 3 is

contacted with an alcohol $R^{11}OH$ in the anhydrous

20 state in the presence of a strong acid or a Lewis

acid, followed by saponification of any CO_2R^{14}

groups concomitantly formed or present in

intermediate 3, to form the corresponding compound of

Formula 3 wherein R^8 is $(CH_2)_nOR^{11}$ and R^{11}

25 is not H.

24. Process of Claim 22 wherein R^8 is

$(CH_2)_nOR^{11}$ and R^{11} is not H and the product

of Formula 3 is contacted with an aqueous acidic

30 medium at a temperature in the range of about 25°C

and the reflux temperature of the solvent for a

period of about 0.5-24 hours to form the

corresponding compound of Formula 3 wherein R^8 is

$(CH_2)_nOH$.

35

1159

88015687

25. Process of Claim 22 wherein R^8 is $(CH_2)_n OH$ and the product of Formula 3 is contacted with

- (a) a carboxylic acid anhydride $(R^{14}CO)_2O$ or chloride $R^{14}COCl$ in a solvent in presence of a base at a temperature in the range of about $0^\circ C$ and the reflux temperature of the solvent for about 0.5-24 hours or
- (b) a carboxylic acid $R^{14}CO_2H$ under anhydrous conditions in presence of a strong acid or Lewis acid at about $0^\circ-100^\circ C$ for about 0.5 to 24 hours, to form the corresponding compound in which R^8 is $(CH_2)_n OCOR^{14}$.

- 15 26. Process of Claim 22 wherein R^8 is $(CH_2)_n OCOR^{14}$ and the product of Formula 3 is contacted with aqueous acid or alkali to form the corresponding compound wherein R^8 is $(CH_2)_n OH$.

- 20 27. Process of Claim 22 wherein R^8 is $(CH_2)_n OH$ and the product of Formula 3 is contacted with an oxidizing agent at a temperature of about $25-45^\circ C$ for about 1-200 hours to produce a corresponding compound of Formula 3 in which R^8 is $(CH_2)_{n-1} COR^{16}$ and R^{16} is H.

- 25 28. Process of Claim 22 wherein R^8 is $(CH_2)_n COR^{16}$ and R^{16} is H and the product of Formula 3 is contacted with an organometallic compound $R^{16}P$ in which P is MgBr or Li in a solvent at a temperature in the range of about $-78^\circ C$ to $100^\circ C$ for about 0.5-24 hours to form a compound of Formula 3 in which R^8 is $(CH_2)_n CH(OH)R^{16}$ and R^{16} is not H.

29. Process of Claim 22 wherein R^8 is $(CH_2)_nCH(OH)R^{16}$ and R^{16} is not H and the product of Formula 3 is contacted with an oxidizing agent in a solvent to form a corresponding compound of Formula 3 in which R^8 is $(CH_2)_nCOR^{16}$ and R^{16} is not H.

30. Process of Claim 22 wherein R^8 is $(CH_2)_nCOR^{16}$ and R^{16} is H and the compound of Formula 3 is contacted with an oxidizing agent in a solvent to form a corresponding compound of Formula 3 in which R^8 is $(CH_2)_nCOR^{16}$ and R^{16} is OH.

31. Process of Claim 22 wherein R^8 is $(CH_2)_nCOR^{16}$ and R^{16} is OH and the compound of Formula 3 is contacted with thionyl chloride in excess or in another solvent at a temperature in the range of about 0°C to the reflux temperature of the solvent for about 5 minutes to about 24 hours to form a corresponding compound of Formula 3 in which R^8 is $(CH_2)_nCOCl$ followed by contact of the latter with an amine $NHR^{18}R^{19}$ in excess or in a solvent at temperatures in the range of about 0°C and reflux temperature of the solvent for about 5 minutes to about 24 hours to form a corresponding compound of Formula 3 in which R^8 is $(CH_2)_nCONR^{18}R^{19}$.

32. Process of Claim 22 wherein R^8 is $(CH_2)_nOR^{11}$ and R^{11} is H and the product of Formula 3 is contacted with thionyl chloride in excess or in a solvent at a temperature in the range of about 20°C to the reflux temperature of the solvent for about 0.5-24 hours to form an intermediate compound of Formula 3 in which R^8 is $(CH_2)_nCl$.

1161

88015687

33. Process of Claim 32 in which the compound of Formula 3 wherein R^8 is $(CH_2)_nCl$ is contacted with imidazole, 1,2,3-triazole, 1,2,4-triazole, tetrazole or phthalimide in the presence of base in a solvent at temperatures in the range of about 55°C to the reflux temperature of the solvent for about 1-24 hours to produce a corresponding compound of Formula 3 in which R^8 is $(CH_2)_m$ -imidazole, $(CH_2)_m$ -triazole, $(CH_2)_m$ -tetrazole or $(CH_2)_m$ -phthalimide.

34. Process of Claim 32 wherein the compound of Formula 3 in which R^8 is $(CH_2)_nCl$ is contacted with sodium or potassium salt of a mercaptan $R^{15}SH$ in a solvent at a temperature in the range of about 25-100°C for about 1-24 hours to form a compound of Formula 3 in which R^8 is $(CH_2)_nSR^{15}$.

35. Process of Claim 32 wherein the compound of Formula 3 in which R^8 is $(CH_2)_nCl$ is contacted with an alkali metal cyanide in a solvent at a temperature in the range of about 20-100°C for about 1-24 hours to form a compound of Formula 3 in which R^8 is $(CH_2)_nCN$ and the latter compound is hydrolyzed to the corresponding compound of Formula 3 in which R^8 is $(CH_2)_nCOR^{16}$ and R^{16} is OH.

36. Process of Claim 32 wherein the compound of Formula 3 in which R^8 is $(CH_2)_{n-1}Cl$ is contacted with the sodium or potassium salt of a dialkyl malonate in a solvent at a temperature in the range of about 20-100°C for about 0.5-24 hours to form a compound of Formula 3 in which R^8 is $(CH_2)_nCH(CO_2alkyl)_2$ followed by saponification of the

latter with aqueous alkali at a temperature in the range of about 25°C to the reflux temperature of the solvent followed by acidification with mineral acid to form a compound of Formula 3 in which R⁸ is (CH₂)_nCH(CO₂H)₂ followed by heating the latter to about 120°C or in dilute mineral acid at reflux temperature to form a product of Formula 3 in which R⁸ is (CH₂)_nCOR¹⁶ and R¹⁶ is OH.

37. Process of Claim 22 wherein R⁸ is (CH₂)_nCN and the compound of Formula 3 is contacted with sodium azide and ammonium chloride in a solvent at a temperature in the range of about 30°C and the reflux temperature of the solvent for about 1 hour to about 10 days to form a compound of the invention in which R⁸ is (CH₂)_n-tetrazole.

38. Process of Claim 22 wherein R⁸ is -CHO and the compound of Formula 3 is contacted with a methylene phosphorane (C₆H₅)₃P=CH(CH₂)₅CHR¹⁴OR¹⁵ or (C₆H₅)₃P=CH(CH₂)₅COR¹⁶ in a solvent at a temperature in the range of about 25°C to the reflux temperature of the solvent for about 1-24 hours to form a compound of Formula 3 in which R⁸ is -CH=CH(CH₂)₅CHR¹⁴OR¹⁵ or -CH=CH(CH₂)₅COR¹⁶ except where R¹⁵ is H and R¹⁶ is OH, and optionally then contacting the compound of Formula 3 in which R⁸ is -CH=CH(CH₂)₅COR¹⁶ with a reducing agent in a solvent at a temperature of about 0°-25°C for about 0.5-24 hours to form a product of Formula 3 in which R⁸ is -CH=CH(CH₂)₅CHR¹⁴OH.

39. Process of Claim 22 wherein R⁸ is (CH₂)_nOH and the compound of Formula 3 is

35

- 1163

88015687

370

contacted with a fluorinating agent in a solvent at a temperature in the range of about -30°C to 25°C for a period of about 0.5-24 hours to form a compound of Formula 3 in which R^8 is $(\text{CH}_2)_n\text{F}$.

5

40. Process of Claim 22 wherein the compound of Formula 3 in which R^8 is $(\text{CH}_2)_n\text{Cl}$ is contacted with silver nitrate in a dipolar aprotic solvent at a temperature in the range of about 25- 80°C for about 1-24 hours to form a compound of Formula 3 in which R^8 is $(\text{CH}_2)_n\text{ONO}_2$.

10

41. Process of Claim 22 wherein R^8 is $(\text{CH}_2)_n\text{OH}$ and the compound of Formula 3 is contacted with an isocyanate of Formula R^{10}NCO in a solvent at a temperature in the range of about 25°C to the reflux temperature of the solvent for a period of about 5 minutes to about 24 hours to form a compound of Formula 3 in which R^8 is $(\text{CH}_2)_n\text{OCONHR}^{10}$.

15

20

42. Process of Claim 22 wherein the compound in which R^8 is $(\text{CH}_2)_n\text{Cl}$ is contacted with an amine R^{11}NH_2 in excess amine or another solvent for a period of about 1-24 hours at a temperature in the range of about 0°C to the reflux temperature of the solvent to form an intermediate of Formula 3 in which R^8 is $(\text{CH}_2)_n\text{NHR}^{11}$.

25

30

43. Process of Claim 22 in which R^8 is $(\text{CH}_2)_n\text{Cl}$ and the compound of Formula 3 is contacted with an alkali metal azide in an aprotic solvent at a temperature in the range of about $25-80^{\circ}\text{C}$ for about 1-24 hours to form a compound of Formula 3 in which R^8 is $(\text{CH}_2)_n\text{N}_3$ and the

35

1164

88015687

311

latter is contacted with a reducing agent to form an intermediate of Formula 3 in which R^8 is $(CH_2)_nNH_2$.

5 44. Process of Claim 42 or 43 in which R^8 is $(CH_2)_nNHR^{11}$ or $(CH_2)_nNH_2$ and the compound of Formula 3 is contacted with a chloroformate of Formula $R^{10}OCOCl$ or a sulfonyl derivative of Formula $R^{10}SO_2Cl$ or $(R^{10}SO_2)O$ in a solvent
10 in the presence of a base at a temperature in the range of about $0^\circ C$ to the reflux temperature of a solvent for about 5 minutes to about 24 hours to form a compound of Formula 3 in which R^8 is $-(CH_2)_nNR^{11}CO_2R^{10}$ or $-(CH_2)_nNR^{11}SO_2R^{10}$.

15 45. Process of Claim 42 or 43 in which the compound of Formula 3 with R^8 equal to $-(CH_2)_nNHR^{11}$ or $(CH_2)_nNH_2$ is contacted with an isocyanate or isothiocyanate $R^{10}NCY$ in a
20 solvent at a temperature in the range of about $25^\circ C$ to the reflux temperature of the solvent for about 5 minutes to about 24 hours to form a compound of the Formula 3 in which R^8 is $-(CH_2)_nNR^{11}CYNHR^{10}$.

25 46. Process of Claim 6 wherein R^1 is NO_2 , R^2 , R^3 , R^6 , R^7 , and R^8 are as defined in Claim 20 in which the compound of Formula 3 wherein R^1 is NO_2 is reduced by means of iron and acetic acid, stannous chloride or hydrogen and palladium to
30 a compound of Formula 3 wherein R^1 is NH_2 and the latter is reacted with an appropriate acid anhydride such as phthalic anhydride or a substituted phthalic anhydride in a solvent or with an appropriate acid chloride such as substituted anthranilic acid
35 chloride in the presence of aqueous alkali or a base